{ full : { 1 : { 1 : "NN conj NN" 2 : 329 3 : { 1 : "drug0 conj *drug0*" 2 : "drug0 conj *drug0*" 3 : "drug0 conj *drug0*" 4 : "drug0 conj *drug0*" 5 : "drug0 conj *drug0*" 6 : "drug0 conj *drug0*" 7 : "drug0 conj *drug0*" 8 : "drug0 conj *drug0*" 9 : "drug0 conj *drug0*" 10 : "drug0 conj *drug0*" } 4 : { 1 : "Therefore , concomitant use of drug1 and drug2 is contraindicated . " 2 : "drug1 : Sporadic cases of seizures have been reported during concomitant use of drug2 and drug3 ( drug4 , drug5 ) . " 3 : "Synergism between drug1 ( e.g. , drug2 ) , drug3 , and other drug4 has been reported . " 4 : "Concurrent administration of drug1 and drug2 , which competes for tubular secretion , has been shown to increase the plasma half-life of drug3 . " 5 : "Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another drug1 and drug2 but may be seen after several months . " 6 : "For these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with drug1 and a drug2 do not outweigh the risks of severe myopathy , rhabdomyolysis , and acute renal failure . " 7 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 " 8 : "Therefore , when drug1 and drug2 are used concomitantly , the patient should be observed closely to determine if the desired effect of the drug3 is obtained . ) " 9 : "In rats , simultaneous ingestion of drug1 and drug2 in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that drug3 may react with drug4 in the rat stomach to form a nitrosamine , which is tumorigenic . " 10 : "Therefore , when drug1 and drug2 are used concomitantly , patients should be observed to determine whether the desired effect on blood pressure is obtained . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 2 : { 1 : "NN nmod NN dobj VB nsubj NN" 2 : 118 3 : { 1 : "drug0 nmod activity dobj *augment* nsubj drug0" 2 : "drug0 nmod responsiveness dobj *decrease* nsubj drug0" 3 : "drug0 nmod responsiveness dobj *increase* nsubj drug0" 4 : "drug0 nmod effect dobj *diminish* nsubj drug0" 5 : "drug0 nmod amount dobj *decrease* nsubj drug0" 6 : "drug0 nmod absorption dobj *decrease* nsubj drug0" 7 : "drug0 nmod clearance dobj *reduce* nsubj drug0" 8 : "drug0 nmod bioavailability dobj *increase* nsubj drug0" 9 : "drug0 nmod absorption dobj *reduce* nsubj drug0" 10 : "drug0 nmod action dobj *potentiate* nsubj drug0" } 4 : { 1 : "drug1 may augment the activity of other drug2 . " 2 : "( drug1 may decrease arterial responsiveness to drug2 . " 3 : "( drug1 may increase the responsiveness to drug2 . ) " 4 : "Tissue culture and animal studies indicate that drug1 can diminish or abolish the effect of drug2 on malignant cells .14 This effect on drug3 activity persists as long as plasma asparagine levels are suppressed . " 5 : "drug1 may decrease the amount of drug2 ( drug3 , drug4 ) that gets absorbed into your body . " 6 : "drug1 may also decrease the absorption of drug2 , which can lead to a deficiency . " 7 : "drug1 reduce the renal clearance of drug2 and add a high risk of drug3 toxicity . " 8 : "Although drug1 may increase the bioavailability of drug2 by increasing gastric emptying , drug3 may also adversely affect disease control by its dopamine receptor antagonistic properties . " 9 : "For example , since drug1 may reduce the gastrointestinal absorption of both the oral drug2 and drug3 , the net effects are unpredictable . " 10 : "Oral drug1 may potentiate the hypoglycemic action of drug2 , eg , drug3 and drug4 , by inhibiting their metabolism in the liver . " } 5 : { 1 : 2 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 3 : { 1 : "NN nmod NN nmod NN" 2 : 106 3 : { 1 : "drug0 nmod *co-administration* nmod drug0" 2 : "drug0 nmod *use* nmod drug0" 3 : "drug0 nmod *use* nmod drug0" 4 : "drug0 nmod *administration* nmod drug0" 5 : "drug0 nmod *use* nmod drug0" 6 : "drug0 nmod *administration* nmod drug0" 7 : "drug0 nmod *administration* nmod drug0" 8 : "drug0 nmod *use* nmod drug0" 9 : "drug0 nmod *use* nmod drug0" 10 : "drug0 nmod *interaction* nmod drug0" } 4 : { 1 : "Co-administration of drug1 with drug2 produced a 25 % increase in AUC and a 33 % increase in the Cmax of drug3 . " 2 : "Limited clinical experience indicates that requirements for drug1 are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following drug2 induction The concomitant use of drug3 with drug4 can significantly inhibit drug5 clearance and may increase the risk of prolonged or delayed respiratory depression . " 3 : "Therefore , the combined use of drug1 with drug2 should generally be avoided . " 4 : "The administration of other drug1 with drug2 has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function . " 5 : "These results would seem to dictate against the clinical use of drug1 with drug2 , or during the period following drug3 therapy when plasma asparagine levels are below normal . " 6 : "Concomitant administration of drug1 with drug2 is contraindicated . " 7 : "Simultaneous administration of drug1 with drug2 should be avoided . " 8 : "The concomitant use of drug1 or drug2 with drug3 is not recommended . " 9 : "drug1 : Use of drug2 with drug3 and other drug4 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed . " 10 : "Although it has not been definitively demonstrated that drug1 is a potent IIIA4 inhibitor , it is likely to be , given the substantial interaction of drug2 with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 4 : { 1 : "NN nmod VBN nsubjpass NN" 2 : 102 3 : { 1 : "drug0 nmod *administered* nsubjpass drug0" 2 : "drug0 nmod *used* nsubjpass drug0" 3 : "drug0 nmod *administered* nsubjpass drug0" 4 : "drug0 nmod *coadministered* nsubjpass drug0" 5 : "drug0 nmod *administered* nsubjpass drug0" 6 : "drug0 nmod *used* nsubjpass drug0" 7 : "drug0 nmod *co-administered* nsubjpass drug0" 8 : "drug0 nmod *administered* nsubjpass drug0" 9 : "drug0 nmod *administered* nsubjpass drug0" 10 : "drug0 nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should not be administered concomitantly with drug2 , drug3 , drug4 , drug5 , or drug6 . " 2 : "Injection : drug1 injection , like other injectable drug2 , produces depression of the central nervous system when administered with drug3 , drug4 , drug5 , drug6 , and other drug7 . When drug8 is used concomitantly with injectable drug9 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed . " 3 : "Serum drug1 levels should be monitored frequently if drug2 is administered concomitantly with drug3 . " 4 : "Blood levels of drug1 increased 24 % when drug2 was coadministered with drug3 ( nonselective inhibitor of cytochrome P-450 ) for 7 days , and decreased 28 % with coadministration of drug4 ( potent inducer of cytochrome P-450 ) for 7 days . " 5 : "Clearance of drug1 decreased by about 27 % when drug2 was administered intravenously concomitantly with drug3 . " 6 : "drug1 should not be used with other drug2 . " 7 : "Therefore , if drug1 is co-administered with drug2 , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drug3 should to monitored . " 8 : "drug1 : When drug2 ( 50 mg tid ) was administered concomitantly with drug3 for two weeks , drug4 plasma concentrations increased by 98 % and prothrombin times were prolonged . " 9 : "However , because some drug1 have been reported to enhance the effects of drug2 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drug3 is administered with drug4 or its derivatives . " 10 : "Caution should be used if drug1 is administered simultaneously with drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 5 : { 1 : "NN conj NN dep NN nsubj NNS acl:relcl VBN conj VBN xcomp VBN nmod NN nmod NN" 2 : 44 3 : { 1 : "drug0 conj drug0 dep *following* nsubj agents acl:relcl found conj expected xcomp decreased nmod presence nmod drug0" } 4 : { 1 : "Agents that have been found , or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 , drug23 , drug24 , drug25 , drug26 , drug27 , drug28 , drug29 , drug30 , oral drug31 ( 3 ) , drug32 , drug33 ( 4 ) , drug34 , drug35 , drug36 , drug37 , drug38 , drug39 , drug40 , drug41 , drug42 , drug43 , drug44 ( 5 ) , drug45 , and drug46 . " } 5 : { 1 : 44 } } 6 : { 1 : "NN nmod NNS dobj VB nsubj NN" 2 : 43 3 : { 1 : "drug0 nmod drugs dobj *displace* nsubj drug0" 2 : "drug0 nmod effects dobj *reduce* nsubj drug0" 3 : "drug0 nmod effects dobj *decrease* nsubj drug0" 4 : "drug0 nmod effects dobj *reduce* nsubj drug0" 5 : "drug0 nmod effects dobj *potentiate* nsubj drug0" 6 : "drug0 nmod effects dobj *potentiate* nsubj drug0" 7 : "drug0 nmod effects dobj *reduce* nsubj drug0" 8 : "drug0 nmod interactions dobj *have* nsubj drug0" 9 : "drug0 nmod effects dobj *enhance* nsubj drug0" 10 : "drug0 nmod effects dobj *antagonize* nsubj drug0" } 4 : { 1 : "drug1 may displace acidic drugs such as drug2 or drug3 from their binding sites . " 2 : "( In some patients , the drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 , and drug4 . " 3 : "drug1 may decrease the hemodynamic effects of drug2 ; " 4 : "drug1 ( e.g. , drug2 , drug3 , drug4 ) and drug5 may reduce the therapeutic effects of drug6 . " 5 : "drug1 : drug2 may potentiate the toxic effects of drug3 . " 6 : "drug1 may potentiate the effects of drug2 . " 7 : "drug1 can reduce the antihypertensive effects of drug2 and drug3 . " 8 : "drug1 may have life-threatening interactions with drug2 . " 9 : "drug1 may enhance the effects of drug2 , drug3 , and other drug4 . " 10 : "drug1 : drug2 may antagonize the hypotensive effects of drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 7 : { 1 : "NN conj NN nmod NN nmod NN" 2 : 43 3 : { 1 : "drug0 conj mg nmod *addition* nmod drug0" 2 : "drug0 nmod *use* nmod drug0 conj drug0" 3 : "drug0 conj drug0 nmod *use* nmod drug0" 4 : "drug0 nmod dose nmod recovery conj *drug0*" 5 : "drug0 conj drug0 nmod *administration* nmod drug0" 6 : "drug0 conj meal nmod *administration* nmod drug0" 7 : "drug0 conj drug0 nmod *use* nmod drug0" 8 : "drug0 conj drug0 nmod *coadministration* nmod drug0" 9 : "drug0 conj drug0 nmod *co-administration* nmod drug0" 10 : "drug0 conj drug0 nmod *coadministration* nmod drug0" } 4 : { 1 : "drug1 and drug2 ( Hypertension ) - In clinical studies of patients with hypertension , the addition of drug3 50 to 100 mg to drug4 and drug5 increased mean serum potassium slightly ( about 0.09-0 .13 mEq/L ) . " 2 : "The concomitant use of drug1 or drug2 with drug3 is not recommended . " 3 : "drug1 : Use of drug2 with drug3 and other drug4 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed . " 4 : "Administration of 0.1-mg / kg ( 2 x ED95 ) drug1 at 10 % or 95 % recovery following an intubating dose of drug2 ( 1 mg/kg ) produced 95 % neuromuscular block . " 5 : "Nephrotoxicity has been reported following concomitant administration of drug1 with drug2 or potent drug3 such as drug4 . " 6 : "However , in the second study , administration of 12 g drug1 1 hour before the evening meal and 0.3 mg drug2 approximately 4 hours after the same evening meal resulted in a decrease in the drug3 AUC of less than 8 % , and a decrease in Cmax of about 30 % when compared to dosing drug4 alone . " 7 : "Co-administration : Concomitant use of drug1 with drug2 , drug3 , and other drug4 may increase the risk of bleeding . " 8 : "Coadministration of drug1 with oral drug2 or drug3 has resulted in elevated plasma concentrations of the latter two drugs . " 9 : "drug1 / drug2 / drug3 / drug4 : Co-administration of drug5 with drug6 , drug7 , drug8 , and drug9 is likely to lead to an enhancement of effects . " 10 : "Coadministration of drug1 with other drug2 , drug3 , and drug4 may cause hypokalemia . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 2 8 : 1 9 : 3 10 : 1 } } 8 : { 1 : "NN conj NN nmod NN dobj VB nsubj NN" 2 : 32 3 : { 1 : "drug0 conj drug0 nmod absorption dobj *reduce* nsubj drug0" 2 : "drug0 conj drug0 nmod action dobj *potentiate* nsubj drug0" 3 : "drug0 conj drug0 nmod metabolism dobj *inhibit* nsubj drug0" 4 : "drug0 conj drug0 nmod effect dobj *reduce* nsubj drug0" 5 : "drug0 conj drug0 nmod effect dobj *counteract* nsubj drug0" 6 : "drug0 conj drug0 nmod activity dobj *enhance* nsubj drug0" 7 : "drug0 conj drug0 nmod effect dobj *reduce* nsubj drug0" 8 : "drug0 conj drug0 nmod activity dobj *antagonize* nsubj drug0" 9 : "drug0 conj drug0 nmod effect dobj *reduce* nsubj drug0" 10 : "drug0 conj drug0 nmod effect dobj *reduce* nsubj drug0" } 4 : { 1 : "For example , since drug1 may reduce the gastrointestinal absorption of both the oral drug2 and drug3 , the net effects are unpredictable . " 2 : "Oral drug1 may potentiate the hypoglycemic action of drug2 , eg , drug3 and drug4 , by inhibiting their metabolism in the liver . " 3 : "drug1 drug2 drug3 , like other drug4 , may inhibit the metabolism of drug5 and drug6 . " 4 : "drug1 and other drug2 can reduce the antihypertensive effect of drug3 and other drug4 . " 5 : "drug1 in large amounts may counteract the antiepileptic effect of drug2 , drug3 and drug4 , and increase the frequency of seizures in susceptible pediatric patients . " 6 : "drug1 , drug2 drug3 may enhance the activity of drug4 or drug5 ; " 7 : "drug1 : Clinical studies , as well as post marketing observations , have shown that drug2 can reduce the natriuretic effect of drug3 and drug4 in some patients . " 8 : "drug1 and drug2 drug3 can antagonize the in vitro antiviral activity of drug4 and drug5 against HIV . " 9 : "drug1 : Clinical studies , as well as post-marketing observations , have shown that drug2 can reduce the natriuretic effect of drug3 and drug4 in some patients . " 10 : "Nevertheless , clinical studies , as well as postmarketing observations have shown that drug1 can reduce the natriuretic effect of drug2 and drug3 in some patients . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 5 : 2 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 9 : { 1 : "NN dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 31 3 : { 1 : "drug0 dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 31 } } 10 : { 1 : "NN nmod NN nmod VBN nsubjpass NN" 2 : 30 3 : { 1 : "drug0 nmod combination nmod *administered* nsubjpass drug0" 2 : "drug0 nmod conjunction nmod *given* nsubjpass drug0" 3 : "drug0 nmod combination nmod *used* nsubjpass drug0" 4 : "drug0 nmod dose nmod *coadministered* nsubjpass drug0" 5 : "drug0 nmod dosing nmod *administered* nsubjpass drug0" 6 : "drug0 nmod formulation nmod *administered* nsubjpass drug0" 7 : "drug0 nmod withdrawal nmod *withdrawn* nsubjpass drug0" 8 : "drug0 nmod combination nmod *used* nsubjpass drug0" 9 : "drug0 nmod administration nmod *displaced* nsubjpass drug0" 10 : "drug0 nmod dose nmod *given* nsubjpass drug0" } 4 : { 1 : "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug1 is administered in combination with other drug2 such as drug3 , drug4 , drug5 , or inhalation general drug6 . " 2 : "Caution should be exercised when drug1 are given in conjunction with drug2 . " 3 : "When other potent parental drug1 , such as drug2 , are used in combination with drug3 , patients should be continuously observed for several hours for any excessive fall in blood pressure . " 4 : "drug1 : The AUC of drug2 was increased about 4-fold when drug3 at 300 mg/day was coadministered with a single 200-mg dose of drug4 to two patients with renal impairment ( CLcr = 15 and 18 mL/min ) . " 5 : "drug1 s : drug2 should be administered at least 2 hours after or 6 hours before dosing with drug3 because plasma concentrations of drug4 are decreased when administered with drug5 containing drug6 , drug7 , or drug8 . " 6 : "In eight HIV-infected patients , the steady-state AUC of drug1 was decreased an average of 26 % ( 95 % CI = 14 % , 37 % ) when drug2 was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of drug3 . " 7 : "If the two drugs are coadministered , the drug1 should be withdrawn several days before the gradual withdrawal of drug2 . " 8 : "Consequently , it is recommended that drug1 not be used in combination with either drug2 , drug3 , or drug4 . " 9 : "Concomitant administration of drug1 and drug2 is not recommended because drug3 is displaced from its binding sites during the concomitant administration of drug4 , resulting in lower plasma concentrations and peak plasma levels . " 10 : "drug1 : When drug2 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of drug3 , significant hypotension developed in a substantial number of subjects . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 11 : { 1 : "NN nmod NN nmod NN nmod NN" 2 : 30 3 : { 1 : "drug0 nmod treatment nmod *consumption* nmod drug0" 2 : "drug0 nmod *inhibition* nmod hydroxylation nmod drug0" 3 : "drug0 nmod mg nmod *addition* nmod drug0" 4 : "drug0 nmod dose nmod *dose* nmod drug0" 5 : "drug0 nmod combination nmod *use* nmod drug0" 6 : "drug0 nmod schedule nmod *addition* nmod drug0" 7 : "drug0 nmod drug0 nmod *effect* nmod drug0" 8 : "drug0 nmod combination nmod drug0 nmod *drug0*" 9 : "drug0 nmod *study* nmod coadministration nmod drug0" 10 : "drug0 nmod *reduction* nmod dosage nmod drug0" } 4 : { 1 : "The consumption of drug1 during treatment with drug2 should be minimized or avoided ( also see a href = bupropz_od . htm #CI CONTRAINDICATIONS ) " 2 : "In an in vitro study in human liver microsomes , inhibition of CYP2A6 hydroxylation of drug1 by drug2 ( 200 m m M i.e. , 350 mg/L ) was 17-28 % . " 3 : "drug1 and drug2 ( Hypertension ) - In clinical studies of patients with hypertension , the addition of drug3 50 to 100 mg to drug4 and drug5 increased mean serum potassium slightly ( about 0.09-0 .13 mEq/L ) . " 4 : "In a single subject given one dose of drug1 2 hours after a dose of drug2 - placebo tablets , a greater than 50 % reduction in the AUC of drug3 was observed . " 5 : "Therefore , use of drug1 in combination with drug2 is not recommended " 6 : "It has been reported that the addition of drug1 to a maintenance schedule of drug2 resulted in reversible acute renal failure in two of four healthy volunteers . " 7 : "Blunting of the antihypertensive effect of drug1 by drug2 including drug3 has been reported . " 8 : "Use lowest possible dose of drug1 with careful monitoring , or consider drug2 that are not primarily metabolized by CYP3A4 , such as drug3 , drug4 , or drug5 in combination with drug6 . " 9 : "The results of a study of coadministration of drug1 ( 50 mg/kg ) with an drug2 containing drug3 to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of drug4 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of drug5 may be reduced by these drug6 . " 10 : "However , due to possible pharmacodynamic interactions , when co-administered with drug1 , a reduction in dosage of drug2 on the concomitant drug3 , drug4 , drug5 or drug6 may be required . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 12 : { 1 : "NN conj NN nmod VBN nsubjpass NN" 2 : 27 3 : { 1 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" 2 : "drug0 conj drug0 nmod *taken* nsubjpass drug0" 3 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" 4 : "drug0 conj drug0 nmod *coadministered* nsubjpass drug0" 5 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" 6 : "drug0 conj drug0 nmod *used* nsubjpass drug0" 7 : "drug0 conj drug0 nmod *coadministered* nsubjpass drug0" 8 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" 9 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" 10 : "drug0 conj drug0 nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should not be administered concomitantly with drug2 , drug3 , drug4 , drug5 , or drug6 . " 2 : "Because of its primary CNS effect , caution should be used when drug1 is taken with other drug2 and drug3 . " 3 : "Additive adverse effects resulting from cholinergic blockade may occur when drug1 is administered concomitantly with other drug2 , drug3 , drug4 , drug5 , drug6 , drug7 or some drug8 . " 4 : "When drug1 was coadministered with drug2 , drug3 , or H2antagonists , reduced plasma concentrations of drug4 were reported . " 5 : "however , it adversely affected response duration suggesting that drug1 should not be administered with drug2 and/or drug3 .1 " 6 : "Close supervision and careful adjustment of the dosage are required when drug1 is used with other drug2 or drug3 . " 7 : "Caution should be observed when drug1 is coadministered with other drug2 , drug3 , drug4 , or drug5 , as these agents may increase respiratory and circulatory depression . " 8 : "Close supervision and careful adjustment of dosage are required when drug1 is administered with drug2 or drug3 . " 9 : "Additional reductions in blood pressure may occur when drug1 is administered with drug2 , drug3 , or other drug4 . " 10 : "- drug1 or drug2 ( with hepatotoxic potential ) must not be administered together with drug3 or drug4 . " } 5 : { 1 : 4 2 : 1 3 : 6 4 : 1 5 : 1 6 : 1 7 : 3 8 : 1 9 : 2 10 : 1 } } 13 : { 1 : "NN nmod NN dobj VBD nsubj NN" 2 : 26 3 : { 1 : "drug0 nmod effect dobj *decreased* nsubj drug0" 2 : "drug0 nmod half-life dobj *prolonged* nsubj drug0" 3 : "drug0 nmod auc0-0 dobj *reduced* nsubj drug0" 4 : "drug0 nmod auc dobj *increased* nsubj drug0" 5 : "drug0 nmod exposure dobj *increased* nsubj drug0" 6 : "drug0 nmod auc dobj *increased* nsubj drug0" 7 : "drug0 nmod auc dobj *increased* nsubj drug0" 8 : "drug0 nmod auc dobj *increased* nsubj drug0" 9 : "drug0 nmod auc dobj *increased* nsubj drug0" 10 : "drug0 nmod bioavailability dobj *reduced* nsubj drug0" } 4 : { 1 : "drug1 decreased the hyperuricemic effect of drug2 . " 2 : "drug1 significantly prolonged the half-life of drug2 to 26 hours . " 3 : "drug1 reduced the blood AUC0-12 of drug2 by approximately 20 % , peak blood concentration ( Cmax ) by 16 % , and 12-hour blood concentration ( C12hr ) by 26 % in healthy subjects when drug3 ( 2 doses of 0.1 mg/kg 12 hours apart ) was administered on the 10th day of drug4 70 mg daily , as compared to results from a control period in which drug5 was administered alone . " 4 : "In two clinical studies , drug1 ( one 4 mg/kg dose or two 3 mg/kg doses ) increased the AUC of drug2 by approximately 35 % . " 5 : "Pharmacokinetic studies have demonstrated that drug1 and drug2 significantly increased the systemic exposure of drug3 and/or its major metabolites . " 6 : "drug1 , when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3 , increased the AUC of drug2 , a CYP3A4 substrate , by 1.34-fold on Day 1 and by 2.5-fold on Day 3 , when drug3 was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3 . " 7 : "drug1 : drug2 increased the AUC of drug3 , a sensitive CYP3A4 substrate , by 2.3-fold on Day 1 and 3.3-fold on Day 5 , when a single oral dose of drug4 2 mg was coadministered on Day 1 and Day 5 of a regimen of drug5 125 mg on Day 1 and 80 mg/day on Days 2 through 5 . " 8 : "drug1 increased the AUC of drug2 by 25 % on Day 4 and decreased the AUC of drug3 by 19 % on Day 8 relative to the dosing of drug4 on Days 1 through 3 . " 9 : "drug1 increased the AUC of drug2 by 50 % . " 10 : "drug1 : In a study of healthy volunteers , drug2 significantly reduced the bioavailability of drug3 . " } 5 : { 1 : 2 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 14 : { 1 : "NN conj NN dep NN nsubj NNS acl VB dobj NNS nmod NN" 2 : 25 3 : { 1 : "drug0 conj drug0 dep *following* nsubj agents acl increase dobj levels nmod drug0" } 4 : { 1 : "Agents that are CYP3A4 inhibitors that have been found , or are expected , to increase plasma levels of drug1 are the following : drug2 , drug3 , drug4 , drug5 ( 1 ) , drug6 , drug7 , drug8 , drug9 , drug10 ( 1 ) , drug11 , drug12 , grapefruit juice , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 , drug23 , drug24 , drug25 ( 1 ) , drug26 , drug27 . " } 5 : { 1 : 25 } } 15 : { 1 : "NN nmod NN dobj VBZ nsubj NN" 2 : 24 3 : { 1 : "drug0 nmod clearance dobj *reduces* nsubj drug0" 2 : "drug0 nmod effect dobj *increases* nsubj drug0" 3 : "drug0 nmod clearance dobj *increases* nsubj drug0" 4 : "drug0 nmod clearance dobj *reduces* nsubj drug0" 5 : "drug0 nmod metabolism dobj *inhibits* nsubj drug0" 6 : "drug0 nmod effect dobj *enhances* nsubj drug0" 7 : "drug0 nmod metabolism dobj *inhibits* nsubj drug0" 8 : "drug0 nmod metabolism dobj *inhibits* nsubj drug0" 9 : "drug0 nmod absorption dobj *inhibits* nsubj drug0" 10 : "drug0 nmod time dobj *prolongs* nsubj drug0" } 4 : { 1 : "drug1 reduces the clearance of drug2 . " 2 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 " 3 : "drug1 increases the clearance of drug2 by 15 % or more , possibly due to the induction of glutathione-S-transferase . " 4 : "Because drug1 reduces the clearance of both drug2 and its active metabolite , drug3 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration . " 5 : "Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug2 resulting in an eight-fold increase in the mean AUC of drug3 . " 6 : "It has been reported that drug1 enhances the anticoagulant effect of drug2 - like drugs . " 7 : "drug1 : In vitro data indicate that drug2 inhibits the metabolism of drug3 , which can result in an increase in plasma drug4 levels and prolongation of the QT interval on the ECG . " 8 : "Human pharmacokinetic data indicate that oral drug1 markedly inhibits the metabolism of drug2 , resulting in a mean eight-fold increase in AUC of drug3 . " 9 : "Oral drug1 inhibits the gastrointestinal absorption of drug2 , oral drug3 , drug4 and drug5 . " 10 : "Animal experience indicates that drug1 prolongs the sleeping time after drug2 or after drug3 , increases the inhibitory effects of drug4 , but does not exhibit monoamine oxidase inhibition . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 16 : { 1 : "NN conj NN nmod VB nsubj NN" 2 : 22 3 : { 1 : "drug0 conj drug0 nmod *interact* nsubj drug0" 2 : "drug0 conj drug0 nmod *interact* nsubj drug0" 3 : "drug0 conj drug0 nmod *interact* nsubj drug0" 4 : "drug0 conj drug0 nmod *interact* nsubj drug0" 5 : "drug0 conj drug0 nmod *interact* nsubj drug0" 6 : "drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 can interact with drug2 or other drug3 ( may potentiate the CNS depressant effects of either these medications or drug4 ) , drug5 or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with drug6 ) , and drug7 ( concurrent use with drug8 may prolong and intensify the anticholinergic and CNS depressant effects of drug9 ) . " 2 : "drug1 may interact with drug2 , drug3 s , drug4 ( allergy , cold , and sinus medicines ) , diabetic drugs , drug5 , drug6 , drug7 like drug8 or drug9 , and high blood pressure medications . " 3 : "drug1 may interact with drug2 or other drug3 , causing increased sedative effects . " 4 : "drug1 may interact with drug2 , drug3 , and certain other agents . " 5 : "drug1 may interact with drug2 , drug3 , drug4 , drug5 , drug6 supplements , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , and drug14 . " 6 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 2 2 : 4 3 : 1 4 : 1 5 : 11 6 : 3 } } 17 : { 1 : "NN conj NN dep VBP nsubj NNS acl:relcl VB dobj NNS compound NN" 2 : 21 3 : { 1 : "drug0 conj intake dep *include* nsubj drugs acl:relcl increase dobj concentrations compound drug0" 2 : "drug0 conj drug0 dep *include* nsubj drugs acl:relcl decrease dobj concentrations compound drug0" 3 : "drug0 conj drug0 dep *include* nsubj drugs acl:relcl increase dobj concentrations compound drug0" } 4 : { 1 : "The most commonly occurring drug interactions are listed below : - Drugs that may increase plasma drug1 concentrations include : acute drug2 intake , drug3 , chboramphenicol , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 " 2 : "- Drugs that may decrease plasma drug1 concentrations include : drug2 , chronic drug3 abuse , drug4 " 3 : "- Drugs that may either increase or decrease plasma drug1 concentrations include : drug2 , vaiproic acid , and drug3 . " } 5 : { 1 : 19 2 : 1 3 : 1 } } 18 : { 1 : "NN conj NN nmod NNS dobj VB nsubj NN" 2 : 21 3 : { 1 : "drug0 conj drug0 nmod drugs dobj *displace* nsubj drug0" 2 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj drug0" 3 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj drug0" 4 : "drug0 conj drug0 nmod effects dobj *enhance* nsubj drug0" 5 : "drug0 conj drug0 nmod effects dobj *counteract* nsubj drug0" 6 : "drug0 conj drug0 nmod effects dobj *enhance* nsubj drug0" 7 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj drug0" 8 : "drug0 conj drug0 nmod effects dobj *decrease* nsubj drug0" 9 : "drug0 conj drug0 nmod effects dobj *enhance* nsubj drug0" 10 : "drug0 conj drug0 nmod effects dobj *have* nsubj drug0" } 4 : { 1 : "drug1 may displace acidic drugs such as drug2 or drug3 from their binding sites . " 2 : "( In some patients , the drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 , and drug4 . " 3 : "drug1 can reduce the antihypertensive effects of drug2 and drug3 . " 4 : "drug1 may enhance the effects of drug2 , drug3 , and other drug4 . " 5 : "drug1 may partially counteract the anticoagulation effects of drug2 or drug3 . " 6 : "drug1 may enhance the effects of drug2 , drug3 , drug4 , and other drug5 . " 7 : "drug1 may reduce the antihypertensive effects of drug2 , drug3 , drug4 and drug5 . " 8 : "drug1 : drug2 may decrease the effects of drug3 , drug4 , and drug5 . " 9 : "- drug1 may enhance the CNS depressive effects of drug2 , drug3 and other drug4 " 10 : "drug1 may have additive effects with drug2 and other drug3 , e.g. , drug4 , drug5 , drug6 , drug7 . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 2 5 : 1 6 : 3 7 : 3 8 : 2 9 : 2 10 : 1 } } 19 : { 1 : "NN nmod VBG dobj NN" 2 : 21 3 : { 1 : "drug0 nmod *taking* dobj drug0" 2 : "drug0 nmod *taking* dobj drug0" 3 : "drug0 nmod *taking* dobj drug0" 4 : "drug0 nmod *taking* dobj drug0" 5 : "drug0 nmod *administering* dobj drug0" 6 : "drug0 nmod *administering* dobj drug0" 7 : "drug0 nmod *receiving* dobj drug0" 8 : "drug0 nmod *using* dobj drug0" 9 : "drug0 nmod *taking* dobj drug0" 10 : "drug0 nmod *receiving* dobj drug0" } 4 : { 1 : "Patients taking drug1 concomitantly with drug2 more commonly reported both weight gain and weight loss , compared with patients taking either medication alone . " 2 : "drug1 Altered coagulation parameters and/or bleeding have been reported in patients taking drug2 concomitantly with drug3 such as drug4 and drug5 . " 3 : "Patients taking drug1 concomitantly with drug2 should be monitored regularly for alterations in their coagulation parameters ( PT or INR ) . " 4 : "This interaction should be given consideration in patients taking drug1 concomitantly with drug2 . " 5 : "However , caution should be used when administering drug1 with drug2 since these patients are at increased risk of bleeding complications . " 6 : "Caution should be exercised when administering drug1 with drug2 since interactions have been seen with other drug3 . " 7 : "In post-marketing experience , bleeding events have been reported , predominantly in the elderly , in association with increases in prothrombin time in patients receiving drug1 concurrently with drug2 . " 8 : "The benefits and risks of using drug1 with drug2 and other potentially nephrotoxic agents should be carefully considered , and the lowest effective dose employed " 9 : "drug1 : Seizures have been reported in patients taking drug2 concomitantly with the drug3 drug4 . " 10 : "Patients receiving other drug1 , drug2 , drug3 , or other drug4 ( including drug5 ) concomitantly with drug6 and drug7 tablets may exhibit an additive CNS depression . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 6 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 20 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NN" 2 : 19 3 : { 1 : "drug0 nmod metabolism dobj decrease xcomp *reported* nsubjpass drug0" 2 : "drug0 nmod secretion dobj reduce xcomp *reported* nsubjpass drug0" 3 : "drug0 nmod absorption dobj reduce xcomp *reported* nsubjpass drug0" 4 : "drug0 nmod metabolism dobj reduce xcomp *reported* nsubjpass drug0" 5 : "drug0 nmod effect dobj blunt xcomp *reported* nsubjpass drug0" 6 : "drug0 nmod metabolism dobj slow xcomp *known* nsubjpass drug0" 7 : "drug0 nmod effect dobj blunt xcomp *reported* nsubjpass drug0" 8 : "drug0 nmod effect dobj intensify xcomp *observed* nsubjpass drug0" 9 : "drug0 nmod metabolism dobj decrease xcomp *reported* nsubjpass drug0" 10 : "drug0 nmod effect dobj enhance xcomp *observed* nsubjpass drug0" } 4 : { 1 : "In addition , other drug1 have been reported to decrease the CYP3A4-mediated metabolism of drug2 . " 2 : "drug1 , drug2 and other drug3 have been reported to reduce the tubular secretion of drug4 in an animal model , possibly increasing the toxicity of drug5 . " 3 : "Interactions for drug1 ( drug2 , drug3 , drug4 , and drug5 ) : drug6 : drug7 has been reported to reduce intestinal absorption of drug8 ; " 4 : "drug1 is reported to reduce hepatic metabolism of certain drug2 , thereby delaying elimination and increasing steady-state concentrations of these drug3 . " 5 : "drug1 have been reported to blunt the hypotensive effect of systemic drug2 . It is not known whether the concurrent use of these agents with drug3 in humans can lead to resulting interference with the IOP lowering effect . " 6 : "drug1 : drug2 is known to slow the metabolism of drug3 and increase its serum levels drug4 levels should be determined prior to concurrent administration with drug5 , signs and symptoms of drug6 toxicity should be monitored closely , and appropriate dosage adjustment of the drug7 should be made . " 7 : "drug1 have been reported to blunt the hypotensive effect of systemic drug2 . " 8 : "In Europe , drug1 was observed to occasionally intensify the effect of drug2 taken concomitantly by patients suffering from hypertension ; " 9 : "drug1 : drug2 has been reported to decrease the metabolism of certain drug3 by up to 60 % , leading to increased risk of drug4 side effects . " 10 : "drug1 - drug2 was observed to enhance ( in tissue culture ) the effect of drug3 in reducing the number of human breast cancer cells that were in the S phase . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 21 : { 1 : "NN compound NN dobj VB dep NN conj NN" 2 : 18 3 : { 1 : "drug0 compound hypokalemia dobj potentiate dep *drug0* conj drug0" 2 : "drug0 conj drug0 dep *inhibit* dobj binding compound drug0" 3 : "drug0 compound reduction dobj consider dep drug0 conj *drug0*" } 4 : { 1 : "drug1 and drug2 ( drug3 ) : may potentiate drug4 - induced hypokalemia which may predispose the patient to cardiac dysfunction . " 2 : "Binding to Serum Proteins : The following agents may either inhibit drug1 binding to serum proteins or alter the concentrations of serum binding proteins : drug2 and related drug3 , drug4 , drug5 , drug6 and drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 . " 3 : "drug1 , drug2 , drug3 ( consider drug4 dose reduction ) . " } 5 : { 1 : 1 2 : 16 3 : 1 } } 22 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN" 2 : 18 3 : { 1 : "drug0 conj drug0 nmod *enhanced* nsubjpass action nmod drug0" 2 : "drug0 conj drug0 nmod *potentiated* nsubjpass action nmod drug0" 3 : "drug0 conj drug0 nmod *potentiated* nsubjpass action nmod drug0" 4 : "drug0 conj drug0 nmod *blunted* nsubjpass response nmod drug0" } 4 : { 1 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . " 2 : "Pharmacodynamic Interactions : The CNS-depressant action of the drug1 of drugs may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , the drug7 , drug8 and drug9 , drug10 and the drug11 , and by other drug12 . " 3 : "The action of the drug1 may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , or other drugs that produce CNS depression . " 4 : "The response to drug1 may be blunted by drug2 and drug3 which cause a rise in prolactin . " } 5 : { 1 : 1 2 : 9 3 : 7 4 : 1 } } 23 : { 1 : "NN nmod NN nmod NN dep NN conj NN" 2 : 18 3 : { 1 : "drug0 nmod *coadministration* nmod drug0 dep drug0 conj drug0" 2 : "drug0 conj drug0 dep drug0 nmod *use* nmod drug0" 3 : "drug0 conj drug0 dep drug0 nmod *use* nmod drug0" 4 : "drug0 conj drug0 dep drug0 nmod *use* nmod drug0" 5 : "drug0 conj drug0 dep inducer nmod *administration* nmod drug0" } 4 : { 1 : "drug1 : In a clinical pharmacology study , coadministration of an drug2 ( drug3 , drug4 , and drug5 ) with drug6 reduced serum levels and urinary excretion of drug7 as compared with drug8 administered alone , suggesting that drug9 may impair absorption of drug10 . " 2 : "Concurrent use of drug1 with drug2 ( e.g. , drug3 , drug4 , drug5 , and drug6 ) may result in increased drug7 effects . " 3 : "Interactions with Other CNS Agents : Concurrent use of drug1 with all drug2 ( eg , drug3 , drug4 , drug5 , other drug6 , general drug7 , drug8 , drug9 , drug10 , drug11 , drug12 and drug13 ) may result in additive central nervous system depressant effects . " 4 : "Use of drug1 with drug2 ( e.g. , drug3 , drug4 , or drug5 ) , drug6 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium . " 5 : "The administration of drug1 concomitantly with known microsomal enzyme inducer ( drug2 or drug3 ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration . " } 5 : { 1 : 2 2 : 3 3 : 10 4 : 2 5 : 1 } } 24 : { 1 : "NN nmod NN" 2 : 17 3 : { 1 : "drug0 nmod *drug0*" 2 : "drug0 nmod *drug0*" 3 : "drug0 nmod *drug0*" 4 : "drug0 nmod *drug0*" 5 : "drug0 nmod *drug0*" 6 : "drug0 nmod *drug0*" 7 : "drug0 nmod *drug0*" 8 : "drug0 nmod *drug0*" 9 : "drug0 nmod *drug0*" 10 : "drug0 nmod *drug0*" } 4 : { 1 : "When other potent parental drug1 , such as drug2 , are used in combination with drug3 , patients should be continuously observed for several hours for any excessive fall in blood pressure . " 2 : "In a small ( n = 30 ) combination study of drug1 with drug2 , a 2 - to 3-fold elevation in liver enzymes was seen in 5 of 30 patients . " 3 : "In vitro mixing of an drug1 with beta-lactamtype drug2 ( drug3 or drug4 ) may result in a significant mutual inactivation . " 4 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " 5 : "drug1 ( drug2 ) : The concomitant administration of a drug3 with a drug4 may increase the risks of CNS stimulation and convulsions . " 6 : "drug1 with drug2 or drug3 and possibly other drug4 cause striking and sustained increases in the concentration of drug5 in the brain ; " 7 : "The concomitant administration of drug1 including drug2 with drug3 ( a drug4 ) has , on rare occasions , resulted in severe hypoglycemia . " 8 : "Interactions with drug1 : drug2 ( eg , drug3 , drug4 , drug5 , drug6 and drug7 ) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug8 such as drug9 . " 9 : "It is recommended that the combination of intravenous drug1 and drug2 , such as drug3 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established . " 10 : "Consequently , the combination of drug1 with drug2 is also contraindicated . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 2 7 : 1 8 : 1 9 : 1 10 : 1 } } 25 : { 1 : "NN conj NN nmod NNS nmod NN" 2 : 17 3 : { 1 : "drug0 conj drug0 nmod *effects* nmod drug0" 2 : "drug0 conj drug0 nmod products nmod *drug0*" 3 : "drug0 conj drug0 nmod *interactions* nmod drug0" 4 : "drug0 conj drug0 nmod *interactions* nmod drug0" } 4 : { 1 : "Similarly , the effects of drug1 on drug2 , drug3 and sodium plasma drug4 concentrations are unpredictable " 2 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " 3 : "Possible drug interactions of drug1 with drug2 or with other drug3 . " 4 : "There have been reports of interactions of drug1 with drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , and drug14 . " } 5 : { 1 : 1 2 : 3 3 : 1 4 : 12 } } 26 : { 1 : "NN nmod NN dobj VB nsubj NN conj NN" 2 : 16 3 : { 1 : "drug0 nmod effect dobj *reduce* nsubj drug0 conj drug0" 2 : "drug0 nmod effect dobj *reduce* nsubj drug0 conj drug0" 3 : "drug0 nmod activity dobj *inhibit* nsubj drug0 conj drug0" 4 : "drug0 nmod action dobj *enhance* nsubj drug0 conj drug0" 5 : "drug0 nmod effect dobj *potentiate* nsubj drug0 conj drug0" 6 : "drug0 nmod effect dobj *increase* nsubj drug0 conj drug0" 7 : "drug0 nmod absorption dobj *reduce* nsubj drug0 conj drug0" 8 : "drug0 nmod absorption dobj *impair* nsubj milk conj drug0" 9 : "drug0 nmod action dobj *counteract* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and other drug2 can reduce the antihypertensive effect of drug3 and other drug4 . " 2 : "drug1 and drug2 may reduce or reverse the pressor effect of drug3 . " 3 : "drug1 : drug2 and other drug3 can inhibit the activity of drug4 . " 4 : "When drug1 or drug2 is used at the same time as other medicines or substances the following interactions must be taken into account : - drug3 and drug4 may enhance the action of drug5 . " 5 : "drug1 , drug2 , drug3 salts , and drug4 may either potentiate or weaken the blood-glucose-lowering effect of drug5 . " 6 : "drug1 , drug2 , and drug3 may increase anticholinergic effect of drug4 . " 7 : "drug1 and drug2 : drug3 and drug4 can reduce absorption of drug5 ; " 8 : "Milk , milk products , and drug1 - rich foods or drugs may impair the absorption of drug2 . " 9 : "Drugs Decreasing drug1 Effect : drug2 , drug3 , drug4 , or drug5 may partially counteract the anticoagulant action of drug6 . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 5 : 4 6 : 2 7 : 1 8 : 1 9 : 3 } } 27 : { 1 : "NN nmod VB nsubj NN" 2 : 16 3 : { 1 : "drug0 nmod *react* nsubj drug0" 2 : "drug0 nmod *interact* nsubj drug0" 3 : "drug0 nmod *add* nsubj drug0" 4 : "drug0 nmod *interact* nsubj drug0" 5 : "drug0 nmod *interact* nsubj drug0" 6 : "drug0 nmod *interact* nsubj drug0" 7 : "drug0 nmod *interact* nsubj drug0" 8 : "drug0 nmod *interact* nsubj drug0" 9 : "drug0 nmod *diminish* nsubj drug0" 10 : "drug0 nmod *interfere* nsubj drug0" } 4 : { 1 : "In rats , simultaneous ingestion of drug1 and drug2 in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that drug3 may react with drug4 in the rat stomach to form a nitrosamine , which is tumorigenic . " 2 : "drug1 can interact with drug2 or other drug3 ( may potentiate the CNS depressant effects of either these medications or drug4 ) , drug5 or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with drug6 ) , and drug7 ( concurrent use with drug8 may prolong and intensify the anticholinergic and CNS depressant effects of drug9 ) . " 3 : "drug1 add some further antihypertensive effect to drug2 , but the overall response is less than additive . " 4 : "Since drug1 ( drug2 ) may interact with concurrently administered drug3 , periodic serum level determinations of these drugs may be necessary ( eg , drug4 may elevate drug5 serum levels and drug6 has been reported to both increase and decrease drug7 levels ) . " 5 : "drug1 may interact with drug2 , drug3 s , drug4 ( allergy , cold , and sinus medicines ) , diabetic drugs , drug5 , drug6 , drug7 like drug8 or drug9 , and high blood pressure medications . " 6 : "drug1 may interact with drug2 or other drug3 , causing increased sedative effects . " 7 : "drug1 can interact with drug2 , increasing the metabolism of drug3 . " 8 : "drug1 may interact with drug2 , drug3 , and certain other agents . " 9 : "drug1 : drug2 may diminish adrenal suppression by drug3 . " 10 : "conversely , drug1 may interfere with drug2 ( i.e. , drug3 , drug4 ) . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 28 : { 1 : "NN nmod VBN nsubjpass NN nmod NN" 2 : 16 3 : { 1 : "drug0 nmod *reduced* nsubjpass binding nmod drug0" 2 : "drug0 nmod *enhanced* nsubjpass toxicity nmod drug0" 3 : "drug0 nmod *blunted* nsubjpass effect nmod drug0" 4 : "drug0 nmod *augmented* nsubjpass effect nmod drug0" 5 : "drug0 nmod *potentiated* nsubjpass action nmod drug0" 6 : "drug0 nmod *enhanced* nsubjpass response nmod drug0" 7 : "drug0 nmod *inhibited* nsubjpass anorectic nmod drug0" 8 : "drug0 nmod *reported* nsubjpass potentiation nmod drug0" 9 : "drug0 nmod *increased* nsubjpass excretion nmod drug0" 10 : "drug0 nmod *enhanced* nsubjpass action nmod drug0" } 4 : { 1 : "drug1 , drug2 , drug3 , and drug4 The in vitro binding of drug5 to plasma proteins is only slightly reduced by drug6 ( 99.5 % control vs 99.3 % ) when drug7 plasma concentrations reach 5 to10 m g/mL . " 2 : "drug1 : Studies in animals demonstrate that the acute toxicity of drug2 is enhanced by the drug3 drug4 . " 3 : "As with other drug1 , the antihypertensive effect of drug2 may be blunted by the drug3 drug4 " 4 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . " 5 : "The action of drug1 is potentiated by drug2 . " 6 : "Response to drug1 may be enhanced by drug2 . " 7 : "drug1 : The anorectic and stimulatory effects of drug2 may be inhibited by drug3 . " 8 : "drug1 : drug2 is not recommended for use in patients who have received drug3 within 14 days because severe and unpredictable potentiation by drug4 has been reported with drug5 " 9 : "drug1 therapy : Urinary excretion of drug2 is increased , and efficacy is reduced , by drug3 used in drug4 therapy . " 10 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 29 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NNS acl:relcl VBN nmod NN dep NN conj NN" 2 : 15 3 : { 1 : "drug0 nmod coadministered advcl *have* nsubj coadministration nmod drugs acl:relcl metabolized nmod cyp0a0 dep drug0 conj drug0" } 4 : { 1 : "Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , and drug16 ) may have elevated plasma concentrations when coadministered with drug17 ; " } 5 : { 1 : 15 } } 30 : { 1 : "NN conj NN compound NN" 2 : 15 3 : { 1 : "drug0 conj *mg* compound drug0" 2 : "drug0 conj *infection* compound drug0" 3 : "drug0 conj *injection* compound drug0" 4 : "drug0 compound q.d. conj *drug0*" 5 : "drug0 compound therapy conj *drug0*" 6 : "drug0 compound g/kg conj *drug0*" 7 : "drug0 compound therapy conj *drug0*" 8 : "drug0 compound parenteral conj *drug0*" 9 : "drug0 compound therapy conj *drug0*" 10 : "drug0 conj *therapy* compound drug0" } 4 : { 1 : "Coadministration of drug1 30 mg and drug2 , a CYP2C19 substrate , resulted in a 45 % decrease in clearance of drug3 . " 2 : "Profound hypotensive episodes may occur when drug1 infection and drug2 are used concomitantly . " 3 : "drug1 injection and drug2 should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias . " 4 : "drug1 : When drug2 ( 100 mg qd ) and drug3 ( 1 mg q.d. were co-administered to steady state , plasma concentration and other pharmacokinetics parameters ( AUC , Cmax , T1/2 , ) of drug4 were approximately twice those observed when drug5 was administered alone ; " 5 : "drug1 : Increased serum drug2 levels and symptoms of drug3 toxicity have been reported in patients receiving concomitant drug4 and drug5 therapy . " 6 : "CNS-Active Drugs drug1 An additive effect on psychomotor performance was seen with coadministration of drug2 and drug3 0.70 g/kg for up to 4 hours after drug4 administration . " 7 : "An additive hypotensive effect has been reported with the combination of systemic drug1 and drug2 therapy . " 8 : "The concomitant use of drug1 and drug2 Parenteral should be avoided . " 9 : "In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug1 and drug2 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with drug3 alone ( 0 % ) . " 10 : "- In isolated cases , a pronounced though reversible , impairment of renal function ( accompanied by a corresponding increase in the serum creatinine level ) has been reported in organ transplant patients receiving drug1 therapy and concomitant drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 31 : { 1 : "NN nmod NN nmod NNS nmod NN" 2 : 14 3 : { 1 : "drug0 nmod action nmod *effects* nmod drug0" 2 : "drug0 nmod cations nmod *administration* nmod drug0" 3 : "drug0 nmod products nmod *drug0* nmod drug0" 4 : "drug0 nmod *use* nmod inhibitors nmod drug0" 5 : "drug0 nmod drugs nmod *co-administration* nmod drug0" 6 : "drug0 nmod patients nmod *administration* nmod drug0" 7 : "drug0 nmod *coadministration* nmod doses nmod drug0" 8 : "drug0 nmod doses nmod *administration* nmod drug0" 9 : "drug0 nmod dose nmod *doses* nmod drug0" 10 : "drug0 nmod drugs nmod *use* nmod drug0" } 4 : { 1 : "While the effects of chronic drug1 or drug2 therapy on the action of drug3 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . " 2 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " 3 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " 4 : "The concomitant use of other CYP3A4 inhibitors such as drug1 and drug2 with transdermal drug3 may also result in an increase in drug4 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression . " 5 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isoenzyme , including other drug2 , drug3 , drug4 , and drug5 ( eg , drug6 , drug7 , and drug8 ) , or that inhibit this enzyme ( eg , drug9 ) , should be approached with caution . " 6 : "Administration of drug1 to patients receiving drug2 or drug3 such as drug4 which sensitize the myocardium , may induce cardiac arrhythmia . . " 7 : "Coadministration of single , oral doses of drug1 with drug2 ( 10 mg and 800 mg , respectively ) , a strong , selective CYP3A4 inhibitor produced a 34 % increase in drug3 s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve . " 8 : "Concomitant single dose administration of drug1 20 mg with multiple doses of drug2 and drug3 produced a significant increase in exposure of drug4 . " 9 : "Repeated doses of drug1 given prior to a single dose of drug2 in human trials have been reported to decrease drug3 absorption . " 10 : "drug1 : Based on reports of profound hypotension and loss of consciousness when drug2 was administered with drug3 , the concomitant use of drug4 with drugs of the drug5 ( including , for example , drug6 , drug7 , drug8 , drug9 , and drug10 ) is contraindicated . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 32 : { 1 : "NN conj NN appos NN" 2 : 14 3 : { 1 : "drug0 conj *drug0* appos drug0" 2 : "drug0 appos drug0 conj *drug0*" 3 : "drug0 conj *drug0* appos drug0" 4 : "drug0 conj *drug0* appos drug0" 5 : "drug0 conj *drug0* appos drug0" 6 : "drug0 appos drug0 conj *drug0*" 7 : "drug0 conj *drug0* appos drug0" 8 : "drug0 conj *drug0* appos drug0" 9 : "drug0 appos drug0 conj *drug0*" 10 : "drug0 appos drug0 conj *drug0*" } 4 : { 1 : "Synergism between drug1 ( e.g. , drug2 ) , drug3 , and other drug4 has been reported . " 2 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " 3 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " 4 : "drug1 ( drug2 ) and drug3 may interfere with the effect of each other when administered concurrently . " 5 : "drug1 ( drug2 ) : Concomitant use of drug3 ( or other drug4 ) and drug5 increases the risk of gastrointestinal side effects . " 6 : "drug1 and drug2 ( drug3 ) Injection , USP should not be taken within 24 hours of each other . . " 7 : "There is one report suggesting that the concomitant use of drug1 ( drug2 ) and drug3 may have caused 3 - to 6-fold elevations on SGPT ( ALT ) in a few patients . " 8 : "drug1 : Concurrent administration of drug2 ( an drug3 ) and another drug4 has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . " 9 : "The concurrent use of drug1 and drug2 ( drug3 ) has been reported to result in fatal renal toxicity . " 10 : "Avoid the concomitant use of drug1 and drug2 ( drug3 ) . " } 5 : { 1 : 1 2 : 2 3 : 2 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 33 : { 1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 13 3 : { 1 : "drug0 dobj taking acl patients nmod *used* nsubjpass drug0" 2 : "drug0 dobj receiving acl patients nmod *given* nsubjpass drug0" 3 : "drug0 dobj taking acl patients nmod *used* nsubjpass drug0" 4 : "drug0 dobj receiving acl patients nmod *introduced* nsubjpass drug0" 5 : "drug0 dobj receiving acl patients nmod *used* nsubjpass drug0" 6 : "drug0 dobj taking acl patients nmod *used* nsubjpass drug0" 7 : "drug0 dobj receiving acl patients nmod *started* nsubjpass drug0" 8 : "drug0 dobj taking acl patients nmod *administered* nsubjpass drug0" 9 : "drug0 dobj receiving acl patients nmod *avoided* nsubjpass drug0" 10 : "drug0 dobj receiving acl patients nmod *given* nsubjpass drug0" } 4 : { 1 : "drug1 : Hallucinations have been reported when drug2 was used in patients taking drug3 ( drug4 , drug5 , drug6 ) . " 2 : "When drug1 is given to patients receiving drug2 , the plasma levels of drug3 are likely to be increased . " 3 : "Other drug1 should be used with caution in patients taking drug2 , since the effects may be additive . " 4 : "drug1 should be introduced at the lowest recommended dose in patients receiving drug2 . " 5 : "drug1 should not be used in patients receiving drug2 . . " 6 : "All drug1 should be used cautiously in patients taking drug2 . " 7 : "It is recommended that if drug1 is started in patients already receiving drug2 , prothrombin times should be closely monitored and adjustment of the drug3 dose may be necessary . " 8 : "drug1 should be administered with caution to patients taking drug2 , because of the possibility of conduction disturbances . " 9 : "Consequently , drug1 should be avoided in patients receiving drug2 and drug3 , which are very potent inhibitors of CYP3A . " 10 : "When drug1 are given to patients receiving drug2 , hypertensive reactions , including hypertensive crises , may occur . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 34 : { 1 : "NN dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 12 3 : { 1 : "drug0 dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 12 } } 35 : { 1 : "NN conj NN dep NNS nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 12 3 : { 1 : "drug0 conj drug0 dep drugs nmod metabolism nmod interact xcomp *known* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 is known to interact with the metabolism or renal tubular excretion of many drugs ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 agents , drug15 , and drug16 ) . " } 5 : { 1 : 12 } } 36 : { 1 : "NN nmod NNS dobj VB nsubj NN nmod NN" 2 : 12 3 : { 1 : "drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 2 : "drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 3 : "drug0 nmod effects dobj *potentiate* nsubj administration nmod drug0" 4 : "drug0 nmod levels dobj *reduce* nsubj administration nmod drug0" 5 : "drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 6 : "drug0 nmod effects dobj *enhance* nsubj drug0 nmod drug0" 7 : "drug0 nmod effects dobj *reduce* nsubj coadministration nmod drug0" 8 : "drug0 nmod concentrations dobj *increase* nsubj ingestion nmod drug0" 9 : "drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 10 : "drug0 nmod effects dobj *enhance* nsubj drug0 nmod drug0" } 4 : { 1 : "- drug1 : In some patients , the administration of a drug2 can reduce the diuretic , natriuretic , and antihypertensive effects of drug3 , drug4 and drug5 . " 2 : "In some patients , the administration of drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 , and drug4 . " 3 : "Concomitant administration of other drug1 may potentiate the undesirable effects of drug2 . " 4 : "drug1 : Concomitant administration of drug2 may reduce plasma levels of drug3 . " 5 : "drug1 : In some patients , the administration of a drug2 can reduce the diuretic , natriuretic , and antihypertensive effects of drug3 , drug4 and drug5 . " 6 : "drug1 , including drug2 , may enhance the effects of oral drug3 , including drug4 or its derivatives or similar agents . " 7 : "Literature reports indicate that coadministration of drug1 may reduce the natriuretic and antihypertensive effects of drug2 in some patients by inhibiting prostaglandin synthesis . " 8 : "Ingestion of drug1 may increase serum concentrations of drug2 and drug3 and increase drug4 s nephrotoxicity . " 9 : "In some patients , the administration of a drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 and drug4 . " 10 : "drug1 , including drug2 , may enhance the effects of the oral drug3 drug4 or its derivatives . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 2 10 : 1 } } 37 : { 1 : "NN conj NN dobj VBD acl:relcl NNS nmod VBN nsubjpass NN nmod NN" 2 : 12 3 : { 1 : "drug0 conj drug0 dobj bound acl:relcl drugs nmod *potentiated* nsubjpass action nmod drug0" } 4 : { 1 : "The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 and other drugs that are highly protein bound , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , and drug9 . " } 5 : { 1 : 12 } } 38 : { 1 : "NN conj NN nmod NNS nmod NN nmod NN" 2 : 12 3 : { 1 : "drug0 conj drug0 nmod cations nmod *administration* nmod drug0" 2 : "drug0 conj drug0 nmod products nmod *drug0* nmod drug0" 3 : "drug0 nmod *use* nmod inhibitors nmod drug0 conj drug0" 4 : "drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" 5 : "drug0 conj drug0 nmod doses nmod *administration* nmod drug0" 6 : "drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " 2 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " 3 : "The concomitant use of other CYP3A4 inhibitors such as drug1 and drug2 with transdermal drug3 may also result in an increase in drug4 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression . " 4 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isoenzyme , including other drug2 , drug3 , drug4 , and drug5 ( eg , drug6 , drug7 , and drug8 ) , or that inhibit this enzyme ( eg , drug9 ) , should be approached with caution . " 5 : "Concomitant single dose administration of drug1 20 mg with multiple doses of drug2 and drug3 produced a significant increase in exposure of drug4 . " 6 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isozyme , including drug2 , drug3 , drug4 , and drug5 ( e.g. , drug6 , drug7 and drug8 ) , or that inhibit this enzyme ( e.g. , drug9 ) , should be approached with caution . " } 5 : { 1 : 1 2 : 3 3 : 1 4 : 3 5 : 1 6 : 3 } } 39 : { 1 : "NN conj NN nmod NNS nmod VBD nsubj NN" 2 : 12 3 : { 1 : "drug0 conj drug0 nmod pharmacokinetics nmod *had* nsubj drug0" } 4 : { 1 : "When used in therapeutic doses , drug1 had a modest effect on the pharmacokinetics of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( intravenous and oral ) , drug13 , drug14 / drug15 or drug16 . " } 5 : { 1 : 12 } } 40 : { 1 : "NN nmod NN dobj VB nsubj NN nmod NN" 2 : 11 3 : { 1 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0 nmod drug0" 2 : "drug0 nmod activity dobj *antagonize* nsubj drug0 nmod drug0" 3 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0" 4 : "drug0 nmod response dobj *decrease* nsubj ingestion nmod drug0" 5 : "drug0 nmod secretion dobj *inhibit* nsubj drug0 nmod drug0" 6 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0" 7 : "drug0 nmod effect dobj *antagonize* nsubj use nmod drug0" 8 : "drug0 nmod clearance dobj *decrease* nsubj drug0 nmod drug0" 9 : "drug0 nmod efficacy dobj *reduce* nsubj use nmod drug0" 10 : "drug0 nmod effect dobj *enhance* nsubj drug0 nmod drug0" } 4 : { 1 : "drug1 drug2 drug3 , like other drug4 , may inhibit the metabolism of drug5 and drug6 . " 2 : "Additionally , drug1 , such as drug2 and drug3 , may antagonize the activity of drug4 . " 3 : "drug1 , drug2 and drug3 : Concomitant treatment with drug4 , drug5 , or drug6 may potentiate a possible hypokalemic effect of drug7 " 4 : "drug1 - prior ingestion of drug2 may decrease the drug3 response to drug4 in the treatment of poisoning . " 5 : "drug1 , such as drug2 and drug3 , can inhibit renal tubular secretion of drug4 . " 6 : "Concomitant treatment with drug1 ( drug2 , drug3 ) , drug4 , or drug5 may potentiate any hypokalemic effect of drug6 . " 7 : "Concurrent use of drug1 may antagonize the anorectic effect of drug2 . " 8 : "drug1 : drug2 , including drug3 , decrease the clearance of drug4 , the less active isomer of racemic drug5 . " 9 : "- Concomitant use of drug1 may reduce the efficacy of drug2 . " 10 : "When taken orally , drug1 like drug2 may enhance the anticoagulant effect of drug3 - like drugs . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 41 : { 1 : "NN conj NN nmod NNS dobj VB nsubj NN nmod NN" 2 : 11 3 : { 1 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 2 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 3 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" 4 : "drug0 conj drug0 nmod concentrations dobj *increase* nsubj ingestion nmod drug0" 5 : "drug0 conj drug0 nmod effects dobj *reduce* nsubj administration nmod drug0" } 4 : { 1 : "- drug1 : In some patients , the administration of a drug2 can reduce the diuretic , natriuretic , and antihypertensive effects of drug3 , drug4 and drug5 . " 2 : "In some patients , the administration of drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 , and drug4 . " 3 : "drug1 : In some patients , the administration of a drug2 can reduce the diuretic , natriuretic , and antihypertensive effects of drug3 , drug4 and drug5 . " 4 : "Ingestion of drug1 may increase serum concentrations of drug2 and drug3 and increase drug4 s nephrotoxicity . " 5 : "In some patients , the administration of a drug1 can reduce the diuretic , natriuretic , and antihypertensive effects of drug2 , drug3 and drug4 . " } 5 : { 1 : 2 2 : 2 3 : 2 4 : 1 5 : 4 } } 42 : { 1 : "NN conj NN dep VBP nsubj NNS acl:relcl VBN nmod NN" 2 : 11 3 : { 1 : "drug0 conj drug0 dep *include* nsubj drugs acl:relcl impaired nmod drug0" } 4 : { 1 : "- Drugs whose efficacy is impaired by drug1 include : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , oral drug9 , drug10 , drug11 , drug12 , drug13 . " } 5 : { 1 : 11 } } 43 : { 1 : "NN conj NN nmod NN" 2 : 11 3 : { 1 : "drug0 conj *administration* nmod drug0" 2 : "drug0 conj *administration* nmod drug0" 3 : "drug0 conj *coadministration* nmod drug0" 4 : "drug0 conj drug0 nmod *drug0*" 5 : "drug0 conj *administration* nmod drug0" 6 : "drug0 conj *drug0* nmod drug0" 7 : "drug0 conj *discontinuation* nmod drug0" 8 : "drug0 conj drug0 nmod *drug0*" 9 : "drug0 conj *administration* nmod drug0" 10 : "drug0 conj *use* nmod drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 and some drug3 has been reported to reduce the clearance of drug4 , enhancing the toxicity of drug5 . " 2 : "Concurrent administration of drug1 ( for the treatment of hypotension related to obstetric blocks ) and drug2 may cause severe , persistent hypertension or cerebrovascular accidents . " 3 : "Oral drug1 : Coadministration of drug2 and an oral drug3 increased AUC values for drug4 and drug5 by approximately 30 % and 20 % . " 4 : "drug1 with drug2 or drug3 and possibly other drug4 cause striking and sustained increases in the concentration of drug5 in the brain ; " 5 : "The effect of concomitant administration of drug1 and drug2 has been demonstrated in a placebo-controlled crossover study in normal volunteers . " 6 : "Because prostaglandins play an important role in hemostasis , and drug1 affect platelet function as well , concurrent therapy with all drug2 , including drug3 , and drug4 requires close monitoring of patients to be certain that no change in their drug5 dosage is required . " 7 : "drug1 toxicity was usually reversible upon discontinuation of drug2 and the drug3 . " 8 : "drug1 : Since drug2 is a drug3 , it is possible that drug4 , such as the drug5 ( drug6 , drug7 , drug8 ) or drug9 , may diminish the effectiveness of drug10 . " 9 : "drug1 : Concomitant administration of drug2 and drug3 has been reported to result in elevated drug4 serum levels . " 10 : "drug1 : Concurrent use of drug2 and drug3 or drug4 has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 2 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 44 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 11 3 : { 1 : "drug0 nmod administration nmod *inhibited* nsubjpass transport nmod drug0" 2 : "drug0 nmod coadministration nmod *increased* nsubjpass auc nmod drug0" 3 : "drug0 nmod therapy nmod *prolonged* nsubjpass action nmod drug0" 4 : "drug0 nmod dose nsubjpass *reduced* nmod administration nmod drug0" 5 : "drug0 nmod auc nsubjpass *lowered* nmod co-administration nmod drug0" 6 : "drug0 nmod addition nmod *enhanced* nsubjpass action nmod drug0" 7 : "drug0 nmod use nmod *increased* nsubjpass clearance nmod drug0" 8 : "drug0 nmod administration nmod *increased* nsubjpass exposure nmod drug0" 9 : "drug0 nmod coadministration nmod *reduced* nsubjpass bioavailability nmod drug0" 10 : "drug0 nmod presence nmod *reported* nsubjpass suppression nmod drug0" } 4 : { 1 : "drug1 Renal tubular transport of drug2 may be inhibited by concomitant administration of drug3 , potentially leading to increased plasma levels of drug4 . " 2 : "The AUC of drug1 was increased 2.2-fold by coadministration of drug2 , a potent inhibitor of CYP3A4 , 400 mg daily for 5 days . " 3 : "Since animal studies suggest that the action of drug1 may be prolonged by therapy with drug2 , drug3 should be employed with caution . " 4 : "Following the administration of drug1 , the dose of other drug2 should be reduced . " 5 : "drug1 s : After repeated co-administration of drug2 , the AUC of drug3 was lowered by 28 % [ 90 % CI : 20-33 ] . " 6 : "It is possible that the cardiovascular action of other drug1 could be enhanced by the addition of drug2 . " 7 : "The clearance of drug1 may be increased with concurrent use of drug2 . " 8 : "Plasma exposure of drug1 ( 10 mg BID ) was increased by 28 % following administration of drug2 ( 40 mg BID ) for 12 days , while plasma exposure of drug3 ( 40 mg BID ) was not substantially increased following administration of drug4 ( 10 mg BID ) for 12 days . " 9 : "The oral bioavailability of drug1 is reduced by 60 % with coadministration of drug2 . " 10 : "drug1 : Enhanced bone marrow suppression by drug2 and other drug3 has been reported among patients with neoplastic disease , except leukemia , in the presence of drug4 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 45 : { 1 : "NN conj NNS compound NN" 2 : 10 3 : { 1 : "drug0 conj *supplements* compound drug0" 2 : "drug0 conj *tablets* compound drug0" 3 : "drug0 compound tablets conj *drug0*" 4 : "drug0 conj *tablets* compound drug0" 5 : "drug0 compound tablets conj *drug0*" 6 : "drug0 conj *s* compound drug0" 7 : "drug0 conj *supplements* compound drug0" 8 : "drug0 compound s conj *drug0*" 9 : "drug0 conj *analogues* compound drug0" 10 : "drug0 conj *capsules* compound drug0" } 4 : { 1 : "Interactions may occur between drug1 supplements and drug2 and other drug3 and herbs such as garlic ( Allium sativum ) and drug4 ( drug5 ) . " 2 : "drug1 : The co-administration of drug2 Tablets and drug3 is generally not advisable . " 3 : "Thus patients receiving oral drug1 and drug2 Tablets should have their prothrombin time monitored and their drug3 dose adjusted accordingly . " 4 : "The concomitant use of drug1 tablets and other drug2 is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy . " 5 : "Tablets Simultaneous administration of drug1 and drug2 tablets may reduce the natriuretic and antihypertensive effects of drug3 . " 6 : "The concomitant use of drug1 s , vasoconstricting agents ( such as drug2 ) and some drug3 may result in severe hypertension . " 7 : "Concomitant use of drug1 supplements and drug2 may increase drug3 absorption " 8 : "A two-way interaction between the drug1 , drug2 , and the drug3 s has been suggested . " 9 : "drug1 : A relationship of functional antagonism exists between drug2 analogues , which promote calcium absorption , and drug3 , which inhibit calcium absorption . " 10 : "Concomitant administration of drug1 capsules and drug2 resulted in substantial increases in plasma concentrations of drug3 , probably at least partially related to cytochrome P450 3A4 inhibition by drug4 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 46 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN" 2 : 10 3 : { 1 : "drug0 nmod *potentiated* nsubjpass effects nmod drug0" 2 : "drug0 nmod *enhanced* nsubjpass effects nmod drug0" 3 : "drug0 nmod *antagonized* nsubjpass effects nmod drug0" 4 : "drug0 nmod *inhibited* nsubjpass effects nmod drug0" 5 : "drug0 nmod *antagonized* nsubjpass effects nmod drug0" 6 : "drug0 nmod *potentiated* nsubjpass actions nmod drug0" 7 : "drug0 nmod *increased* nsubjpass effects nmod drug0" 8 : "drug0 nmod *reduced* nsubjpass effects nmod drug0" 9 : "drug0 nmod *enhanced* nsubjpass effects nmod drug0" 10 : "drug0 nmod *antagonized* nsubjpass effects nmod drug0" } 4 : { 1 : "The effects of drug1 may be potentiated by drug2 which inhibits the metabolism of drug3 . " 2 : "The pressor effects of drug1 such as drug2 or drug3 are enhanced by drug4 . " 3 : "The effects of drug1 are antagonized by drug2 such as drug3 and drug4 . " 4 : "drug1 : The stimulatory effects of drug2 may be inhibited by drug3 . " 5 : "Cardiac effects of drug1 are antagonized by drug2 , such as drug3 and drug4 . " 6 : "The actions of the drug1 may be potentiated by drug2 , drug3 , drug4 , drug5 or other drug6 . " 7 : "Effects of drug1 are increased with drug2 and drug3 . " 8 : "The antihypertensive effects of drug1 , drug2 , drug3 , and drug4 may be reduced by drug5 . " 9 : "The CNS effects of drug1 may be enhanced by drug2 . " 10 : "In monkeys , the effects of drug1 , but not drug2 or drug3 , were antagonized by drug4 ; " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 47 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS acl VBN xcomp VB dobj NN nmod NN conj NN" 2 : 10 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass substrates acl known xcomp have dobj index nmod drug0 conj drug0" } 4 : { 1 : "Therefore , CYP3A4 substrates known to have a narrow therapeutic index such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , or drug11 ( drug12 , drug13 ) should be administered with caution in patients receiving drug14 . " } 5 : { 1 : 10 } } 48 : { 1 : "NN nmod NN nmod NN compound NN" 2 : 10 3 : { 1 : "drug0 nmod use nmod *anesthesia* compound drug0" 2 : "drug0 compound drug0 nmod *administration* nmod drug0" 3 : "drug0 nmod *inhibition* nmod metabolism compound drug0" 4 : "drug0 compound mg nmod *co-administration* nmod drug0" 5 : "drug0 nmod therapy nmod *use* compound drug0" 6 : "drug0 compound coadministration nmod *adjustment* nmod drug0" 7 : "drug0 compound natriuresis nmod *effect* nmod drug0" 8 : "drug0 nmod *use* nmod injection compound drug0" 9 : "drug0 nmod *reduction* nmod cytotoxicity compound drug0" 10 : "drug0 compound requirement nmod *effect* nmod drug0" } 4 : { 1 : "drug1 Anesthesia : Severe hypotension has been reported during drug2 anesthesia with concomitant use of a drug3 and a drug4 . " 2 : "drug1 : The concomitant administration of drug2 with the drug3 drug4 has , on rare occasions , resulted in severe hypoglycemia . " 3 : "This increase is due to the inhibition of drug1 metabolism via P450 2C9 by drug2 ( see CLINICAL PHARMACOLOGY - Pharmacokinetics : Metabolism ) . " 4 : "drug1 : Co-administration of drug2 with drug3 600 mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in drug4 plasma concentrations . " 5 : "It would be expected that drug1 use during therapy with drug2 would worsen the incidence or severity of diarrhea , but this has not been studied . " 6 : "Because changes in glucose concentrations with drug1 coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL , dose adjustment for drug2 ( 5 mg QD and 10 mg BID ) with drug3 coadministration ( up to 40 mg QD ) is not indicated . " 7 : "This antagonistic effect of drug1 on drug2 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drug3 . " 8 : "The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity , such as drug3 , drug4 , or drug5 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects . " 9 : "We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral drug1 cytotoxicity by drug2 . " 10 : "The effect of drug1 on the drug2 requirement of our patient appeared to be maximal 5 to 7 days after the initiation of drug3 and extended a similar length of time after drug4 withdrawal . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 49 : { 1 : "NN compound NNS nmod NN nmod NN" 2 : 10 3 : { 1 : "drug0 compound tablets nmod *coadministration* nmod drug0" 2 : "drug0 compound preparations nmod *use* nmod drug0" 3 : "drug0 nmod *coadministration* nmod capsules compound drug0" 4 : "drug0 compound tablets nmod *coadministration* nmod drug0" 5 : "drug0 nmod *administration* nmod tablets compound drug0" 6 : "drug0 nmod *coadministration* nmod tablets compound drug0" 7 : "drug0 nmod *administration* nmod tablets compound drug0" 8 : "drug0 compound tablets nmod *administration* nmod drug0" 9 : "drug0 compound capsules nmod *administration* nmod drug0" 10 : "drug0 compound solutions nmod *ethanolysis* nmod drug0" } 4 : { 1 : "Coadministration of drug1 with 40 mg drug2 tablets in epileptic patients lowered the drug3 plasma concentrations to undetectable levels . " 2 : "The use of drug1 or drug2 with drug3 preparations may increase the effect of either the drug4 or drug5 . " 3 : "drug1 : Coadministration ( N = 18 ) of drug2 capsules ( 250 mg ) with drug3 ( 125 mg ) appears to increase the amount of drug4 absorbed by 12 % to 15 % . " 4 : "Coadministration of drug1 with drug2 tablets is therefore contraindicated . " 5 : "Therefore concomitant administration of drug1 tablets with drug2 is contraindicated . " 6 : "Coadministration of drug1 Tablets with drug2 or drug3 has resulted in elevated plasma concentrations of the latter two drugs . " 7 : "Concomitant administration of drug1 tablets with drug2 may alter the metabolism of one or both of the drugs . " 8 : "Concomitant administration of drug1 with drug2 tablets reduces the blood levels of the latter . " 9 : "Concomitant administration of drug1 with drug2 capsules is not recommended . " 10 : "Acid-catalyzed ethanolysis of drug1 in anhydrous and aqueous drug2 solutions . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 50 : { 1 : "NN conj NN dep NN dobj VBP acl:relcl NN nmod NN" 2 : 10 3 : { 1 : "drug0 conj drug0 dep isoenzyme dobj affect acl:relcl *interaction* nmod drug0" 2 : "drug0 conj drug0 dep cyp0a0 dobj inhibit acl:relcl *use* nmod drug0" } 4 : { 1 : "Therefore , the potential exists for a drug interaction between drug1 and drugs that affect the CYP2B6 isoenzyme ( e.g. , drug2 and drug3 ) . " 2 : "Concomitant use of drug1 and drugs that inhibit CYP3A4 ( eg , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ) may increase exposure to drug13 and should be avoided . " } 5 : { 1 : 1 2 : 9 } } 51 : { 1 : "NN dobj VBG acl NNS nmod NN nmod NN" 2 : 10 3 : { 1 : "drug0 dobj taking acl patients nmod *administration* nmod drug0" 2 : "drug0 dobj receiving acl volunteers nmod *administration* nmod drug0" 3 : "drug0 dobj receiving acl patients nmod *use* nmod drug0" 4 : "drug0 dobj receiving acl patients nmod *administration* nmod drug0" 5 : "drug0 dobj receiving acl patients nmod *administration* nmod drug0" 6 : "drug0 dobj receiving acl patients nmod *therapy* nmod drug0" 7 : "drug0 dobj receiving acl patients nmod *use* nmod drug0" 8 : "drug0 nmod combination nmod *patients* acl receiving dobj drug0" 9 : "drug0 dobj containing acl products nmod *administration* nmod drug0" 10 : "drug0 dobj taking acl patients nmod *use* nmod drug0" } 4 : { 1 : "Although these results do not indicate a significant interaction between drug1 and drug2 or drug3 , the administration of drug4 to patients taking drug5 should be done extremely cautiously , and patients should be closely monitored . " 2 : "drug1 : The administration of drug2 to normal volunteers receiving drug3 decreased the renal clearance and significantly increased the plasma levels of drug4 . " 3 : "The use of drug1 in patients receiving drug2 may be rarely associated with ventricular fibrillation . " 4 : "Administration of drug1 to patients receiving drug2 or drug3 such as drug4 which sensitize the myocardium , may induce cardiac arrhythmia . . " 5 : "Administration of drug1 to patients receiving drug2 has been reported to lead to hypotension and bradycardia . " 6 : "drug1 serum concentrations should be monitored closely when initiating or changing therapy with drug2 in patients receiving drug3 . " 7 : "Experience with co-administration of drug1 and drug2 in patients is limited , therefore , consideration should be given to temporarily suspending use of drug3 in patients receiving drug4 . " 8 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " 9 : "Also , concomitant administration of drug1 with products containing drug2 , drug3 containing drug4 , or drug5 ( drug6 ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels . " 10 : "drug1 - Although drug2 did not potentiate the cognitive and motor effects of drug3 in a clinical trial , as with other drug4 , the use of drug5 by patients taking drug6 is not recommended . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 52 : { 1 : "NN nmod NNS dobj VB xcomp VBN nsubjpass NN" 2 : 10 3 : { 1 : "drug0 nmod effects dobj enhance xcomp *reported* nsubjpass drug0" 2 : "drug0 nmod effects dobj enhance xcomp *reported* nsubjpass drug0" 3 : "drug0 nmod concentrations dobj raise xcomp *found* nsubjpass drug0" 4 : "drug0 nmod effects dobj block xcomp *reported* nsubjpass drug0" 5 : "drug0 nmod concentrations dobj reduce xcomp *expected* nsubjpass drug0" 6 : "drug0 nmod concentrations dobj reduce xcomp *expected* nsubjpass drug0" 7 : "drug0 nmod effects dobj enhance xcomp *reported* nsubjpass drug0" 8 : "drug0 nmod levels dobj decrease xcomp *shown* nsubjpass drug0" 9 : "drug0 nmod levels dobj increase xcomp *shown* nsubjpass drug0" 10 : "drug0 nmod levels dobj increase xcomp *reported* nsubjpass drug0" } 4 : { 1 : "However , because some drug1 have been reported to enhance the effects of drug2 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drug3 is administered with drug4 or its derivatives . " 2 : "drug1 : drug2 have been reported to enhance the effects of the oral drug3 drug4 or its derivatives . " 3 : "drug1 has been found to temporarily raise serum concentrations of drug2 . " 4 : "Several drug1 have been reported to block the pharmacologic effects of drug2 , drug3 , or similar agents , and such an effect may be anticipated with drug4 because of its structural similarity to other drug5 . " 5 : "drug1 is also expected to reduce plasma concentrations of other oral drug2 that are predominantly metabolized by CYP2C9 or CYP3A4 . " 6 : "drug1 is also expected to reduce plasma concentrations of other drug2 that have significant metabolism by CYP3A4 , such as drug3 and drug4 . " 7 : "However , because some drug1 have been reported to enhance the anticoagulant effects of drug2 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a drug3 is administered concomitantly with drug4 or its derivatives . " 8 : "drug1 : drug2 , drug3 , drug4 , and drug5 have been shown to decrease plasma levels of drug6 ; " 9 : "drug1 has been shown to increase plasma levels of drug2 . " 10 : "drug1 : drug2 has been reported to increase the plasma levels and cardiovascular effects of drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 9 : 1 10 : 1 } } 53 : { 1 : "NN conj NN dep NN nmod NN" 2 : 10 3 : { 1 : "drug0 conj drug0 dep *administration* nmod drug0" 2 : "drug0 conj drug0 dep drug0 nmod *drug0*" 3 : "drug0 conj drug0 dep *interaction* nmod drug0" 4 : "drug0 conj drug0 dep *administration* nmod drug0" } 4 : { 1 : "Drugs that Lower Seizure Threshold : Concurrent administration of drug1 and agents ( e.g. , drug2 , other drug3 , drug4 , systemic drug5 , etc. ) that lower seizure threshold should be undertaken only with extreme caution . " 2 : "In vitro mixing of an drug1 with beta-lactamtype drug2 ( drug3 or drug4 ) may result in a significant mutual inactivation . " 3 : "Data from in vitro studies of drug1 suggest a possible drug interaction with drug2 for the following : drug3 and drug4 . " 4 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [ e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . " } 5 : { 1 : 3 2 : 1 3 : 1 4 : 5 } } 54 : { 1 : "NN nmod NN dobj VBP nsubj NN" 2 : 10 3 : { 1 : "drug0 nmod effect dobj *enhance* nsubj drug0" 2 : "drug0 nmod effect dobj *inhibit* nsubj drug0" 3 : "drug0 nmod toxicity dobj *enhance* nsubj drug0" 4 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0" 5 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0" 6 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0" 7 : "drug0 nmod ed0 dobj *decrease* nsubj drug0" 8 : "drug0 nmod half-life dobj *decrease* nsubj drug0" } 4 : { 1 : "drug1 : drug2 enhance the adrenergic effect of drug3 . " 2 : "drug1 : drug2 inhibit the hypotensive effect of drug3 . " 3 : "drug1 enhance the renal toxicity of drug2 in animals . 7 drug3 interferes with the action of drug4 preparations by chelating the drug5 . 7 " 4 : "drug1 : In vitro and/or in vivo data show that drug2 , drug3 , and drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . " 5 : "drug1 : In vitro and/or in vivo data indicate that drug2 , drug3 , and oral drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . " 6 : "drug1 : In vitro data indicate that drug2 and drug3 markedly inhibit the metabolism of drug4 which can result in an increase in plasma drug5 levels and prolongation of the QT interval on the ECG . " 7 : "drug1 , drug2 , and drug3 decrease the ED50 of drug4 by 30 % to 45 % . " 8 : "drug1 , drug2 , and drug3 decrease the half-life of drug4 . " } 5 : { 1 : 2 2 : 2 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 } } 55 : { 1 : "NN conj NN nmod NN dobj VBZ nsubj NN" 2 : 10 3 : { 1 : "drug0 conj drug0 nmod absorption dobj *inhibits* nsubj drug0" 2 : "drug0 conj drug0 nmod time dobj *prolongs* nsubj drug0" 3 : "drug0 conj drug0 nmod effect dobj *diminishes* nsubj drug0" 4 : "drug0 conj drug0 nmod drug0 dobj *potentiates* nsubj drug0" 5 : "drug0 conj drug0 nmod oxidation dobj *inhibits* nsubj drug0" 6 : "drug0 conj drug0 nmod auc dobj *increases* nsubj drug0" 7 : "drug0 conj drug0 nmod clearance dobj *decreases* nsubj drug0" } 4 : { 1 : "Oral drug1 inhibits the gastrointestinal absorption of drug2 , oral drug3 , drug4 and drug5 . " 2 : "Animal experience indicates that drug1 prolongs the sleeping time after drug2 or after drug3 , increases the inhibitory effects of drug4 , but does not exhibit monoamine oxidase inhibition . " 3 : "drug1 diminishes the effect of drug2 and drug3 . " 4 : "drug1 potentiates other drug2 such as drug3 or drug4 and drug5 s. " 5 : "drug1 / drug2 : drug3 inhibits the enzymatic oxidation of drug4 and drug5 to drug6 . " 6 : "drug1 : drug2 increases the AUC for drug3 and drug4 . " 7 : "drug1 significantly decreases clearance of drug2 and drug3 , and the combination is poorly tolerated . " } 5 : { 1 : 3 2 : 1 3 : 1 4 : 2 5 : 1 6 : 1 7 : 1 } } 56 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NN conj NN" 2 : 9 3 : { 1 : "drug0 nmod *coadministered* nsubjpass inhibitors nmod isoenzyme dep drug0 conj drug0" } 4 : { 1 : "Inhibitors of this isoenzyme ( e.g. , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , grapefruit juice , drug8 , drug9 , drug10 , drug11 ) should be cautiously coadministered with drug12 as they can potentially increase drug13 levels . " } 5 : { 1 : 9 } } 57 : { 1 : "NN conj NN nmod NN dobj VB xcomp VBN parataxis NN nsubj NN" 2 : 9 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj reduce xcomp reported parataxis *effect* nsubj drug0" } 4 : { 1 : "drug1 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , certain drug8 , drug9 , drug10 and drug11 , thereby delaying elimination and increasing blood levels of these drugs . " } 5 : { 1 : 9 } } 58 : { 1 : "NN nmod NN dobj VBP nsubj NN conj NN" 2 : 9 3 : { 1 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0 conj drug0" 2 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0 conj drug0" 3 : "drug0 nmod metabolism dobj *inhibit* nsubj drug0 conj drug0" 4 : "drug0 nmod ed0 dobj *decrease* nsubj drug0 conj drug0" 5 : "drug0 nmod half-life dobj *decrease* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 : In vitro and/or in vivo data show that drug2 , drug3 , and drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . " 2 : "drug1 : In vitro and/or in vivo data indicate that drug2 , drug3 , and oral drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . " 3 : "drug1 : In vitro data indicate that drug2 and drug3 markedly inhibit the metabolism of drug4 which can result in an increase in plasma drug5 levels and prolongation of the QT interval on the ECG . " 4 : "drug1 , drug2 , and drug3 decrease the ED50 of drug4 by 30 % to 45 % . " 5 : "drug1 , drug2 , and drug3 decrease the half-life of drug4 . " } 5 : { 1 : 2 2 : 2 3 : 1 4 : 2 5 : 2 } } 59 : { 1 : "NN nmod NN nmod VBG dobj NN" 2 : 9 3 : { 1 : "drug0 nmod treatment nmod *drinking* dobj drug0" 2 : "drug0 nmod combination nmod *receiving* dobj drug0" 3 : "drug0 nmod combination nmod *receiving* dobj drug0" 4 : "drug0 nmod combination nmod *taking* dobj drug0" 5 : "drug0 nmod therapy nmod *receiving* dobj drug0" 6 : "drug0 nmod combination nmod *taking* dobj drug0" 7 : "drug0 nmod association nmod *using* dobj drug0" 8 : "drug0 nmod conjunction nmod *giving* dobj drug0" } 4 : { 1 : "drug1 : In post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced drug2 tolerance in patients who were drinking drug3 during treatment with drug4 . " 2 : "In patients receiving another drug1 in combination with drug2 ( drug3 ) , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma . " 3 : "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drug1 in combination with drug2 than those receiving drug3 800 mg q8h . " 4 : "Paralytic ileus may occur in patients taking drug1 in combination with drug2 - type drugs . " 5 : "drug1 : Increased serum drug2 levels and symptoms of drug3 toxicity have been reported in patients receiving drug4 during therapy with drug5 . " 6 : "In one survey , 2.3 % of patients taking drug1 in combination with drug2 experienced tremor , as compared to 0.7 % reported to occur with drug3 alone . " 7 : "During controlled hypotensive anesthesia using drug1 in association with drug2 , high concentrations ( 3 % or above ) of drug3 should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure . " 8 : "Since bacteriostatic drugs may interfere with the bactericidal action of drug1 , it is advisable to avoid giving drug2 in conjunction with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 2 6 : 1 7 : 1 8 : 1 } } 60 : { 1 : "NN nmod NN nmod NNS dep NN conj NN" 2 : 9 3 : { 1 : "drug0 nmod *co-administration* nmod inducers dep drug0 conj drug0" 2 : "drug0 conj drug0 dep inhibitors nmod *administration* nmod drug0" } 4 : { 1 : "In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( drug1 , drug2 , drug3 , drug4 , or drug5 ) with drug6 may result in clinically meaningful reductions in drug7 concentrations . " 2 : "Consequently , concomitant administration of drug1 with strong CYP3A4 inhibitors ( e.g. , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) should be approached with caution . " } 5 : { 1 : 4 2 : 5 } } 61 : { 1 : "NN nmod NN nmod VB nsubj NN" 2 : 8 3 : { 1 : "drug0 nmod metabolism nmod *interfere* nsubj drug0" 2 : "drug0 nmod absorption nmod *interfere* nsubj drug0" 3 : "drug0 nmod effect nmod *interfere* nsubj drug0" 4 : "drug0 nmod effect nmod *add* nsubj drug0" 5 : "drug0 nmod action nmod *add* nsubj drug0" 6 : "drug0 nmod action nmod *interfere* nsubj drug0" 7 : "drug0 nsubj *kill* nmod combination nmod drug0" 8 : "drug0 nmod absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "Because oral drug1 may interfere with the hepatic metabolism of drug2 , toxic levels of the drug3 may occur when an oral drug4 and drug5 are administered concurrently . " 2 : "drug1 may interfere with the absorption of drug2 . " 3 : "drug1 : drug2 , drug3 , drug4 , or drug5 may interfere with the bactericidal effect of drug6 . " 4 : "drug1 may add to or potentiate the therapeutic effect of other drug2 . " 5 : "drug1 may add to or potentiate the action of other drug2 . " 6 : "drug1 may interfere with the anti-glaucoma action of drug2 or drug3 ; " 7 : "In combination with other drug1 , drug2 may still kill even experienced users , particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased . " 8 : "Because drug1 may interfere with the absorption of drug2 , simultaneous use of these drugs should be avoided . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 } } 62 : { 1 : "NN nmod NN nmod VBZ nsubj NN" 2 : 8 3 : { 1 : "drug0 nmod secretion nmod *interferes* nsubj drug0" 2 : "drug0 nmod fraction nmod *causes* nsubj drug0" 3 : "drug0 nmod phosphorylation nmod *has* nsubj drug0" 4 : "drug0 nmod metabolism nmod *interferes* nsubj drug0" 5 : "drug0 nmod action nmod *interferes* nsubj drug0" 6 : "drug0 nmod absorption nmod *interferes* nsubj drug0" 7 : "drug0 nmod toxicity nmod *protects* nsubj drug0" } 4 : { 1 : "drug1 : drug2 interferes with renal tubular secretion of drug3 and produces an increase in the level of drug4 in serum . " 2 : "drug1 : drug2 causes increase ( by about 80 % ) in the free fraction of drug3 . " 3 : "drug1 also has no significant effect on the intracellular phosphorylation of drug2 , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines ( U937 and Molt-4 ) . " 4 : "drug1 interferes with the metabolism of drug2 resulting in a 42 % to 74 % dose-related decrease in drug3 clearance and a subsequent 260 % to 350 % increase in serum theophylline levels . " 5 : "drug1 interferes with the therapeutic action of drug2 . " 6 : "drug1 interferes with the absorption of drug2 , including drug3 . " 7 : "drug1 protects mouse tumour and normal tissues from the toxicity of oral drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 2 7 : 1 } } 63 : { 1 : "NN conj FW dep NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 8 3 : { 1 : "drug0 conj g. dep drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 8 } } 64 : { 1 : "NN conj FW dep NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NNS nmod NN" 2 : 8 3 : { 1 : "drug0 conj g. dep drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod agents nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug2 ( e. g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 ) , drug11 salts , drug12 , local drug13 , drug14 , and drug15 . " } 5 : { 1 : 8 } } 65 : { 1 : "NN dep SYM dep NNS dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 8 3 : { 1 : "drug0 dep * dep deficiencies dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 8 } } 66 : { 1 : "NN conj FW dep NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN nmod NN" 2 : 8 3 : { 1 : "drug0 conj g. dep drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0 nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 8 } } 67 : { 1 : "NN conj NN ccomp JJ parataxis NN nsubj NNS acl VB dobj NNS nmod NN" 2 : 8 3 : { 1 : "drug0 conj drug0 ccomp reasonable parataxis *following* nsubj agents acl decrease dobj levels nmod drug0" } 4 : { 1 : "Agents that are CYP inducers that have been found , or are expected , to decrease plasma levels of drug1 are the following : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 ( 2 ) , drug8 , drug9 , and drug10 Thus , if a patient has been titrated to a stable dosage on drug11 , and then begins a course of treatment with one of these CYP3A4 inducers , it is reasonable to expect that a dose increase for drug12 may be necessary . " } 5 : { 1 : 8 } } 68 : { 1 : "NN compound NN conj NN compound NN" 2 : 8 3 : { 1 : "drug0 compound mg conj *mg* compound drug0" 2 : "drug0 compound mg conj *mg* compound drug0" 3 : "drug0 compound mg conj *mg* compound drug0" 4 : "drug0 compound mg conj *mg* compound drug0" 5 : "drug0 compound mg conj *mg* compound drug0" 6 : "drug0 compound mg conj *mg* compound drug0" 7 : "drug0 compound mg conj *mg* compound drug0" 8 : "drug0 compound mg conj *mg* compound drug0" } 4 : { 1 : "A case report of one patient taking drug1 200 mg and drug2 800 mg three times a day resulted in increases in drug3 concentrations from 0.9 mg/L to 1.3 mg/L . " 2 : "With simultaneous dosing of drug1 10 mg and drug2 10 mg , 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg . " 3 : "With simultaneous dosing of drug1 20 mg and drug2 10 mg , 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg . " 4 : "In a similar study with drug1 in healthy volunteers , 1 of 24 subjects dosed with drug2 20 mg and drug3 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg . " 5 : "Two of 16 subjects dosed simultaneously with drug1 10 mg and drug2 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg . " 6 : "drug1 : Coadministration of drug2 3 mg and drug3 10 mg produced a decrease in DSST scores . " 7 : "drug1 : Coadministration of single doses of drug2 20 mg and drug3 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration . " 8 : "drug1 : Coadministration of single doses of drug2 20 mg and drug3 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 } } 69 : { 1 : "NN dep NN nmod NN" 2 : 8 3 : { 1 : "drug0 dep *metabolism* nmod drug0" 2 : "drug0 dep *administration* nmod drug0" 3 : "drug0 dep drug0 nmod *drug0*" 4 : "drug0 dep *interaction* nmod drug0" 5 : "drug0 dep *administration* nmod drug0" 6 : "drug0 dep *coadministration* nmod drug0" 7 : "drug0 nmod concentration dep *drug0*" 8 : "drug0 nmod metabolism dep *drug0*" } 4 : { 1 : "While not systematically studied , certain drugs may induce the metabolism of drug1 ( e.g. , drug2 , drug3 , drug4 ) . " 2 : "Drugs that Lower Seizure Threshold : Concurrent administration of drug1 and agents ( e.g. , drug2 , other drug3 , drug4 , systemic drug5 , etc. ) that lower seizure threshold should be undertaken only with extreme caution . " 3 : "In vitro mixing of an drug1 with beta-lactamtype drug2 ( drug3 or drug4 ) may result in a significant mutual inactivation . " 4 : "Data from in vitro studies of drug1 suggest a possible drug interaction with drug2 for the following : drug3 and drug4 . " 5 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [ e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . " 6 : "therefore , coadministration of drug1 with drugs that strongly induce CYP3A4 activity ( e.g. , drug2 , drug3 , drug4 ) may result in reduced plasma concentrations of drug5 that may result in decreased efficacy of drug6 . " 7 : "drug1 : May increase plasma concentration of drug2 , possibly by inhibiting conjugation . " 8 : "drug1 : May increase CYP metabolism of drug2 leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 8 : 1 } } 70 : { 1 : "NN compound NN nmod VBN nsubjpass NN" 2 : 7 3 : { 1 : "drug0 compound treatment nmod *administered* nsubjpass drug0" 2 : "drug0 compound therapy nmod *added* nsubjpass drug0" 3 : "drug0 nsubjpass *noted* nmod treatment compound drug0" 4 : "drug0 compound therapy nmod *added* nsubjpass drug0" 5 : "drug0 compound administration nmod *taken* nsubjpass drug0" 6 : "drug0 compound therapy nmod *added* nsubjpass drug0" 7 : "drug0 compound administration nmod *taken* nsubjpass drug0" } 4 : { 1 : "drug1 , drug2 and drug3 should not be administered during drug4 treatment . " 2 : "When drug1 is added to drug2 therapy , plasma drug3 levels may increase two-fold or more in some patients , if drug4 dosage is not reduced . " 3 : "With oral drug1 treatment , drug2 such as drug3 have been noted to possibly increase the likelihood of hematologic reactions " 4 : "There have been isolated reports of patients experiencing increases in their prothrombin times when drug1 was added to drug2 therapy . " 5 : "It is recommended that drug1 be taken at least 2 hours following drug2 administration . " 6 : "When drug1 is added to drug2 therapy , drug3 dose should be doubled . " 7 : "Median gastric pH was significantly higher when drug1 was taken after drug2 administration ; " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 } } 71 : { 1 : "NN conj NN nmod VBN dep VBG acl NN nmod NN nmod NN appos NN compound NN" 2 : 7 3 : { 1 : "drug0 conj drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0 appos system compound drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 7 } } 72 : { 1 : "NN conj NN nmod NN nmod VBN nsubjpass NN" 2 : 7 3 : { 1 : "drug0 conj drug0 nmod combination nmod *used* nsubjpass drug0" 2 : "drug0 conj drug0 nmod drug0 nmod *administered* nsubjpass drug0" 3 : "drug0 conj drug0 nmod drug0 nmod *administered* nsubjpass drug0" 4 : "drug0 conj drug0 nmod time nmod *taken* nsubjpass drug0" 5 : "drug0 conj drug0 nmod combination nmod *taken* nsubjpass drug0" } 4 : { 1 : "Consequently , it is recommended that drug1 not be used in combination with either drug2 , drug3 , or drug4 . " 2 : "Additive CNS depression may occur when drug1 are administered concomitantly with other drug2 including drug3 , drug4 , and drug5 . " 3 : "drug1 should not be administered concomitantly with potent drug2 such as drug3 and drug4 as the potential for ototoxicity is enhanced by the combination . " 4 : "drug1 should not be taken closely in time with drug2 and drug3 containing drug4 . " 5 : "Drug-Drug Interactions Given the primary CNS effects of drug1 , caution should be used when drug2 is taken in combination with other drug3 and drug4 . " } 5 : { 1 : 2 2 : 2 3 : 1 4 : 1 5 : 1 } } 73 : { 1 : "NN nmod VBN nsubjpass NN compound NN" 2 : 7 3 : { 1 : "drug0 nmod *separated* nsubjpass dosing compound drug0" 2 : "drug0 nmod *decreased* nsubjpass exposure compound drug0" 3 : "drug0 nmod *administered* nsubjpass hcl compound drug0" 4 : "drug0 nmod *used* nsubjpass injection compound drug0" 5 : "drug0 nmod *prolonged* nsubjpass half-life compound drug0" 6 : "drug0 nmod *decreased* nsubjpass cmax compound drug0" 7 : "drug0 nmod *increased* nsubjpass cmax compound drug0" } 4 : { 1 : "When drug1 dosing was separated from drug2 10 mg by 6 hours , 7 of 28 subjects who received 20 mg of drug3 experienced a decrease in standing systolic blood pressure below 85 mm Hg . " 2 : "drug1 exposure was significantly decreased by drug2 ; " 3 : "When drug1 HCl is administered concomitantly with an drug2 , the risk of hyperkalemia may be increased . " 4 : "drug1 : drug2 ( drug3 ) Injection , USP should not be used with drug4 because the combination may cause synergistic elevation of blood pressure . " 5 : "drug1 : drug2 s plasma half-life may be prolonged by drug3 , since drug4 and drug5 may compete for excretion in the renal tubule . " 6 : "drug1 steady-state Cmax , A.C. and Cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant drug2 . " 7 : "drug1 steady-state Cmax , A.C. and Cmin were increased 21 % , decreased 19 % , and decreased 48 % , respectively , by concomitant drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 } } 74 : { 1 : "NN conj NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 7 3 : { 1 : "drug0 conj drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 7 } } 75 : { 1 : "NN compound NN dobj VBD nsubj NN nmod NN" 2 : 7 3 : { 1 : "drug0 compound cmax dobj *reduced* nsubj administration nmod drug0" 2 : "drug0 compound auc dobj *decreased* nsubj pre-treatment nmod drug0" 3 : "drug0 compound binding dobj *decreased* nsubj administration nmod drug0" 4 : "drug0 compound exposure dobj *increased* nsubj co-administration nmod drug0" 5 : "drug0 compound cmax dobj *reduced* nsubj co-administration nmod drug0" 6 : "drug0 compound excretion dobj *enhanced* nsubj injection nmod drug0" 7 : "drug0 compound requirement dobj *decreased* nsubj withdrawal nmod drug0" } 4 : { 1 : "Multiple-dose administration of the potent CYP3A4 inducer drug1 ( 600 mg every 24 hours , q24h , for 14 days ) , however , reduced drug2 Cmax and AUC by approximately 80 % . " 2 : "Pre-treatment with the CYP3A4 inducer drug1 decreased drug2 AUC by about 2/3 . " 3 : "however , in a study of 12 normal subjects , concurrent administration of drug1 decreased drug2 protein binding and increased drug3 plasma clearance from 0.07 L/kg/h without drug4 to 0.11 L/kg/h with drug5 . " 4 : "Co-administration of drug1 , a strong inhibitor of CYP3A4 , increased drug2 exposure following a single 90 mg dose of drug3 by 2.3 fold . " 5 : "Co-administration of drug1 reduced drug2 Cmax up to 50 % after multiple dosing . " 6 : "[ The effect of drug1 on the renal excretion of drug2 and drug3 in dogs ] The intravenous injection of drug4 in a dose of 20 mg/kg enhanced drug5 and drug6 excretion in chronic canine experiments . " 7 : "Withdrawal of drug1 decreased the drug2 requirement by 50 % . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 } } 76 : { 1 : "NN compound NNS dobj VB nsubj NN" 2 : 7 3 : { 1 : "drug0 compound pharmacodynamics dobj *affect* nsubj drug0" 2 : "drug0 compound levels dobj *elevate* nsubj drug0" 3 : "drug0 compound s dobj *displace* nsubj drug0" 4 : "drug0 compound levels dobj *elevate* nsubj drug0" 5 : "drug0 compound levels dobj *raise* nsubj drug0" 6 : "drug0 compound concentrations dobj *reduce* nsubj drug0" 7 : "drug0 compound levels dobj *decrease* nsubj drug0" } 4 : { 1 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 " 2 : "Since drug1 ( drug2 ) may interact with concurrently administered drug3 , periodic serum level determinations of these drugs may be necessary ( eg , drug4 may elevate drug5 serum levels and drug6 has been reported to both increase and decrease drug7 levels ) . " 3 : "In vitro studies have shown drug1 can displace drug2 s , such as drug3 , from their protein-binding sites . " 4 : "drug1 may elevate drug2 levels . " 5 : "drug1 : drug2 may raise serum drug3 levels in some individuals . " 6 : "drug1 : It appears that drug2 may reduce plasma drug3 concentrations . " 7 : "drug1 , drug2 , and drug3 may decrease drug4 plasma levels , resulting in a decrease in effectiveness of a previously effective drug5 dose . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 } } 77 : { 1 : "NN compound NN dobj VBZ nsubj NN" 2 : 7 3 : { 1 : "drug0 compound clearance dobj *decreases* nsubj drug0" 2 : "drug0 compound metabolism dobj *inhibits* nsubj drug0" 3 : "drug0 compound clearance dobj *decreases* nsubj drug0" 4 : "drug0 compound metabolism dobj *modifies* nsubj drug0" 5 : "drug0 compound excretion dobj *increases* nsubj drug0" 6 : "drug0 compound absorption dobj *enhances* nsubj drug0" 7 : "drug0 compound secretion dobj *decreases* nsubj drug0" } 4 : { 1 : "drug1 decreases drug2 clearance by up to 25 % , and may produce AUCs 1500 M min in some patients . " 2 : "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of drug1 on drug2 indicates that drug3 inhibits drug4 metabolism , which is mediated by CYP1A2 . " 3 : "drug1 : drug2 decreases drug3 renal clearance and increases drug4 plasma levels . " 4 : "drug1 modifies drug2 metabolism with increased serum levels of drug3 . " 5 : "drug1 increases drug2 excretion and the drug3 may be decreased . " 6 : "These studies indicate that drug1 or drug2 co-administration enhances drug3 gastrointestinal absorption . " 7 : "This observed increase in the bioavailability of drug1 may be due to transport-related effects , such as p-glycoprotein . in vivo animal studies also suggest that in addition to enhancing absorption , drug2 decreases drug3 gastrointestinal secretion , while drug4 may also decrease biliary excretion . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 7 : 1 } } 78 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN conj NN" 2 : 7 3 : { 1 : "drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0 conj drug0" 2 : "drug0 nmod action dobj *reduce* nsubj drugs nmod drug0 conj drug0" 3 : "drug0 nmod metabolism dobj *inhibit* nsubj drugs nmod drug0 conj drug0" } 4 : { 1 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " 2 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . " 3 : "Drugs such as drug1 and drug2 may inhibit the metabolism of drug3 and thus decrease their clearance . " } 5 : { 1 : 3 2 : 3 3 : 1 } } 79 : { 1 : "NN nmod NN dobj VB nsubj NN nmod NN conj NN" 2 : 7 3 : { 1 : "drug0 nmod activity dobj *antagonize* nsubj drug0 nmod drug0 conj drug0" 2 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0 conj drug0" 3 : "drug0 nmod secretion dobj *inhibit* nsubj drug0 nmod drug0 conj drug0" 4 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0 conj drug0" 5 : "drug0 nmod effectiveness dobj *diminish* nsubj drug0 nmod drug0 conj drug0" } 4 : { 1 : "Additionally , drug1 , such as drug2 and drug3 , may antagonize the activity of drug4 . " 2 : "drug1 , drug2 and drug3 : Concomitant treatment with drug4 , drug5 , or drug6 may potentiate a possible hypokalemic effect of drug7 " 3 : "drug1 , such as drug2 and drug3 , can inhibit renal tubular secretion of drug4 . " 4 : "Concomitant treatment with drug1 ( drug2 , drug3 ) , drug4 , or drug5 may potentiate any hypokalemic effect of drug6 . " 5 : "drug1 : Since drug2 is a drug3 , it is possible that drug4 , such as the drug5 ( drug6 , drug7 , drug8 ) or drug9 , may diminish the effectiveness of drug10 . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 2 5 : 1 } } 80 : { 1 : "NN compound NN dobj VBP nsubj NN conj NN" 2 : 7 3 : { 1 : "drug0 compound concentration dobj *raise* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , and drug8 raise the serum drug9 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drug10 intoxication may result . " } 5 : { 1 : 7 } } 81 : { 1 : "NN conj NN nmod VBN dep VBG acl NN nmod NN nmod NN" 2 : 7 3 : { 1 : "drug0 conj drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 7 } } 82 : { 1 : "NN conj NN nmod NN nmod NN nmod NN" 2 : 6 3 : { 1 : "drug0 conj drug0 nmod *reduction* nmod dosage nmod drug0" 2 : "drug0 conj drug0 nmod availability nmod *effect* nmod drug0" 3 : "drug0 conj mg nmod *increase* nmod course nmod drug0" 4 : "drug0 conj drug0 nmod therapy nmod *use* nmod drug0" } 4 : { 1 : "However , due to possible pharmacodynamic interactions , when co-administered with drug1 , a reduction in dosage of drug2 on the concomitant drug3 , drug4 , drug5 or drug6 may be required . " 2 : "Particular caution should be observed with drug1 since there are conflicting results for the effect of drug2 on the availability of drug3 and drug4 . " 3 : "drug1 : A study in 6 healthy volunteers has shown a significant increase in peak drug2 plasma levels ( 80 % ) and area-under-the-curve ( 74 % ) after a 1 week course of drug3 at 1000 mg per day and drug4 at 40 mg per day . " 4 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . " } 5 : { 1 : 3 2 : 1 3 : 1 4 : 1 } } 83 : { 1 : "NN nmod NNS nmod NN" 2 : 6 3 : { 1 : "drug0 nmod *effects* nmod drug0" 2 : "drug0 nmod infusions nmod *drug0*" 3 : "drug0 nmod products nmod *drug0*" 4 : "drug0 nmod *interactions* nmod drug0" 5 : "drug0 nmod *interactions* nmod drug0" 6 : "drug0 nmod *combinations* nmod drug0" } 4 : { 1 : "Similarly , the effects of drug1 on drug2 , drug3 and sodium plasma drug4 concentrations are unpredictable " 2 : "Infusion requirements of drug1 in patients administered drug2 prior to infusions of drug3 were comparable to or slightly greater than when drug4 was not administered . " 3 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " 4 : "Possible drug interactions of drug1 with drug2 or with other drug3 . " 5 : "There have been reports of interactions of drug1 with drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , and drug14 . " 6 : "The antimicrobial combinations of drug1 with four drug2 resulted in additive effect in most instances , synergism in two instances , and antagonism in two instances . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 } } 84 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS compound NN" 2 : 6 3 : { 1 : "drug0 nmod combination nmod *used* nsubjpass tablets compound drug0" 2 : "drug0 nmod presence nmod *decreased* nsubjpass concentrations compound drug0" 3 : "drug0 nmod use nmod *recommended* nsubjpass preparations compound drug0" 4 : "drug0 nmod treatment nmod *increased* nsubjpass levels compound drug0" 5 : "drug0 nmod presence nmod *increased* nsubjpass levels compound drug0" 6 : "drug0 nmod therapy nmod *evaluated* nsubjpass levels compound drug0" } 4 : { 1 : "Therefore , it is recommended that drug1 Tablets not be used in combination with drug2 , or within 14 days of discontinuing treatment with a drug3 . " 2 : "drug1 concentrations may be decreased in the presence of drug2 . " 3 : "Microdosed minipill drug1 preparations are not recommended for use with drug2 . " 4 : "drug1 : Reports indicate that drug2 levels may be increased during concomitant treatment with drug3 for injection . " 5 : "When intravenous drug1 and drug2 were concomitantly administered in normal subjects , no effect on drug3 blood levels was seen , but drug4 steady-state blood levels were increased by 46 % in the presence of drug5 . " 6 : "drug1 usually does not alter the plasma levels of drug2 , however , serum drug3 levels should be evaluated after concomitant therapy with drug4 is initiated . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 } } 85 : { 1 : "NN conj NN dep NN dobj VB xcomp VBN acl NNS nmod NN nsubj VB acl:relcl NN nmod NN" 2 : 6 3 : { 1 : "drug0 conj drug0 dep conduction dobj alter xcomp known acl drugs nmod coadministration nsubj contribute acl:relcl *interaction* nmod drug0" } 4 : { 1 : "This appears to be the only clinically relevant interaction of this kind with drug1 , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , drug2 or drug3 , drug4 , drug5 or drug6 , drug7 and drug8 ) might also contribute to a prolongation of the QTc interval . " } 5 : { 1 : 6 } } 86 : { 1 : "NN dobj VBG acl NNS nmod VBG dobj NN" 2 : 6 3 : { 1 : "drug0 dobj receiving acl patients nmod *containing* dobj drug0" 2 : "drug0 dobj receiving acl patients nmod *containing* dobj drug0" 3 : "drug0 dobj receiving acl patients nmod *administering* dobj drug0" 4 : "drug0 dobj receiving acl patients nmod *administering* dobj drug0" 5 : "drug0 dobj taking acl patients nmod *administering* dobj drug0" } 4 : { 1 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 , drug5 or drug6 may produce severe , prolonged hypotension or hypertension . " 2 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 or drug5 may produce severe , prolonged hypertension . " 3 : "Therefore , EXTREME CAUTION should be exercised when administering drug1 to patients receiving drug2 or drug3 . " 4 : "Caution is therefore advised when administering drug1 to patients receiving drug2 . " 5 : "The physician should be cautious when administering drug1 to patients taking drug2 . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 5 : 1 } } 87 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 6 3 : { 1 : "drug0 nmod dosing nmod *administered* nsubjpass drugs nmod drug0" 2 : "drug0 nmod drug0 nmod *antagonized* nsubjpass effects nmod drug0" 3 : "drug0 nmod doses nsubjpass *required* nmod presence nmod drug0" 4 : "drug0 nmod drug0 nmod *antagonized* nsubjpass effects nmod drug0" 5 : "drug0 nmod use nmod *reported* nsubjpass levels nmod drug0" 6 : "drug0 nmod pretreatment nmod *reduced* nsubjpass effects nmod drug0" } 4 : { 1 : "Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach : Drugs such as drug1 and drug2 should be administered at least 2 hours prior to dosing with drug3 . " 2 : "The effects of drug1 are antagonized by drug2 such as drug3 and drug4 . " 3 : "In the presence of these drug1 , larger doses of drug2 may be required or drug3 may not be effective . " 4 : "Cardiac effects of drug1 are antagonized by drug2 , such as drug3 and drug4 . " 5 : "Elevated plasma levels of drug1 have been reported with concomitant use of some drug2 . " 6 : "The anxiogenic effects of drug1 were reduced by pretreatment with drug2 , an A2-selective agonist , but not by drug3 ( drug4 ) , an A1-selective agonist . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 } } 88 : { 1 : "NN nmod NN nmod VB nsubj NNS nmod NN" 2 : 6 3 : { 1 : "drug0 nmod initiation nmod *experience* nsubj patients nmod drug0" 2 : "drug0 nmod initiation nmod *experience* nsubj patients nmod drug0" 3 : "drug0 nmod initiation nmod *show* nsubj patients nmod drug0" 4 : "drug0 nmod initiation nmod *experience* nsubj patients nmod drug0" 5 : "drug0 nmod action nmod *interfere* nsubj drugs nmod drug0" 6 : "drug0 nmod initiation nmod *experience* nsubj patients nmod drug0" } 4 : { 1 : "Hypotension : Patients on Diuretic Therapy : Patients on drug1 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2 or drug3 . " 2 : "drug1 : Patients on drug2 , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug3 . " 3 : "However , patients on drug1 may show elevations of drug2 concentrations after initiation of therapy with drug3 , which may be clinically significant in patients prone to drug4 toxicity . " 4 : "Hypotension - Patients on Diuretic Therapy : Patients on drug1 , and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2 . " 5 : "Since bacteriostatic drugs , such as the drug1 of drug2 , may interfere with the bactericidal action of drug3 , it is not advisable to administer these drugs concomitantly . " 6 : "drug1 : Patients on drug2 , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 } } 89 : { 1 : "NN conj NN dep VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 6 3 : { 1 : "drug0 conj drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; drug3 ; drug4 ; certain drug5 , especially the drug6 and drug7 ; drug8 ; drug9 salts ; drug10 ; and drug11 . " } 5 : { 1 : 6 } } 90 : { 1 : "NN conj NN dobj VBD acl:relcl NNS conj NN nmod NNS nmod VBN nsubjpass NN nmod NN" 2 : 6 3 : { 1 : "drug0 conj drug0 dobj bound acl:relcl drugs conj drug0 nmod drugs nmod *potentiated* nsubjpass action nmod drug0" } 4 : { 1 : "Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 , some drug3 and other drugs that are highly protein bound , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 . " } 5 : { 1 : 6 } } 91 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN conj VB nsubj NNS nmod NN conj NN" 2 : 6 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod used conj *induce* nsubj drugs nmod drug0 conj drug0" } 4 : { 1 : "drug1 : Drugs such as drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 and others that interfere with platelet-aggregation reactions ( the main hemostatic defense of heparinized patients ) may induce bleeding and should be used with caution in patients receiving drug9 . " } 5 : { 1 : 6 } } 92 : { 1 : "NN nmod RB advmod VB nsubj NNS acl VBG dobj NNS conj NN" 2 : 6 3 : { 1 : "drug0 nmod concomitantly advmod *exhibit* nsubj patients acl receiving dobj s conj drug0" } 4 : { 1 : "Patients receiving other drug1 s , general drug2 , drug3 , drug4 , drug5 , drug6 or other drug7 ( including drug8 ) concomitantly with drug9 may exhibit an additive CNS depression . " } 5 : { 1 : 6 } } 93 : { 1 : "NN conj NN nmod NN dobj VB nsubj NNS nmod NN conj NN" 2 : 6 3 : { 1 : "drug0 conj drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0 conj drug0" 2 : "drug0 conj drug0 nmod action dobj *reduce* nsubj drugs nmod drug0 conj drug0" } 4 : { 1 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " 2 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . " } 5 : { 1 : 3 2 : 3 } } 94 : { 1 : "NN conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 6 3 : { 1 : "drug0 conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 6 } } 95 : { 1 : "NN compound NNS nmod NN dobj VBZ nsubj NN" 2 : 6 3 : { 1 : "drug0 compound s nmod action dobj *augments* nsubj drug0" 2 : "drug0 compound concentrations nmod decrease dobj *causes* nsubj drug0" 3 : "drug0 compound concentrations nmod increase dobj *causes* nsubj drug0" 4 : "drug0 compound concentrations nmod decrease dobj *causes* nsubj drug0" 5 : "drug0 compound concentrations nmod increase dobj *causes* nsubj drug0" 6 : "drug0 compound pharmacokinetics nmod effect dobj *has* nsubj drug0" } 4 : { 1 : "drug1 augments the action of drug2 s and the muscle relaxant effects of drug3 . " 2 : "drug1 : drug2 causes a slight decrease ( about 10 % ) in steady-state drug3 concentrations . " 3 : "Specific Effects of drug1 on Other drug2 drug3 : drug4 causes an increase in steady-state drug5 plasma concentrations . " 4 : "drug1 : drug2 causes a decrease in the steady-state drug3 plasma concentrations and an increase in the steady-state drug4 plasma concentration . " 5 : "drug1 : drug2 causes an increase in steady-state drug3 concentrations . " 6 : "drug1 has a complex effect on oral drug2 pharmacokinetics . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 6 : 1 } } 96 : { 1 : "NN conj NNS nmod NNS dobj VB nsubj NN conj NN" 2 : 6 3 : { 1 : "drug0 conj s nmod effects dobj *enhance* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 6 } } 97 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN nmod NN" 2 : 5 3 : { 1 : "drug0 nmod coadministered advcl *accelerated* nsubjpass absorption nmod drug0" 2 : "drug0 nmod coadministered advcl *increased* nsubjpass exposure nmod drug0" 3 : "drug0 nmod given advcl *reduced* nsubjpass dose nmod drug0" 4 : "drug0 nmod administered advcl *reduced* nsubjpass dose nmod drug0" 5 : "drug0 nmod given advcl *decreased* nsubjpass absorption nmod drug0" } 4 : { 1 : "The gastrointestinal absorption of drug1 and drug2 is accelerated when they are coadministered with drug3 . " 2 : "Plasma exposure ( AUC ) to drug1 was increased 62 % when coadministered with drug2 and 38 % when coadministered with drug3 . " 3 : "Studies with drug1 in combination with drug2 indicate that the dose of the drug3 can be reduced when it is given with a drug4 . " 4 : "It is recommended that the dose of drug1 be reduced to one-half the usual dose when administered with drug2 . " 5 : "The absorption of drug1 , drug2 , drug3 , drug4 , and drug5 was significantly decreased when given simultaneously with drug6 ; " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 98 : { 1 : "NN compound NN dobj VB nsubj NN" 2 : 5 3 : { 1 : "drug0 compound synthesis dobj *inhibit* nsubj drug0" 2 : "drug0 compound vasodilation dobj *suppress* nsubj drug0" 3 : "drug0 compound absorption dobj *increase* nsubj drug0" 4 : "drug0 compound absorption dobj *increase* nsubj drug0" 5 : "drug0 compound concentration dobj *decrease* nsubj drug0" } 4 : { 1 : "In addition , drug1 alone can inhibit adrenal drug2 synthesis and may cause adrenal insufficiency during corticosteroid withdrawal . " 2 : "drug1 ( such as drug2 ) and drug3 can suppress the drug4 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion . " 3 : "drug1 and drug2 ( and possibly other drug3 ) and drug4 may increase drug5 absorption in patients who inactivate drug6 by bacterial metabolism in the lower intestine , so that drug7 intoxication may result . " 4 : "drug1 and drug2 , by decreasing gut motility , may increase drug3 absorption . " 5 : "drug1 may decrease serum drug2 concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 99 : { 1 : "NN dep SYM dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 5 3 : { 1 : "drug0 dep * dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 5 } } 100 : { 1 : "NN nmod NN nmod NNS dep NN" 2 : 5 3 : { 1 : "drug0 nmod *co-administration* nmod inducers dep drug0" 2 : "drug0 dep inhibitors nmod *administration* nmod drug0" 3 : "drug0 nmod combination nmod *patients* dep drug0" 4 : "drug0 dep compounds nmod *use* nmod drug0" 5 : "drug0 nmod effect nmod interferes dep *drug0*" } 4 : { 1 : "In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( drug1 , drug2 , drug3 , drug4 , or drug5 ) with drug6 may result in clinically meaningful reductions in drug7 concentrations . " 2 : "Consequently , concomitant administration of drug1 with strong CYP3A4 inhibitors ( e.g. , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) should be approached with caution . " 3 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " 4 : "Concomitant use of drug1 with other cardioactive compounds that could cause heart failure ( e.g. , drug2 ) , requires close monitoring of cardiac function throughout treatment . " 5 : "drug1 : Interferes with the contraceptive effect of microdosed drug2 - containing minipill preparations . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 101 : { 1 : "NN dobj VBZ nsubj NN" 2 : 5 3 : { 1 : "drug0 dobj *binds* nsubj drug0" 2 : "drug0 dobj *displaces* nsubj drug0" 3 : "drug0 dobj *potentiates* nsubj drug0" 4 : "drug0 dobj *increases* nsubj drug0" 5 : "drug0 dobj *enhances* nsubj drug0" } 4 : { 1 : "drug1 : drug2 binds both drug3 and drug4 in the intestine , thus impairing absorption of these drug5 . " 2 : "This may occur because drug1 competitively displaces drug2 from protein binding sites . " 3 : "drug1 potentiates other drug2 such as drug3 or drug4 and drug5 s. " 4 : "drug1 : drug2 increases both free and bound drug3 by reducing the plasma clearance of drug4 to about one-third , as well as decreasing its protein binding . " 5 : "only drug1 enhances drug2 - induced increases in accumbal dopamine . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 102 : { 1 : "NN nmod NN dobj VB nsubj NNS dep NN conj NN" 2 : 5 3 : { 1 : "drug0 nmod metabolism dobj *enhance* nsubj drugs dep drug0 conj drug0" 2 : "drug0 nmod exposure dobj *decrease* nsubj co-medications dep drug0 conj drug0" } 4 : { 1 : "Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , drug1 , drug2 , drug3 , drug4 ) may enhance the metabolism of drug5 and require that the dosage of the drug6 be increased . " 2 : "Co-medications that induce CYP 3A4 ( e.g. , drug1 , drug2 , drug3 , drug4 , or St. John s wort ) may significantly decrease exposure to drug5 . " } 5 : { 1 : 2 2 : 3 } } 103 : { 1 : " NN compound NN" 2 : 5 3 : { 1 : " *drug0* compound drug0" 2 : " *drug0* compound drug0" 3 : " *drug0* compound drug0" 4 : " *drug0* compound drug0" 5 : " *drug0* compound drug0" } 4 : { 1 : "Marked symptomatic orthostatic hypotension has been reported when drug1 and organic drug2 were used in combination . " 2 : "Severe hypoglycemia has been reported in patients concomitantly receiving drug1 and oral drug2 . " 3 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " 4 : "Drugs Which Require a Dose Reduction When Coadminstered With drug1 drug2 : drug3 " 5 : "drug1 - drug2 may potentiate the tardive dyskinesia side reactions of drug3 if used concomitantly with them . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 104 : { 1 : "NN conj VBG dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 5 3 : { 1 : "drug0 conj acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 5 } } 105 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN nmod NN conj NN" 2 : 5 3 : { 1 : "drug0 nmod coadministered advcl *accelerated* nsubjpass absorption nmod drug0 conj drug0" 2 : "drug0 nmod given advcl *decreased* nsubjpass absorption nmod drug0 conj drug0" } 4 : { 1 : "The gastrointestinal absorption of drug1 and drug2 is accelerated when they are coadministered with drug3 . " 2 : "The absorption of drug1 , drug2 , drug3 , drug4 , and drug5 was significantly decreased when given simultaneously with drug6 ; " } 5 : { 1 : 1 2 : 4 } } 106 : { 1 : "NN conj NN dep NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 5 3 : { 1 : "drug0 conj drug0 dep drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 5 } } 107 : { 1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 5 3 : { 1 : "drug0 nmod metabolism nmod interfere xcomp *shown* nsubjpass drug0" 2 : "drug0 nmod metabolism nmod interfere xcomp *shown* nsubjpass drug0" 3 : "drug0 nmod metabolism nmod interfere xcomp *shown* nsubjpass drug0" 4 : "drug0 nmod elimination nmod interfere xcomp *demonstrated* nsubjpass drug0" 5 : "drug0 nmod metabolism nmod interfere xcomp *shown* nsubjpass drug0" } 4 : { 1 : "Some drug1 , including drug2 , have also been shown to interfere with the metabolism of drug3 . " 2 : "Some drug1 have also been shown to interfere with the metabolism of drug2 . " 3 : "drug1 have been shown to interfere with the metabolism of drug2 . " 4 : "drug1 : drug2 has been demonstrated to interfere with the elimination of other drug3 . " 5 : "drug1 have also been shown to interfere with the metabolism of drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 108 : { 1 : "NN nmod VBN acl NNS nmod NN dobj VB nsubj NN nmod NN nmod NN conj NN" 2 : 5 3 : { 1 : "drug0 nmod treated acl keratoses nmod reaction dobj *increase* nsubj use nmod drug0 nmod drug0 conj drug0" } 4 : { 1 : "It is , however , possible that concomitant use of other known drug1 such as drug2 , drug3 , drug4 , drug5 , drug6 and drug7 might increase the photosensitivity reaction of actinic keratoses treated with the drug8 for Topical Solution . " } 5 : { 1 : 5 } } 109 : { 1 : "NN nmod VBN dep NN" 2 : 5 3 : { 1 : "drug0 nmod *given* dep drug0" 2 : "drug0 nmod given dep *drug0*" 3 : "drug0 nmod reversed dep *drug0*" 4 : "drug0 nmod inhibited dep *drug0*" 5 : "drug0 nmod *prevented* dep drug0" } 4 : { 1 : "- drug1 : Generally should not be given with drug2 . " 2 : "drug1 : generally should not be given with drug2 . " 3 : "It has been reported that results of studies in animals indicate that drug1 - induced ventricular arrhythmias during anesthesia can be reversed by drug2 . " 4 : "drug1 ( drug2 , drug3 , drug4 ) : Metabolism may be inhibited by drug5 , increasing plasma levels of drug6 ; " 5 : "drug1 - induced oxidative stress in rat brain and liver is prevented by drug2 or drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 110 : { 1 : "NN nmod NN nmod NN dep NN" 2 : 5 3 : { 1 : "drug0 nmod *coadministration* nmod drug0 dep drug0" 2 : "drug0 dep drug0 nmod *use* nmod drug0" 3 : "drug0 dep drug0 nmod *use* nmod drug0" 4 : "drug0 dep drug0 nmod *use* nmod drug0" 5 : "drug0 dep inducer nmod *administration* nmod drug0" } 4 : { 1 : "drug1 : In a clinical pharmacology study , coadministration of an drug2 ( drug3 , drug4 , and drug5 ) with drug6 reduced serum levels and urinary excretion of drug7 as compared with drug8 administered alone , suggesting that drug9 may impair absorption of drug10 . " 2 : "Concurrent use of drug1 with drug2 ( e.g. , drug3 , drug4 , drug5 , and drug6 ) may result in increased drug7 effects . " 3 : "Interactions with Other CNS Agents : Concurrent use of drug1 with all drug2 ( eg , drug3 , drug4 , drug5 , other drug6 , general drug7 , drug8 , drug9 , drug10 , drug11 , drug12 and drug13 ) may result in additive central nervous system depressant effects . " 4 : "Use of drug1 with drug2 ( e.g. , drug3 , drug4 , or drug5 ) , drug6 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium . " 5 : "The administration of drug1 concomitantly with known microsomal enzyme inducer ( drug2 or drug3 ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 111 : { 1 : "NN compound NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN nmod NNS nmod NN conj NN" 2 : 5 3 : { 1 : "drug0 compound dose nmod reduction nsubjpass *considered* advcl indicated nsubjpass treatment nmod inhibitors nmod drug0 conj drug0" } 4 : { 1 : "If treatment with inhibitors of CYP3A4 activity ( such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , etc. ) is indicated , reduction of the drug7 dose should be considered . " } 5 : { 1 : 5 } } 112 : { 1 : "NN conj NN nmod VBN nsubjpass NNS nmod NN" 2 : 5 3 : { 1 : "drug0 conj drug0 nmod *potentiated* nsubjpass actions nmod drug0" 2 : "drug0 conj drug0 nmod *increased* nsubjpass effects nmod drug0" } 4 : { 1 : "The actions of the drug1 may be potentiated by drug2 , drug3 , drug4 , drug5 or other drug6 . " 2 : "Effects of drug1 are increased with drug2 and drug3 . " } 5 : { 1 : 4 2 : 1 } } 113 : { 1 : "NN compound NNS nsubj VB dep SYM" 2 : 5 3 : { 1 : "drug0 compound interactions nsubj *pose* dep drug0" 2 : "drug0 compound interactions nsubj *pose* dep drug0" } 4 : { 1 : "The extent to which drug1 - drug2 interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the drug3 involved . " 2 : "The extent to which drug1 - drug2 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drug3 involved . " } 5 : { 1 : 1 2 : 4 } } 114 : { 1 : "NN nmod VBN acl NN" 2 : 5 3 : { 1 : "drug0 nmod given acl *drug0*" 2 : "drug0 nmod given acl *drug0*" 3 : "drug0 nmod administered acl *drug0*" 4 : "drug0 nmod given acl *drug0*" 5 : "drug0 nmod given acl *drug0*" } 4 : { 1 : "drug1 given concomitantly with drug2 has been reported to increase the serum concentration and prolong the half-life of drug3 . " 2 : "Results of preliminary studies in humans and rats suggest that nonabsorbable drug1 given concurrently with drug2 may inhibit the desired drug3 - induced drop in colonic pH. " 3 : "There is insufficient experience to assess the safety and efficacy of drug1 administered concurrently with drug2 , and therefore such use is not recommended . " 4 : "drug1 : drug2 , given concomitantly with drug3 or 60 minutes following drug4 administration , decreased drug5 bioavailability by approximately 25 % . " 5 : "drug1 : drug2 , given concomitantly with drug3 , produces a reduction in urinary potassium and chloride excretion compared to drug4 alone . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 115 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN" 2 : 5 3 : { 1 : "drug0 nmod efficacy dobj *reduce* nsubj doses nmod drug0" 2 : "drug0 nmod mg dobj *receive* nsubj patients nmod drug0" 3 : "drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0" 4 : "drug0 nmod action dobj *reduce* nsubj drugs nmod drug0" 5 : "drug0 nmod metabolism dobj *inhibit* nsubj drugs nmod drug0" } 4 : { 1 : "However , high doses of drug1 may reduce the efficacy of intrathecally administered drug2 . " 2 : "Patients on drug1 should receive 70 mg of drug2 daily . " 3 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " 4 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . " 5 : "Drugs such as drug1 and drug2 may inhibit the metabolism of drug3 and thus decrease their clearance . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 116 : { 1 : "NN nmod NN compound NN" 2 : 5 3 : { 1 : "drug0 nmod *metabolism* compound drug0" 2 : "drug0 nmod *absorption* compound drug0" 3 : "drug0 nmod *use* compound drug0" 4 : "drug0 compound protection nmod *drug0*" } 4 : { 1 : "Increasing the drug1 dose to 1000 mg every 8 hours does not compensate for the increased drug2 metabolism due to drug3 . " 2 : "drug1 : drug2 ( drug3 , drug4 , drug5 , drug6 , fruit juices , etc. ) lower absorption of drug7 . " 3 : "May interact with the following : drug1 , drug2 ( use with drug3 may prevent the drug4 from working properly ; " 4 : "High-dose drug1 with drug2 protection . " } 5 : { 1 : 2 2 : 1 3 : 1 4 : 1 } } 117 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NN" 2 : 5 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod *used* nsubjpass drug0" 2 : "drug0 dobj taking acl patients nmod caution nmod *used* nsubjpass drug0" 3 : "drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass drug0" 4 : "drug0 dobj receiving acl patients nmod caution nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with caution in patients receiving drug2 . " 2 : "drug1 should be used with caution in patients taking drug2 , and renal function should be carefully monitored . " 3 : "drug1 should be administered with caution to patients receiving drug2 ( drug3 , Wyeth-Ayerst Laboratories ) . " 4 : "drug1 should be used with caution in patients receiving other local drug2 or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive . " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 } } 118 : { 1 : "NN conj NN dep NN nmod NNS nmod NNS acl VBN xcomp VB dobj NN nmod NN" 2 : 5 3 : { 1 : "drug0 conj drug0 dep inhibition nmod *examples* nmod drugs acl known xcomp inhibit dobj metabolism nmod drug0" } 4 : { 1 : "The following are examples of drugs known to inhibit the metabolism of other related drug1 , presumably through inhibition of CYP3A : drug2 , drug3 , drug4 , drug5 , drug6 , and some drug7 . " } 5 : { 1 : 5 } } 119 : { 1 : "NN conj NN conj NN" 2 : 5 3 : { 1 : "drug0 conj *drug0* conj drug0" 2 : "drug0 conj *drug0* conj drug0" 3 : "drug0 conj *drug0* conj drug0" 4 : "drug0 conj *drug0* conj drug0" 5 : "drug0 conj drug0 conj *drug0*" } 4 : { 1 : "Synergism between drug1 ( e.g. , drug2 ) , drug3 , and other drug4 has been reported . " 2 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " 3 : "Although drug1 or drug2 and drug3 may be useful in combination to control atrial fibrillation , their additive effects on AV node conduction can result in advanced or complete heart block . " 4 : "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of drug1 , drug2 and drug3 should not be co-administered . " 5 : "Interaction on the antinociceptive effect between drug1 and drug2 or drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 120 : { 1 : "NN nmod NN nsubjpass VBN nmod NNS nmod NN" 2 : 5 3 : { 1 : "drug0 nmod binding nsubjpass *reduced* nmod concentrations nmod drug0" 2 : "drug0 nmod drugs nmod *potentiated* nsubjpass action nmod drug0" 3 : "drug0 nmod drugs nmod *potentiated* nsubjpass action nmod drug0" 4 : "drug0 nmod inducers nmod *affected* nsubjpass metabolism nmod drug0" } 4 : { 1 : "In vitro studies indicate that , at therapeutic concentrations of drug1 ( 300 m g/mL ) , the binding of drug2 was reduced from approximately 99.2 % to 97.5 % , representing a potential twofold increase in unbound drug3 plasma levels . " 2 : "The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 and other drugs that are highly protein bound , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , and drug9 . " 3 : "Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 , some drug3 and other drugs that are highly protein bound , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 . " 4 : "Although no clinical studies have been conducted , it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers ( such as drug2 , drug3 , drug4 ) , CYP3A4 inhibitors ( azole antimycotics e.g. , drug5 ; " } 5 : { 1 : 1 2 : 2 3 : 1 4 : 1 } } 121 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBG dobj NN" 2 : 5 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod *containing* dobj drug0" 2 : "drug0 conj drug0 dobj receiving acl patients nmod *containing* dobj drug0" 3 : "drug0 conj drug0 dobj receiving acl patients nmod *administering* dobj drug0" } 4 : { 1 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 , drug5 or drug6 may produce severe , prolonged hypotension or hypertension . " 2 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 or drug5 may produce severe , prolonged hypertension . " 3 : "Therefore , EXTREME CAUTION should be exercised when administering drug1 to patients receiving drug2 or drug3 . " } 5 : { 1 : 2 2 : 2 3 : 1 } } 122 : { 1 : "NN dep NN" 2 : 5 3 : { 1 : "drug0 dep *drug0*" 2 : "drug0 dep *drug0*" 3 : "drug0 dep *drug0*" 4 : "drug0 dep *drug0*" 5 : "drug0 dep *drug0*" } 4 : { 1 : "drug1 : Sporadic cases of seizures have been reported during concomitant use of drug2 and drug3 ( drug4 , drug5 ) . " 2 : "Blood glucose concentrations should be carefully monitored when drug1 and oral drug2 are coadministered . " 3 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " 4 : "There have been reports of increased anticoagulant effects when drug1 and oral drug2 were used concomitantly . " 5 : "drug1 : There have been reports of increased anticoagulant effects when drug2 and oral drug3 were used concomitantly . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 5 : 1 } } 123 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 nmod d0-antagonists nmod *administered* nsubjpass drug0" 2 : "drug0 nmod hours nmod *taken* nsubjpass drug0" 3 : "drug0 nmod hours nmod *taken* nsubjpass drug0" 4 : "drug0 nmod patients nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should not be administered concurrently with D2-antagonists , such as drug2 , drug3 , drug4 , or drug5 . " 2 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " 3 : "drug1 should not be taken within 2 hours of drug2 . " 4 : "However , because bleeding has been reported when drug1 and other drug2 have been administered to patients on drug3 , the physician should be cautious when administering drug4 to patients on drug5 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 124 : { 1 : "NN nmod DT nmod VBN nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod any nmod *indicated* nmod coadministration nmod drug0" 2 : "drug0 nmod any nmod *indicated* nmod co-administration nmod drug0" } 4 : { 1 : "Nevertheless , caution is indicated in the coadministration of drug1 with any of the drug2 and also in switching from one class to the other . " 2 : "Nevertheless , caution is indicated in the co-administration of drug1 with any of the drug2 and also in switching from one class to the other . " } 5 : { 1 : 1 2 : 3 } } 125 : { 1 : "NN nsubjpass VBN advcl VBN nsubjpass NN nmod NN" 2 : 4 3 : { 1 : "drug0 nsubjpass discontinued advcl *compromised* nsubjpass efficacy nmod drug0" 2 : "drug0 nmod treatment nsubjpass *interrupted* advcl required nsubjpass drug0" 3 : "drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" 4 : "drug0 nsubjpass added advcl *reduced* nsubjpass clearance nmod drug0" } 4 : { 1 : "The therapeutic efficacy of drug1 may be compromised in these patients when drug2 is discontinued . " 2 : "If intravenous drug1 is required to treat Pneumocystis carinii pneumonia , treatment with drug2 should be interrupted . " 3 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " 4 : "Total body clearance of drug1 was reduced by an average 22 % and 51 % when drug2 and drug3 , respectively , were added to a regimen consisting of drug4 , USP ( MODIFIED ) and drug5 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 126 : { 1 : "NN conj NN nmod NN nmod VBN conj VBP acl:relcl NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod 0a0 nmod metabolized conj induce acl:relcl compounds nmod administration nmod *modified* nsubjpass metabolism nmod drug0" } 4 : { 1 : "In vitro studies have shown that the metabolism of drug1 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome P450 3A4 , such as drug2 , drug3 , drug4 , drug5 , and drug6 . " } 5 : { 1 : 4 } } 127 : { 1 : "NN compound NN nmod NN dobj VBD nsubj NN" 2 : 4 3 : { 1 : "drug0 compound auc nmod increase dobj *produced* nsubj drug0" 2 : "drug0 compound auc nmod increase dobj *produced* nsubj drug0" 3 : "drug0 compound phosphorylation nmod decrease dobj *caused* nsubj drug0" 4 : "drug0 compound activity nmod enhancement dobj *elicited* nsubj drug0" } 4 : { 1 : "drug1 ( 500 mg t.i.d ) produced a 4-fold increase in drug2 AUC and a 3-fold increase in Cmax when co-administered with drug3 5 mg in healthy volunteers . " 2 : "drug1 ( 200 mg once daily ) produced a 10-fold increase in drug2 AUC and a 4-fold increase in Cmax when co-administered with drug3 ( 5 mg ) in healthy volunteers . " 3 : "drug1 : drug2 caused a decrease in drug3 phosphorylation ( 50 % inhibition of total phosphate formation ) in U937/Molt 4 cells . " 4 : "drug1 elicited 62 % enhancement of post - drug2 lipolytic activity and 100 % increase of 3H-triglyceride fractional clearance rate compared with placebo treatment . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 128 : { 1 : "NN nmod NNS dobj VB xcomp VBN nsubjpass NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod effects dobj compromise xcomp *expected* nsubjpass administration nmod drug0" 2 : "drug0 nmod levels dobj increase xcomp *reported* nsubjpass administration nmod drug0" 3 : "drug0 nmod concentrations dobj elevate xcomp *shown* nsubjpass administration nmod drug0" } 4 : { 1 : "drug1 : Concurrent administration of certain drug2 , such as drug3 and drug4 , would be expected to compromise the beneficial effects of drug5 . " 2 : "Administration of drug1 has been reported to increase the plasma levels of drug2 , if given concomitantly . " 3 : "However , the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug2 , interfere with the metabolism of drug3 , and enhance the effects of the oral drug4 drug5 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drug6 concomitantly . " } 5 : { 1 : 2 2 : 1 3 : 1 } } 129 : { 1 : "NN conj NN dep NN conj NN nmod NNS nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" 2 : "drug0 conj drug0 dep drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isoenzyme , including other drug2 , drug3 , drug4 , and drug5 ( eg , drug6 , drug7 , and drug8 ) , or that inhibit this enzyme ( eg , drug9 ) , should be approached with caution . " 2 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isozyme , including drug2 , drug3 , drug4 , and drug5 ( e.g. , drug6 , drug7 and drug8 ) , or that inhibit this enzyme ( e.g. , drug9 ) , should be approached with caution . " } 5 : { 1 : 2 2 : 2 } } 130 : { 1 : "NN compound NN dobj VB dep NN" 2 : 4 3 : { 1 : "drug0 compound hypokalemia dobj potentiate dep *drug0*" 2 : "drug0 dep *inhibit* dobj binding compound drug0" 3 : "drug0 compound action dobj decrease dep *drug0*" 4 : "drug0 compound reduction dobj consider dep *drug0*" } 4 : { 1 : "drug1 and drug2 ( drug3 ) : may potentiate drug4 - induced hypokalemia which may predispose the patient to cardiac dysfunction . " 2 : "Binding to Serum Proteins : The following agents may either inhibit drug1 binding to serum proteins or alter the concentrations of serum binding proteins : drug2 and related drug3 , drug4 , drug5 , drug6 and drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 . " 3 : "drug1 : May decrease drug2 anti-inflammatory action by competing for the same receptors . " 4 : "drug1 , drug2 , drug3 ( consider drug4 dose reduction ) . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 131 : { 1 : "NN nmod VBN nsubjpass NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod *administered* nsubjpass drug0 conj drug0" 2 : "drug0 nmod *used* nsubjpass drug0 conj drug0" 3 : "drug0 nmod *administered* nsubjpass drug0 conj drug0" 4 : "drug0 nmod *used* nsubjpass drug0 conj drug0" } 4 : { 1 : "Because both of these drugs have negative inotropic properties and the effects of coadministration with drug1 are unknown , neither drug2 nor drug3 should be administered concurrently with drug4 unless , in the judgment of the physician , the benefits of this combination outweigh the risks . " 2 : "- When drug1 or drug2 is used concurrently with drug3 ( e.g. drug4 ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of drug5 or drug6 is impaired " 3 : "- drug1 or drug2 ( with hepatotoxic potential ) must not be administered together with drug3 or drug4 . " 4 : "Prolonged recovery time may occur if drug1 and/or drug2 are used concurrently with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 132 : { 1 : "NN conj NN dep NN conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep drug0 conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 4 } } 133 : { 1 : "NN nmod NNS dobj VBZ nsubj NN" 2 : 4 3 : { 1 : "drug0 nmod effects dobj *blocks* nsubj drug0" 2 : "drug0 nmod effects dobj *has* nsubj drug0" 3 : "drug0 nmod actions dobj *amplifies* nsubj drug0" 4 : "drug0 nmod effects dobj *potentiates* nsubj drug0" } 4 : { 1 : "drug1 blocks the central effects of drug2 by competitive interaction at the receptor level . " 2 : "drug1 has additive effects with drug2 and other drug3 ( drug4 , drug5 , drug6 , etc ) . " 3 : "If drug1 is given concomitantly with drug2 , the drug3 dose should be reduced ( by approx . 50 % ) , because drug4 amplifies the therapeutic actions and side-effects of drug5 massively . " 4 : "drug1 attenuates , but drug2 potentiates , the acute locomotor effects of drug3 ; " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 134 : { 1 : "NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 nsubjpass started advcl *decreased* nsubjpass drug0" 2 : "drug0 nsubjpass *considered* advcl co-administered nsubjpass drug0" 3 : "drug0 nsubjpass *taken* advcl required nsubjpass drug0" 4 : "drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free drug1 may be decreased when drug2 are started thus increasing drug3 requirements . " 2 : "When drug1 is co-administered with inducers of drug clearance , such as drug2 , drug3 , drug4 , drug5 , or drug6 , use of a daily dose of 70 mg of drug7 should be considered " 3 : "If drug1 are required during drug2 therapy , drug3 should be taken at least 2 hours before or after the supplement . " 4 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 135 : { 1 : "NN conj NN nmod VBN advcl VB nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod coadministered advcl *result* nsubj use nmod drug0" } 4 : { 1 : "The use of drug1 may result in additive CNS depressant effects when coadministered with drug2 , drug3 , drug4 or other drugs that produce CNS depression . " } 5 : { 1 : 4 } } 136 : { 1 : "NN conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NNS nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod agents nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug2 ( e. g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 ) , drug11 salts , drug12 , local drug13 , drug14 , and drug15 . " } 5 : { 1 : 4 } } 137 : { 1 : "NN nmod NN dobj VBD nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod auc dobj *doubled* nsubj administration nmod drug0" 2 : "drug0 nmod concentration dobj *decreased* nsubj coadministration nmod drug0" 3 : "drug0 nmod concentration dobj *increased* nsubj coadministration nmod drug0" 4 : "drug0 nmod exposure dobj *increased* nsubj coadministration nmod drug0" } 4 : { 1 : "Concomitant administration of drug1 doubled the AUC for drug2 . " 2 : "Coadministration of drug1 decreased the maximum plasma concentration of drug2 by 6 % , decreased clearance by 38 % , and increased half-life by 58 % . " 3 : "Coadministration of oral drug1 increased the maximum plasma concentration of drug2 by 18 % , decreased clearance by 22 % , and increased half-life by 29 % . " 4 : "Coadministration with drug1 increased exposure of drug2 ( AUC ) by 46 % . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 138 : { 1 : "NN nmod VBG dobj NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod *receiving* dobj drug0 conj drug0" 2 : "drug0 nmod *using* dobj drug0 conj drug0" } 4 : { 1 : "Patients receiving other drug1 , drug2 , drug3 , or other drug4 ( including drug5 ) concomitantly with drug6 and drug7 tablets may exhibit an additive CNS depression . " 2 : "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using drug1 or drug2 concomitantly with drug3 . " } 5 : { 1 : 3 2 : 1 } } 139 : { 1 : "NN conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 4 } } 140 : { 1 : "NN nmod VBN nsubjpass NNS nmod NNS nmod NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod *exacerbated* nsubjpass effects nmod properties nmod drug0 conj drug0" } 4 : { 1 : "The effects of medicinal products with similar properties such as inotropes drug1 , drug2 , drug3 , drug4 and drug5 may be exacerbated by drug6 . " } 5 : { 1 : 4 } } 141 : { 1 : "NN conj NN nmod NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 4 } } 142 : { 1 : "NN nmod VBN advcl VB xcomp VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0" 2 : "drug0 nmod given advcl produce xcomp *reported* nsubjpass drug0" 3 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0" 4 : "drug0 nmod given advcl have xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 ( drug2 ) : drug3 ( e.g. , drug4 , drug5 , drug6 , drug7 ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drug8 . " 2 : "drug1 ( drug2 ) has been reported to produce ANTABUSE-like side effects when given concomitantly with drug3 . " 3 : "drug1 ( drug2 ) ( e.g. , drug3 , drug4 , drug5 , drug6 ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drug7 . " 4 : "drug1 has been shown to have an additive CNS depressant effect when given with either drug2 , drug3 , drug4 or drug5 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 143 : { 1 : "NN nmod VBN advcl VB xcomp VBN nsubjpass NN dep NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0 conj drug0" 2 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0 conj drug0" } 4 : { 1 : "drug1 ( drug2 ) : drug3 ( e.g. , drug4 , drug5 , drug6 , drug7 ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drug8 . " 2 : "drug1 ( drug2 ) ( e.g. , drug3 , drug4 , drug5 , drug6 ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drug7 . " } 5 : { 1 : 2 2 : 2 } } 144 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NNS dep NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod produced acl tendency dobj *increase* nsubj drugs dep drug0 conj drug0" } 4 : { 1 : "Drugs that reduce the number of blood platelets by causing bone marrow depression ( such as drug1 ) or drugs which inhibit platelet function ( eg , drug2 and other drug3 , drug4 , drug5 , drug6 , drug7 ) may increase the bleeding tendency produced by drug8 without altering prothrombin time determinations . " } 5 : { 1 : 4 } } 145 : { 1 : "NN conj NN conj VB nsubj NN compound NN" 2 : 4 3 : { 1 : "drug0 conj drug0 conj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 4 } } 146 : { 1 : "NN nmod NN nmod NN nmod NN dobj VBN acl:relcl NN nmod VBN nsubjpass NN dep NN conj NN" 2 : 4 3 : { 1 : "drug0 nmod drug0 nmod therapy nmod course dobj received acl:relcl patient nmod *administered* nsubjpass drug0 dep drug0 conj drug0" } 4 : { 1 : "Interactions with drug1 : drug2 ( eg , drug3 , drug4 , drug5 , drug6 and drug7 ) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug8 such as drug9 . " } 5 : { 1 : 4 } } 147 : { 1 : "NN appos NN dep NN conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 4 3 : { 1 : "drug0 appos drug0 dep drug0 conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 4 } } 148 : { 1 : "NN conj NN nmod NN conj NNS nmod NNS dobj VB nsubj NN conj NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod drug0 conj s nmod effects dobj *enhance* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 4 } } 149 : { 1 : "NN conj NN dep NN conj NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep drug0 conj *drug0*" } 4 : { 1 : "If concomitant treatment with drug1 and an drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) is clinically warranted , appropriate observation of the patient is advised . " } 5 : { 1 : 4 } } 150 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NN" 2 : 4 3 : { 1 : "drug0 nmod seen acl hypotension dobj *potentiate* nsubj drug0" 2 : "drug0 nmod observed acl depression dobj *exaggerate* nsubj drug0" 3 : "drug0 nmod caused acl loss dobj *attenuate* nsubj drug0" 4 : "drug0 nmod produced acl blockade dobj *antagonize* nsubj drug0" } 4 : { 1 : "Although drug1 have been shown to reduce drug2 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drug3 may reduce the antitumor effectiveness of drug4 and thus should be avoided . 12 drug5 and other drug6 may potentiate the hypotension seen with drug7 . " 2 : "drug1 could exaggerate the depression of AV nodal conduction observed with drug2 . " 3 : "drug1 Supplements and drug2 : drug3 can attenuate potassium loss caused by drug4 . " 4 : "drug1 may antagonize the neuron blockade produced by drug2 resulting in decreased antihypertensive effect and requiring increased dosage of the latter . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 151 : { 1 : "NN conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0 nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 4 } } 152 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBG dobj NN conj NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod *containing* dobj drug0 conj drug0" 2 : "drug0 conj drug0 dobj receiving acl patients nmod *containing* dobj drug0 conj drug0" } 4 : { 1 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 , drug5 or drug6 may produce severe , prolonged hypotension or hypertension . " 2 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 or drug5 may produce severe , prolonged hypertension . " } 5 : { 1 : 2 2 : 2 } } 153 : { 1 : "NN compound NN dobj VBD nsubj NN" 2 : 4 3 : { 1 : "drug0 compound half-life dobj *increased* nsubj drug0" 2 : "drug0 compound phosphorylation dobj *inhibited* nsubj drug0" 3 : "drug0 compound phosphorylation dobj *inhibited* nsubj drug0" 4 : "drug0 compound binding dobj *decreased* nsubj drug0" } 4 : { 1 : "Concurrent administration of drug1 and drug2 may cause severe orthostatic hypotension . drug3 , an inhibitor of microsomal drug metabolism , increased drug4 s half-life and toxicity in a rat model . " 2 : "drug1 : In vitro studies in peripheral blood mononuclear cells , U937 and Molt-4 cells revealed that drug2 significantly inhibited drug3 phosphorylation in a dose dependent manner . " 3 : "drug1 inhibited drug2 phosphorylation at high concentration ratios ( 10 and 100 ) ; " 4 : "drug1 : The addition of drug2 to patients taking drug3 chronically had no effect on drug4 pharmacokinetics , but drug5 significantly decreased drug6 binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 154 : { 1 : "NN conj NN dep NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 4 } } 155 : { 1 : "NN compound NN nmod VBN acl NNS nmod NN nmod VBN conj VB nsubj NN conj NNS nmod NN conj NN" 2 : 4 3 : { 1 : "drug0 compound parenteral nmod treated acl patients nmod caution nmod used conj *potentiate* nsubj drug0 conj drugs nmod ether conj drug0" } 4 : { 1 : "drug1 ( eg , drug2 ) and other drugs , including ether , drug3 , drug4 , drug5 and drug6 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug7 Parenteral . " } 5 : { 1 : 4 } } 156 : { 1 : "NN nmod NN nmod VBD nsubj NN" 2 : 4 3 : { 1 : "drug0 nmod administration nmod *attenuated* nsubj drug0" 2 : "drug0 nmod curve nmod *increased* nsubj drug0" 3 : "drug0 nmod curve nmod *increased* nsubj drug0" 4 : "drug0 nmod administration nmod *produced* nsubj drug0" } 4 : { 1 : "drug1 attenuated the heart rate increase following administration of immediate release drug2 . " 2 : "drug1 : In the fed state , drug2 ( 40 mg/kg ) increased mean maximum plasma concentration and area under the curve of drug3 by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given drug4 alone . " 3 : "drug1 significantly increased the area under the curve at steady state ( AUC ( ss ) ) of drug2 by 2.93-fold and the AUC ( ss ) of drug3 by 13.3-fold . " 4 : "drug1 produced significantly increased vasoconstriction after a single administration of drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 157 : { 1 : "NN conj NN nmod VBN acl NNS nmod VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod treated acl patients nmod *administered* nsubjpass drug0" 2 : "drug0 conj drug0 nmod treated acl patients nmod *titrated* nsubjpass drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " 2 : "Although the interactions observed in these studies do not appear to be of major clinical importance , drug1 should be titrated with caution in patients being treated concurrently with drug2 , drug3 , drug4 or drug5 . " } 5 : { 1 : 1 2 : 3 } } 158 : { 1 : "NN conj NN nmod NNS conj NN nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod inhibitors conj drug0 nmod *use* nmod drug0" } 4 : { 1 : "The concomitant use of transdermal drug1 with drug2 or other potent 3A4 inhibitors such as drug3 , drug4 , drug5 , drug6 , drug7 , and nefazadone may result in an increase in drug8 plasma concentrations . " } 5 : { 1 : 4 } } 159 : { 1 : "NN compound NNS nmod NN nmod VB xcomp VBN nmod NN nmod NN nmod NN conj NN" 2 : 4 3 : { 1 : "drug0 compound concentrations nmod increase nmod lead xcomp *expected* nmod basis nmod metabolism nmod 0a0 conj drug0" } 4 : { 1 : "On the basis of the metabolism of drug1 by cytochrome P450 3A4 , drug2 , drug3 , drug4 , drug5 , grapefruit juice , and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug6 concentrations . " } 5 : { 1 : 4 } } 160 : { 1 : "NN compound NN nmod VBN acl NN dobj VB nsubj NN" 2 : 4 3 : { 1 : "drug0 compound therapy nmod associated acl loss dobj *accentuate* nsubj drug0" 2 : "drug0 compound withdrawl nmod seen acl response dobj *exacerbate* nsubj drug0" 3 : "drug0 compound scintigraphy nmod seen acl uptake dobj *cause* nsubj drug0" } 4 : { 1 : "drug1 may accentuate the electrolyte loss associated with drug2 therapy . " 2 : "drug1 may exacerbate the hypertensive response seen with drug2 withdrawl . " 3 : "Due to its nephrotoxicity , drug1 may cause abnormal renal uptake to be seen on drug2 bone scintigraphy . " } 5 : { 1 : 2 2 : 1 3 : 1 } } 161 : { 1 : "NN conj NN dep NN dobj VBP nsubj NNS nmod NNS nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep interaction dobj *suggest* nsubj data nmod studies nmod drug0" } 4 : { 1 : "Data from in vitro studies of drug1 other than drug2 suggest a possible drug interaction for the following : drug3 , drug4 , drug5 , drug6 , and drug7 . " } 5 : { 1 : 4 } } 162 : { 1 : "NN nmod NN dobj VB nsubj NN compound NN" 2 : 4 3 : { 1 : "drug0 nmod effect dobj *increase* nsubj deficiency compound drug0" 2 : "drug0 nmod effect dobj *enhance* nsubj hypokalemia compound drug0" 3 : "drug0 nmod drug0 dobj *occur* nsubj syndrome compound drug0" 4 : "drug0 nmod requirement dobj *increase* nsubj administration compound drug0" } 4 : { 1 : "drug1 or drug2 excess may decrease the effect of drug3 , and an drug4 deficiency can increase the effect of drug5 . " 2 : "drug1 : drug2 - induced hypokalemia may enhance the curariform effect of drug3 ( e.g. , drug4 ) . " 3 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " 4 : "drug1 administration to a digitalized , hypothyroid patient may increase the dose requirement of drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 163 : { 1 : "NN compound NNS dobj VB xcomp VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 compound concentrations dobj affect xcomp *reported* nsubjpass drug0" 2 : "drug0 compound levels dobj increase xcomp *reported* nsubjpass drug0" 3 : "drug0 compound levels dobj raise xcomp *known* nsubjpass drug0" 4 : "drug0 compound requirements dobj increase xcomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 ( drug2 ) is also reported to affect drug3 concentrations adversely . " 2 : "drug1 : drug2 have been reported to increase steadystate plasma drug3 levels . " 3 : "drug1 is known to raise serum drug2 levels . " 4 : "drug1 has been reported to increase the drug2 requirements in human subjects ingesting these agents simultaneously . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 164 : { 1 : "NN conj NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nsubjpass *considered* advcl co-administered nsubjpass drug0" } 4 : { 1 : "When drug1 is co-administered with inducers of drug clearance , such as drug2 , drug3 , drug4 , drug5 , or drug6 , use of a daily dose of 70 mg of drug7 should be considered " } 5 : { 1 : 4 } } 165 : { 1 : "NN conj NN nmod VBN advcl VBZ nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod administered advcl *produces* nsubj injection nmod drug0" } 4 : { 1 : "Injection : drug1 injection , like other injectable drug2 , produces depression of the central nervous system when administered with drug3 , drug4 , drug5 , drug6 , and other drug7 . When drug8 is used concomitantly with injectable drug9 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed . " } 5 : { 1 : 4 } } 166 : { 1 : "NN conj NN dep NN dobj VBP nsubj NNS nmod NNS nmod NN amod JJ nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep interaction dobj *suggest* nsubj data nmod studies nmod drug0 amod other nmod drug0" } 4 : { 1 : "Data from in vitro studies of drug1 other than drug2 suggest a possible drug interaction for the following : drug3 , drug4 , drug5 , drug6 , and drug7 . " } 5 : { 1 : 4 } } 167 : { 1 : "NN conj NN dep NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep drug0 nmod effect nmod possibility nsubjpass *considered* advcl conducted nmod drug0" } 4 : { 1 : "Although specific drug interaction studies have not been conducted with drug1 , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , or drug7 ) should be considered . " } 5 : { 1 : 4 } } 168 : { 1 : "NN nmod NNS dobj VBD nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod values dobj *increased* nsubj coadministration nmod drug0" 2 : "drug0 nmod concentrations dobj *decreased* nsubj co-administration nmod drug0" 3 : "drug0 nmod concentrations dobj *decreased* nsubj co-administration nmod drug0" 4 : "drug0 nmod concentrations dobj *decreased* nsubj co-administration nmod drug0" } 4 : { 1 : "Oral drug1 : Coadministration of drug2 and an oral drug3 increased AUC values for drug4 and drug5 by approximately 30 % and 20 % . " 2 : "Co-administration of drug1 decreased the plasma concentrations of drug2 ( a CYP3A4 substrate ) by approximately 50 % . " 3 : "Co-administration of drug1 decreased the plasma concentrations of drug2 by approximately 40 % . " 4 : "drug1 and Other drug2 : Co-administration of drug3 decreased the plasma concentrations of drug4 ( a CYP3A4 substrate ) , and its active - hydroxy acid metabolite , by approximately 50 % . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 169 : { 1 : "NN conj NN dep NNS nmod VBN advcl VB nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dep inhibitors nmod coadministered advcl *exceed* nsubj dose nmod drug0" } 4 : { 1 : "The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors ( e.g. , drug2 , drug3 , drug4 , drug5 , drug6 and nefazadone ) . " } 5 : { 1 : 4 } } 170 : { 1 : "NN conj NN dobj VBG acl NN nmod VBN advcl VBN nsubjpass NNS nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 nmod administered advcl *decreased* nsubjpass concentrations nmod drug0" 2 : "drug0 conj drug0 dobj containing acl drug0 nmod administered advcl *decreased* nsubjpass concentrations nmod drug0" } 4 : { 1 : "drug1 s : drug2 should be administered at least 2 hours after or 6 hours before dosing with drug3 because plasma concentrations of drug4 are decreased when administered with drug5 containing drug6 , drug7 , or drug8 . " 2 : "Plasma concentrations of drug1 are decreased when administered with drug2 containing drug3 , drug4 , or drug5 . " } 5 : { 1 : 2 2 : 2 } } 171 : { 1 : "NN compound NN nmod VB nsubj NN appos NN conj NN" 2 : 4 3 : { 1 : "drug0 compound absorption nmod *interfere* nsubj drug0 appos pectin conj drug0" } 4 : { 1 : "drug1 , drug2 - pectin , drug3 , drug4 , drug5 , certain anticancer drugs , and drug6 may interfere with intestinal drug7 absorption , resulting in unexpectedly low serum concentrations . " } 5 : { 1 : 4 } } 172 : { 1 : "NN compound NN dobj VB nsubj NN conj NN" 2 : 4 3 : { 1 : "drug0 compound vasodilation dobj *suppress* nsubj drug0 conj drug0" 2 : "drug0 compound absorption dobj *increase* nsubj drug0 conj drug0" 3 : "drug0 compound absorption dobj *increase* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 ( such as drug2 ) and drug3 can suppress the drug4 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion . " 2 : "drug1 and drug2 ( and possibly other drug3 ) and drug4 may increase drug5 absorption in patients who inactivate drug6 by bacterial metabolism in the lower intestine , so that drug7 intoxication may result . " 3 : "drug1 and drug2 , by decreasing gut motility , may increase drug3 absorption . " } 5 : { 1 : 1 2 : 2 3 : 1 } } 173 : { 1 : "NN nmod NN nmod NN dobj VBZ nsubj NN" 2 : 4 3 : { 1 : "drug0 nmod excretion nmod rate dobj *increases* nsubj drug0" 2 : "drug0 nmod clearance nmod doubling dobj *causes* nsubj drug0" 3 : "drug0 nmod clearance nmod increase dobj *causes* nsubj drug0" 4 : "drug0 nmod interaction nmod potential dobj *has* nsubj drug0" } 4 : { 1 : "Because drug1 has not been shown to produce any additional effect beyond that obtained with drug2 alone and because drug3 increases the rate of excretion of drug4 , the concomitant use of drug5 and drug6 is not recommended . " 2 : "Effects of Other drug1 on drug2 drug3 : drug4 causes an approximate doubling of the clearance of drug5 ( drug6 ) at steady state and , therefore , the addition of drug7 causes an approximate 45 % decrease in the steady-state trough concentrations of drug8 as compared to the same dose of drug9 given as monotherapy . " 3 : "drug1 : drug2 causes an approximate 50 % increase in the clearance of drug3 at steady state and , therefore , the addition of drug4 results in an approximate 40 % decrease in the steady-state trough concentrations of drug5 as compared to the same dose of drug6 given as monotherapy . " 4 : "Therefore , drug1 has the potential for interaction with drug2 and drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 174 : { 1 : "NN nmod NN dobj VBZ nsubj NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod half-life dobj *decreases* nsubj coadministration nmod drug0" 2 : "drug0 nmod elimination dobj *decreases* nsubj administration nmod drug0" 3 : "drug0 nmod clearance dobj *increases* nsubj use nmod drug0" 4 : "drug0 nmod depletion dobj *produces* nsubj injection nmod drug0" } 4 : { 1 : "The coadministration of drug1 decreases the biologic half-life of drug2 because of an increase in metabolic clearance that results in a greater amount of drug3 in the urine . " 2 : "drug1 or drug2 : Concomitant administration of drug3 or drug4 decreases the elimination of drug5 , most likely by inhibition of renal tubular secretion of drug6 . " 3 : "Concurrent use of drug1 increases the metabolic clearance of drug2 , resulting in a shortened elimination half-life of drug3 . " 4 : "An intravenous injection of drug1 given later also produces a complete and immediately beginning depletion of drug2 already accumulated in the thyroid , within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 175 : { 1 : "NN conj NN nmod VBN advcl VBZ nsubj NN compound NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod administered advcl *produces* nsubj injection compound drug0" } 4 : { 1 : "Injection : drug1 injection , like other injectable drug2 , produces depression of the central nervous system when administered with drug3 , drug4 , drug5 , drug6 , and other drug7 . When drug8 is used concomitantly with injectable drug9 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed . " } 5 : { 1 : 4 } } 176 : { 1 : "NN dobj VBG advcl VBG dobj NN" 2 : 4 3 : { 1 : "drug0 dobj taking advcl *taking* dobj drug0" 2 : "drug0 dobj drinking advcl *taking* dobj drug0" 3 : "drug0 dobj starting advcl *stopping* dobj drug0" 4 : "drug0 dobj starting advcl *stopping* dobj drug0" } 4 : { 1 : "In the case that you are taking drug1 while taking drug2 , higher doses of drug3 may be needed . " 2 : "Taking drug1 after drinking drug2 may worsen side effects and may cause severe hypotension and cardiovascular collapse . " 3 : "Wait 5 weeks after stopping drug1 before starting a drug2 . " 4 : "Wait 2 weeks after stopping an drug1 before starting drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 4 : 1 } } 177 : { 1 : "NN nmod NN nmod VBN conj VB dep VBG dep NN" 2 : 3 3 : { 1 : "drug0 nmod therapy nmod taken conj cause dep *containing* dep drug0" } 4 : { 1 : "drug1 : drug2 - containing preparations ( eg , drug3 ) may cause hypermagnesemia and should therefore not be taken during therapy with drug4 by patients on chronic renal dialysis . " } 5 : { 1 : 3 } } 178 : { 1 : "NN appos NN nmod NN nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 appos drug0 nmod therapy nmod *use* nmod drug0" 2 : "drug0 nmod therapy nmod *use* nmod drug0 appos drug0" 3 : "drug0 appos drug0 nmod drug0 nmod *co-administration* nmod drug0" } 4 : { 1 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . " 2 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . " 3 : "Spontaneous reports of serotonin syndrome associated with co-administration of drug1 and drug2 , including drug3 such as drug4 ( drug5 ) , have been reported . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 179 : { 1 : "NN appos NN conj NN nmod NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 3 3 : { 1 : "drug0 appos drug0 conj drug0 nmod drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 3 } } 180 : { 1 : "NN compound NN appos NN dep NN nsubj VBD dep NNS nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 compound qd appos mg dep drug0 nsubj resulted dep inhibitors nmod *administration* nmod drug0" 2 : "drug0 compound tid appos mg dep drug0 nsubj resulted dep inhibitors nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with other CYP3A4 inhibitors ( e.g. , drug2 500 mg BID , drug3 240 mg QD , drug4 1200 mg TID , drug5 200 mg QD ) resulted in increases in Cmax of drug6 ranging from 1.4 - to 1.6 - fold and AUC from 2.0 - to 2.9 - fold . " 2 : "Administration of drug1 with other CYP3A4 inhibitors ( e.g. , drug2 500 mg BID , drug3 240 mg QD , drug4 1200 mg TID , drug5 200 mg QD ) resulted in increases in Cmax of drug6 ranging from 1.4 - to 1.6 - fold and AUC from 2.0 - to 2.9 - fold . " } 5 : { 1 : 2 2 : 1 } } 181 : { 1 : "NN dobj VBG acl NNS nmod NN" 2 : 3 3 : { 1 : "drug0 dobj receiving acl hours nmod *drug0*" 2 : "drug0 dobj taking acl women nmod *drug0*" 3 : "drug0 nmod *patients* acl receiving dobj drug0" } 4 : { 1 : "drug1 - In one report , drug2 at a dose of 10 grams three times daily , given 24 hours after receiving drug3 , appeared to prevent the development of myalgia and arthralgia , adverse reactions of drug4 . " 2 : "These increased exposures of drug1 and drug2 should be taken into consideration when selecting an oral drug3 for women taking drug4 . " 3 : "drug1 / drug2 : An increase in the frequency of skin rash has been reported among patients receiving drug3 or drug4 concurrently with drug5 compared to patients who are not receiving both drugs . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 182 : { 1 : "NN conj NN conj NN dobj VB nsubj NN compound NN" 2 : 3 3 : { 1 : "drug0 conj drug0 conj drug0 dobj *occur* nsubj syndrome compound drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 3 } } 183 : { 1 : "NN conj NN dep NN nmod NN nmod NNS acl VBG dobj NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 3 } } 184 : { 1 : "NN nmod VBN acl NNS nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 nmod treated acl patients nmod *administered* nsubjpass drug0" 2 : "drug0 nmod treated acl patients nmod *titrated* nsubjpass drug0" 3 : "drug0 nmod treated acl rats nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " 2 : "Although the interactions observed in these studies do not appear to be of major clinical importance , drug1 should be titrated with caution in patients being treated concurrently with drug2 , drug3 , drug4 or drug5 . " 3 : "Core temperature was decreased in rats in a dose-dependent manner when drug1 was administered to rats treated with drug2 8 hours before the drug3 challenge . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 185 : { 1 : "NN conj NN conj NN dobj VB advcl VBN nsubjpass NNS nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 conj drug0 dobj *occur* advcl administered nsubjpass agents nmod drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 3 } } 186 : { 1 : "NN conj VBG conj NN" 2 : 3 3 : { 1 : "drug0 conj *containing* conj drug0" 2 : "drug0 conj *containing* conj drug0" 3 : "drug0 conj *containing* conj drug0" } 4 : { 1 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided . " 2 : "Due to a theoretical risk of a pharmacodynamic interaction , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided ( see a href = frova_od . htm #CI CONTRAINDICATIONS ) . " 3 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours is contraindicated . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 187 : { 1 : "NN nmod DT nmod JJ nsubj NNS nmod NN" 2 : 3 3 : { 1 : "drug0 nmod those nmod *additive* nsubj effects nmod drug0" } 4 : { 1 : "The vasodilating effects of drug1 may be additive with those of other drug2 . " } 5 : { 1 : 3 } } 188 : { 1 : "NN nmod VBN nsubjpass NNS compound NN" 2 : 3 3 : { 1 : "drug0 nmod *potentiated* nsubjpass effects compound drug0" 2 : "drug0 nmod *administered* nsubjpass capsules compound drug0" 3 : "drug0 nmod *increased* nsubjpass levels compound drug0" } 4 : { 1 : "drug1 effects are potentiated by drug2 . " 2 : "Therefore , close monitoring of prothrombin time is recommended and adjustment of the drug1 dose may be necessary when drug2 Capsules are administered concomitantly with drug3 . " 3 : "drug1 : Serum drug2 levels may be increased by drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 189 : { 1 : "NN conj NN nmod NN nmod NN nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod combination nmod *administered* nsubjpass drug0" } 4 : { 1 : "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug1 is administered in combination with other drug2 such as drug3 , drug4 , drug5 , or inhalation general drug6 . " } 5 : { 1 : 3 } } 190 : { 1 : "NN nmod NN nmod VB nsubj NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod effect nmod *interfere* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 : drug2 , drug3 , drug4 , or drug5 may interfere with the bactericidal effect of drug6 . " } 5 : { 1 : 3 } } 191 : { 1 : "NN nmod JJ dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod synthetic dobj *inhibit* nsubj drug0" } 4 : { 1 : "drug1 : drug2 may inhibit both synthetic and catabolic enzymes of drug3 . " } 5 : { 1 : 3 } } 192 : { 1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 nmod combination nmod *administered* nsubjpass drug0" 2 : "drug0 nmod blockade nmod prolongation nmod *implicated* nsubjpass drug0" 3 : "drug0 nmod dose nmod conjunction nmod *administered* nsubjpass drug0" } 4 : { 1 : "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when drug1 is administered in combination with other drug2 such as drug3 , drug4 , drug5 , or inhalation general drug6 . " 2 : "drug1 : When used in the perioperative period , drug2 has been implicated in the prolongation of the neuromuscular blockade of drug3 . " 3 : "When drug1 was administered ( at a dose of 60 mg BID ) in conjunction with a single 50-mg dose of drug2 , a CYP2D6 substrate , the AUC of drug3 increased 3-fold . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 193 : { 1 : "NN conj VBG nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 conj *containing* nmod drug0 conj drug0" 2 : "drug0 conj *containing* nmod drug0 conj drug0" 3 : "drug0 conj *containing* nmod drug0 conj drug0" } 4 : { 1 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided . " 2 : "Due to a theoretical risk of a pharmacodynamic interaction , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided ( see a href = frova_od . htm #CI CONTRAINDICATIONS ) . " 3 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours is contraindicated . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 194 : { 1 : "NN nmod NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NN compound NN" 2 : 3 3 : { 1 : "drug0 nmod treatment dobj undergoing acl patients nmod care nmod *determined* nsubjpass dosage compound drug0" } 4 : { 1 : "drug1 : drug2 dosage must be determined with care in patients undergoing treatment with drug3 , as hypercalcemia in such patients may precipitate cardiac arrhythmias . " } 5 : { 1 : 3 } } 195 : { 1 : "NN conj VBG nmod NN" 2 : 3 3 : { 1 : "drug0 conj *containing* nmod drug0" 2 : "drug0 conj *containing* nmod drug0" 3 : "drug0 conj *containing* nmod drug0" } 4 : { 1 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided . " 2 : "Due to a theoretical risk of a pharmacodynamic interaction , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided ( see a href = frova_od . htm #CI CONTRAINDICATIONS ) . " 3 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours is contraindicated . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 196 : { 1 : "NN nmod NN dobj VB dep NN" 2 : 3 3 : { 1 : "drug0 nmod secretion dobj decrease dep *drug0*" 2 : "drug0 dep *bind* dobj absorption nmod drug0" 3 : "drug0 nmod metabolism dobj increase dep *drug0*" } 4 : { 1 : "drug1 : May decrease renal tubular secretion of drug2 resulting in increased blood levels and/or drug3 toxicity . " 2 : "drug1 Absorption : The following agents may bind and decrease absorption of drug2 from the gastrointestinal tract : drug3 , drug4 resin , drug5 , drug6 , drug7 , soybean flour ( e.g. , infant formula ) , drug8 . " 3 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 197 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod *augmented* nsubjpass effect nmod drug0 conj drug0" 2 : "drug0 nmod *enhanced* nsubjpass action nmod drug0 conj drug0" 3 : "drug0 conj drug0 nmod administration nsubjpass *recommended* nmod drug0" } 4 : { 1 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . " 2 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . " 3 : "drug1 : As with other drug2 , concomitant administration of drug3 and drug4 is not generally recommended because of the potential of increased adverse effects . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 198 : { 1 : "NN nmod NN nmod VBN conj VB dep VBG dobj NNS dep FW appos NN" 2 : 3 3 : { 1 : "drug0 nmod therapy nmod taken conj cause dep *containing* dobj preparations dep eg appos drug0" } 4 : { 1 : "drug1 : drug2 - containing preparations ( eg , drug3 ) may cause hypermagnesemia and should therefore not be taken during therapy with drug4 by patients on chronic renal dialysis . " } 5 : { 1 : 3 } } 199 : { 1 : "NN conj NN nmod NN nmod NN dobj VB nsubj NN compound NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod medication nmod absorption dobj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 3 } } 200 : { 1 : "NN nmod NNS nmod VBG dobj NN" 2 : 3 3 : { 1 : "drug0 nmod drugs nmod *receiving* dobj drug0" 2 : "drug0 nmod patients nmod *administering* dobj drug0" } 4 : { 1 : "drug1 : drug2 toxicity has been reported in patients receiving drug3 concomitantly with drugs which cause elimination of sodium , including drug4 . " 2 : "However , because bleeding has been reported when drug1 and other drug2 have been administered to patients on drug3 , the physician should be cautious when administering drug4 to patients on drug5 . " } 5 : { 1 : 2 2 : 1 } } 201 : { 1 : "NN nmod NN root , punct NNS nmod CC root , punct IN dep VBN nsubjpass NN conj NNS acl VBG dobj NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod administration root , punct hours nmod or root , punct with dep *administered* nsubjpass drug0 conj products acl containing dobj drug0 conj drug0" } 4 : { 1 : "drug1 , or other products containing drug2 or drug3 , drug4 or drug5 should not be administered concomitantly with , or within 2 hours of , the administration of drug6 , because they may interfere with absorption resulting in lower serum and urine levels of drug7 . " } 5 : { 1 : 3 } } 202 : { 1 : "NN nmod NNS compound NN" 2 : 3 3 : { 1 : "drug0 nmod *s* compound drug0" 2 : "drug0 nmod *concentrations* compound drug0" 3 : "drug0 nmod *interactions* compound drug0" } 4 : { 1 : "In vitro studies have shown drug1 can displace drug2 s , such as drug3 , from their protein-binding sites . " 2 : "Inducers and Inhibitors of Hepatic Metabolism : drug1 reduced plasma concentrations of drug2 by about 70 % . " 3 : "Clinical implications of drug1 interactions with five drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 203 : { 1 : "NN dep NN conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 3 3 : { 1 : "drug0 dep drug0 conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 3 } } 204 : { 1 : "NN nmod NN nmod NNS dobj VB nsubj NN nmod NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 nmod effects dobj *enhance* nsubj drug0 nmod drug0" 2 : "drug0 nmod elimination nmod changes dobj *cause* nsubj drug0 nmod drug0" 3 : "drug0 nmod drug0 nmod effects dobj *enhance* nsubj drug0 nmod drug0" } 4 : { 1 : "drug1 , including drug2 , may enhance the effects of oral drug3 , including drug4 or its derivatives or similar agents . " 2 : "drug1 : drug2 , like other drug3 , may cause changes in the elimination of drug4 leading to elevated serum levels of the drug and increased toxicity . " 3 : "drug1 , including drug2 , may enhance the effects of oral drug3 , such as drug4 or its derivatives . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 205 : { 1 : "NN compound NN nmod VB nsubj NN" 2 : 3 3 : { 1 : "drug0 compound absorption nmod *interfere* nsubj drug0" 2 : "drug0 compound preparation nmod *interact* nsubj drug0" 3 : "drug0 compound absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "There is a single case report , which suggests that drug1 may interfere with drug2 absorption . " 2 : "drug1 may interact with the drug2 preparation causing a gritty substance to form or may interact with the preservative in the drug3 preparation causing a toxic effect in the eye . " 3 : "drug1 , drug2 - pectin , drug3 , drug4 , drug5 , certain anticancer drugs , and drug6 may interfere with intestinal drug7 absorption , resulting in unexpectedly low serum concentrations . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 206 : { 1 : "NN nmod NN nmod NN dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 nmod effect dobj *increase* nsubj drug0" 2 : "drug0 nmod drug0 nmod effect dobj *diminish* nsubj drug0" 3 : "drug0 nmod metabolism nmod effect dobj *have* nsubj drug0" } 4 : { 1 : "drug1 may increase slightly the effect of drug2 , e.g. , drug3 , drug4 , drug5 . " 2 : "Reports suggest that drug1 may diminish the antihypertensive effect of drug2 , including drug3 . " 3 : "This study demonstrated that the potent cytochrome P450 enzyme-inducer drug1 did indeed have a marked effect on the metabolism of drug2 , resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 207 : { 1 : "NN nmod NN nsubj VB nmod NNS acl VBG dobj NN dep NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod use nsubj *reduce* nmod patients acl taking dobj drug0 dep drug0 conj drug0" } 4 : { 1 : "In patients taking an drug1 ( eg , drug2 , drug3 , drug4 or drug5 ) , the concomitant use of drug6 may reduce seizure control by lowering the plasma levels of the drug7 . " } 5 : { 1 : 3 } } 208 : { 1 : "NN conj NNS nmod NNS dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 conj s nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 3 } } 209 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 nmod coadministered advcl *discontinued* nsubjpass drug0" 2 : "drug0 nmod recovered advcl *administered* nsubjpass drug0" 3 : "drug0 nmod *monitored* advcl combined nsubjpass drug0" } 4 : { 1 : "drug1 should either be temporarily discontinued or decreased by 50 % when coadministered with drug2 on the day of drug3 infusion . " 2 : "drug1 should not be administered until a patient has recovered from drug2 - induced neuromuscular block . " 3 : "Therefore , such combined treatment should be approached with caution and patients should be monitored closely when drug1 is combined with these drugs , particularly with drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 210 : { 1 : "NN conj NN nmod NNS nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod d0-antagonists nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should not be administered concurrently with D2-antagonists , such as drug2 , drug3 , drug4 , or drug5 . " } 5 : { 1 : 3 } } 211 : { 1 : "NN nmod NN nmod NNS dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 nmod effects dobj *enhance* nsubj drug0" 2 : "drug0 nmod elimination nmod changes dobj *cause* nsubj drug0" 3 : "drug0 nmod drug0 nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 , including drug2 , may enhance the effects of oral drug3 , including drug4 or its derivatives or similar agents . " 2 : "drug1 : drug2 , like other drug3 , may cause changes in the elimination of drug4 leading to elevated serum levels of the drug and increased toxicity . " 3 : "drug1 , including drug2 , may enhance the effects of oral drug3 , such as drug4 or its derivatives . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 212 : { 1 : "NN compound NN nmod NN nmod VBD nsubj NN nmod NN" 2 : 3 3 : { 1 : "drug0 compound concentration nmod increase nmod *resulted* nsubj administration nmod drug0" 2 : "drug0 compound clearance nmod decrease nmod *resulted* nsubj coadministration nmod drug0" 3 : "drug0 compound cmax nmod increase nmod *resulted* nsubj co-administration nmod drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 at 200 mg QD resulted in a two-fold increase in drug3 plasma concentration . " 2 : "drug1 : Coadministration of drug2 resulted in a 27 % decrease in drug3 clearance and an increase in Cmax of approximately 6 % . " 3 : "Co-administration of drug1 resulted in about a 50 % increase in drug2 Cmax and AUC after multiple dosing . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 213 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod *reduced* nsubjpass effects nmod drug0 conj drug0" } 4 : { 1 : "The antihypertensive effects of drug1 , drug2 , drug3 , and drug4 may be reduced by drug5 . " } 5 : { 1 : 3 } } 214 : { 1 : "NN nmod VBN advcl VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod given advcl *have* nsubj drug0" 2 : "drug0 nmod administered advcl *increase* nsubj drug0" 3 : "drug0 nmod given advcl *have* nsubj drug0" } 4 : { 1 : "drug1 may also have an additive effect when given with drug2 . " 2 : "drug1 including coumarin derivatives , indandione derivatives , and drug2 such as drug3 ( drug4 ) , and drug5 may increase the risk of bleeding when administered concomitantly with drug6 . " 3 : "drug1 , such as drug2 , may have an additive effect when given with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 215 : { 1 : "NN conj NN nmod NN conj NN nmod NNS dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod drug0 conj drug0 nmod effects dobj *have* nsubj drug0" } 4 : { 1 : "drug1 may have additive effects with drug2 and other drug3 , e.g. , drug4 , drug5 , drug6 , drug7 . " } 5 : { 1 : 3 } } 216 : { 1 : "NN conj NN nmod NN dobj VB xcomp VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj induce xcomp *shown* nsubjpass drug0" 2 : "drug0 conj drug0 nmod clearance dobj decrease xcomp *reported* nsubjpass drug0" 3 : "drug0 conj drug0 nmod metabolism dobj alter xcomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 has been shown to induce the metabolism of drug2 and drug3 , which are metabolized through CYP2C9 . " 2 : "drug1 has been reported to decrease the clearance of drug2 and drug3 and thus may increase the pharmacologic effect of these drug4 . " 3 : "drug1 has been reported to significantly alter the metabolism of nonsedating drug2 drug3 and drug4 when taken concomitantly . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 217 : { 1 : "NN nmod VBN acl NN dobj VBZ nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod caused acl loss dobj *attenuates* nsubj drug0" 2 : "drug0 nmod produced acl tachycardia dobj *blunts* nsubj drug0" 3 : "drug0 nmod stimulated acl proliferation dobj *inhibits* nsubj drug0" } 4 : { 1 : "Agents Increasing Serum Potassium : drug1 attenuates potassium loss caused by drug2 . " 2 : "drug1 blunts the reflex tachycardia produced by drug2 without preventing its hypotensive effect . " 3 : "drug1 at 10 ( -10 ) M or drug2 at about 3 X 10 ( -9 ) M inhibits proliferation stimulated by drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 218 : { 1 : "NN nmod NN dobj VB nsubj NN nmod NN dep NN appos NN" 2 : 3 3 : { 1 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0 dep drug0 appos drug0" 2 : "drug0 nmod effectiveness dobj *diminish* nsubj drug0 nmod drug0 dep drug0 appos drug0" } 4 : { 1 : "Concomitant treatment with drug1 ( drug2 , drug3 ) , drug4 , or drug5 may potentiate any hypokalemic effect of drug6 . " 2 : "drug1 : Since drug2 is a drug3 , it is possible that drug4 , such as the drug5 ( drug6 , drug7 , drug8 ) or drug9 , may diminish the effectiveness of drug10 . " } 5 : { 1 : 1 2 : 2 } } 219 : { 1 : "NN conj NN dep NN nmod NN nmod NNS dep NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep drug0 nmod combination nmod *patients* dep drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 3 } } 220 : { 1 : "NN compound NNS nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 compound tablets nmod *co-administered* nsubjpass drug0" 2 : "drug0 compound agents nmod *administered* nsubjpass drug0" 3 : "drug0 compound s nmod *used* nsubjpass drug0" } 4 : { 1 : "This interaction , which has not been investigated using higher doses of drug1 , may be more pronounced if a 300 mg daily dose is co-administered , particularly since drug2 exhibits non-linear pharmacokinetics over the dosage range 100-300 mg . If drug3 is co-administered with drug4 Tablets , the initial drug5 dosage should be at least halved and titration to the lowest effective dose is recommended . " 2 : "Hyperpyrexia has been reported when drug1 is administered with drug2 agents or with drug3 drugs , particularly during hot weather . " 3 : "Care should be taken if drug1 is used concomitantly with drug2 s of the drug3 type . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 221 : { 1 : "NN dobj VBG acl NNS nmod VBG dobj NN conj NN" 2 : 3 3 : { 1 : "drug0 dobj receiving acl patients nmod *containing* dobj drug0 conj drug0" 2 : "drug0 dobj receiving acl patients nmod *containing* dobj drug0 conj drug0" } 4 : { 1 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 , drug5 or drug6 may produce severe , prolonged hypotension or hypertension . " 2 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 or drug5 may produce severe , prolonged hypertension . " } 5 : { 1 : 1 2 : 2 } } 222 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN compound NN" 2 : 3 3 : { 1 : "drug0 nmod used advcl *exceeded* nsubjpass dose compound drug0" 2 : "drug0 nmod combined advcl *associated* nsubjpass use compound drug0" 3 : "drug0 nmod coadministered advcl *reduced* nsubjpass dose compound drug0" } 4 : { 1 : "A 5-mg drug1 dose should not be exceeded when used in combination with 200 mg once daily drug2 . " 2 : "drug1 and drug2 use may be rarely associated with ventricular fibrillation when combined with drug3 . " 3 : "The IV drug1 dose should be reduced by approximately 25 % , and the oral drug2 dose should be reduced by approximately 50 % when coadministered with drug3 to achieve exposures of drug4 similar to those obtained when it is given without drug5 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 223 : { 1 : "NN compound NNS dobj VBZ nsubj NN" 2 : 3 3 : { 1 : "drug0 compound concentrations dobj *increases* nsubj drug0" 2 : "drug0 compound values dobj *increases* nsubj drug0" 3 : "drug0 compound levels dobj *increases* nsubj drug0" } 4 : { 1 : "drug1 increases drug2 s serum concentrations . " 2 : "drug1 increases drug2 AUC values by 14 % . " 3 : "drug1 : drug2 increases drug3 plasma levels . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 224 : { 1 : "NN nmod VBP nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod *have* nsubj drug0" 2 : "drug0 nmod *are* nsubj drug0" 3 : "drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "Other drug1 ( e.g. drug2 , drug3 , drug4 and general drug5 ) have additive or potentiating effects with drug6 . " 2 : "Oral drug1 CAUTION SHOULD BE EXERCISED WHEN drug2 ARE GIVEN IN CONJUNCTION WITH drug3 . " 3 : "drug1 and drug2 interact pharmacologically with orally administered drug3 , but the effect is not clinically significant . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 225 : { 1 : "NN appos NN nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 appos drug0 nmod *used* nsubjpass drug0" 2 : "drug0 appos drug0 nmod *administered* nsubjpass drug0" 3 : "drug0 appos drug0 nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "- When drug1 or drug2 is used concurrently with drug3 ( e.g. drug4 ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of drug5 or drug6 is impaired " 2 : "Considerable caution should be exercised if drug1 is administered concurrently with drug2 ( drug3 ) since paranoid symptoms have been reported during therapy with this combination . " 3 : "Serious toxicity may result if drug1 is coadministered with drug2 ( drug3 ) . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 226 : { 1 : "NN nmod NNS dobj VB nsubj NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod effects dobj *reduce* nsubj drug0 conj drug0" 2 : "drug0 nmod levels dobj *increase* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 ( e.g. , drug2 , drug3 , drug4 ) and drug5 may reduce the therapeutic effects of drug6 . " 2 : "drug1 , drug2 , and drug3 may increase plasma levels of drug4 , potentially resulting in adverse effects . " } 5 : { 1 : 1 2 : 2 } } 227 : { 1 : "NN conj NN nmod VBN advcl VBP nsubj NN nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod co-administered advcl *produce* nsubj drug0 nmod drug0" } 4 : { 1 : "The drug1 , including drug2 , produce additive CNS depressant effects when co-administered with other drug3 , drug4 , drug5 , drug6 , and other drugs which themselves produce CNS depression . " } 5 : { 1 : 3 } } 228 : { 1 : "NN nmod NN dep NN nmod NNS dobj VB xcomp VBN conj VBN nsubjpass NNS nmod NNS nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod enantiomer dep r nmod levels dobj increase xcomp expected conj *studied* nsubjpass interactions nmod inhibitors nmod drug0 conj drug0" } 4 : { 1 : "poor metabolizers of drug1 : Interactions of drug2 with strong inhibitors of CYP2D6 ( such as drug3 , drug4 , drug5 , and drug6 ) have not been studied , but these drugs would be expected to increase blood levels of the R ( + ) enantiomer of drug7 . " } 5 : { 1 : 3 } } 229 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NNS nmod NN" 2 : 3 3 : { 1 : "drug0 nmod exposure dobj increase xcomp *expected* nsubjpass inhibitors nmod drug0" 2 : "drug0 nmod action dobj prolong xcomp *reported* nsubjpass ureidopenicillins nmod drug0" 3 : "drug0 nmod concentration dobj increase xcomp *reported* nsubjpass doses nmod drug0" } 4 : { 1 : "Other strong selective CYP3A4 inhibitors such as drug1 can also be expected to increase the exposure of drug2 . " 2 : "In one controlled clinical study , the ureidopenicillins , including drug1 , were reported to prolong the action of drug2 . " 3 : "drug1 : Doses of drug2 ( drug3 ) 1 g/day have been reported to increase plasma concentration of drug4 by ~ 47 % , possibly by inhibiting conjugation ; " } 5 : { 1 : 1 2 : 1 3 : 1 } } 230 : { 1 : "NN nmod NNS dobj VBG advcl VBZ nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod effects dobj inhibiting advcl *blocks* nsubj drug0" 2 : "drug0 nmod effects dobj inhibiting advcl *blocks* nsubj drug0" 3 : "drug0 nmod effects dobj inhibiting advcl *blocks* nsubj drug0" } 4 : { 1 : "drug1 : drug2 blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of drug3 and can be used to treat drug4 poisoning . " 2 : "drug1 : drug2 blocks dopamine receptors , thus inhibiting the central stimulant effects of drug3 . " 3 : "drug1 : drug2 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 231 : { 1 : "NN conj NN dep VB dobj NN nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep *bind* dobj absorption nmod drug0" } 4 : { 1 : "drug1 Absorption : The following agents may bind and decrease absorption of drug2 from the gastrointestinal tract : drug3 , drug4 resin , drug5 , drug6 , drug7 , soybean flour ( e.g. , infant formula ) , drug8 . " } 5 : { 1 : 3 } } 232 : { 1 : "NN appos NN dep NN conj NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 appos drug0 dep drug0 conj drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 3 } } 233 : { 1 : "NN conj NN nmod NN dobj VB nsubj NNS compound NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod bioavailability dobj *reduce* nsubj salts compound drug0" 2 : "drug0 conj drug0 nmod metabolism dobj *alter* nsubj tablets compound drug0" } 4 : { 1 : "drug1 salts may reduce the bioavailability of drug2 and drug3 . " 2 : "drug1 tablets may alter the metabolism of drug2 , drug3 , and drug4 , resulting in elevated plasma concentrations of the latter drugs . " } 5 : { 1 : 1 2 : 2 } } 234 : { 1 : "NN conj NN nmod NNS acl:relcl NNS appos NN nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod inducers acl:relcl compounds appos cyp0a nmod *drug0*" } 4 : { 1 : "While no in vivo drug-drug interaction studies were conducted between drug1 and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as drug2 , drug3 , drug4 , and drug5 ) would be expected to decrease drug6 concentrations . " } 5 : { 1 : 3 } } 235 : { 1 : "NN nmod NN nmod VBN acl NN nmod NN" 2 : 3 3 : { 1 : "drug0 nmod combination nmod used acl *drug0* nmod drug0" 2 : "drug0 nmod dose nmod followed acl *course* nmod drug0" 3 : "drug0 nmod combination nmod isrecommended acl food nmod *drug0*" } 4 : { 1 : "Other drug1 ( including drug2 ) used in combination with drug3 may also result in similar toxicities . " 2 : "drug1 : In a study in healthy volunteers , a six-day course of drug2 at 600 mg/day followed by a single 5 mg dose of drug3 resulted in a reduction in drug4 levels to below detectable limits . " 3 : "A dose increase of drug1 / drug2 to 533/133 mg twice daily with food isrecommended in combination with drug3 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 236 : { 1 : "NN nmod NN dobj VB dep NN dep NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod metabolism dobj increase dep *drug0* dep drug0 conj drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 3 } } 237 : { 1 : "NN compound NN nmod NN dobj VB advcl VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 compound toxicity nmod risk dobj *increase* advcl used nsubjpass drug0" 2 : "drug0 nsubjpass started advcl *require* dobj titration nmod dosage compound drug0" 3 : "drug0 nsubjpass withdrawn advcl *increase* dobj risk nmod toxicity compound drug0" } 4 : { 1 : "If a drug1 is also used , it may increase the risk of drug2 toxicity . " 2 : "Nonetheless , individual patients may require additional titration of their drug1 dosage when drug2 is started or stopped to ensure clinically effective blood levels . " 3 : "This could lead to decreased drug1 serum levels or increase the risk of drug2 toxicity when drug3 is withdrawn . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 238 : { 1 : "NN nmod NN dobj VBD nsubj NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod exposure dobj *increased* nsubj drug0 conj drug0" 2 : "drug0 nmod clearance dobj *increased* nsubj drug0 conj drug0" } 4 : { 1 : "Pharmacokinetic studies have demonstrated that drug1 and drug2 significantly increased the systemic exposure of drug3 and/or its major metabolites . " 2 : "drug1 , drug2 , or drug3 increased metabolic clearance of drug4 because of the induction of hepatic enzymes . " } 5 : { 1 : 1 2 : 2 } } 239 : { 1 : "NN dep NNS nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 dep drugs nmod *used* nsubjpass drug0" 2 : "drug0 dep agents nmod *administered* nsubjpass drug0" 3 : "drug0 dep hours nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 also should be used cautiously with other drugs ( e.g. , drug2 , drug3 ) that sensitize the myocardium to the actions of drug4 . " 2 : "drug1 injection and potassium-depleting agents : When drug2 are administered concomitantly with potassium-depleting agents ( e.g. , drug3 , drug4 ) , patients should be observed closely for development of hypokalemia . " 3 : "This decrease in bioavailability was about 5 % when drug1 was administered 2 hours after drug2 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 240 : { 1 : "NN conj NN nmod NN dobj VB dep NN dep NN conj NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj increase dep *drug0* dep drug0 conj drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 3 } } 241 : { 1 : "NN conj NN nmod NN dobj VBZ dep VBN nmod NNS nmod JJ acl:relcl VBP" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod action dobj removes dep *shown* nmod rats nmod toxic acl:relcl drug0" } 4 : { 1 : "[ The GABA-ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that drug1 ( 1 mg/kg ) removes the antiedematous action of drug2 , drug3 , drug4 and drug5 and reduces the action of drug6 . " } 5 : { 1 : 3 } } 242 : { 1 : "NN nmod NN nmod NN nmod RB advmod VBG conj VBG dobj NN" 2 : 3 3 : { 1 : "drug0 nmod treatment nmod initiation nmod prior advmod increasing conj *discontinuing* dobj drug0" 2 : "drug0 nmod treatment nmod initiation nmod prior advmod increasing conj *discontinuing* dobj drug0" } 4 : { 1 : "The possibility of hypotensive effects can be minimized by either discontinuing the drug1 or increasing salt intake prior to initiation of treatment with drug2 . " 2 : "The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug2 or increasing the salt intake prior to initiation of treatment with drug3 . " } 5 : { 1 : 1 2 : 2 } } 243 : { 1 : "NN conj NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 3 } } 244 : { 1 : "NN nmod NNS nmod NN dobj VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod drugs nmod response dobj *decrease* nsubj drug0" 2 : "drug0 nmod drugs nmod potential dobj *increase* nsubj drug0" 3 : "drug0 nmod effects nmod duration dobj *prolong* nsubj drug0" } 4 : { 1 : "drug1 may decrease vascular response to pressor drugs such as drug2 . " 2 : "drug1 may increase the ototoxic potential of other drugs such as drug2 and some drug3 . " 3 : "Epidural drug1 may prolong the duration of pharmacologic effects of epidural local drug2 , including both sensory and motor blockade . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 245 : { 1 : "NN nmod NN compound NN appos NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod *absorption* compound drug0 appos drug0 conj drug0" } 4 : { 1 : "drug1 : drug2 ( drug3 , drug4 , drug5 , drug6 , fruit juices , etc. ) lower absorption of drug7 . " } 5 : { 1 : 3 } } 246 : { 1 : "NN conj NN dep VBP nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep *result* nmod efficacy nmod drug0" } 4 : { 1 : "Compounds in these categories result in a decreased efficacy of drug1 : drug2 , drug3 , drug4 , drug5 . " } 5 : { 1 : 3 } } 247 : { 1 : "NN appos NN conj NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 3 3 : { 1 : "drug0 appos drug0 conj drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 3 } } 248 : { 1 : "NN nmod NN nmod VBN acl NN" 2 : 3 3 : { 1 : "drug0 nmod combination nmod used acl *drug0*" 2 : "drug0 nmod mg nmod co-administered acl *drug0*" 3 : "drug0 nmod dose nmod caused acl *drug0*" } 4 : { 1 : "Other drug1 ( including drug2 ) used in combination with drug3 may also result in similar toxicities . " 2 : "At 24 hours postdose , a similar proportion of patients treated with drug1 alone ( 94 % ) and subsequently treated with drug2 co-administered with 75 mg of drug3 ( 88 % ) had drug4 plasma concentrations below the measurable limit ( 5 ng/mL ) . " 3 : "There was a small decrease in the clearance of drug1 caused by a 400-mg dose of drug2 ; " } 5 : { 1 : 1 2 : 1 3 : 1 } } 249 : { 1 : "NN conj NN nmod VBN advcl VBP nsubj NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod co-administered advcl *produce* nsubj drug0" } 4 : { 1 : "The drug1 , including drug2 , produce additive CNS depressant effects when co-administered with other drug3 , drug4 , drug5 , drug6 , and other drugs which themselves produce CNS depression . " } 5 : { 1 : 3 } } 250 : { 1 : "NN compound NN dobj VBG advcl VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 compound test dobj conducting advcl *withdrawn* nsubjpass drug0" 2 : "drug0 compound therapy dobj initiating advcl *withdrawn* nsubjpass drug0" 3 : "drug0 nsubjpass initiated advcl *receiving* dobj therapy compound drug0" } 4 : { 1 : "drug1 should be withdrawn at least 48 hours before conducting an drug2 - mediated stress test . " 2 : "If possible , drug1 should be withdrawn at least 24 hours before initiating drug2 therapy . " 3 : "Increases in prothrombin time have been noted in patients receiving long - term drug1 therapy after drug2 was initiated . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 251 : { 1 : "NN nmod NN dobj VB ccomp VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 nmod secretion dobj decrease ccomp *reported* nsubjpass drug0" 2 : "drug0 nmod secretion dobj decrease ccomp *reported* nsubjpass drug0" 3 : "drug0 nmod effect dobj increase ccomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 has been reported to decrease the tubular secretion of drug2 and to potentiate its toxicity . " 2 : "drug1 have been reported to decrease the tubular secretion of drug2 and to potentiate its toxicity . " 3 : "drug1 : drug2 has been reported to decrease the clearance of drug3 and , thus , may increase the pharmacologic effect of drug4 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 252 : { 1 : "NN nmod NN conj NN nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 conj drug0 nmod *administration* nmod drug0" 2 : "drug0 nmod treatment nmod initiation conj *discontinuation* nmod drug0" 3 : "drug0 nmod drug0 conj drug0 nmod combination nmod *drug0*" } 4 : { 1 : "Nephrotoxicity has been reported following concomitant administration of drug1 with drug2 or potent drug3 such as drug4 . " 2 : "At least 3 weeks should elapse between discontinuation of drug1 and initiation of treatment with a drug2 . " 3 : "drug1 in combination with other drug2 , general drug3 , drug4 , drug5 , drug6 , or other drug7 ( including drug8 ) has additive depressant effects . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 253 : { 1 : "NN compound NN nmod VBN nsubjpass NNS nmod NN" 2 : 3 3 : { 1 : "drug0 compound induction nmod *reduced* nsubjpass requirements nmod drug0" 2 : "drug0 compound use nmod *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "Limited clinical experience indicates that requirements for drug1 are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following drug2 induction The concomitant use of drug3 with drug4 can significantly inhibit drug5 clearance and may increase the risk of prolonged or delayed respiratory depression . " 2 : "Elevated plasma levels of drug1 have been reported with concomitant drug2 use . " } 5 : { 1 : 1 2 : 2 } } 254 : { 1 : "NN nmod NN nsubj VB dep NN" 2 : 3 3 : { 1 : "drug0 nmod use nsubj *result* dep drug0" 2 : "drug0 nmod administration nsubj increase dep *drug0*" 3 : "drug0 nmod administration nsubj increase dep *drug0*" } 4 : { 1 : "drug1 or other drug2 ( concurrent use with drug3 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ; " 2 : "drug1 : Concomitant administration with drug2 may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels . " 3 : "drug1 ( drug2 , drug3 , and possibly drug4 ) : Concomitant administration with drug5 may increase the risk of gastrointestinal ulceration . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 255 : { 1 : "NN dobj VBG acl NNS nmod JJR nsubj NN compound NN" 2 : 3 3 : { 1 : "drug0 dobj taking acl patients nmod *greater* nsubj clearance compound drug0" 2 : "drug0 dobj taking acl patients nmod *greater* nsubj clearance compound drug0" 3 : "drug0 dobj taking acl patients nmod *greater* nsubj clearance compound drug0" } 4 : { 1 : "Effects of other Antiepilepsy Drugs ( drug1 ) on drug2 : drug3 : Population pharmacokinetic analyses indicate that drug4 clearance is 60 % greater in patients taking drug5 with or without other enzyme - inducing drug6 . " 2 : "drug1 : Population pharmacokinetic analyses indicate that drug2 clearance is 60 % greater in patients taking drug3 with or without other enzyme - inducing drug4 . " 3 : "drug1 ( drug2 ) : Population pharmacokinetic analyses indicate that drug3 clearance is 60 % greater in patients taking drug4 ( drug5 ) with or without other enzyme-inducing drug6 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 256 : { 1 : "NN nmod NNS dobj VB xcomp VBN nsubjpass NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod levels dobj decrease xcomp *shown* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 : drug2 , drug3 , drug4 , and drug5 have been shown to decrease plasma levels of drug6 ; " } 5 : { 1 : 3 } } 257 : { 1 : "NN compound NN dobj VBG acl NNS nmod NN nmod VB nsubj NN compound NN" 2 : 3 3 : { 1 : "drug0 compound therapy dobj receiving acl patients nmod period nmod *exceed* nsubj dose compound drug0" 2 : "drug0 compound therapy dobj receiving acl patients nmod period nmod *exceed* nsubj dose compound drug0" 3 : "drug0 compound therapy dobj receiving acl patients nmod period nmod *exceed* nsubj dose compound drug0" } 4 : { 1 : "drug1 dose should not exceed a maximum of 25 mg in a 48 - hour period in patients receiving concomitant drug2 therapy . " 2 : "drug1 dose should not exceed a maximum of 10 mg in a 72 - hour period in patients receiving concomitant drug2 therapy . " 3 : "drug1 dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant drug2 therapy . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 258 : { 1 : "NN nmod NNS dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 nmod drugs dobj receiving acl patients nmod *administered* nsubjpass drug0" 2 : "drug0 nmod cations dobj containing acl medications nmod *taken* nsubjpass drug0" 3 : "drug0 nmod drugs dobj receiving acl patients nmod *administered* nsubjpass drug0" } 4 : { 1 : "Close observation of the patient is recommended when a drug1 is administered to patients receiving catecholamine-depleting drugs such as drug2 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope or postural hypotension . " 2 : "drug1 should be taken at least 60 minutes before any oral medications containing multivalent cations ( including drug2 , supplements or drug3 ) . " 3 : "Close observation of the patient is recommended when a drug1 is administered to patients receiving catecholamine-depleting drugs such as drug2 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope , or postural hypotension . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 259 : { 1 : "NN conj NN nmod VBN advcl VB xcomp VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 conj drug0 nmod given advcl have xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 has been shown to have an additive CNS depressant effect when given with either drug2 , drug3 , drug4 or drug5 . " } 5 : { 1 : 3 } } 260 : { 1 : "NN conj NN dep NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NNS nmod NN compound NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep drug0 nmod effect nmod possibility nsubjpass *considered* advcl identified nmod studies nmod solution compound drug0" } 4 : { 1 : "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , drug7 ) should be considered . " } 5 : { 1 : 3 } } 261 : { 1 : "NN nmod NNS nmod VB nsubj NN" 2 : 3 3 : { 1 : "drug0 nmod drugs nmod *interact* nsubj drug0" 2 : "drug0 nmod effects nmod *protect* nsubj drug0" 3 : "drug0 nmod effects nmod *interfere* nsubj drug0" } 4 : { 1 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 " 2 : "drug1 - drug2 may protect against the ototoxic effects of drug3 . " 3 : "drug1 : Studies in normal volunteers have shown that drug2 like other drug3 , can interfere with the effects of drug4 . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 262 : { 1 : "NN compound NNS nmod NN dobj VBN nsubj NN" 2 : 3 3 : { 1 : "drug0 compound levels nmod elevation dobj *produced* nsubj drug0" } 4 : { 1 : "drug1 : drug2 have produced an elevation of plasma drug3 levels and a reduction in renal drug4 clearance . " } 5 : { 1 : 3 } } 263 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NN" 2 : 3 3 : { 1 : "drug0 nmod given advcl *have* nsubj drug0 nmod drug0" 2 : "drug0 nmod coadministered advcl *result* nsubj use nmod drug0" } 4 : { 1 : "drug1 , such as drug2 , may have an additive effect when given with drug3 . " 2 : "The use of drug1 may result in additive CNS depressant effects when coadministered with drug2 , drug3 , drug4 or other drugs that produce CNS depression . " } 5 : { 1 : 1 2 : 2 } } 264 : { 1 : "NN nsubjpass VBN advcl VBG dobj NN" 2 : 3 3 : { 1 : "drug0 nsubjpass given advcl *taking* dobj drug0" 2 : "drug0 nsubjpass administered advcl *taking* dobj drug0" 3 : "drug0 nsubjpass added advcl *receiving* dobj drug0" } 4 : { 1 : "Patients taking drug1 when drug2 is given should be observed for the appearance of unsteady gait or marked changes in mental status ; " 2 : "drug1 : There have been rare reports of increased prothrombin time in patients taking drug2 to whom drug3 was administered . " 3 : "Hypotension , AV conduction disturbances , and left ventricular failure have been reported in some patients receiving drug1 when an oral drug2 was added to the treatment regimen . " } 5 : { 1 : 1 2 : 1 3 : 1 } } 265 : { 1 : "NN conj NN dep NN nmod NN nmod NNS acl VBG dobj NN appos NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0 appos drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 3 } } 266 : { 1 : "NN appos NN dep NN nmod NN" 2 : 3 3 : { 1 : "drug0 appos drug0 dep *metabolism* nmod drug0" 2 : "drug0 appos drug0 dep *coadministration* nmod drug0" } 4 : { 1 : "While not systematically studied , certain drugs may induce the metabolism of drug1 ( e.g. , drug2 , drug3 , drug4 ) . " 2 : "therefore , coadministration of drug1 with drugs that strongly induce CYP3A4 activity ( e.g. , drug2 , drug3 , drug4 ) may result in reduced plasma concentrations of drug5 that may result in decreased efficacy of drug6 . " } 5 : { 1 : 2 2 : 1 } } 267 : { 1 : "NN conj NN nmod DT conj CC advmod VBZ nsubj NN" 2 : 3 3 : { 1 : "drug0 conj binding nmod all conj or advmod *interferes* nsubj drug0" } 4 : { 1 : "Protein Binding In vitro , drug1 interferes minimally or not at all with the protein binding of drug2 ( 20 % decrease in binding ) , drug3 , drug4 ( 10 % decrease in binding ) , or drug5 . " } 5 : { 1 : 3 } } 268 : { 1 : "NN dobj VB nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 dobj *occur* nsubj syndrome compound drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 2 } } 269 : { 1 : "NN compound NNS nmod NN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound preparations nmod *use* nmod drug0 conj drug0" 2 : "drug0 conj drug0 nmod *coadministration* nmod tablets compound drug0" } 4 : { 1 : "The use of drug1 or drug2 with drug3 preparations may increase the effect of either the drug4 or drug5 . " 2 : "Coadministration of drug1 Tablets with drug2 or drug3 has resulted in elevated plasma concentrations of the latter two drugs . " } 5 : { 1 : 1 2 : 1 } } 270 : { 1 : "NN nmod NN dobj VB nsubj NN conj NN acl VBG dobj NNS dep FW appos NN" 2 : 2 3 : { 1 : "drug0 nmod effect dobj *reduce* nsubj drug0 conj drug0 acl containing dobj enzymes dep g. appos drug0" } 4 : { 1 : "drug1 ( e. g. , drug2 ) and drug3 containing carbohydrate-splitting enzymes ( e. g. , drug4 , drug5 ) may reduce the effect of drug6 and should not be taken concomitantly . " } 5 : { 1 : 2 } } 271 : { 1 : "NN nmod VBN nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod *administered* nsubj drug0" 2 : "drug0 nmod *administered* nsubj drug0" } 4 : { 1 : "drug1 administered concurrently with drug2 reduced the urine volume in 4 healthy volunteers . " 2 : "drug1 - and drug2 - containing drug3 , administered concomitantly with drug4 , significantly decreased the bioavailability ( 48 % ) of drug5 . " } 5 : { 1 : 1 2 : 1 } } 272 : { 1 : "NN nmod NN dobj VB nsubj NNS acl:relcl VBP dobj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod clearance dobj *increase* nsubj drugs acl:relcl induce dobj enzymes nmod drug0 conj drug0" } 4 : { 1 : "Drugs that induce hepatic enzymes such as drug1 , drug2 and drug3 may increase the clearance of drug4 and may require increases in drug5 dose to achieve the desired response . " } 5 : { 1 : 2 } } 273 : { 1 : "NN nmod NN conj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod mg conj *gram* nmod drug0" 2 : "drug0 nmod initiation conj *discontinuation* nmod drug0" } 4 : { 1 : "Transient delirium has been reported in patients who were treated with one gram of drug1 and 75 - 150 mg of drug2 . " 2 : "At least 14 days should elapse between discontinuation of a drug1 and initiation of treatment with drug2 . " } 5 : { 1 : 1 2 : 1 } } 274 : { 1 : "NN dep NN conj NN nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 dep drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 2 } } 275 : { 1 : "NN compound NN nmod NNS dobj VB conj VB nsubj NNS acl:relcl VBP dobj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound dose nmod increases dobj require conj *increase* nsubj drugs acl:relcl induce dobj enzymes nmod drug0 conj drug0" } 4 : { 1 : "Drugs that induce hepatic enzymes such as drug1 , drug2 and drug3 may increase the clearance of drug4 and may require increases in drug5 dose to achieve the desired response . " } 5 : { 1 : 2 } } 276 : { 1 : "NN nmod NNS dobj VB nsubj NNS compound NN" 2 : 2 3 : { 1 : "drug0 nmod effects dobj *potentiate* nsubj supplements compound drug0" 2 : "drug0 nmod concentrations dobj *decrease* nsubj s compound drug0" } 4 : { 1 : "Organic drug1 - drug2 supplements theoretically may potentiate the effects of organic drug3 if taken concomitantly . " 2 : "In addition , several drug1 s that are cytochrome P450 inducers can decrease plasma concentrations of drug2 and drug3 . " } 5 : { 1 : 1 2 : 1 } } 277 : { 1 : "NN nmod VBN advcl VBN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod coadministered advcl *recommended* nmod drug0" 2 : "drug0 nmod used advcl *reported* nmod drug0" } 4 : { 1 : "Caution is warranted and therapeutic concentration monitoring is recommended for drug1 when coadministered with drug2 . " 2 : "Clinically significant effects have been reported with the drug1 when used concomitantly with drug2 . " } 5 : { 1 : 1 2 : 1 } } 278 : { 1 : "NN conj NNS dobj VBG acl NN nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj preparations dobj containing acl drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 2 } } 279 : { 1 : "NN conj NNS acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj *patients* acl receiving dobj drug0" 2 : "drug0 conj *patients* acl taking dobj drug0" } 4 : { 1 : "In patients receiving drug1 and a drug2 concomitantly , any reduction in drug3 dosage should be gradual in order to avoid the possible complications of sudden drug4 withdrawal . " 2 : "Seizures have been reported in patients taking another drug1 and the drug2 drug3 concurrently . " } 5 : { 1 : 1 2 : 1 } } 280 : { 1 : "NN compound NN conj NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound cause conj drug0 nmod *drug0*" } 4 : { 1 : "drug1 with drug2 or drug3 and possibly other drug4 cause striking and sustained increases in the concentration of drug5 in the brain ; " } 5 : { 1 : 2 } } 281 : { 1 : "NN nmod NNS dobj VB conj VB nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod levels dobj reduce conj *affect* nsubj coadministration nmod drug0" } 4 : { 1 : "drug1 / drug2 : The coadministration of drug3 or drug4 will not affect plasma concentrations of drug5 , but may reduce endogenous plasma levels of drug6 / ergocalcitriol by accelerating metabolism . " } 5 : { 1 : 2 } } 282 : { 1 : "NN dep VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 dep *increases* nsubj drug0" 2 : "drug0 nsubj inhibits dep *drug0*" } 4 : { 1 : "Agents with Increased Levels in the Presence of drug1 : drug2 increases the plasma levels of the following agents : drug3 , drug4 ( 6 ) , and drug5 Thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drug6 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary . " 2 : "drug1 : drug2 inhibits CYP3A4 and can increase serum drug3 levels . " } 5 : { 1 : 1 2 : 1 } } 283 : { 1 : "NN conj NN nmod NN nmod NN dobj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod effect dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 may increase slightly the effect of drug2 , e.g. , drug3 , drug4 , drug5 . " } 5 : { 1 : 2 } } 284 : { 1 : "NN conj NN dep VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *increases* nsubj drug0" } 4 : { 1 : "Agents with Increased Levels in the Presence of drug1 : drug2 increases the plasma levels of the following agents : drug3 , drug4 ( 6 ) , and drug5 Thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with drug6 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary . " } 5 : { 1 : 2 } } 285 : { 1 : "NN dep NN conj NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep drug0 conj drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 2 } } 286 : { 1 : "NN nmod NN nsubj VB nmod NNS acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 nmod addition nsubj *prolong* nmod patients acl receiving dobj drug0" 2 : "drug0 nmod use nsubj *reduce* nmod patients acl taking dobj drug0" } 4 : { 1 : "In patients receiving drug1 , the addition of drug2 to therapy could prolong the prothrombin time . " 2 : "In patients taking an drug1 ( eg , drug2 , drug3 , drug4 or drug5 ) , the concomitant use of drug6 may reduce seizure control by lowering the plasma levels of the drug7 . " } 5 : { 1 : 1 2 : 1 } } 287 : { 1 : "NN appos NN dep NNS nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 2 } } 288 : { 1 : "NN nmod VBN advcl VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod given advcl *monitored* nsubjpass concentrations nmod drug0" 2 : "drug0 nmod given advcl *reduced* nsubjpass concentrations nmod drug0" } 4 : { 1 : "therefore , plasma concentrations of drug1 should also be monitored when it is given concurrently with drug2 . " 2 : "Plasma concentrations of drug1 are reduced when given concurrently with drug2 . " } 5 : { 1 : 1 2 : 1 } } 289 : { 1 : "NN nmod NN nmod VBG acl NNS dobj VB nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod clearance nmod interfering acl events dobj *increase* nsubj drugs nmod drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 , and drug3 : Drugs such as drug4 , drug5 , and drug6 may increase the risk of developing peripheral neuropathy or other drug7 - associated adverse events by interfering with the renal clearance of drug8 ( thereby raising systemic exposure ) . " } 5 : { 1 : 2 } } 290 : { 1 : "NN conj NN dobj VBG advcl VBP xcomp VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj taking advcl *begin* xcomp taking dobj drug0" } 4 : { 1 : "Patients who begin taking drug1 or who increase their drug2 dose or any other drug3 while taking drug4 , drug5 , or drug6 may develop toxicity characteristics for these drugs . " } 5 : { 1 : 2 } } 291 : { 1 : "NN conj NN dobj VBG advcl VBP xcomp VBG dobj NN conj VBP dobj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj taking advcl *begin* xcomp taking dobj drug0 conj increase dobj dose conj drug0" } 4 : { 1 : "Patients who begin taking drug1 or who increase their drug2 dose or any other drug3 while taking drug4 , drug5 , or drug6 may develop toxicity characteristics for these drugs . " } 5 : { 1 : 2 } } 292 : { 1 : "NN nmod NN nsubjpass VBN advcl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 nmod therapy nsubjpass initiated advcl *receiving* dobj drug0" 2 : "drug0 dobj taking advcl *reduced* nsubjpass level nmod drug0" } 4 : { 1 : "In clinical trials , drug1 was used with drug2 , drug3 , drug4 , oral drug5 , and supplemental drug6 . In a pharmacokinetic substudy in patients with congestive heart failure receiving drug7 or drug8 in whom therapy with drug9 was initiated , apparent oral clearance values for drug10 ( n = 23 ) and drug11 ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 . " 2 : "However , the peak plasma level of drug1 was reduced by approximately 20 % when taking drug2 due to a slight delay in the absorption of drug3 . " } 5 : { 1 : 1 2 : 1 } } 293 : { 1 : "NN conj NN dobj VBG acl NNS conj NNS dobj VBD acl NN nmod NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj containing acl products conj tablets dobj chewable/buffered acl drug0 nmod products nmod *drug0*" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 2 } } 294 : { 1 : "NN conj NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod accuracy nmod *made* nsubjpass measurements nmod drug0" } 4 : { 1 : "Renal clearance measurements of drug1 can not be made with any significant accuracy in patients receiving drug2 , drug3 , or drug4 . " } 5 : { 1 : 2 } } 295 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS compound NN conj NN" 2 : 2 3 : { 1 : "drug0 compound therapy nmod initiation nmod *monitored* nsubjpass concentrations compound drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 concentrations should be monitored at the initiation of drug4 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately . " } 5 : { 1 : 2 } } 296 : { 1 : "NN dep NN dobj VBP acl:relcl NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep isoenzyme dobj affect acl:relcl *interaction* nmod drug0" 2 : "drug0 dep cyp0a0 dobj inhibit acl:relcl *use* nmod drug0" } 4 : { 1 : "Therefore , the potential exists for a drug interaction between drug1 and drugs that affect the CYP2B6 isoenzyme ( e.g. , drug2 and drug3 ) . " 2 : "Concomitant use of drug1 and drugs that inhibit CYP3A4 ( eg , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ) may increase exposure to drug13 and should be avoided . " } 5 : { 1 : 1 2 : 1 } } 297 : { 1 : "NN appos NN nmod VBG acl NNS conj NN" 2 : 2 3 : { 1 : "drug0 appos transmission nmod interfering acl agents conj *drug0*" } 4 : { 1 : "Co-administration of drug1 and drug2 or other agents interfering with neuromuscular transmission ( e.g. , drug3 ) should only be performed with caution as the effect of the drug4 may be potentiated . " } 5 : { 1 : 2 } } 298 : { 1 : "NN appos NN dep NN conj NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep drug0 conj drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 2 } } 299 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS compound NN" 2 : 2 3 : { 1 : "drug0 compound therapy nmod initiation nmod *monitored* nsubjpass concentrations compound drug0" 2 : "drug0 compound therapy nmod initiation nmod *monitored* nsubjpass concentrations compound drug0" } 4 : { 1 : "drug1 , drug2 and drug3 concentrations should be monitored at the initiation of drug4 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately . " 2 : "Due to wide interindividual variability in the dose adjustment required , it is recommended that drug1 concentrations be monitored closely after initiation of drug2 therapy and that the dose of drug3 be adjusted as appropriate . " } 5 : { 1 : 1 2 : 1 } } 300 : { 1 : "NN conj NN dep NNS nmod NN dobj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj triazolo dep drugs nmod plasmaconcentration dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo - drug2 , drug3 , certain drug4 , etc. ) . " } 5 : { 1 : 2 } } 301 : { 1 : "NN appos NN dep NN nmod NN dobj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep drug0 nmod clearance dobj *decrease* nsubj drug0" } 4 : { 1 : "drug1 : Combination drug2 may decrease the clearance of some drug3 ( drug4 , drug5 , drug6 ) and increase the clearance of others ( drug7 , drug8 , drug9 ) . " } 5 : { 1 : 2 } } 302 : { 1 : "NN conj NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drugs nmod combination nmod *avoided* nsubjpass use nmod drug0" } 4 : { 1 : "Because of drug1 s tendency to cause renal impairment , the use of drug2 should be avoided in combination with potentially nephrotoxic drugs such as drug3 , drug4 and intravenous drug5 unless the potential benefits outweigh the risks to the patient . " } 5 : { 1 : 2 } } 303 : { 1 : "NN conj NN nmod NN nmod NN nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod activity nmod *use* nmod injection compound drug0" } 4 : { 1 : "The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity , such as drug3 , drug4 , or drug5 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects . " } 5 : { 1 : 2 } } 304 : { 1 : "NN nmod NNS nmod VB nsubj NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod levels nmod *result* nsubj coadministration dep drug0 conj drug0" } 4 : { 1 : "Coadministration with compounds that are potent inducers of CYP3A4 ( eg , drug1 , drug2 , drug3 , drug4 ) may result in decreased plasma levels of drug5 . " } 5 : { 1 : 2 } } 305 : { 1 : "NN compound NN dobj VB nsubj NNS nmod NN conj NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 compound elimination dobj *inhibit* nsubj inhibitors nmod cyp0a0 conj cyp0d0 dep drug0 conj drug0" } 4 : { 1 : "Inhibitors of CYP3A4 ( eg , drug1 ) or CYP2D6 ( eg , drug2 , drug3 , or drug4 ) can inhibit drug5 elimination and cause increased blood levels . " } 5 : { 1 : 2 } } 306 : { 1 : "NN compound NNS conj VB nsubj NNS nmod NN" 2 : 2 3 : { 1 : "drug0 compound requirements conj *decrease* nsubj effects nmod drug0" } 4 : { 1 : "In diabetic patients , the metabolic effects of drug1 may decrease blood glucose and therefore , drug2 requirements . " } 5 : { 1 : 2 } } 307 : { 1 : "NN nmod NN dobj VB acl:relcl NNS dobj VB xcomp VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 nmod action dobj enhance acl:relcl properties dobj have xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 has been shown to have neuromuscular blocking properties that may enhance the action of other drug2 . " } 5 : { 1 : 2 } } 308 : { 1 : "NN conj NN dobj VBG acl NNS conj NNS dobj VBD acl NN nmod NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj containing acl products conj tablets dobj chewable/buffered acl drug0 nmod products nmod *drug0* nmod drug0" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 2 } } 309 : { 1 : "NN compound NN nmod VBN advcl VB nmod NN nmod NN acl VBN nmod NN conj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound therapy nmod administered advcl *increase* nmod addition nmod bleeding acl associated nmod drug0 conj drugs nmod drug0 conj drug0" } 4 : { 1 : "In addition to bleeding associated with drug1 and drug2 , drugs that alter platelet function ( such as drug3 , drug4 and drug5 ) may increase the risk of bleeding if administered prior to , during , or after drug6 therapy . " } 5 : { 1 : 2 } } 310 : { 1 : "NN compound NNS nmod NN dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 compound levels nmod elevation dobj *produced* nsubj drug0" 2 : "drug0 compound treatments nmod absorption dobj *inhibited* nsubj drug0" } 4 : { 1 : "drug1 : drug2 produced an elevation of plasma drug3 levels and a reduction in renal drug4 clearance in a study of eleven normal volunteers . " 2 : "Additional drug1 significantly inhibited the absorption of drug2 in both dietary drug3 treatments . " } 5 : { 1 : 1 2 : 1 } } 311 : { 1 : "NN appos NN dep NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep drugs nmod *used* nsubjpass drug0" 2 : "drug0 appos drug0 dep agents nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 also should be used cautiously with other drugs ( e.g. , drug2 , drug3 ) that sensitize the myocardium to the actions of drug4 . " 2 : "drug1 injection and potassium-depleting agents : When drug2 are administered concomitantly with potassium-depleting agents ( e.g. , drug3 , drug4 ) , patients should be observed closely for development of hypokalemia . " } 5 : { 1 : 1 2 : 1 } } 312 : { 1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 dobj receiving acl patients nmod *reported* nsubjpass levels nmod drug0" 2 : "drug0 nmod alternatives nsubjpass *used* nmod patients acl receiving dobj drug0" } 4 : { 1 : "drug1 : Altered serum levels of drug2 ( increased and decreased ) have been reported in patients receiving concomitant drug3 . " 2 : "It is suggested that in patients receiving drug1 , alternatives to drug2 should be used if drug3 therapy is needed . " } 5 : { 1 : 1 2 : 1 } } 313 : { 1 : "NN conj NN dep VBP dobj NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *suggest* dobj interaction nmod drug0" } 4 : { 1 : "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving drug1 metabolized similarly to drug2 or on the basis of in vitro studies with drug3 or other drug4 ( caution is recommended during coadministration with drug5 ) : Available data from clinical studies of drug6 other than drug7 suggest a possible drug interaction with drug8 for the following : drug9 , drug10 , drug11 such as drug12 and drug13 , and grapefruit juice . " } 5 : { 1 : 2 } } 314 : { 1 : "NN compound NN nsubj JJ nmod NNS nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 compound stimulation nsubj *potentiated* nmod cases nmod overdosage compound drug0" } 4 : { 1 : "drug1 : In cases of drug2 overdosage , drug3 CNS stimulation is potentiated and fatal convulsions can occur . " } 5 : { 1 : 2 } } 315 : { 1 : "NN conj NN dep NNS nmod VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep inhibitors nmod *administering* dobj drug0" } 4 : { 1 : "Drugs that may alter drug1 plasma concentrations Drugs that may increase drug2 plasma concentrations : Caution is recommended when administering drug3 with inhibitors of the CYP3A4 family ( e.g. , drug4 , drug5 , drug6 , drug7 ) . " } 5 : { 1 : 2 } } 316 : { 1 : "NN appos NN dep NNS nmod NN dobj VB conj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep others nmod clearance dobj increase conj *decrease* nsubj drug0" } 4 : { 1 : "drug1 : Combination drug2 may decrease the clearance of some drug3 ( drug4 , drug5 , drug6 ) and increase the clearance of others ( drug7 , drug8 , drug9 ) . " } 5 : { 1 : 2 } } 317 : { 1 : "NN compound NN nmod NN nsubjpass VBN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound therapy nmod need nsubjpass *reviewed* nmod administration nmod drug0" 2 : "drug0 compound level nmod increase nsubjpass *reported* nmod introduction nmod drug0" } 4 : { 1 : "On administration of oral drug1 , the need for drug2 therapy should be reviewed and the dose reduced by approximately 50 % or discontinued . " 2 : "drug1 : After introduction of drug2 ( oral form ) , a sudden increase in serum drug3 level has been reported . " } 5 : { 1 : 1 2 : 1 } } 318 : { 1 : "NN dep NN dep NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep drug0 dep *administration* nmod drug0" 2 : "drug0 nmod *administration* dep mg dep drug0" } 4 : { 1 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [ e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . " 2 : "Concomitant administration of drug1 ( equivalent to 145 mg drug2 ) with drug3 ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in drug4 AUC values in 22 healthy males . " } 5 : { 1 : 1 2 : 1 } } 319 : { 1 : "NN conj NN nmod JJ acl:relcl NNS nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod vasoconstrictive acl:relcl agents nmod presence nmod control xcomp *used* nsubjpass drug0" } 4 : { 1 : "Additionally , drug1 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug2 , drug3 , and drug4 because of the danger of blocking cardiac contractility when systemic vascular resistance is high . " } 5 : { 1 : 2 } } 320 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBG acl NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod containing acl *drug0*" } 4 : { 1 : "The administration of local drug1 containing drug2 or drug3 to patients receiving drug4 , drug5 or drug6 may produce severe , prolonged hypotension or hypertension . " } 5 : { 1 : 2 } } 321 : { 1 : "NN conj NN dep NN conj NN dobj VB xcomp VBN acl NNS nmod VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep conduction conj function dobj affect xcomp known acl agents nmod *receiving* dobj drug0" } 4 : { 1 : "Also , due to the potential for additive effects such as bradycardia and AV block , caution is warranted in patients receiving drug1 with agents known to affect sinus node function or AV nodal conduction ( e.g. , drug2 , drug3 , and drug4 . ) " } 5 : { 1 : 2 } } 322 : { 1 : "NN nmod NN nsubj VB nmod NNS acl:relcl VBN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod co-administration nsubj *result* nmod patients acl:relcl treated nmod drug0" } 4 : { 1 : "drug1 : In some patients with compromised renal function who are being treated with drug2 , the co-administration of drug3 may result in a further deterioration of renal function . " } 5 : { 1 : 2 } } 323 : { 1 : "NN dobj VB advcl VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 dobj *occur* advcl administered nsubjpass agents nmod drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 2 } } 324 : { 1 : "NN conj NN dobj VBG acl NN dobj VB nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj neuropathy dobj developing acl risk dobj *increase* nsubj drugs nmod drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 , and drug3 : Drugs such as drug4 , drug5 , and drug6 may increase the risk of developing peripheral neuropathy or other drug7 - associated adverse events by interfering with the renal clearance of drug8 ( thereby raising systemic exposure ) . " } 5 : { 1 : 2 } } 325 : { 1 : "NN conj NN dep NN dep NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep drug0 dep *administration* nmod drug0" } 4 : { 1 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [ e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . " } 5 : { 1 : 2 } } 326 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NNS dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod clearance dobj increase xcomp *expected* nsubjpass drugs dep drug0 appos drug0" } 4 : { 1 : "Drugs which induce CYP3A4 activity ( eg , drug1 , drug2 , drug3 ) would be expected to increase the clearance of drug4 resulting in lowered plasma concentrations . " } 5 : { 1 : 2 } } 327 : { 1 : "NN dobj VBG advcl VBN nsubjpass NN nmod NNS nmod NN" 2 : 2 3 : { 1 : "drug0 dobj discontinuing advcl *minimized* nsubjpass possibility nmod effects nmod drug0" 2 : "drug0 dobj discontinuing advcl *minimized* nsubjpass possibility nmod effects nmod drug0" } 4 : { 1 : "The possibility of hypotensive effects with drug1 or drug2 can be minimized by either discontinuing the drug3 or increasing the salt intake prior to initiation of treatment with drug4 or drug5 . " 2 : "The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug2 or increasing the salt intake approximately one week prior to initiation of treatment with drug3 ( drug4 tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) . " } 5 : { 1 : 1 2 : 1 } } 328 : { 1 : "NN compound NNS conj NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound s conj drug0 nmod *use* nmod drug0" 2 : "drug0 compound supplements conj drug0 nmod *use* nmod drug0" } 4 : { 1 : "The concomitant use of drug1 with drug2 and drug3 s may have additive effects on prolonging atrioventricular conduction time . " 2 : "Use of drug1 with drug2 ( e.g. , drug3 , drug4 , or drug5 ) , drug6 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium . " } 5 : { 1 : 1 2 : 1 } } 329 : { 1 : "NN conj NN nmod NNS nmod NNS dobj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod hormones nmod levels dobj decrease acl:relcl drugs nmod *administered* nsubjpass drug0" } 4 : { 1 : "Caution should be exercised if an drug1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drug2 , drug3 , and drug4 . " } 5 : { 1 : 2 } } 330 : { 1 : "NN appos NN conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 2 } } 331 : { 1 : "NN conj NN root , punct NN root , punct RB dep NNS acl VBG dobj NNS acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 root , punct drug0 root , punct specifically dep *patients* acl receiving dobj regimens acl containing dobj drug0" } 4 : { 1 : "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug2 , specifically , drug3 , drug4 , drug5 and drug6 . " } 5 : { 1 : 2 } } 332 : { 1 : "NN conj NN dobj VBG acl NN nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 nmod *impaired* nsubjpass absorption nmod drug0" } 4 : { 1 : "Absorption of drug1 is impaired by drug2 containing drug3 , drug4 , or drug5 , and drug6 - containing preparations . " } 5 : { 1 : 2 } } 333 : { 1 : "NN dobj VB xcomp VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 dobj reduce xcomp *shown* nsubjpass drug0" 2 : "drug0 dobj change xcomp *shown* nsubjpass drug0" } 4 : { 1 : "Although drug1 have been shown to reduce drug2 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drug3 may reduce the antitumor effectiveness of drug4 and thus should be avoided . 12 drug5 and other drug6 may potentiate the hypotension seen with drug7 . " 2 : "drug1 has been shown to change the bioavailabillty drug2 when they are co-administered , which may require drug3 dose adjustment . " } 5 : { 1 : 1 2 : 1 } } 334 : { 1 : "NN dobj VBG acl:relcl NNS nmod NN nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 dobj receiving acl:relcl patients nmod caution nmod *used* nsubjpass drug0" 2 : "drug0 dobj taking acl:relcl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with caution in patients who are receiving a drug2 orally because of the potential for additive effects on systemic beta-blockade . " 2 : "drug1 should be administered with caution to patients who are taking other drug2 or drug3 , including drug4 , drug5 and drug6 , or to those with a history of psychiatric disorder ( including manic-depressive illness and schizophrenia ) . " } 5 : { 1 : 1 2 : 1 } } 335 : { 1 : "NN nmod VBN dep NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod inhibited dep *drug0* dep drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 ) : Metabolism may be inhibited by drug5 , increasing plasma levels of drug6 ; " } 5 : { 1 : 2 } } 336 : { 1 : "NN nmod VBP nsubj NN appos NN compound FW conj NN" 2 : 2 3 : { 1 : "drug0 nmod *have* nsubj drug0 appos drug0 compound drug0 conj drug0" } 4 : { 1 : "Other drug1 ( e.g. drug2 , drug3 , drug4 and general drug5 ) have additive or potentiating effects with drug6 . " } 5 : { 1 : 2 } } 337 : { 1 : "NN nmod VBN advcl VB nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod administered advcl *enhance* nsubj depressasnts nmod drug0 conj drug0" } 4 : { 1 : "Other depressasnts such as drug1 , drug2 , and drug3 may enhance CNS depression when administered with drug4 . " } 5 : { 1 : 2 } } 338 : { 1 : "NN compound NN acl:relcl NNS nsubj VB advcl VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 compound therapy acl:relcl patients nsubj *require* advcl shown nsubjpass drug0" 2 : "drug0 compound therapy acl:relcl patients nsubj *require* advcl shown nsubjpass drug0" } 4 : { 1 : "Because the drug1 have been shown to depress plasma prothrombin activity , patients who are on drug2 therapy may require downward adjustment of their drug3 dosage . " 2 : "Because drug1 have been shown to depress plasma prothrombin activity , patients who are on drug2 therapy may require downward adjustment of their drug3 dosage . " } 5 : { 1 : 1 2 : 1 } } 339 : { 1 : "NN nmod NNS nmod NN dobj VBZ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod interactions nmod potential dobj *suggests* nsubj experience nmod drug0" 2 : "drug0 nmod concentrations nmod decrease dobj *causes* nsubj addition nmod drug0" } 4 : { 1 : "Experience with drug1 ( drug2 ) suggests the potential for interactions with drug3 and drug4 . " 2 : "Effects of Other drug1 on drug2 drug3 : drug4 causes an approximate doubling of the clearance of drug5 ( drug6 ) at steady state and , therefore , the addition of drug7 causes an approximate 45 % decrease in the steady-state trough concentrations of drug8 as compared to the same dose of drug9 given as monotherapy . " } 5 : { 1 : 1 2 : 1 } } 340 : { 1 : "NN nmod VBN advcl VB nsubj NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod administered advcl *enhance* nsubj depressasnts nmod drug0" 2 : "drug0 nmod given advcl *have* nsubj drugs nmod drug0" } 4 : { 1 : "Other depressasnts such as drug1 , drug2 , and drug3 may enhance CNS depression when administered with drug4 . " 2 : "Catecholamine-depleting drugs , e.g. , drug1 , may have an additive effect when given with drug2 . " } 5 : { 1 : 1 2 : 1 } } 341 : { 1 : "NN nmod NNS dobj VB conj VB nsubj NN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod levels dobj reduce conj *affect* nsubj coadministration nmod drug0 conj drug0" } 4 : { 1 : "drug1 / drug2 : The coadministration of drug3 or drug4 will not affect plasma concentrations of drug5 , but may reduce endogenous plasma levels of drug6 / ergocalcitriol by accelerating metabolism . " } 5 : { 1 : 2 } } 342 : { 1 : "NN conj NN dobj VBG acl NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 2 } } 343 : { 1 : "NN appos NN dep NN dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep drug0 dobj taking acl patients nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 : Hallucinations have been reported when drug2 was used in patients taking drug3 ( drug4 , drug5 , drug6 ) . " } 5 : { 1 : 2 } } 344 : { 1 : "NN conj NN nmod NNS dobj VBG acl NN nsubjpass VBN advcl VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drugs dobj using acl caution nsubjpass *advised* advcl reduce nsubj drug0" } 4 : { 1 : "Since drug1 may reduce pulse and blood pressure , caution in using drugs such as drug2 ( ophthalmic and systemic ) , drug3 , and drug4 is advised . " } 5 : { 1 : 2 } } 345 : { 1 : "NN nmod NN nmod NN nmod VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod activity nmod modification nmod *regulate* nsubj drug0 conj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 2 } } 346 : { 1 : "NN conj NN nmod NN nmod NN nmod VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod activity nmod modification nmod *regulate* nsubj drug0 conj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 2 } } 347 : { 1 : "NN dep VB nmod NN" 2 : 2 3 : { 1 : "drug0 dep *interact* nmod drug0" 2 : "drug0 dep *interact* nmod drug0" } 4 : { 1 : "When administered concurrently , the following drugs may interact with drug1 : drug2 , general : exaggeration of the hypotension induced by general drug3 . " 2 : "When administered concurrently , the following drugs may interact with drug1 : drug2 : may enhance the potential for renal toxicity , bronchospasm and hypotension . " } 5 : { 1 : 1 2 : 1 } } 348 : { 1 : "NN dep VBP conj NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep inhibit conj drugs nmod *co-administration* nmod drug0" 2 : "drug0 dep inhibit conj drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isoenzyme , including other drug2 , drug3 , drug4 , and drug5 ( eg , drug6 , drug7 , and drug8 ) , or that inhibit this enzyme ( eg , drug9 ) , should be approached with caution . " 2 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isozyme , including drug2 , drug3 , drug4 , and drug5 ( e.g. , drug6 , drug7 and drug8 ) , or that inhibit this enzyme ( e.g. , drug9 ) , should be approached with caution . " } 5 : { 1 : 1 2 : 1 } } 349 : { 1 : "NN nmod NNS nmod NN dobj VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod catecholamines nmod effect dobj *increases* nsubj drug0" 2 : "drug0 nmod acids nmod secretion dobj *depresses* nsubj drug0" } 4 : { 1 : "drug1 s : drug2 increases the adrenergic effect of catecholamines such as drug3 and drug4 . " 2 : "drug1 depresses tubular secretion of certain weak acids such as drug2 . " } 5 : { 1 : 1 2 : 1 } } 350 : { 1 : "NN compound NNS dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 compound concentrations dobj *increased* nsubj drug0" 2 : "drug0 compound concentrations dobj *increased* nsubj drug0" } 4 : { 1 : "drug1 increased mean drug2 plasma concentrations ( AUC ) approximately 6-fold and prolonged the half-life by approximately 3-fold . " 2 : "drug1 increased mean drug2 plasma concentrations ( AUC ) by 29 % . " } 5 : { 1 : 1 2 : 1 } } 351 : { 1 : "NN dep NN conj NN nmod NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" 2 : "drug0 dep drug0 conj drug0 nmod drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isoenzyme , including other drug2 , drug3 , drug4 , and drug5 ( eg , drug6 , drug7 , and drug8 ) , or that inhibit this enzyme ( eg , drug9 ) , should be approached with caution . " 2 : "Therefore , co-administration of drug1 with other drugs that are metabolized by this isozyme , including drug2 , drug3 , drug4 , and drug5 ( e.g. , drug6 , drug7 and drug8 ) , or that inhibit this enzyme ( e.g. , drug9 ) , should be approached with caution . " } 5 : { 1 : 1 2 : 1 } } 352 : { 1 : "NN nmod NN nsubj VB dep NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod administration nsubj increase dep *drug0* dep drug0 conj drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , and possibly drug4 ) : Concomitant administration with drug5 may increase the risk of gastrointestinal ulceration . " } 5 : { 1 : 2 } } 353 : { 1 : "NN nmod NN nmod VBN advcl VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod combination nmod administered advcl *recommended* nsubjpass adjustment nmod drug0" 2 : "drug0 nmod combination nmod used advcl *recommended* nsubjpass increase nmod drug0" } 4 : { 1 : "Although a dose adjustment of drug1 is not recommended when administered in combination with drug2 , close monitoring for known side effects of drug3 , such as liver enzyme abnormalities and hearing impairment , is warranted . " 2 : "A dose increase of drug1 / drug2 to 533/133 mg ( 4 capsules or 6.5 mL ) twice daily taken with food is recommended when used in combination with drug3 . " } 5 : { 1 : 1 2 : 1 } } 354 : { 1 : "NN conj NN nmod NN nmod VBN nsubjpass NN acl VBN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod administration nmod *converted* nsubjpass tachycardia acl induced nmod drug0" } 4 : { 1 : "Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug2 , drug3 , or drug4 but not after administration of drug5 alone or after drug6 . " } 5 : { 1 : 2 } } 355 : { 1 : "NN dep VBN acl NN nmod NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep contraindicated acl drug0 nmod drugs nmod *use* nmod drug0" } 4 : { 1 : "drug1 : Based on reports of profound hypotension and loss of consciousness when drug2 was administered with drug3 , the concomitant use of drug4 with drugs of the drug5 ( including , for example , drug6 , drug7 , drug8 , drug9 , and drug10 ) is contraindicated . " } 5 : { 1 : 2 } } 356 : { 1 : "NN conj NN dep JJR nsubj NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *lower* nsubj concentrations nmod drug0" } 4 : { 1 : "drug1 : In a pharmacokinetic study , maximum plasma concentrations of drug2 were considerably lower in epileptic patients on long-term drug3 therapy ( eg , drug4 , drug5 , or drug6 ) than in healthy volunteers . " } 5 : { 1 : 2 } } 357 : { 1 : "NN nmod NN nsubj VBN nmod NN nmod NN nmod NNS amod JJ nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod dosage nsubj *needed* nmod comparison nmod tolerance nmod dogs amod anesthetized nmod drug0 conj drug0" } 4 : { 1 : "In a comparison of drug1 tolerance in dogs anesthetized with drug2 , drug3 , or drug4 , the dosage of drug5 needed to cause ventricular tachycardia was significantly higher , as was the LD50 of drug6 , with drug7 or drug8 than with drug9 . " } 5 : { 1 : 2 } } 358 : { 1 : "NN conj NN nsubjpass VBN acl NN nmod NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nsubjpass contraindicated acl drug0 nmod drugs nmod *use* nmod drug0" } 4 : { 1 : "drug1 : Based on reports of profound hypotension and loss of consciousness when drug2 was administered with drug3 , the concomitant use of drug4 with drugs of the drug5 ( including , for example , drug6 , drug7 , drug8 , drug9 , and drug10 ) is contraindicated . " } 5 : { 1 : 2 } } 359 : { 1 : "NN appos NN nmod NNS nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 appos drug0 nmod inducers nmod *affected* nsubjpass metabolism nmod drug0" } 4 : { 1 : "Although no clinical studies have been conducted , it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers ( such as drug2 , drug3 , drug4 ) , CYP3A4 inhibitors ( azole antimycotics e.g. , drug5 ; " } 5 : { 1 : 2 } } 360 : { 1 : "NN conj NN dep NN nmod VBN acl:relcl NN nmod NN dobj VBP nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep cyp0a0 nmod metabolized acl:relcl drug0 nmod metabolism dobj *inhibit* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : drug1 inhibit the metabolism of drug2 that are metabolized by CYP3A4 ( i.e. , drug3 , drug4 , drug5 , drug6 ) . " } 5 : { 1 : 2 } } 361 : { 1 : "NN conj NN nmod NNS nmod NNS dobj VB advcl VBN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drugs nmod consequences dobj *have* advcl studied nmod drug0" } 4 : { 1 : "Although not studied with drug1 , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug2 , drug3 , and drug4 . " } 5 : { 1 : 2 } } 362 : { 1 : "NN nsubjpass VBN acl:relcl NN" 2 : 2 3 : { 1 : "drug0 nsubjpass administered acl:relcl *drug0*" 2 : "drug0 nsubjpass added acl:relcl *drug0*" } 4 : { 1 : "There have been greater than 2-fold increases in previously stable plasma levels of other drug1 , including drug2 , when drug3 has been administered in combination with these agents . " 2 : "Patients in a clinical study who were on established therapy with drug1 , to which drug2 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drug3 CI or drug4 alone . " } 5 : { 1 : 1 2 : 1 } } 363 : { 1 : "NN conj NNS nmod NNS dobj VB dep VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj medications nmod effects dobj potentiate dep *interact* nsubj drug0" } 4 : { 1 : "drug1 can interact with drug2 or other drug3 ( may potentiate the CNS depressant effects of either these medications or drug4 ) , drug5 or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with drug6 ) , and drug7 ( concurrent use with drug8 may prolong and intensify the anticholinergic and CNS depressant effects of drug9 ) . " } 5 : { 1 : 2 } } 364 : { 1 : "NN conj NN nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod *antagonized* nsubjpass effects nmod drug0" 2 : "drug0 conj drug0 nmod drug0 nmod *antagonized* nsubjpass effects nmod drug0" } 4 : { 1 : "The effects of drug1 are antagonized by drug2 such as drug3 and drug4 . " 2 : "Cardiac effects of drug1 are antagonized by drug2 , such as drug3 and drug4 . " } 5 : { 1 : 1 2 : 1 } } 365 : { 1 : "NN nmod NN nmod NNS nmod NN conj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod action nmod *effects* nmod drug0 conj therapy compound drug0" 2 : "drug0 compound drug0 conj drug0 nmod products nmod *drug0* nmod drug0" } 4 : { 1 : "While the effects of chronic drug1 or drug2 therapy on the action of drug3 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . " 2 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 1 2 : 1 } } 366 : { 1 : "NN conj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj *interact* nsubj drug0" } 4 : { 1 : "drug1 can interact with drug2 or other drug3 ( may potentiate the CNS depressant effects of either these medications or drug4 ) , drug5 or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with drug6 ) , and drug7 ( concurrent use with drug8 may prolong and intensify the anticholinergic and CNS depressant effects of drug9 ) . " } 5 : { 1 : 2 } } 367 : { 1 : "NN nmod NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod use appos *drug0*" 2 : "drug0 nmod co-administration appos *drug0*" } 4 : { 1 : "May interact with the following : drug1 , drug2 ( use with drug3 may prevent the drug4 from working properly ; " 2 : "drug1 : As with other drug2 , co-administration of drug3 with drug4 resulted in an increase in the plasma exposure of drug5 , with a 49 % increase in mean Cmax , a 122 % increase in mean AUC , and a 53 % increase in half-life . " } 5 : { 1 : 1 2 : 1 } } 368 : { 1 : "NN compound NN nmod NN nmod VBD nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 compound elimination nmod inhibition nmod *led* nsubj administration compound drug0" 2 : "drug0 compound auc nmod decrease nmod *resulted* nsubj treatment compound drug0" } 4 : { 1 : "drug1 administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of drug2 elimination .14 The effect of alternate-day administration of 0.25 mg of drug3 on drug metabolism in MS patients is unknown . " 2 : "drug1 treatment resulted in a 42 % decrease in the drug2 AUC 0-24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of drug3 . " } 5 : { 1 : 1 2 : 1 } } 369 : { 1 : "NN nmod NN dobj VB nsubj NNS dep NN" 2 : 2 3 : { 1 : "drug0 nmod metabolism dobj *enhance* nsubj drugs dep drug0" 2 : "drug0 nmod exposure dobj *decrease* nsubj co-medications dep drug0" } 4 : { 1 : "Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , drug1 , drug2 , drug3 , drug4 ) may enhance the metabolism of drug5 and require that the dosage of the drug6 be increased . " 2 : "Co-medications that induce CYP 3A4 ( e.g. , drug1 , drug2 , drug3 , drug4 , or St. John s wort ) may significantly decrease exposure to drug5 . " } 5 : { 1 : 1 2 : 1 } } 370 : { 1 : "NN conj NN nmod NNS nmod VBN dep NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drugs nmod reduced dep *effectiveness* nmod drug0" } 4 : { 1 : "The effectiveness of drug1 - only pills is reduced by hepatic enzyme-inducing drugs such as the drug2 drug3 , drug4 , and drug5 , and the drug6 drug7 . " } 5 : { 1 : 2 } } 371 : { 1 : "NN conj NN dep FW dep VBN advcl JJ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep e.g. dep coadministered advcl *necessary* nsubj adjustment nmod drug0" } 4 : { 1 : "Dosage adjustment of drug1 may be necessary when coadministered with CYP2D6 inhibitors , e.g. , drug2 , drug3 , and drug4 . " } 5 : { 1 : 2 } } 372 : { 1 : "NN conj NN nmod NN nmod NN dobj VB nsubj NNS acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod response nmod enhancement dobj *experience* nsubj individuals acl receiving dobj drug0" } 4 : { 1 : "drug1 : Some individuals receiving drug2 may experience a reversible enhancement of the pressor response to indirect-acting drug3 , drug4 or drug5 . " } 5 : { 1 : 2 } } 373 : { 1 : "NN nmod NN dobj VB nsubj NN conj NNS compound NN" 2 : 2 3 : { 1 : "drug0 nmod effect dobj *potentiate* nsubj drug0 conj salts compound drug0" } 4 : { 1 : "drug1 , drug2 , drug3 salts , and drug4 may either potentiate or weaken the blood-glucose-lowering effect of drug5 . " } 5 : { 1 : 2 } } 374 : { 1 : "NN dobj VBD acl:relcl NNS nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 dobj bound acl:relcl drugs nmod *potentiated* nsubjpass action nmod drug0" } 4 : { 1 : "The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 and other drugs that are highly protein bound , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , and drug9 . " } 5 : { 1 : 2 } } 375 : { 1 : "NN dobj VBG conj VBG advcl VBN nsubjpass NNS compound NN" 2 : 2 3 : { 1 : "drug0 dobj discontinuing conj initiating advcl *monitored* nsubjpass levels compound drug0" 2 : "drug0 dobj discontinuing conj initiating advcl *monitored* nsubjpass levels compound drug0" } 4 : { 1 : "drug1 : Immediate Release Capsules : Since there have been isolated reports of patients with elevated drug2 levels , and there is a possible interaction between drug3 and drug4 , it is recommended that drug5 levels be monitored when initiating , adjusting , and discontinuing drug6 to avoid possible over - or under-digitalization . " 2 : "Since there have been isolated reports of patients with elevated drug1 levels , it is recommended that drug2 levels be monitored when initiating , adjusting , and discontinuing drug3 to avoid possible over - or under-digitalization . " } 5 : { 1 : 1 2 : 1 } } 376 : { 1 : "NN nmod NN nmod NN nmod NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 nmod reaction nmod history nmod patients nmod *avoided* nsubjpass drug0" } 4 : { 1 : "drug1 should be avoided by patients with a history of serious reaction to any drug2 , including drug3 and drug4 . " } 5 : { 1 : 2 } } 377 : { 1 : "NN compound NNS dobj VBD nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound levels dobj *increased* nsubj administration nmod drug0" 2 : "drug0 compound concentrations dobj *decreased* nsubj coadministration nmod drug0" } 4 : { 1 : "Extended Release Tablets : Administration of drug1 with drug2 increased drug3 levels in 9 of 12 normal volunteers . " 2 : "Coadministration of drug1 significantly decreased drug2 plasma concentrations . " } 5 : { 1 : 1 2 : 1 } } 378 : { 1 : "NN nmod NN nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod *isomer* nsubj drug0" 2 : "drug0 nmod *agent* nsubj drug0" } 4 : { 1 : "Concomitant Administration with Racemic drug1 drug2 - Since drug3 is the active isomer of racemic drug4 ( drug5 ) , the two agents should not be coadministered . " 2 : "drug1 is a neutralizing agent for drug2 that protects against renal damage . " } 5 : { 1 : 1 2 : 1 } } 379 : { 1 : "NN conj NN nmod NN dobj VB nsubj NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0" 2 : "drug0 conj drug0 nmod action dobj *reduce* nsubj drugs nmod drug0" } 4 : { 1 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " 2 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . " } 5 : { 1 : 1 2 : 1 } } 380 : { 1 : "NN compound NNS conj NN nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 compound s conj drug0 nmod *interact* nsubj drug0" 2 : "drug0 compound supplements conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 , drug3 s , drug4 ( allergy , cold , and sinus medicines ) , diabetic drugs , drug5 , drug6 , drug7 like drug8 or drug9 , and high blood pressure medications . " 2 : "drug1 may interact with drug2 , drug3 , drug4 , drug5 , drug6 supplements , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , and drug14 . " } 5 : { 1 : 1 2 : 1 } } 381 : { 1 : "NN dep NN nmod VB nsubj NN" 2 : 2 3 : { 1 : "drug0 dep absorption nmod *interfere* nsubj drug0" 2 : "drug0 dep drug0 nmod *interfere* nsubj drug0" } 4 : { 1 : "Therefore , drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , drug2 , drug3 salts and drug4 ) . " 2 : "conversely , drug1 may interfere with drug2 ( i.e. , drug3 , drug4 ) . " } 5 : { 1 : 1 2 : 1 } } 382 : { 1 : "NN compound NN dobj VBP nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound metabolism dobj *induce* nsubj inducers nmod drug0 conj drug0" } 4 : { 1 : "Cytochrome P-450 inducers , such as drug1 , drug2 and drug3 , induce drug4 metabolism , causing an approximately 30 % decrease in plasma drug5 levels . " } 5 : { 1 : 2 } } 383 : { 1 : "NN conj NN nmod NNS nmod VBG acl NNS dobj VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod levels nmod leading acl changes dobj *cause* nsubj cyclosporine conj drug0" } 4 : { 1 : "Cyclosporine , Digoxin , Methotrexate drug1 , like other drug2 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drug3 , drug4 , drug5 , and increased toxicity . " } 5 : { 1 : 2 } } 384 : { 1 : "NN nmod VBN advcl JJR nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod given advcl *lower* nsubj cmax nmod drug0" 2 : "drug0 nmod coadministered advcl *higher* nsubj cmax nmod drug0" } 4 : { 1 : "In a study in which the 2 mg drug1 orally disintegrating tablet was administered with and without drug2 ( an drug3 with multiple effects on the GI tract ) to healthy volunteers , the AUC of drug4 was 10 % lower and the Cmax of drug5 was 20 % lower when the orally disintegrating tablet was given with drug6 compared to when it was given alone . " 2 : "The Cmax of drug1 was 13 % higher when it was coadministered with drug2 ; " } 5 : { 1 : 1 2 : 1 } } 385 : { 1 : "NN compound NN nmod VBN conj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 compound pretreatment nmod prevented conj *induced* nsubj drug0" 2 : "drug0 compound pretreatment nmod potentiated conj *produced* nsubj drug0" } 4 : { 1 : "It was observed that drug1 induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by drug2 pretreatment . " 2 : "drug1 , like drug2 , produced depletions of striatal dopamine but these actions were potentiated by drug3 pretreatment . " } 5 : { 1 : 1 2 : 1 } } 386 : { 1 : "NN nmod NNS dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod concentrations dobj *decreased* nsubj drug0" 2 : "drug0 nmod effects dobj *antagonized* nsubj drug0" } 4 : { 1 : "drug1 , an inducer of drug metabolism , decreased the concentrations of drug2 and its active metabolite . " 2 : "In both species , drug1 , but not drug2 , antagonized the rate-decreasing effects of drug3 on FI and FR responding . " } 5 : { 1 : 1 2 : 1 } } 387 : { 1 : "NN compound NN dep NN dep NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 compound drug0 dep drug0 dep drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 2 } } 388 : { 1 : "NN conj VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj *potentiated* nsubjpass action nmod drug0" 2 : "drug0 conj *impaired* nsubjpass absorption nmod drug0" } 4 : { 1 : "Pharmacodynamic Interactions : The CNS-depressant action of the drug1 of drugs may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , the drug7 , drug8 and drug9 , drug10 and the drug11 , and by other drug12 . " 2 : "Absorption of drug1 is impaired by drug2 containing drug3 , drug4 , or drug5 , and drug6 - containing preparations . " } 5 : { 1 : 1 2 : 1 } } 389 : { 1 : "NN conj NN nmod NNS nmod VBG acl NNS dobj VB nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod levels nmod leading acl changes dobj *cause* nsubj cyclosporine nmod drug0" } 4 : { 1 : "Cyclosporine , Digoxin , Methotrexate drug1 , like other drug2 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drug3 , drug4 , drug5 , and increased toxicity . " } 5 : { 1 : 2 } } 390 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod *avoided* nsubjpass drug0" 2 : "drug0 conj drug0 dobj taking acl patients nmod *initiated* nsubjpass drug0" } 4 : { 1 : "Consequently , drug1 should be avoided in patients receiving drug2 and drug3 , which are very potent inhibitors of CYP3A . " 2 : "Although it has not been established that there is an interaction between drug1 and drug2 or other drug3 , caution is advised when drug4 is initiated in patients taking a drug5 or any other drug6 . " } 5 : { 1 : 1 2 : 1 } } 391 : { 1 : "NN conj NN dep NNS conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep compounds conj *drug0*" } 4 : { 1 : "Concomitant administration of drug1 and other related compounds ( eg , drug2 , drug3 and drug4 ) may produce electrocardiographic abnormalities and increase the risk of convulsions . " } 5 : { 1 : 2 } } 392 : { 1 : "NN dep NN nmod NN dobj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 dep drug0 nmod amount dobj *decrease* nsubj drug0" 2 : "drug0 dep drug0 nmod clearance dobj *decrease* nsubj drug0" } 4 : { 1 : "drug1 may decrease the amount of drug2 ( drug3 , drug4 ) that gets absorbed into your body . " 2 : "drug1 : Combination drug2 may decrease the clearance of some drug3 ( drug4 , drug5 , drug6 ) and increase the clearance of others ( drug7 , drug8 , drug9 ) . " } 5 : { 1 : 1 2 : 1 } } 393 : { 1 : "NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 2 } } 394 : { 1 : "NN nmod NNS dobj VBZ conj VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod effects dobj increases conj *prolongs* nsubj drug0" 2 : "drug0 nmod effects dobj potentiates conj *attenuates* nsubj drug0" } 4 : { 1 : "Animal experience indicates that drug1 prolongs the sleeping time after drug2 or after drug3 , increases the inhibitory effects of drug4 , but does not exhibit monoamine oxidase inhibition . " 2 : "drug1 attenuates , but drug2 potentiates , the acute locomotor effects of drug3 ; " } 5 : { 1 : 1 2 : 1 } } 395 : { 1 : "NN nmod NN nmod VBN nsubjpass NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod coadministration nmod *changed* nsubjpass clearance compound drug0" 2 : "drug0 nmod treatment nmod *stopped* nsubjpass treatment compound drug0" } 4 : { 1 : "Although in vivo studies have not been done to see if drug1 clearance is changed by coadministration of drug2 , it is not recommended that they be coadministered . " 2 : "drug1 treatment should be stopped during treatment with drug2 . " } 5 : { 1 : 1 2 : 1 } } 396 : { 1 : "NN nmod NN dobj VB nsubj NNS compound NN" 2 : 2 3 : { 1 : "drug0 nmod bioavailability dobj *reduce* nsubj salts compound drug0" 2 : "drug0 nmod metabolism dobj *alter* nsubj tablets compound drug0" } 4 : { 1 : "drug1 salts may reduce the bioavailability of drug2 and drug3 . " 2 : "drug1 tablets may alter the metabolism of drug2 , drug3 , and drug4 , resulting in elevated plasma concentrations of the latter drugs . " } 5 : { 1 : 1 2 : 1 } } 397 : { 1 : "NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod treated acl:relcl patients nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 to hypoparathyroid patients who are concurrently being treated with drug2 may cause hypercalcemia . " } 5 : { 1 : 2 } } 398 : { 1 : "NN nmod VBN acl NN dobj VBD nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod induced acl inhibition dobj *blocked* nsubj dose nmod drug0" 2 : "drug0 nmod induced acl inhibition dobj *antagonized* nsubj injection nmod drug0" } 4 : { 1 : "Intrathecal injection of drug1 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug2 , and a high dose of drug3 ( 40 micrograms ) completely blocked the tail-flick inhibition induced by intraventricular drug4 ( 16 micrograms ) . " 2 : "Intraventricular injection of drug1 at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drug2 and drug3 . " } 5 : { 1 : 1 2 : 1 } } 399 : { 1 : "NN nmod NN dobj VBD nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod response dobj *reduced* nsubj iv/im compound drug0" 2 : "drug0 nmod effect dobj *augmented* nsubj pretreatment compound drug0" } 4 : { 1 : "drug1 : drug2 IV/IM reduced the drug3 response to drug4 in normovolemic healthy subjects by approximately 20 % ( mean sodium and urinary output decreased 17 % ) . " 2 : "drug1 pretreatment augmented the depressant effect of drug2 on the early components P1 and N1 , while attenuating drug3 's influence on components P2 and P3 . " } 5 : { 1 : 1 2 : 1 } } 400 : { 1 : "NN compound NN nmod VBN nsubjpass NN conj NN" 2 : 2 3 : { 1 : "drug0 compound treatment nmod *administered* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 should not be administered during drug4 treatment . " } 5 : { 1 : 2 } } 401 : { 1 : "NN nmod NN acl NN dobj VBN dep VB dobj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod dosing acl hour dobj given dep *avoid* dobj interaction conj drug0" } 4 : { 1 : "To avoid this interaction , drug1 or drug2 should be given 1 hour prior to dosing with drug3 . " } 5 : { 1 : 2 } } 402 : { 1 : "NN compound NN nmod NN dobj VB conj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 compound toxicity nmod risk dobj add conj *reduce* nsubj drug0" } 4 : { 1 : "drug1 reduce the renal clearance of drug2 and add a high risk of drug3 toxicity . " } 5 : { 1 : 2 } } 403 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod reversed xcomp *reported* nsubjpass effects nmod drug0" 2 : "drug0 nmod exacerbated xcomp *expected* nsubjpass effects nmod drug0" } 4 : { 1 : "In addition , the beneficial effects of drug1 in Parkinsons disease have been reported to be reversed by drug2 and drug3 . " 2 : "The adverse effects of drug1 , such as myelosuppression and diarrhea , would be expected to be exacerbated by other drug2 having similar adverse effects . " } 5 : { 1 : 1 2 : 1 } } 404 : { 1 : "NN nmod NNS dobj VB nsubj NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod effects dobj *reduce* nsubj drug0 dep drug0 appos drug0" } 4 : { 1 : "drug1 ( e.g. , drug2 , drug3 , drug4 ) and drug5 may reduce the therapeutic effects of drug6 . " } 5 : { 1 : 2 } } 405 : { 1 : "NN conj NN nmod NN dobj VBD dep VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod effect dobj decreased dep *used* nsubj drug0" } 4 : { 1 : "drug1 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug2 , drug3 ( only in the tail-flick test ) and drug4 . " } 5 : { 1 : 2 } } 406 : { 1 : "NN conj NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod window dobj have conj metabolized acl:relcl medications nmod *used* nsubjpass drug0" } 4 : { 1 : "Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window , such as drug2 , drug3 and drug4 ( see CLINICAL PHARMACOLOGY ) . " } 5 : { 1 : 2 } } 407 : { 1 : "NN nmod RB advmod NNS dobj VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 nmod prior advmod hours dobj *administered* nsubjpass drug0" 2 : "drug0 nmod prior advmod hours dobj *given* nsubjpass drug0" } 4 : { 1 : "A 21 ( 17 ) % decrease in the steady-state AUC of drug1 was observed when drug2 was administered 2 hours prior to drug3 , but not when the two drugs were administered simultaneously ( n = 12 ) . " 2 : "Although this effect was noted even when drug1 was given 4 hours prior to drug2 , this regimen did not result in diminished efficacy . " } 5 : { 1 : 1 2 : 1 } } 408 : { 1 : "NN dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 dobj *inhibited* nsubj drug0" 2 : "drug0 dobj *inhibited* nsubj drug0" } 4 : { 1 : "drug1 inhibited the drug2 - stimulated intracellular Ca ( 2 + ) concentration ( [ Ca ( 2 + ) ] ( i ) ) increase due to release from the Ca ( 2 + ) store . " 2 : "drug1 and drug2 ( 0.1 and 1.0 mg/kg , s.c. ) inhibited the drug3 ( 0.3 mg/kg , p.o. ) - induced diarrhea in cecectomized rats . " } 5 : { 1 : 1 2 : 1 } } 409 : { 1 : "NN dep VBP nsubj NNS acl:relcl VB dobj NNS compound NN" 2 : 2 3 : { 1 : "drug0 dep *include* nsubj drugs acl:relcl decrease dobj concentrations compound drug0" 2 : "drug0 dep *include* nsubj drugs acl:relcl increase dobj concentrations compound drug0" } 4 : { 1 : "- Drugs that may decrease plasma drug1 concentrations include : drug2 , chronic drug3 abuse , drug4 " 2 : "- Drugs that may either increase or decrease plasma drug1 concentrations include : drug2 , vaiproic acid , and drug3 . " } 5 : { 1 : 1 2 : 1 } } 410 : { 1 : "NN dobj VBG acl NN nmod VBN advcl VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 dobj containing acl drug0 nmod administered advcl *decreased* nsubjpass concentrations nmod drug0" 2 : "drug0 dobj containing acl drug0 nmod administered advcl *decreased* nsubjpass concentrations nmod drug0" } 4 : { 1 : "drug1 s : drug2 should be administered at least 2 hours after or 6 hours before dosing with drug3 because plasma concentrations of drug4 are decreased when administered with drug5 containing drug6 , drug7 , or drug8 . " 2 : "Plasma concentrations of drug1 are decreased when administered with drug2 containing drug3 , drug4 , or drug5 . " } 5 : { 1 : 1 2 : 1 } } 411 : { 1 : "NN dobj VBD nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 dobj *increased* nsubj exposure nmod drug0" 2 : "drug0 dobj *inhibited* nsubj pretreatment nmod drug0" } 4 : { 1 : "Exposure of the muscle to drug1 ( 10 ( -5 ) M ) markedly increased the drug2 - induced release . " 2 : "Pretreatment of megakaryocytes with extracellular drug1 ( 50 microM ) also inhibited drug2 - induced responses . " } 5 : { 1 : 1 2 : 1 } } 412 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN acl VBG ccomp VBD nsubj NN conj NNS acl VBG dobj NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 acl containing ccomp chewable/buffered nsubj drug0 conj products acl containing dobj drug0 appos drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " } 5 : { 1 : 2 } } 413 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 conj drug0" 2 : "drug0 nmod patients nmod *administered* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " 2 : "However , because bleeding has been reported when drug1 and other drug2 have been administered to patients on drug3 , the physician should be cautious when administering drug4 to patients on drug5 . " } 5 : { 1 : 1 2 : 1 } } 414 : { 1 : "NN nsubjpass VBN advcl VBN dep VBD advcl VBN nsubjpass NN nmod NN conj NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nsubjpass used advcl expected dep *increased* advcl studied nsubjpass interaction nmod drug0 conj inhibitors dep drug0 conj drug0" } 4 : { 1 : "Although the interaction between drug1 and other potent CYP3A4 inhibitors ( e.g. , drug2 , drug3 , and drug4 ) has not been studied , increased exposures to drug5 may be expected when drug6 is used concomitantly with these medications . " } 5 : { 1 : 2 } } 415 : { 1 : "NN compound NN appos NN conj NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound metabolism appos *drug0* conj metabolite nmod drug0" 2 : "drug0 compound metabolism appos *drug0* conj metabolite nmod drug0" } 4 : { 1 : "drug1 drug2 , as well as a metabolite of drug3 , slow drug4 metabolism . " 2 : "drug1 : drug2 , as well as a metabolite of drug3 , slow drug4 metabolism . " } 5 : { 1 : 1 2 : 1 } } 416 : { 1 : "NN compound NN appos NN" 2 : 2 3 : { 1 : "drug0 compound metabolism appos *drug0*" 2 : "drug0 compound metabolism appos *drug0*" } 4 : { 1 : "drug1 drug2 , as well as a metabolite of drug3 , slow drug4 metabolism . " 2 : "drug1 : drug2 , as well as a metabolite of drug3 , slow drug4 metabolism . " } 5 : { 1 : 1 2 : 1 } } 417 : { 1 : "NN nmod NNS nmod VB nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod concentrations nmod *result* nsubj coadministration nmod drug0" 2 : "drug0 nmod effects nmod *interfere* nsubj drug0 nmod drug0" } 4 : { 1 : "therefore , coadministration of drug1 with drugs that strongly induce CYP3A4 activity ( e.g. , drug2 , drug3 , drug4 ) may result in reduced plasma concentrations of drug5 that may result in decreased efficacy of drug6 . " 2 : "drug1 : Studies in normal volunteers have shown that drug2 like other drug3 , can interfere with the effects of drug4 . " } 5 : { 1 : 1 2 : 1 } } 418 : { 1 : "NN conj NN nmod NN dobj VBG advcl JJ ccomp VBN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 dobj potentiating advcl capable ccomp *noted* nmod drug0" } 4 : { 1 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 2 } } 419 : { 1 : "NN dep NNS nmod VBN advcl VB nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep inhibitors nmod given advcl *increase* nsubj concentration nmod drug0" 2 : "drug0 dep inhibitors nmod coadministered advcl *exceed* nsubj dose nmod drug0" } 4 : { 1 : "The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e.g. , drug2 , drug3 ) and decrease by concomitant administration of hepatic enzyme inducers ( e.g. , drug4 , drug5 ) , and adjustment of the dosage of drug6 may therefore be necessary . " 2 : "The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors ( e.g. , drug2 , drug3 , drug4 , drug5 , drug6 and nefazadone ) . " } 5 : { 1 : 1 2 : 1 } } 420 : { 1 : "NN nmod NN conj NNS nmod NNS dobj VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 conj s nmod effects dobj *enhance* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 2 } } 421 : { 1 : "NN nmod NN nmod NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod mg/day nmod regimen nmod day0 nmod *administered* nsubjpass dose nmod drug0" 2 : "drug0 nmod mg/day nmod regimen nmod day0 nmod *administered* nsubjpass dose nmod drug0" } 4 : { 1 : "drug1 : When a single 125-mg dose of drug2 was administered on Day5 of a 10-day regimen of 400 mg/day of drug3 , a strong CYP3A4 inhibitor , the AUC of drug4 increased approximately 5-fold and the mean terminal half-life of drug5 increased approximately 3-fold . " 2 : "drug1 : When a single 375-mg dose of drug2 was administered on Day9 of a 14-day regimen of 600 mg/day of drug3 , a strong CYP3A4 inducer , the AUC of drug4 decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold . " } 5 : { 1 : 1 2 : 1 } } 422 : { 1 : "NN conj NN nmod NN dobj VBG acl:relcl NNS nmod NN nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 dobj taking acl:relcl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should be administered with caution to patients who are taking other drug2 or drug3 , including drug4 , drug5 and drug6 , or to those with a history of psychiatric disorder ( including manic-depressive illness and schizophrenia ) . " } 5 : { 1 : 2 } } 423 : { 1 : "NN nmod NN dobj VBD conj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod auc dobj decreased conj *increased* nsubj drug0" 2 : "drug0 nmod effect dobj antagonized conj *antagonized* nsubj drug0" } 4 : { 1 : "drug1 increased the AUC of drug2 by 25 % on Day 4 and decreased the AUC of drug3 by 19 % on Day 8 relative to the dosing of drug4 on Days 1 through 3 . " 2 : "drug1 ( 5 mg/kg , s.c. ) completely antagonized the inhibitory effect of drug2 and partly antagonized the effect of drug3 . " } 5 : { 1 : 1 2 : 1 } } 424 : { 1 : "NN compound NN dobj VBZ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound activity dobj *depresses* nsubj use nmod drug0" 2 : "drug0 compound auc dobj *increases* nsubj co-treatment nmod drug0" } 4 : { 1 : "Concomitant use of drug1 usually depresses drug2 activity and may necessitate raising the dosage . " 2 : "Co-treatment with the potent CYP3A4 inhibitor drug1 increases drug2 AUC by 2/3 . " } 5 : { 1 : 1 2 : 1 } } 425 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod secretion dobj reduce xcomp *reported* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and other drug3 have been reported to reduce the tubular secretion of drug4 in an animal model , possibly increasing the toxicity of drug5 . " } 5 : { 1 : 2 } } 426 : { 1 : "NN compound NN dep NN" 2 : 2 3 : { 1 : "drug0 compound therapy dep *drug0*" 2 : "drug0 compound interaction dep *drug0*" } 4 : { 1 : "There have been reports of drug1 - related side-effects in patients on concomitant drug2 - drug3 therapy . " 2 : "Therapeutic drug monitoring can avoid iatrogenic alterations caused by drug1 ( MDP ) - drug2 interaction . " } 5 : { 1 : 1 2 : 1 } } 427 : { 1 : "NN dobj VBG acl:relcl NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dobj receiving acl:relcl patients nmod *use* nmod drug0" 2 : "drug0 dobj receiving acl:relcl patients nmod *administration* nmod drug0" } 4 : { 1 : "The use of drug1 in patients who are receiving drug2 may potentiate renal disease states . " 2 : "Administration of drug1 to patients who are receiving drug2 or drug3 may result in an additive pressor effect . " } 5 : { 1 : 1 2 : 1 } } 428 : { 1 : "NN conj NN dep NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *drug0*" 2 : "drug0 dep drug0 conj *drug0*" } 4 : { 1 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " 2 : "If concomitant treatment with drug1 and an drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) is clinically warranted , appropriate observation of the patient is advised . " } 5 : { 1 : 1 2 : 1 } } 429 : { 1 : "NN nsubj VBZ ccomp VBN conj VBN nsubjpass NN conj NN" 2 : 2 3 : { 1 : "drug0 nsubj blocks ccomp demonstrated conj *metabolized* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 are all metabolized by the cytochrome P450IIIA4 isozyme , and it has been demonstrated that drug4 , a potent inhibitor of IIIA4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug . " } 5 : { 1 : 2 } } 430 : { 1 : "NN nmod VBN advcl VB xcomp VBN nsubjpass NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0 appos drug0" 2 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 ) : drug3 ( e.g. , drug4 , drug5 , drug6 , drug7 ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drug8 . " 2 : "drug1 ( drug2 ) ( e.g. , drug3 , drug4 , drug5 , drug6 ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drug7 . " } 5 : { 1 : 1 2 : 1 } } 431 : { 1 : "NN conj NN nmod NN conj NNS nmod NNS dobj VB nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 conj s nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 2 } } 432 : { 1 : "NN compound NN dobj VBD csubj VBG dobj NN compound NN" 2 : 2 3 : { 1 : "drug0 compound cmin dobj *increased* csubj increasing dobj dose compound drug0" 2 : "drug0 compound cmin dobj *increased* csubj increasing dobj dose compound drug0" } 4 : { 1 : "Increasing the drug1 dose to 1800 mg/day in six of these subjects increased the steady-state drug2 Cmin to 25 7 micrograms/mL . " 2 : "Increasing the drug1 dose to 2400 mg/day increased the steadystate drug2 Cmin to 96 25 micrograms/mL . " } 5 : { 1 : 1 2 : 1 } } 433 : { 1 : "NN nmod NN nmod VBN nmod NNS acl:relcl VB dobj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod combination nmod *used* nmod effects acl:relcl depress dobj system conj drug0" } 4 : { 1 : "Because of the possible additive effects of drugs that may depress the nervous system , drug1 or drug2 should be used cautiously in combination with drug3 . " } 5 : { 1 : 2 } } 434 : { 1 : "NN conj NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj remedies nmod administration nmod *affected* nsubjpass absorption nmod drug0" 2 : "drug0 conj congeners nmod interaction nmod *enhanced* nsubjpass hepatoxicity nmod drug0" } 4 : { 1 : "The absorption of drug1 may be affected by the simultaneous administration of indigestion remedies , drug2 or drug3 supplements . " 2 : "These results suggest that the hepatoxicity of drug1 in alcoholic beverages is enhanced by interaction with its congeners and drug2 ; " } 5 : { 1 : 1 2 : 1 } } 435 : { 1 : "NN nmod NN nmod NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod dose nmod b.i.d. nmod *course* nmod drug0" 2 : "drug0 nmod mg/kg/day nmod *addition* nmod mg/kg/day nmod drug0" } 4 : { 1 : "drug1 : In a study in healthy volunteers , a one-week course of drug2 at 400 mg b.i.d. with a single 5 mg dose of drug3 on the sixth day showed an increase in drug4 mean peak plasma concentrations ( 36 % ) and significant increase in area under the curve ( 50 % ) . " 2 : "The addition of 540 mg/kg/day of drug1 ( approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis ) to 2.7 mg/kg/day of drug2 ( approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis ) appears to have increased the incidence of both resorptions and malformations . " } 5 : { 1 : 1 2 : 1 } } 436 : { 1 : "NN dobj VBG advcl JJ nsubj NN" 2 : 2 3 : { 1 : "drug0 dobj taking advcl *effective* nsubj drug0" 2 : "drug0 dobj potentiating advcl *capable* nsubj drug0" } 4 : { 1 : "Oral drug1 may be less effective while you are taking drug2 . " 2 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 1 2 : 1 } } 437 : { 1 : "NN compound NNS nmod NNS dobj VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 compound s nmod effects dobj *enhance* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 2 } } 438 : { 1 : "NN nmod NN dobj VB nsubj NN acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 nmod effectiveness dobj *decrease* nsubj drug0 acl containing dobj drug0" 2 : "drug0 nmod absorption dobj *reduce* nsubj drug0 acl containing dobj drug0" } 4 : { 1 : "Interactions may occur with the following : adrenocorticoids ( cortisone-like medicine ) , drug1 ( drug2 s ) , drug3 , drug4 ( drug5 may decrease the effects of these medicines ) , drug6 ( using these medicines with drug7 may result in increased CNS depressant effects ) , drug8 , drug9 ( using these medicines with drug10 may change the amount of either medicine that you need to take ) , and oral drug11 containing drug12 ( drug13 may decrease the effectiveness of these oral drug14 , and you may need to change to a different type of birth control ) . " 2 : "drug1 containing drug2 and drug3 reduce the oral absorption of drug4 by 75 % . " } 5 : { 1 : 1 2 : 1 } } 439 : { 1 : "NN nmod NN nsubjpass VBN nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 nsubjpass *noted* nmod treatment compound drug0" 2 : "drug0 nmod clearance nsubjpass *reduced* nmod administration compound drug0" } 4 : { 1 : "With oral drug1 treatment , drug2 such as drug3 have been noted to possibly increase the likelihood of hematologic reactions " 2 : "During drug1 administration , systemic clearance of drug2 was reduced from 234 + / - 72 ml/min ( mean + / - standard deviation ) to 172 + / - 33 ml/min ( p less than 0.01 ) . " } 5 : { 1 : 1 2 : 1 } } 440 : { 1 : "NN nmod NN dobj VB nsubj NN nmod NN dep NN" 2 : 2 3 : { 1 : "drug0 nmod effect dobj *potentiate* nsubj treatment nmod drug0 dep drug0" 2 : "drug0 nmod effectiveness dobj *diminish* nsubj drug0 nmod drug0 dep drug0" } 4 : { 1 : "Concomitant treatment with drug1 ( drug2 , drug3 ) , drug4 , or drug5 may potentiate any hypokalemic effect of drug6 . " 2 : "drug1 : Since drug2 is a drug3 , it is possible that drug4 , such as the drug5 ( drug6 , drug7 , drug8 ) or drug9 , may diminish the effectiveness of drug10 . " } 5 : { 1 : 1 2 : 1 } } 441 : { 1 : "NN nmod VBN xcomp VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod combined xcomp *is* nsubj drug0" 2 : "drug0 nmod displaced xcomp *appears* nsubj drug0" } 4 : { 1 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " 2 : "In vitro , drug1 appears to be displaced from its binding sites by drug2 . " } 5 : { 1 : 1 2 : 1 } } 442 : { 1 : "NN compound NN compound NN" 2 : 2 3 : { 1 : "drug0 compound *clearance* compound drug0" 2 : "drug0 compound *interaction* compound drug0" } 4 : { 1 : "After multiple dosing , drug1 ( drug2 30 mcg IM once weekly ) reduced drug3 clearance by approximately 30 % . " 2 : "Because of the pronounced intersubject variability in the extent of the drug1 - drug2 interaction , whole blood drug3 concentrations should be monitored closely in patients treated with the two drugs . " } 5 : { 1 : 1 2 : 1 } } 443 : { 1 : "NN nmod JJ amod NN" 2 : 2 3 : { 1 : "drug0 nmod co-administered amod *drug0*" 2 : "drug0 nmod co-administered amod *drug0*" } 4 : { 1 : "drug1 at 400 mg BID ( the usual prescription dose ) co-administered with drug2 ( 500 mcg BID ) for 7 days has been shown to increase drug3 plasma levels by 58 % . " 2 : "drug1 at 400 mg daily ( the maximum approved prescription dose ) co-administered with drug2 ( 500 mcg BID ) for 7 days has been shown to increase drug3 Cmax by 53 % in males and 97 % in females , and AUC by 41 % in males and 69 % in females . " } 5 : { 1 : 1 2 : 1 } } 444 : { 1 : "NN conj NN dep VB nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *occur* nmod use nmod drug0" } 4 : { 1 : "Reciprocal interactions may occur with concomitant use of drug1 and drugs that increase or inhibit the cytochrome P450 system ( e.g. , drug2 , drug3 , drug4 , drug5 ) , though this has not been studied " } 5 : { 1 : 2 } } 445 : { 1 : "NN conj NN nmod NN dobj VBG advcl JJ nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 dobj potentiating advcl *capable* nsubj drug0" } 4 : { 1 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 2 } } 446 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod elimination nmod rate dobj *decreased* nsubj drug0" 2 : "drug0 nmod half-life nmod increase dobj *caused* nsubj drug0" } 4 : { 1 : "Similarly , drug1 decreased the rate of elimination of drug2 ( by approximately 50 % ) by the same mechanism . " 2 : "In a multiple-dose study , drug1 caused a dose-related increase in the mean elimination half-life of drug2 , thereby decreasing the clearance of drug3 by up to 80 % and leading to a five-fold increase in the AUC and the half-life of drug4 . " } 5 : { 1 : 1 2 : 1 } } 447 : { 1 : "NN nmod NN nmod JJ amod NNS nmod NN nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod metabolism nmod responsible amod isozymes nmod *inhibitor* nsubj drug0" } 4 : { 1 : "drug1 : drug2 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug3 . " } 5 : { 1 : 2 } } 448 : { 1 : "NN conj NN dep NN conj NN nmod NNS dobj VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep drug0 conj drug0 nmod effects dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has additive effects with drug2 and other drug3 ( drug4 , drug5 , drug6 , etc ) . " } 5 : { 1 : 2 } } 449 : { 1 : "NN dep VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" 2 : "drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; " 2 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; drug3 ; drug4 ; certain drug5 , especially the drug6 and drug7 ; drug8 ; drug9 salts ; drug10 ; and drug11 . " } 5 : { 1 : 1 2 : 1 } } 450 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod VB dobj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod combination nmod used acl:relcl period nmod *exceed* dobj dose compound drug0" 2 : "drug0 nmod combination nmod used acl:relcl period nmod *exceed* dobj dose compound drug0" } 4 : { 1 : "It is recommended not to exceed a single 2.5 mg drug1 dose in a 24-hour period when used in combination with drug2 . " 2 : "Consequently , it is recommended not to exceed a single 2.5 mg drug1 dose in a 72-hour period when used in combination with drug2 . " } 5 : { 1 : 1 2 : 1 } } 451 : { 1 : "NN dep VB nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 dep *occur* nmod use nmod drug0" 2 : "drug0 nmod absorption nmod *interfere* dep drug0" } 4 : { 1 : "Reciprocal interactions may occur with concomitant use of drug1 and drugs that increase or inhibit the cytochrome P450 system ( e.g. , drug2 , drug3 , drug4 , drug5 ) , though this has not been studied " 2 : "and drug1 , ( drug2 ) , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drug3 , resulting in systemic levels considerably lower than desired . " } 5 : { 1 : 1 2 : 1 } } 452 : { 1 : "NN nmod VBN advcl VB xcomp VBN nsubjpass NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod given advcl produce xcomp *reported* nsubjpass drug0 appos drug0" 2 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 ) has been reported to produce ANTABUSE-like side effects when given concomitantly with drug3 . " 2 : "drug1 ( drug2 ) ( e.g. , drug3 , drug4 , drug5 , drug6 ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drug7 . " } 5 : { 1 : 1 2 : 1 } } 453 : { 1 : "NN compound NNS dobj VB nsubj NN conj NN" 2 : 2 3 : { 1 : "drug0 compound levels dobj *decrease* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 , drug2 , and drug3 may decrease drug4 plasma levels , resulting in a decrease in effectiveness of a previously effective drug5 dose . " } 5 : { 1 : 2 } } 454 : { 1 : "NN conj NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 2 } } 455 : { 1 : "NN compound NN conj VBG dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 2 3 : { 1 : "drug0 compound drug0 conj acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" 2 : "drug0 compound overdosage conj acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " 2 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 1 2 : 1 } } 456 : { 1 : "NN nmod VBN advcl VB xcomp VBN nsubjpass NN dep NN" 2 : 2 3 : { 1 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0" 2 : "drug0 nmod coadministered advcl cause xcomp *reported* nsubjpass drug0 dep drug0" } 4 : { 1 : "drug1 ( drug2 ) : drug3 ( e.g. , drug4 , drug5 , drug6 , drug7 ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with drug8 . " 2 : "drug1 ( drug2 ) ( e.g. , drug3 , drug4 , drug5 , drug6 ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drug7 . " } 5 : { 1 : 1 2 : 1 } } 457 : { 1 : "NN conj VBG dep NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj containing dep *use* nmod drug0" 2 : "drug0 conj containing dep *use* nmod drug0" } 4 : { 1 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided . " 2 : "Because there is a theoretical basis that these effects may be additive , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours is contraindicated . " } 5 : { 1 : 1 2 : 1 } } 458 : { 1 : "NN conj NN nmod NN dep NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod drug0 dep drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 2 } } 459 : { 1 : "NN dep SYM dep VBG dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 2 3 : { 1 : "drug0 dep * dep acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 2 } } 460 : { 1 : "NN dep NNS dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 2 3 : { 1 : "drug0 dep deficiencies dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 2 } } 461 : { 1 : "NN nmod VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod *used* nsubj drug0" 2 : "drug0 nsubj *failed* nmod drug0" } 4 : { 1 : "drug1 used concurrently with drug2 may also result in increased cardiotoxicity . " 2 : "In the presence of drug1 ( 10 ( -5 ) M ) , drug2 ( 10 ( -8 ) M ) failed to cause the first contraction ; " } 5 : { 1 : 1 2 : 1 } } 462 : { 1 : "NN compound NN nmod NN nmod NN dobj VBP nsubj NNS nmod NNS acl VBG dobj NNS dep NN appos NN" 2 : 2 3 : { 1 : "drug0 compound elimination nmod rate nmod increase dobj *indicate* nsubj data nmod patients acl receiving dobj inducers dep drug0 appos drug0" } 4 : { 1 : "Limited data in patients receiving known enzyme inducers ( drug1 , drug2 , drug3 ) indicate only a 30 % increase in the rate of drug4 elimination . " } 5 : { 1 : 2 } } 463 : { 1 : "NN compound NNS dobj VB advcl VBN nsubjpass NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 compound levels dobj increase advcl *co-administered* nsubjpass drugs dep drug0 conj drug0" } 4 : { 1 : "In addition , drugs that are actively secreted via this route ( e.g. , drug1 , drug2 and drug3 ) should be co-administered with care as they might increase drug4 levels . " } 5 : { 1 : 2 } } 464 : { 1 : "NN nmod NN nsubj VBD nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod clearance nsubj *fell* nmod presence nmod drug0" 2 : "drug0 nmod coadministration nmod *increased* nsubj life nmod drug0" } 4 : { 1 : "drug1 : In the presence of drug2 at 300 mg QID ( N = 12 ) the mean apparent oral clearance of drug3 fell by 14 % and creatinine clearance fell by 10 % . " 2 : "The elimination half life of drug1 and drug2 also increased ( 1.5-2 .5 fold ) during coadministration with drug3 . " } 5 : { 1 : 1 2 : 1 } } 465 : { 1 : "NN nmod NN dobj VB xcomp VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod excretion dobj alter xcomp *appeared* nsubj drug0" 2 : "drug0 nmod percentage dobj influence xcomp *appeared* nsubj drug0" } 4 : { 1 : "Thus drug1 appeared to alter the renal excretion of both drug2 and creatinine , an endogenous marker of renal function . " 2 : "Exogenous drug1 also appeared to influence the percentage of drug2 - induced deaths in a dose-dependent manner . " } 5 : { 1 : 1 2 : 1 } } 466 : { 1 : "NN compound NNS nmod NN nmod VBZ nsubj NN" 2 : 2 3 : { 1 : "drug0 compound preparations nmod action nmod *interferes* nsubj drug0" 2 : "drug0 compound preparations nmod effect nmod *interferes* nsubj drug0" } 4 : { 1 : "drug1 enhance the renal toxicity of drug2 in animals . 7 drug3 interferes with the action of drug4 preparations by chelating the drug5 . 7 " 2 : "However , it has been established that drug1 interferes with the contraceptive effect of microdosed drug2 minipill preparations . " } 5 : { 1 : 1 2 : 1 } } 467 : { 1 : "NN nmod NN nmod VB xcomp JJ nsubj NNPS acl VBG dobj NN conj NNS nmod NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod absorption nmod interfere xcomp *likely* nsubj products acl containing dobj drug0 conj cations nmod drug0 appos drug0" } 4 : { 1 : "Products containing drug1 and other multivalent cations ( such as drug2 , drug3 , drug4 ) are likely to interfere with absorption of drug5 . " } 5 : { 1 : 2 } } 468 : { 1 : "NN appos NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 appos drug0 conj *drug0* conj drug0" 2 : "drug0 conj *drug0* conj drug0 appos drug0" } 4 : { 1 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " 2 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " } 5 : { 1 : 1 2 : 1 } } 469 : { 1 : "NN nmod VBN nsubjpass NNS nmod NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod *exacerbated* nsubjpass effects nmod properties nmod drug0" 2 : "drug0 nmod *blocked* nsubjpass effects nmod receptors nmod drug0" } 4 : { 1 : "The effects of medicinal products with similar properties such as inotropes drug1 , drug2 , drug3 , drug4 and drug5 may be exacerbated by drug6 . " 2 : "The effects of nonbenzodiazepine agonists at benzodiazepine receptors , such as drug1 , triazolopyridazines and others , are also blocked by drug2 . " } 5 : { 1 : 1 2 : 1 } } 470 : { 1 : "NN appos NN conj NN appos NN" 2 : 2 3 : { 1 : "drug0 appos drug0 conj *drug0* appos drug0" } 4 : { 1 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " } 5 : { 1 : 2 } } 471 : { 1 : "NN appos NN dep NN nmod NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod combination nmod *patients* dep drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 472 : { 1 : "NN compound NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 compound concentration dobj *raise* nsubj drug0" } 4 : { 1 : "drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , and drug8 raise the serum drug9 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that drug10 intoxication may result . " } 5 : { 1 : 1 } } 473 : { 1 : "NN appos NNS root , punct FW dep FW root -LRB- punct VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos esters root , punct drug0 dep e.g. root ( punct *interfere* nsubj drug0" } 4 : { 1 : "therefore , it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( e.g. drug2 , drug3 esters , drug4 salts , drug5 ) . " } 5 : { 1 : 1 } } 474 : { 1 : "NN compound NN dobj VB nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound absorption dobj *increase* nsubj drug0 appos drug0" } 4 : { 1 : "drug1 and drug2 ( and possibly other drug3 ) and drug4 may increase drug5 absorption in patients who inactivate drug6 by bacterial metabolism in the lower intestine , so that drug7 intoxication may result . " } 5 : { 1 : 1 } } 475 : { 1 : "NN compound NN nmod VB nsubj NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 compound absorption nmod *interfere* nsubj drug0 appos pectin compound drug0" } 4 : { 1 : "drug1 , drug2 - pectin , drug3 , drug4 , drug5 , certain anticancer drugs , and drug6 may interfere with intestinal drug7 absorption , resulting in unexpectedly low serum concentrations . " } 5 : { 1 : 1 } } 476 : { 1 : "NN compound NN nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "- drug1 may enhance the effects of drug2 therapy " } 5 : { 1 : 1 } } 477 : { 1 : "NN compound NNS appos NNS root , punct FW dep FW root -LRB- punct VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound salts appos esters root , punct drug0 dep e.g. root ( punct *interfere* nsubj drug0" } 4 : { 1 : "therefore , it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( e.g. drug2 , drug3 esters , drug4 salts , drug5 ) . " } 5 : { 1 : 1 } } 478 : { 1 : "NN appos NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod *addition* nmod drug0" } 4 : { 1 : "Use in Conjunction with Other drug1 : The addition of drug2 to drug3 ( drug4 ) affects the steady-state plasma concentrations of drug5 . " } 5 : { 1 : 1 } } 479 : { 1 : "FW dep FW root -LRB- punct VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep e.g. root ( punct *interfere* nsubj drug0" } 4 : { 1 : "therefore , it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( e.g. drug2 , drug3 esters , drug4 salts , drug5 ) . " } 5 : { 1 : 1 } } 480 : { 1 : "NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 481 : { 1 : "NN dep NN nmod NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod combination nmod *patients* dep drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 482 : { 1 : "NN compound NNS root , punct FW dep FW root -LRB- punct VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound esters root , punct drug0 dep e.g. root ( punct *interfere* nsubj drug0" } 4 : { 1 : "therefore , it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( e.g. drug2 , drug3 esters , drug4 salts , drug5 ) . " } 5 : { 1 : 1 } } 483 : { 1 : "NN nmod NN nmod VB nsubj NNPS acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod *interfere* nsubj products acl containing dobj drug0 conj drug0" } 4 : { 1 : "Products containing drug1 and other drug2 likely will interfere with absorption of drug3 . " } 5 : { 1 : 1 } } 484 : { 1 : "NN appos NN nmod NN nmod NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod therapy nmod *use* nmod drug0 appos drug0" } 4 : { 1 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . " } 5 : { 1 : 1 } } 485 : { 1 : "NN nmod VBN acl:relcl JJ nmod VBN advcl VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod prevented acl:relcl cerebral nmod indicated advcl *results* nsubj exposure compound drug0" } 4 : { 1 : "Thus , the results suggest that drug1 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by drug2 and drug3 . " } 5 : { 1 : 1 } } 486 : { 1 : "NN nmod NN nmod VB xcomp JJ nsubj NNPS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod interfere xcomp *likely* nsubj products acl containing dobj drug0" } 4 : { 1 : "Products containing drug1 and other multivalent cations ( such as drug2 , drug3 , drug4 ) are likely to interfere with absorption of drug5 . " } 5 : { 1 : 1 } } 487 : { 1 : "NN nmod NN dobj VBZ dep NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj has dep *drug0*" } 4 : { 1 : "drug1 : Has a synergistic effect with drug2 in causing gastrointestinal bleeding . " } 5 : { 1 : 1 } } 488 : { 1 : "NN compound NN nmod NNS dobj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound capsule nmod hours dobj *administered* nsubjpass capsule compound drug0" } 4 : { 1 : "drug1 : A literature article reported that when a 60-mg controlled-release drug2 capsule was administered 2 hours prior to a 600-mg drug3 capsule ( N = 12 ) , mean drug4 AUC increased by 44 % compared to drug5 administered without drug6 . " } 5 : { 1 : 1 } } 489 : { 1 : "NN conj VBG dep NN" 2 : 1 3 : { 1 : "drug0 conj containing dep *drug0*" } 4 : { 1 : "Due to a theoretical risk of a pharmacodynamic interaction , use of drug1 - containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided ( see a href = frova_od . htm #CI CONTRAINDICATIONS ) . " } 5 : { 1 : 1 } } 490 : { 1 : "NN nmod NN nsubj VB dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj increase dep *drug0* dep drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , and possibly drug4 ) : Concomitant administration with drug5 may increase the risk of gastrointestinal ulceration . " } 5 : { 1 : 1 } } 491 : { 1 : "NN nmod NN nmod VB xcomp JJ nsubj NNPS acl VBG dobj NN conj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod interfere xcomp *likely* nsubj products acl containing dobj drug0 conj cations nmod drug0" } 4 : { 1 : "Products containing drug1 and other multivalent cations ( such as drug2 , drug3 , drug4 ) are likely to interfere with absorption of drug5 . " } 5 : { 1 : 1 } } 492 : { 1 : "NN nmod NN nmod NN dobj VB nsubj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod response nmod enhancement dobj *experience* nsubj individuals acl receiving dobj drug0" } 4 : { 1 : "drug1 : Some individuals receiving drug2 may experience a reversible enhancement of the pressor response to indirect-acting drug3 , drug4 or drug5 . " } 5 : { 1 : 1 } } 493 : { 1 : "NN conj NN nmod NNS dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod cations dobj containing acl medications nmod *taken* nsubjpass drug0" } 4 : { 1 : "drug1 should be taken at least 60 minutes before any oral medications containing multivalent cations ( including drug2 , supplements or drug3 ) . " } 5 : { 1 : 1 } } 494 : { 1 : "NN nmod VBN acl:relcl NN conj VBN conj VBN nmod NN appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered acl:relcl % conj reduced conj *delayed* nmod gram appos absorption nmod drug0" } 4 : { 1 : "In a single-dose crossover study examining drug1 30 mg and drug2 20 mg each administered alone and concomitantly with drug3 1 gram , absorption of the drug4 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with drug5 . " } 5 : { 1 : 1 } } 495 : { 1 : "NN nmod NN nmod VB nsubj NNPS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod *interfere* nsubj products acl containing dobj drug0" } 4 : { 1 : "Products containing drug1 and other drug2 likely will interfere with absorption of drug3 . " } 5 : { 1 : 1 } } 496 : { 1 : "NN nmod NN nmod VB conj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod *interfere* conj drug0" } 4 : { 1 : "and drug1 , ( drug2 ) , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drug3 , resulting in systemic levels considerably lower than desired . " } 5 : { 1 : 1 } } 497 : { 1 : "NN compound NN nmod NN nsubj NN" 2 : 1 3 : { 1 : "drug0 compound toxicity nmod *factor* nsubj drug0" } 4 : { 1 : "drug1 are a major contributing factor to drug2 toxicity . " } 5 : { 1 : 1 } } 498 : { 1 : "NN nmod NN conj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod % conj *increased* nsubjpass cmax compound drug0" } 4 : { 1 : "drug1 steady-state Cmax , A.C. and Cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant drug2 . " } 5 : { 1 : 1 } } 499 : { 1 : "VB xcomp JJ acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 xcomp hypersensitive acl:relcl patients nmod *contraindicated* nsubjpass drug0" } 4 : { 1 : "drug1 Agents : drug2 is contraindicated in patients who are hypersensitive to drug3 agents . " } 5 : { 1 : 1 } } 500 : { 1 : "NN nsubj VBZ advcl VBP dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj decreases advcl *increase* dobj rate nmod absorption nmod drug0" } 4 : { 1 : "drug1 increase the rate of absorption of drug2 , while drug3 decreases it . " } 5 : { 1 : 1 } } 501 : { 1 : "NN nmod RB advmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod prior advmod *taken* nsubjpass drug0" } 4 : { 1 : "Therefore , drug1 should be taken at least 30 minutes prior to drug2 . " } 5 : { 1 : 1 } } 502 : { 1 : "NN compound NN nsubj JJ acl:relcl NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound reduction nsubj necessary acl:relcl mg/day nmod *dose* compound drug0" } 4 : { 1 : "In order to maintain drug1 levels , limit adverse experiences , and achieve the drug2 dose of 3600 mg/day , a drug3 dose reduction of approximately 40 % was necessary for eight of these 10 subjects . " } 5 : { 1 : 1 } } 503 : { 1 : "NN compound NN dobj VB dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound reduction dobj consider dep drug0 conj *drug0* conj drug0" } 4 : { 1 : "drug1 , drug2 , drug3 ( consider drug4 dose reduction ) . " } 5 : { 1 : 1 } } 504 : { 1 : "NN nmod NNS nmod NN nmod VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod decrease nmod *results* nsubj addition nmod drug0" } 4 : { 1 : "drug1 : drug2 causes an approximate 50 % increase in the clearance of drug3 at steady state and , therefore , the addition of drug4 results in an approximate 40 % decrease in the steady-state trough concentrations of drug5 as compared to the same dose of drug6 given as monotherapy . " } 5 : { 1 : 1 } } 505 : { 1 : "NN nsubjpass VBN advcl VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass coadministered advcl *decreased* nsubj cmin compound drug0" } 4 : { 1 : "The drug1 steady-state Cmin decreased 31 % to 5 1 micrograms/mL when drug2 ( 3000 mg/day , divided into three doses ) was coadministered . " } 5 : { 1 : 1 } } 506 : { 1 : "NN conj NN nmod NN nmod NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod therapy nmod *use* nmod drug0 appos drug0" } 4 : { 1 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . " } 5 : { 1 : 1 } } 507 : { 1 : "NN appos NN nmod NN nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod clearance nmod doubling dobj *causes* nsubj drug0" } 4 : { 1 : "Effects of Other drug1 on drug2 drug3 : drug4 causes an approximate doubling of the clearance of drug5 ( drug6 ) at steady state and , therefore , the addition of drug7 causes an approximate 45 % decrease in the steady-state trough concentrations of drug8 as compared to the same dose of drug9 given as monotherapy . " } 5 : { 1 : 1 } } 508 : { 1 : "NN nmod NN nmod NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod rate dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 increase the rate of absorption of drug2 , while drug3 decreases it . " } 5 : { 1 : 1 } } 509 : { 1 : "NN compound NN dobj VBZ dep NN" 2 : 1 3 : { 1 : "drug0 compound effectiveness dobj decreases dep *drug0*" } 4 : { 1 : "drug1 : Decreases drug2 effectiveness by enzyme induction . " } 5 : { 1 : 1 } } 510 : { 1 : "NN nmod NN nmod NN nmod VBN nsubjpass NNP nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treatment nmod course nmod *considered* nsubjpass alternatives nmod drug0" } 4 : { 1 : "Alternatives to drug1 should be considered during the course of PCP treatment with drug2 . " } 5 : { 1 : 1 } } 511 : { 1 : "NN conj NN nmod NN nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod interaction nmod potential dobj *has* nsubj drug0" } 4 : { 1 : "Therefore , drug1 has the potential for interaction with drug2 and drug3 . " } 5 : { 1 : 1 } } 512 : { 1 : "NN compound NN nmod VB acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound cure nmod treat acl *prescription* nmod drug0" } 4 : { 1 : "Among the risk factors studied , two appear to increase the risk of ARE : the prescription of drug1 to treat strongyloidiasis during the drug2 cure and the bad general clinical conditions of patients . " } 5 : { 1 : 1 } } 513 : { 1 : "NN dep NN nmod NN nmod NNS acl VBG dobj NN appos NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0 appos drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 514 : { 1 : "NN nmod NN nmod VBN conj VBP acl:relcl NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod 0a0 nmod metabolized conj induce acl:relcl compounds nmod administration nmod *modified* nsubjpass metabolism nmod drug0" } 4 : { 1 : "In vitro studies have shown that the metabolism of drug1 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome P450 3A4 , such as drug2 , drug3 , drug4 , drug5 , and drug6 . " } 5 : { 1 : 1 } } 515 : { 1 : "NN dobj VBG acl NNS nmod VBG dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *changing* dobj dose nmod drug0" } 4 : { 1 : "Caution is advised when beginning , discontinuing , or changing the dose of drug1 in patients receiving drug2 . " } 5 : { 1 : 1 } } 516 : { 1 : "NN nmod NNS nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod *modifies* nsubj drug0" } 4 : { 1 : "drug1 modifies drug2 metabolism with increased serum levels of drug3 . " } 5 : { 1 : 1 } } 517 : { 1 : "NN dobj VBG acl NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patient nmod *initiated* nsubjpass therapy compound drug0" } 4 : { 1 : "If drug1 therapy is initiated in a patient currently receiving drug2 , cautious titration is advised . " } 5 : { 1 : 1 } } 518 : { 1 : "NN dep NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used together with drug2 ( drug3 , drug4 ) , another arthritis medication . " } 5 : { 1 : 1 } } 519 : { 1 : "NN conj NN nmod NN nmod NN nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod reaction nmod history nmod patients nmod *avoided* nsubjpass drug0" } 4 : { 1 : "drug1 should be avoided by patients with a history of serious reaction to any drug2 , including drug3 and drug4 . " } 5 : { 1 : 1 } } 520 : { 1 : "NN appos NN dep NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used together with drug2 ( drug3 , drug4 ) , another arthritis medication . " } 5 : { 1 : 1 } } 521 : { 1 : "NN nmod VBN xcomp VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered xcomp *are* nsubj doses nmod drug0" } 4 : { 1 : "Renal function should be monitored carefully if high doses of drug1 are to be administered with drug2 because of the increased potential of nephrotoxicity and ototoxicity of drug3 . " } 5 : { 1 : 1 } } 522 : { 1 : "NN nmod NN nmod NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod regimen nmod day nmod *administration* nmod dose nmod drug0" } 4 : { 1 : "In a placebo-controlled trial in normal volunteers , the administration of a single 1 mg dose of drug1 on day 1 of a four-day regimen of oral drug2 ( 400 mg twice daily ) resulted in a 10 % increase in mean AUC of drug3 ( p = 0.006 ) , and a slight but not statistically significant increase in mean Cmax and mean half-life of drug4 . " } 5 : { 1 : 1 } } 523 : { 1 : "NN nmod NN dobj VB conj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod half-life dobj prolong conj increase xcomp *reported* nsubjpass drug0" } 4 : { 1 : "Conversely , the drug1 have been reported to increase the serum levels and prolong the serum half-life of drug2 by inhibiting its metabolism . " } 5 : { 1 : 1 } } 524 : { 1 : "NN nmod VBN acl NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod *concentrations* nmod drug0" } 4 : { 1 : "Population pharmacokinetic studies showed higher concentrations of drug1 among patients concurrently treated with drug2 , an inhibitor of C.P.A. . " } 5 : { 1 : 1 } } 525 : { 1 : "NN nmod NN nmod NNS conj NN nmod NNP nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod cyp0c0 nmod inhibitors conj drug0 nmod c.p.a. nmod inhibitors nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes , caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug3 and drug4 or inhibitors of CYP2C19 such as drug5 . " } 5 : { 1 : 1 } } 526 : { 1 : "NN nmod NNS nmod NNS dobj VB advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drugs nmod consequences dobj *have* advcl studied nmod drug0" } 4 : { 1 : "Although not studied with drug1 , inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug2 , drug3 , and drug4 . " } 5 : { 1 : 1 } } 527 : { 1 : "NN appos NN" 2 : 1 3 : { 1 : "drug0 appos *drug0*" } 4 : { 1 : "A two-way interaction between the drug1 , drug2 , and the drug3 s has been suggested . " } 5 : { 1 : 1 } } 528 : { 1 : "NN nmod NNS dobj VB xcomp VBN conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod levels dobj cause xcomp reported conj *acts* nsubj drug0" } 4 : { 1 : "Presumably , drug1 acts as a stimulator of drug2 metabolism and has been reported to cause decreased serum levels of the drug3 and increased prothrombin-proconvertin concentrations . " } 5 : { 1 : 1 } } 529 : { 1 : "NN compound NN nmod NN nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound metabolism nmod stimulator nmod *acts* nsubj drug0" } 4 : { 1 : "Presumably , drug1 acts as a stimulator of drug2 metabolism and has been reported to cause decreased serum levels of the drug3 and increased prothrombin-proconvertin concentrations . " } 5 : { 1 : 1 } } 530 : { 1 : "NN nmod NN conj NN dobj VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod exposure conj increase dobj *permits* nsubj administration nmod drug0" } 4 : { 1 : "This study demonstrates that concurrent administration of drug1 permits at least a twofold increase in dose and total exposure to drug2 . " } 5 : { 1 : 1 } } 531 : { 1 : "NN nmod VBN acl NNS nmod NN dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl keratoses nmod reaction dobj *increase* nsubj use nmod drug0" } 4 : { 1 : "It is , however , possible that concomitant use of other known drug1 such as drug2 , drug3 , drug4 , drug5 , drug6 and drug7 might increase the photosensitivity reaction of actinic keratoses treated with the drug8 for Topical Solution . " } 5 : { 1 : 1 } } 532 : { 1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod caution nmod *prescribed* nsubjpass drug0" } 4 : { 1 : "drug1 and drug2 should be prescribed with caution to patients on drug3 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse . " } 5 : { 1 : 1 } } 533 : { 1 : "NN nmod NN dep NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod completion dep days nmod *decrease* nmod drug0" } 4 : { 1 : "Although there was no effect of drug1 on the plasma AUC of drug2 or drug3 determined on Day 3 , there was a 34 % decrease in drug4 ( a CYP2C9 substrate ) trough concentration accompanied by a 14 % decrease in the prothrombin time ( reported as International Normalized Ratio or INR ) 5 days after completion of dosing with drug5 . " } 5 : { 1 : 1 } } 534 : { 1 : "NN nmod VBN advcl VBN conj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod coadministered advcl reduced conj *reduced* nsubjpass dose compound drug0" } 4 : { 1 : "The IV drug1 dose should be reduced by approximately 25 % , and the oral drug2 dose should be reduced by approximately 50 % when coadministered with drug3 to achieve exposures of drug4 similar to those obtained when it is given without drug5 . " } 5 : { 1 : 1 } } 535 : { 1 : "NN nmod NNS nmod VBN acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod studies nmod administered acl *dose* nmod drug0" } 4 : { 1 : "The daily dose of drug1 administered in clinical studies with drug2 reflects an approximate 50 % reduction of the dose of drug3 . " } 5 : { 1 : 1 } } 536 : { 1 : "NN nmod NN nmod NN nmod NNS nmod VBN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod regimen nmod initiation nmod days nmod *monitored* nmod patients nmod therapy compound drug0" } 4 : { 1 : "In patients on chronic drug1 therapy , the prothrombin time ( INR ) should be closely monitored in the 2-week period , particularly at 7 to 10 days , following initiation of the 3-day regimen of drug2 with each chemotherapy cycle . " } 5 : { 1 : 1 } } 537 : { 1 : "NN nmod NN dobj VBG acl NN nmod NN nmod VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod mcg dobj containing acl drug0 nmod capsule nmod given acl:relcl *drug0*" } 4 : { 1 : "Oral drug1 : drug2 , when given once daily for 14 days as a 100-mg capsule with an oral drug3 containing 35 mcg of drug4 and 1 mg of drug5 , decreased the AUC of drug6 by 43 % , and decreased the AUC of drug7 by 8 % ; " } 5 : { 1 : 1 } } 538 : { 1 : "NN nmod NN nmod NN nmod RB advmod JJ root , punct JJ nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod regimen nmod administration nmod prior advmod stered root , punct *admini* nsubj dose nmod mg compound drug0" } 4 : { 1 : "drug1 : drug2 , when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3 , decreased the AUC of drug3 ( a CYP2C9 substrate ) by 23 % on Day 4 , 28 % on Day 8 , and 15 % on Day 15 , when a single dose of drug4 500 mg was admini , stered orally prior to the administration of the 3-day regimen of drug5 and on Days 4,8 , and 15 . " } 5 : { 1 : 1 } } 539 : { 1 : "NN nmod VBN acl NNS nmod NN dobj VB nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl keratoses nmod reaction dobj *increase* nsubj use nmod drug0 nmod drug0" } 4 : { 1 : "It is , however , possible that concomitant use of other known drug1 such as drug2 , drug3 , drug4 , drug5 , drug6 and drug7 might increase the photosensitivity reaction of actinic keratoses treated with the drug8 for Topical Solution . " } 5 : { 1 : 1 } } 540 : { 1 : "NN nmod VBN advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod coadministered advcl *reduced* nsubjpass doses compound drug0" } 4 : { 1 : "The oral drug1 doses should be reduced by approximately 50 % when coadministered with drug2 , to achieve exposures of drug3 similar to those obtained when it is given without drug4 . " } 5 : { 1 : 1 } } 541 : { 1 : "NN nmod NN nmod VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod regimen nmod given acl:relcl *drug0*" } 4 : { 1 : "drug1 : drug2 : drug3 , when given as a regimen of 125mg with drug4 coadministered orally as 20 mg on Day 1 , and drug5 when given as 80 mg/day with drug6 coadministered orally as 8 mg on Days 2 through 5 , increased the AUC of drug7 , a CYP3A4 substrate by 2.2-fold , on Days 1 and 5 . " } 5 : { 1 : 1 } } 542 : { 1 : "NN nmod NN nmod IN advcl VBN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treatment nmod while advcl *warned* nmod danger nmod self-administration nmod drug0" } 4 : { 1 : "Patients should be warned of the potential danger of the intravenous self-administration of drug1 while under treatment with drug2 or drug3 . " } 5 : { 1 : 1 } } 543 : { 1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod caution nmod *prescribed* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 should be prescribed with caution to patients on drug3 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse . " } 5 : { 1 : 1 } } 544 : { 1 : "NN nmod NN nmod VBN advcl NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod mg/day nmod given advcl *drug0* conj drug0" } 4 : { 1 : "drug1 : drug2 : drug3 , when given as a regimen of 125mg with drug4 coadministered orally as 20 mg on Day 1 , and drug5 when given as 80 mg/day with drug6 coadministered orally as 8 mg on Days 2 through 5 , increased the AUC of drug7 , a CYP3A4 substrate by 2.2-fold , on Days 1 and 5 . " } 5 : { 1 : 1 } } 545 : { 1 : "NN conj NN nmod NN nmod IN advcl VBN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod treatment nmod while advcl *warned* nmod danger nmod self-administration nmod drug0" } 4 : { 1 : "Patients should be warned of the potential danger of the intravenous self-administration of drug1 while under treatment with drug2 or drug3 . " } 5 : { 1 : 1 } } 546 : { 1 : "NN dobj VBD nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj *inhibited* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 ( 0.1 and 1.0 mg/kg , s.c. ) inhibited the drug3 ( 0.3 mg/kg , p.o. ) - induced diarrhea in cecectomized rats . " } 5 : { 1 : 1 } } 547 : { 1 : "NN nmod NN nmod VBN xcomp VBN acl:relcl NNS conj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod cyp0c0 nmod metabolized xcomp known acl:relcl drugs conj drugs nmod *coadministration* nmod drug0" } 4 : { 1 : "Coadministration of drug1 with these drugs or other drugs that are known to be metabolized by CYP2C9 , such as drug2 , may result in lower plasma concentrations of these drugs . " } 5 : { 1 : 1 } } 548 : { 1 : "NN nmod NN conj NN dobj VBG acl NN nmod NN nmod VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod mg conj mcg dobj containing acl drug0 nmod capsule nmod given acl:relcl *drug0*" } 4 : { 1 : "Oral drug1 : drug2 , when given once daily for 14 days as a 100-mg capsule with an oral drug3 containing 35 mcg of drug4 and 1 mg of drug5 , decreased the AUC of drug6 by 43 % , and decreased the AUC of drug7 by 8 % ; " } 5 : { 1 : 1 } } 549 : { 1 : "NN conj NN nmod NNP nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod c.p.a. nmod inhibitors nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes , caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug3 and drug4 or inhibitors of CYP2C19 such as drug5 . " } 5 : { 1 : 1 } } 550 : { 1 : "NN nmod VBN nsubjpass NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *treated* nsubjpass patients acl treated nmod drug0" } 4 : { 1 : "Patients with major psychotic disorders , treated with drug1 , should be treated with drug2 only if the potential benefits outweigh the risks . " } 5 : { 1 : 1 } } 551 : { 1 : "NN compound NNS nsubjpass VBN advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound tablets nsubjpass added advcl *observed* nsubjpass patients nmod drug0" } 4 : { 1 : "Therefore , patients on drug1 should be observed when drug2 Tablets are either added or deleted from a therapeutic regimen . " } 5 : { 1 : 1 } } 552 : { 1 : "NN dep NNS acl:relcl VBP advcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dep *drugs* acl:relcl require advcl coadminstered nmod drug0 compound drug0" } 4 : { 1 : "Drugs Which Require a Dose Reduction When Coadminstered With drug1 drug2 : drug3 " } 5 : { 1 : 1 } } 553 : { 1 : "NN compound NNS appos NN dep NN dep NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound agents appos drug0 dep drug0 dep drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 554 : { 1 : "NN dep NN nmod VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep hour nmod administered advcl *decreased* nsubjpass absorption nmod drug0" } 4 : { 1 : "Studies in humans show that the absorption of drug1 as reflected in urinary excretion is markedly decreased even when administered one hour before drug2 . " } 5 : { 1 : 1 } } 555 : { 1 : "NN compound NNS nmod NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound supplements nmod absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "drug1 may also interfere with the absorption of oral drug2 supplements and drug3 . " } 5 : { 1 : 1 } } 556 : { 1 : "NN nmod NN nmod NNS nsubj VBP advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effect nmod results nsubj are advcl *observed* nmod drug0" } 4 : { 1 : "Particular caution should be observed with drug1 since there are conflicting results for the effect of drug2 on the availability of drug3 and drug4 . " } 5 : { 1 : 1 } } 557 : { 1 : "NN conj NNS nmod NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj supplements nmod absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "drug1 may also interfere with the absorption of oral drug2 supplements and drug3 . " } 5 : { 1 : 1 } } 558 : { 1 : "NN dep NN dep NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 559 : { 1 : "NN compound NN dep NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound drug0 dep drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 560 : { 1 : "NN compound NN appos NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound drug0 appos drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 561 : { 1 : "NN nsubjpass VBN advcl VBN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl reported dep *drug0* conj drug0" } 4 : { 1 : "drug1 and drug2 : Increased prothrombin time , with or without clinical bleeding , has been reported when drug3 is administered concomitantly . " } 5 : { 1 : 1 } } 562 : { 1 : "NN dep NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 563 : { 1 : "NN appos NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 564 : { 1 : "NN compound NN appos NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound antimigraine appos drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 565 : { 1 : "NN dep NN dep NNS acl:relcl JJ nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep *drugs* acl:relcl coadministered nmod drug0 compound drug0" } 4 : { 1 : "Drugs That Should Not Be Coadministered With drug1 drug2 : drug3 , drug4 drug5 : drug6 , drug7 Antimigraine : drug8 drug9 : drug10 drug11 drug12 , drug13 GI motility agents : drug14 " } 5 : { 1 : 1 } } 566 : { 1 : "NN nmod NNP nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod c.p.a. nmod inhibitors nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes , caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug3 and drug4 or inhibitors of CYP2C19 such as drug5 . " } 5 : { 1 : 1 } } 567 : { 1 : "NN nmod VB nsubj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *benefit* nsubj patients acl taking dobj drug0" } 4 : { 1 : "Patients taking drug1 may not benefit from drug2 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and drug3 . " } 5 : { 1 : 1 } } 568 : { 1 : "NN nmod NN nsubj JJR nmod NN acl:relcl VBN nmod NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod amount nsubj *greater* nmod situation acl:relcl administered nmod patient acl receiving dobj drug0" } 4 : { 1 : "In an emergency situation when opioid analgesia must be administered to a patient receiving drug1 , the amount of drug2 required may be greater than usual , and the resulting respiratory depression may be deeper and more prolonged . " } 5 : { 1 : 1 } } 569 : { 1 : "NN appos NN dep NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod *interfere* nsubj drug0" } 4 : { 1 : "conversely , drug1 may interfere with drug2 ( i.e. , drug3 , drug4 ) . " } 5 : { 1 : 1 } } 570 : { 1 : "NN nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *inhibited* nmod drug0" } 4 : { 1 : "drug1 : As with other drug2 , renal excretion of drug3 is inhibited by drug4 and resulted in an approximate 80 % increase in the AUC for drug5 . " } 5 : { 1 : 1 } } 571 : { 1 : "NN compound NNS nmod NN dobj VBN nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod decrease dobj *shown* nsubj study nmod drug0" } 4 : { 1 : "A drug-drug interaction study with drug1 in healthy volunteers has shown a 30 % decrease in drug2 trough concentrations . " } 5 : { 1 : 1 } } 572 : { 1 : "NN nmod NN dep NN dobj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod effect dep glucose dobj *potentiated* nsubj treatment compound drug0" } 4 : { 1 : "drug1 : In a study of 7 healthy male volunteers , drug2 treatment potentiated the blood glucose lowering effect of drug3 ( a drug4 similar to drug5 ) in 3 of the 7 subjects . " } 5 : { 1 : 1 } } 573 : { 1 : "NN nsubjpass VBN acl NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass contraindicated acl drug0 nmod drugs nmod *use* nmod drug0" } 4 : { 1 : "drug1 : Based on reports of profound hypotension and loss of consciousness when drug2 was administered with drug3 , the concomitant use of drug4 with drugs of the drug5 ( including , for example , drug6 , drug7 , drug8 , drug9 , and drug10 ) is contraindicated . " } 5 : { 1 : 1 } } 574 : { 1 : "NN dep VB csubj VBN advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep *occur* csubj used advcl administering dobj drug0" } 4 : { 1 : "Therefore , caution should be used when administering drug1 concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices , as competition for binding sites may occur ( e.g. , drug2 ) . " } 5 : { 1 : 1 } } 575 : { 1 : "NN conj NNS dobj VBG acl NN nmod VB nsubj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj medicines dobj containing acl drug0 nmod *benefit* nsubj patients acl taking dobj drug0" } 4 : { 1 : "Patients taking drug1 may not benefit from drug2 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and drug3 . " } 5 : { 1 : 1 } } 576 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN acl VBG ccomp VBD nsubj NN conj NNS acl VBG dobj NN appos NN acl VBG dobj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 acl containing ccomp chewable/buffered nsubj drug0 conj products acl containing dobj drug0 appos drug0 acl containing dobj drug0 conj drug0 appos drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " } 5 : { 1 : 1 } } 577 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN acl VBG ccomp VBD nsubj NN conj NNS acl VBG dobj NN appos NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 acl containing ccomp chewable/buffered nsubj drug0 conj products acl containing dobj drug0 appos drug0 acl containing dobj drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " } 5 : { 1 : 1 } } 578 : { 1 : "NN nsubj VBD dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj produced dep *administration* nmod drug0" } 4 : { 1 : "Concomitant administration of drug1 and drug2 , drug3 , drug4 , or an drug5 / drug6 oral drug7 produced minor changes in the pharmacokinetics of drug8 , which were considered to be without clinical significance . " } 5 : { 1 : 1 } } 579 : { 1 : "NN compound NN nsubj VBD dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound drug0 nsubj produced dep *administration* nmod drug0" } 4 : { 1 : "Concomitant administration of drug1 and drug2 , drug3 , drug4 , or an drug5 / drug6 oral drug7 produced minor changes in the pharmacokinetics of drug8 , which were considered to be without clinical significance . " } 5 : { 1 : 1 } } 580 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN acl VBG ccomp VBD nsubj NN conj NNS acl VBG dobj NN appos NN acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 acl containing ccomp chewable/buffered nsubj drug0 conj products acl containing dobj drug0 appos drug0 acl containing dobj drug0 conj drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " } 5 : { 1 : 1 } } 581 : { 1 : "NN dobj VBG acl NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nmod administration nmod *reduced* nsubjpass absorption nmod drug0" } 4 : { 1 : "The absorption of oral drug1 is significantly reduced by the concomitant administration of an drug2 containing drug3 and drug4 . " } 5 : { 1 : 1 } } 582 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN acl VBG ccomp VBD nsubj NN conj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod hours nmod *taken* nsubjpass drug0 acl containing ccomp chewable/buffered nsubj drug0 conj products acl containing dobj drug0" } 4 : { 1 : "drug1 - and/or drug2 - containing drug3 , products containing drug4 ( drug5 ) , drug6 containing drug7 or other metal cations , or drug8 ( drug9 ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug10 . " } 5 : { 1 : 1 } } 583 : { 1 : "NN conj NN dobj VBG acl NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 nmod administration nmod *reduced* nsubjpass absorption nmod drug0" } 4 : { 1 : "The absorption of oral drug1 is significantly reduced by the concomitant administration of an drug2 containing drug3 and drug4 . " } 5 : { 1 : 1 } } 584 : { 1 : "NN appos NN dep NN nmod NN nmod NNS acl VBG dobj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0 appos drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 585 : { 1 : "NN nmod VBN acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod given acl *regimen* nmod drug0" } 4 : { 1 : "Although a 3-day regimen of drug1 given concomitantly with oral drug2 has not been studied , alternative or back-up methods of contraception should be used . " } 5 : { 1 : 1 } } 586 : { 1 : "NN nmod VBG advcl VBN nsubjpass NNS nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod coadministering advcl *considered* nsubjpass effects nmod concentrations nmod drug0 conj drug0" } 4 : { 1 : "The potential effects of increased plasma concentrations of drug1 or other drug2 metabolized via CYP3A4 ( drug3 , drug4 ) should be considered when coadministering these agents with drug5 . " } 5 : { 1 : 1 } } 587 : { 1 : "NN conj NN nmod NN nmod NN nmod NN dobj VB nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod dose nmod one-fourth nmod reduction dobj *require* nsubj administration nmod mg nmod drug0" } 4 : { 1 : "In patients receiving drug1 ( drug2 ) or drug3 ( drug4 ) , the concomitant administration of 300-600 mg of drug5 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug6 or drug7 . " } 5 : { 1 : 1 } } 588 : { 1 : "NN nmod NN nmod NN nmod NN dobj VB nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod one-fourth nmod reduction dobj *require* nsubj administration nmod mg nmod drug0" } 4 : { 1 : "In patients receiving drug1 ( drug2 ) or drug3 ( drug4 ) , the concomitant administration of 300-600 mg of drug5 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug6 or drug7 . " } 5 : { 1 : 1 } } 589 : { 1 : "NN appos NN dep VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep *bind* dobj absorption nmod drug0" } 4 : { 1 : "drug1 Absorption : The following agents may bind and decrease absorption of drug2 from the gastrointestinal tract : drug3 , drug4 resin , drug5 , drug6 , drug7 , soybean flour ( e.g. , infant formula ) , drug8 . " } 5 : { 1 : 1 } } 590 : { 1 : "NN appos NN nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod half-life dobj *prolongs* nsubj drug0" } 4 : { 1 : "drug1 : It has been reported that drug2 prolongs the half-life of the drug3 , drug4 . " } 5 : { 1 : 1 } } 591 : { 1 : "NN nmod NNS acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *patients* acl receiving dobj drug0 conj drug0" } 4 : { 1 : "drug1 / drug2 : An increase in the frequency of skin rash has been reported among patients receiving drug3 or drug4 concurrently with drug5 compared to patients who are not receiving both drugs . " } 5 : { 1 : 1 } } 592 : { 1 : "NN nmod NN dobj VB xcomp JJ advcl JJ nmod DT nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod excretion dobj increase xcomp *likely* advcl similar nmod that nmod urate appos drug0" } 4 : { 1 : "drug1 : Since the excretion of drug2 is similar to that of urate , drug3 , which increase the excretion of urate , are also likely to increase the excretion of drug4 and thus lower the degree of inhibition of xanthine oxidase . " } 5 : { 1 : 1 } } 593 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *reported* nsubjpass suppression nmod drug0 conj drug0" } 4 : { 1 : "drug1 : Enhanced bone marrow suppression by drug2 and other drug3 has been reported among patients with neoplastic disease , except leukemia , in the presence of drug4 . " } 5 : { 1 : 1 } } 594 : { 1 : "NN conj NN nmod NNS nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drugs nmod potential dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 may increase the ototoxic potential of other drugs such as drug2 and some drug3 . " } 5 : { 1 : 1 } } 595 : { 1 : "NN compound NN conj NN dep VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound resin conj drug0 dep *bind* dobj absorption nmod drug0" } 4 : { 1 : "drug1 Absorption : The following agents may bind and decrease absorption of drug2 from the gastrointestinal tract : drug3 , drug4 resin , drug5 , drug6 , drug7 , soybean flour ( e.g. , infant formula ) , drug8 . " } 5 : { 1 : 1 } } 596 : { 1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NNS nmod NN acl:relcl NN nsubj NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod interact xcomp *shown* nsubjpass agents nmod drug0 acl:relcl member nsubj injection compound drug0 appos drug0" } 4 : { 1 : "drug1 ( e. g. drug2 and drug3 ) : Agents of the drug4 , of which drug5 ( drug6 ) Injection , USP is a member , have been shown to interact with drug7 of the drug8 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction . " } 5 : { 1 : 1 } } 597 : { 1 : "NN appos NN nmod JJ conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod additive conj *reported* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 has been reported to cause coronary artery vasospasm , and its effect could be additive with drug3 ( drug4 ) Injection , USP . " } 5 : { 1 : 1 } } 598 : { 1 : "NN nmod JJ conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod additive conj *reported* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 has been reported to cause coronary artery vasospasm , and its effect could be additive with drug3 ( drug4 ) Injection , USP . " } 5 : { 1 : 1 } } 599 : { 1 : "NN nmod VBN advcl VBG acl NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod co-administered advcl containing acl *doses* nmod drug0" } 4 : { 1 : "Vasospastic reactions have been reported with therapeutic doses of drug1 - containing drugs when co-administered with these drug2 . " } 5 : { 1 : 1 } } 600 : { 1 : "NN compound NN nmod NN nmod VBG advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod response nmod predisposing advcl *provoke* nsubj drug0" } 4 : { 1 : "drug1 : drug2 may provoke vasoconstriction in some patients , predisposing to a greater ischemic response to drug3 therapy . " } 5 : { 1 : 1 } } 601 : { 1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NNS nmod NN acl:relcl NN nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod interact xcomp *shown* nsubjpass agents nmod drug0 acl:relcl member nsubj injection compound drug0" } 4 : { 1 : "drug1 ( e. g. drug2 and drug3 ) : Agents of the drug4 , of which drug5 ( drug6 ) Injection , USP is a member , have been shown to interact with drug7 of the drug8 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction . " } 5 : { 1 : 1 } } 602 : { 1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod interact xcomp *shown* nsubjpass agents nmod drug0" } 4 : { 1 : "drug1 ( e. g. drug2 and drug3 ) : Agents of the drug4 , of which drug5 ( drug6 ) Injection , USP is a member , have been shown to interact with drug7 of the drug8 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction . " } 5 : { 1 : 1 } } 603 : { 1 : "NN nmod VBN nsubjpass NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *used* nsubjpass injection compound drug0 appos drug0" } 4 : { 1 : "drug1 : drug2 ( drug3 ) Injection , USP should not be used with drug4 because the combination may cause synergistic elevation of blood pressure . " } 5 : { 1 : 1 } } 604 : { 1 : "NN dobj VB xcomp VBN nsubjpass NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj displace xcomp *shown* nsubjpass number nmod drugs nmod drug0" } 4 : { 1 : "A number of drugs , including drug1 , have been shown to displace drug2 from plasma protein ; " } 5 : { 1 : 1 } } 605 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod accuracy nmod *made* nsubjpass measurements nmod drug0" } 4 : { 1 : "Renal clearance measurements of drug1 can not be made with any significant accuracy in patients receiving drug2 , drug3 , or drug4 . " } 5 : { 1 : 1 } } 606 : { 1 : "NN nmod JJ acl:relcl NNS nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod vasoconstrictive acl:relcl agents nmod presence nmod control xcomp *used* nsubjpass drug0" } 4 : { 1 : "Additionally , drug1 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug2 , drug3 , and drug4 because of the danger of blocking cardiac contractility when systemic vascular resistance is high . " } 5 : { 1 : 1 } } 607 : { 1 : "NN nmod JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *unaffected* nsubj onset nmod drug0" } 4 : { 1 : "The onset of neuromuscular blockade by drug1 was unaffected by drug2 , but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes . " } 5 : { 1 : 1 } } 608 : { 1 : "NN nmod VBN advcl JJR nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod given advcl *higher* nsubj concentrations compound drug0" } 4 : { 1 : "drug1 concentrations were equivocally higher when given with drug2 , but this is not likely to be clinically important . " } 5 : { 1 : 1 } } 609 : { 1 : "NN dep NN nmod NN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 610 : { 1 : "NN nmod NN nmod NNS acl VBG dobj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod *patients* acl receiving dobj drug0 appos drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 611 : { 1 : "NN appos NN dep NN nmod NN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod combination nmod *patients* acl receiving dobj drug0" } 4 : { 1 : "In patients receiving nonselective drug1 ( drug2 ) ( e.g. , drug3 ) in combination with drug4 ( e.g. , drug5 , drug6 , drug7 , drug8 , drug9 ) , there have been reports of serious , sometimes fatal , reactions . " } 5 : { 1 : 1 } } 612 : { 1 : "NN nmod NN dobj VBZ nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod secretion dobj *reduces* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 : drug2 , as well as other drug3 , probably reduces the tubular secretion of drug4 based on in vitro studies in rabbit kidney slices . " } 5 : { 1 : 1 } } 613 : { 1 : "NN nmod NN nmod VBN acl NN conj NN nmod VBD nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod mg nmod supplemented acl drug0 conj drug0 nmod *fortified* nmod administration nmod drug0" } 4 : { 1 : "drug1 and Foods Fortified With drug2 Concomitant administration of drug3 with a therapeutic drug4 containing 60 mg of elemental drug5 ( as FeSO4 ) or drug6 supplemented with 10 mg of elemental drug7 reduced extent of absorption by 80 % and 31 % , respectively . " } 5 : { 1 : 1 } } 614 : { 1 : "NN nmod NN dobj VBZ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod excretion dobj *inhibits* nmod drug0" } 4 : { 1 : "drug1 : As with other drug2 , drug3 inhibits the renal excretion of drug4 , resulting in an approximate doubling in A.C. a 54 % increase in peak drug5 plasma levels , and a 50 % prolongation in the apparent elimination half-life . " } 5 : { 1 : 1 } } 615 : { 1 : "NN nmod JJ nsubj NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod *due* nsubj potentiation nmod rashes compound drug0" } 4 : { 1 : "It is not known whether this potentiation of drug1 rashes is due to drug2 or the hyperuricemia present in these patients . " } 5 : { 1 : 1 } } 616 : { 1 : "NN compound NNS conj NN dobj VB nsubj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound values conj erpf dobj *have* nsubj patients acl receiving dobj drug0" } 4 : { 1 : "Therefore , patients receiving drug1 will have erroneously low ERPF and Tm drug2 values . " } 5 : { 1 : 1 } } 617 : { 1 : "NN nmod NN dobj VBG acl NN nmod VBD nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod mg dobj containing acl drug0 nmod *fortified* nmod administration nmod drug0" } 4 : { 1 : "drug1 and Foods Fortified With drug2 Concomitant administration of drug3 with a therapeutic drug4 containing 60 mg of elemental drug5 ( as FeSO4 ) or drug6 supplemented with 10 mg of elemental drug7 reduced extent of absorption by 80 % and 31 % , respectively . " } 5 : { 1 : 1 } } 618 : { 1 : "NN nmod NN dobj VB nmod JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod efficacy dobj *reduce* nmod common nmod drug0" } 4 : { 1 : "In common with other drug1 , drug2 may reduce the efficacy of oral drug3 " } 5 : { 1 : 1 } } 619 : { 1 : "NN nmod NNS dobj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod hours dobj *taken* nsubjpass drug0" } 4 : { 1 : "If drug1 are required during drug2 therapy , drug3 should be taken at least 2 hours before or after the drug4 . " } 5 : { 1 : 1 } } 620 : { 1 : "NN compound NN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound suspension nmod *administration* nmod capsules compound drug0" } 4 : { 1 : "drug1 ( drug2 - or drug3 - containing ) : Concomitant administration of 300-mg drug4 capsules with 30 mL drug5 suspension reduces the rate ( Cmax ) and extent ( AUC ) of absorption by approximately 40 % . " } 5 : { 1 : 1 } } 621 : { 1 : "NN nmod VBG advcl VBN nsubjpass NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod coadministering advcl *considered* nsubjpass effects nmod concentrations nmod drug0" } 4 : { 1 : "The potential effects of increased plasma concentrations of drug1 or other drug2 metabolized via CYP3A4 ( drug3 , drug4 ) should be considered when coadministering these agents with drug5 . " } 5 : { 1 : 1 } } 622 : { 1 : "NN compound NNS nmod NN conj NN conj NN dobj VB advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound salts nmod drug0 conj drug0 conj drug0 dobj *occur* advcl administered nsubjpass agents nmod drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 1 } } 623 : { 1 : "NN conj NN nmod VBN acl:relcl JJ nmod VBN advcl VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod prevented acl:relcl cerebral nmod indicated advcl *results* nsubj exposure compound drug0" } 4 : { 1 : "Thus , the results suggest that drug1 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by drug2 and drug3 . " } 5 : { 1 : 1 } } 624 : { 1 : "NN nmod NN nmod VBN nsubjpass VBZ nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod discontinuation nmod *reported* nsubjpass decreases nmod levels nmod drug0" } 4 : { 1 : "Conversely , decreases in plasma levels of the drug1 have been reported upon discontinuation of drug2 which may result in the loss of the therapeutic efficacy of the drug3 6 . " } 5 : { 1 : 1 } } 625 : { 1 : "NN nmod DT nmod JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod those nmod *additive* nsubj sedative nmod drug0" } 4 : { 1 : "Both the sedative and anticholinergic effects of the drug1 are also additive to those of drug2 . " } 5 : { 1 : 1 } } 626 : { 1 : "NN nsubjpass VBN advcl VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *given* advcl is nsubj drug0" } 4 : { 1 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " } 5 : { 1 : 1 } } 627 : { 1 : "NN nsubjpass VBN advcl JJR nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl *greater* nmod increases nmod levels nmod drug0" } 4 : { 1 : "There have been greater than two-fold increases of previously stable plasma levels of drug1 when drug2 has been administered in combination with these agents . " } 5 : { 1 : 1 } } 628 : { 1 : "NN appos NN dep NN dobj VBP acl:relcl NNS dobj VB nsubj NNS acl:relcl VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos n dep drug0 dobj contain acl:relcl products dobj *use* nsubj patients acl:relcl applying dobj gel compound drug0" } 4 : { 1 : "Patients who are applying drug1 gel should not concurrently use products that contain drug2 ( N , drug3 ) , a common component of insect repellent products . " } 5 : { 1 : 1 } } 629 : { 1 : "NN dobj VBP acl:relcl NNS dobj VB nsubj NNS acl:relcl VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj contain acl:relcl products dobj *use* nsubj patients acl:relcl applying dobj gel compound drug0" } 4 : { 1 : "Patients who are applying drug1 gel should not concurrently use products that contain drug2 ( N , drug3 ) , a common component of insect repellent products . " } 5 : { 1 : 1 } } 630 : { 1 : "NN nmod DT nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod that nmod *augmented* nsubjpass effect nmod drug0" } 4 : { 1 : "The hypotensive effect of drug1 is augmented by that of most other drug2 , including drug3 , negative inotropic agents , and inhaled drug4 . " } 5 : { 1 : 1 } } 631 : { 1 : "NN conj NN nmod NN nmod VBN xcomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod combined xcomp *is* nsubj drug0" } 4 : { 1 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " } 5 : { 1 : 1 } } 632 : { 1 : "NN compound NN nmod NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod *coadministration* nmod doses nmod drug0" } 4 : { 1 : "drug1 : Coadministration of once daily doses of drug2 , as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation , with drug3 20 mg once daily , resulted in a decrease in AUC by approximately 25 % and Cmax , by approximately 20 % of both drug4 and drug5 . " } 5 : { 1 : 1 } } 633 : { 1 : "NN nmod VBG advcl VBN nsubjpass NNS acl VBN nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod coadministering advcl *considered* nsubjpass effects acl metabolized nmod cyp0a0 dep drug0 appos drug0" } 4 : { 1 : "The potential effects of increased plasma concentrations of drug1 or other drug2 metabolized via CYP3A4 ( drug3 , drug4 ) should be considered when coadministering these agents with drug5 . " } 5 : { 1 : 1 } } 634 : { 1 : "NN nmod VBG advcl VBN nsubjpass NNS acl VBN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod coadministering advcl *considered* nsubjpass effects acl metabolized nmod cyp0a0 dep drug0" } 4 : { 1 : "The potential effects of increased plasma concentrations of drug1 or other drug2 metabolized via CYP3A4 ( drug3 , drug4 ) should be considered when coadministering these agents with drug5 . " } 5 : { 1 : 1 } } 635 : { 1 : "NN nmod NN nmod VBN xcomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod combined xcomp *is* nsubj drug0" } 4 : { 1 : "If drug1 is to be combined with other drug2 such as drug3 or drug4 / drug5 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of drug6 and drug7 ( e.g. , drug8 or drug9 ) are additive . " } 5 : { 1 : 1 } } 636 : { 1 : "NN appos NN dep NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep inhibitors nmod *administration* nmod drug0" } 4 : { 1 : "Consequently , concomitant administration of drug1 with strong CYP3A4 inhibitors ( e.g. , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) should be approached with caution . " } 5 : { 1 : 1 } } 637 : { 1 : "NN compound NN nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod *resulted* nsubj administration nmod drug0" } 4 : { 1 : "drug1 : In patients with mild to moderate hypertension , administration of drug2 once daily , as a tablet formulation comparable to 230 mg of the capsule formulation , with drug3 120 mg 3 times daily for 5 days , resulted in a 2-fold increase of drug4 AUC and a simultaneous 1.7-fold increase of drug5 AUC . " } 5 : { 1 : 1 } } 638 : { 1 : "NN nmod NNS nmod NN nmod VBP nsubj NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod increase nmod *result* nsubj inhibitors appos drug0" } 4 : { 1 : "Because moderate CYP3A4 inhibitors ( e.g. , drug1 ) result in 2-fold increase in plasma concentrations of drug2 , concomitant administration should also be approached with caution . " } 5 : { 1 : 1 } } 639 : { 1 : "NN conj NN dobj VB advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj *occur* advcl administered nsubjpass agents nmod drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 1 } } 640 : { 1 : "NN nmod NN nmod DT nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod that nmod *augmented* nsubjpass effect nmod drug0" } 4 : { 1 : "The hypotensive effect of drug1 is augmented by that of most other drug2 , including drug3 , negative inotropic agents , and inhaled drug4 . " } 5 : { 1 : 1 } } 641 : { 1 : "NN nmod NN nmod IN xcomp VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod therapy nmod while xcomp *occurred* nmod patients acl consuming dobj drug0" } 4 : { 1 : "drug1 - related adverse effects have occurred in patients consuming drug2 while on therapy with drug3 . " } 5 : { 1 : 1 } } 642 : { 1 : "NN nmod NN nmod NN nmod NN acl VBG dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod 0-mg nmod *ingestion* nmod drug0 acl containing dobj 0.0-gram nmod drug0" } 4 : { 1 : "drug1 : In a single dose study ( n = 6 ) , ingestion of an drug2 containing 1.7-gram of drug3 with 500-mg of drug4 increased the Cmax and AUC of drug5 by 125 % and 36 % , respectively . A number of compounds are inhibitors of CYP2C9 including drug6 , drug7 and drug8 . " } 5 : { 1 : 1 } } 643 : { 1 : "NN compound NN nmod NN conj NN dobj VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 compound clearance nmod reduction conj elevation dobj *produced* nsubj drug0" } 4 : { 1 : "drug1 : drug2 have produced an elevation of plasma drug3 levels and a reduction in renal drug4 clearance . " } 5 : { 1 : 1 } } 644 : { 1 : "NN compound NN dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound accumulation dobj inhibit xcomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 have been reported to competitively inhibit drug3 accumulation in rabbit kidney slices . " } 5 : { 1 : 1 } } 645 : { 1 : "NN conj NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj *occur* nsubj syndrome compound drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 1 } } 646 : { 1 : "NN nmod NN dobj VB advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dobj *occur* advcl administered nsubjpass agents nmod drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 1 } } 647 : { 1 : "NN compound NNS nmod NN conj NN conj NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound salts nmod drug0 conj drug0 conj drug0 dobj *occur* nsubj syndrome compound drug0" } 4 : { 1 : "Drug Interactions : The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions , e.g. , certain drug3 such as drug4 , the drug5 and other drug6 , drug7 , certain drug8 such as the drug9 salts , and drug10 . " } 5 : { 1 : 1 } } 648 : { 1 : "NN conj NN nmod NN nmod DT nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod that nmod *augmented* nsubjpass effect nmod drug0" } 4 : { 1 : "The hypotensive effect of drug1 is augmented by that of most other drug2 , including drug3 , negative inotropic agents , and inhaled drug4 . " } 5 : { 1 : 1 } } 649 : { 1 : "NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 650 : { 1 : "NN nmod NN dobj VB conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj increase conj *reported* nsubjpass drug0" } 4 : { 1 : "drug1 has been reported to decrease the clearance of drug2 and drug3 and thus may increase the pharmacologic effect of these drug4 . " } 5 : { 1 : 1 } } 651 : { 1 : "NN nmod NN dobj VB nsubj NN acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption dobj *reduce* nsubj drug0 acl containing dobj drug0 conj drug0" } 4 : { 1 : "drug1 containing drug2 and drug3 reduce the oral absorption of drug4 by 75 % . " } 5 : { 1 : 1 } } 652 : { 1 : "NN compound NNS conj NN nmod VB nmod NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations conj plasma nmod *interfere* nmod drug0 acl containing dobj drug0" } 4 : { 1 : "or with drug1 containing drug2 may substantially interfere with drug absorption and result in insufficient plasma and tissue drug3 concentrations . " } 5 : { 1 : 1 } } 653 : { 1 : "NN nmod NN nsubjpass VBN ccomp VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod activity nsubjpass confirmed ccomp *inhibit* nsubj drug0" } 4 : { 1 : "Preliminary data which suggest that drug1 may inhibit the anti-inflammatory activity of drug2 have not been confirmed . " } 5 : { 1 : 1 } } 654 : { 1 : "NN nmod VBG dobj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *receiving* dobj drug0 conj drug0 nmod drug0" } 4 : { 1 : "Patients receiving other drug1 , drug2 , drug3 , or other drug4 ( including drug5 ) concomitantly with drug6 and drug7 tablets may exhibit an additive CNS depression . " } 5 : { 1 : 1 } } 655 : { 1 : "NN compound NN dobj VBG advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj receiving advcl *reduced* nsubjpass dose nmod drug0" } 4 : { 1 : "In case of drug1 toxicity and/or elevated serum drug2 levels , the dose of drug3 should be reduced while the patient is receiving concomitant drug4 therapy . " } 5 : { 1 : 1 } } 656 : { 1 : "NN nmod NNS dobj VBG acl:relcl NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod doses dobj receiving acl:relcl patients nmod *use* compound drug0" } 4 : { 1 : "drug1 use in patients who are receiving high doses of drug2 may be associated with an increase in serum drug3 levels and potential drug4 toxicity . " } 5 : { 1 : 1 } } 657 : { 1 : "NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 658 : { 1 : "NN dep NNS nmod NN dobj VB conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep others nmod clearance dobj increase conj *decrease* nsubj drug0" } 4 : { 1 : "drug1 : Combination drug2 may decrease the clearance of some drug3 ( drug4 , drug5 , drug6 ) and increase the clearance of others ( drug7 , drug8 , drug9 ) . " } 5 : { 1 : 1 } } 659 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 660 : { 1 : "NN compound NNS conj NN conj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound preparations conj drug0 conj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 1 } } 661 : { 1 : "NN conj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 1 } } 662 : { 1 : "NN compound NN conj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound drug0 conj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 1 } } 663 : { 1 : "NN nmod NN nmod NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod medication nmod absorption dobj *delay* nsubj drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug3 , drug4 , drug5 ( acidic ) or drug6 ( basic ) , as well as drug7 drug8 , drug9 , thyroid and drug10 preparations , drug11 and drug12 , and drug13 . " } 5 : { 1 : 1 } } 664 : { 1 : "NN nmod NN nsubjpass VBN advcl VB nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod drug nsubjpass filtrated advcl *pose* nsubj discontinuance nmod drug0 compound drug0" } 4 : { 1 : "drug1 drug2 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , The discontinuance of drug3 drug4 could pose a hazard to health if a potentially toxic drug such as drug5 has been filtrated to a maintenance level while the patient was taking drug6 drug7 . " } 5 : { 1 : 1 } } 665 : { 1 : "NN nmod NNS dobj VBG acl NNS nmod NN dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod doses dobj receiving acl volunteers nmod increase dobj produce xcomp *found* nsubjpass drug0" } 4 : { 1 : "However , another drug1 has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of drug2 . " } 5 : { 1 : 1 } } 666 : { 1 : "NN nmod NN nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod member nmod *used* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 or drug2 : The risk of myopathy/rhabdomyolysis is increased when either drug3 or drug4 is used concomitantly with a closely related member of the drug5 ( see WARNINGS , Myopathy/Rhabdomyolysis ) . " } 5 : { 1 : 1 } } 667 : { 1 : "NN nmod NN dobj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod catabolism dobj *mediated* nmod ability nmod drug0" } 4 : { 1 : "This effect may be mediated by the ability of drug1 to induce microsomal enzymes and , thus , the catabolism of drug2 . " } 5 : { 1 : 1 } } 668 : { 1 : "NN nmod VBG dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod *taking* dobj s compound drug0" } 4 : { 1 : "Also , bleeding and/or increased prothrombin time have been reported in a few patients taking drug1 s concomitantly with drug2 . " } 5 : { 1 : 1 } } 669 : { 1 : "NN conj NN nmod NNS nmod VB nsubj NNS acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effects nmod *result* nsubj effects acl seen nmod coadministration compound drug0" } 4 : { 1 : "These pharmacokinetic effects seen during drug1 coadministration can result in increased clinical effects ( e.g. , prolonged sodation ) of both drug2 and drug3 . " } 5 : { 1 : 1 } } 670 : { 1 : "NN nmod NN nmod VBD nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod coadministration nmod *increased* nsubj life nmod drug0 conj drug0" } 4 : { 1 : "The elimination half life of drug1 and drug2 also increased ( 1.5-2 .5 fold ) during coadministration with drug3 . " } 5 : { 1 : 1 } } 671 : { 1 : "NN compound NN dobj VBG conj VBG advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj discontinuing conj initiating advcl *monitored* nsubjpass levels compound drug0" } 4 : { 1 : "Since there have been conflicting results regarding the effect of drug1 levels , it is recommended that drug2 levels be monitored when initiating , adjusting , and discontinuing drug3 therapy to avoid possible over - or under-digitalization . " } 5 : { 1 : 1 } } 672 : { 1 : "NN nmod VBG conj VBG advcl VBN nsubjpass NNS acl VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod discontinuing conj initiating advcl *monitored* nsubjpass patients acl receiving dobj therapy compound drug0" } 4 : { 1 : "Patients currently receiving drug1 therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with drug2 . " } 5 : { 1 : 1 } } 673 : { 1 : "NN nmod NNS nmod VB nsubj NNS acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod *result* nsubj effects acl seen nmod coadministration compound drug0" } 4 : { 1 : "These pharmacokinetic effects seen during drug1 coadministration can result in increased clinical effects ( e.g. , prolonged sodation ) of both drug2 and drug3 . " } 5 : { 1 : 1 } } 674 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *potentiated* nsubjpass depression nmod contractility conj dilation acl associated nmod drug0" } 4 : { 1 : "The depression of cardiac contractility , conductivity , and automaticity as well as the vascular dilation associated with drug1 may be potentiated by drug2 . " } 5 : { 1 : 1 } } 675 : { 1 : "NN compound NN nsubjpass VBN advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nsubjpass initiated advcl *monitored* nsubjpass concentrations compound drug0" } 4 : { 1 : "If these agents are to be administered concurrently , drug1 concentrations should be monitored , especially when drug2 therapy is initiated , adjusted , or discontinued . " } 5 : { 1 : 1 } } 676 : { 1 : "NN nmod NN nmod JJ xcomp VBN acl DT nmod JJ amod NNS dobj VB xcomp JJ nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod addition nmod prior xcomp seen acl those nmod similar amod concentrations dobj maintain xcomp *necessary* nsubj reduction nmod dose compound drug0" } 4 : { 1 : "In renal and cardiac transplant recipients , a reduction of drug1 dose ranging from 15 % to 48 % was necessary to maintain drug2 trough concentrations similar to those seen prior to the addition of drug3 . " } 5 : { 1 : 1 } } 677 : { 1 : "NN conj NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod auc dobj *increased* nsubj drug0" } 4 : { 1 : "Studies showed that drug1 increased the AUC of drug2 and drug3 by 3-4 fold and the Cmax by 2-fold , compared to placebo . " } 5 : { 1 : 1 } } 678 : { 1 : "NN nmod NN nmod JJ amod NN appos NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod responsible amod system appos *s* compound drug0" } 4 : { 1 : "The effect may be mediated by drug1 s known inhibition of hepatic cytochrome P-450 , the enzyme system responsible for the first-pass metabolism of drug2 . " } 5 : { 1 : 1 } } 679 : { 1 : "NN dobj VBG advcl VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj starting advcl *determined* nmod patients acl taking dobj drug0" } 4 : { 1 : "It is recommended that in patients taking drug1 , prothrombin time be determined before starting drug2 and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs . " } 5 : { 1 : 1 } } 680 : { 1 : "NN nmod NN nsubj VBD ccomp VBN nsubj NNS nmod NN acl:relcl VBN dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod use nsubj potentiated ccomp *shown* nsubj studies nmod design acl:relcl demonstrated dobj association nmod use nmod drug0" } 4 : { 1 : "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drug1 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drug2 or drug3 potentiated the risk of bleeding . " } 5 : { 1 : 1 } } 681 : { 1 : "NN nmod NN conj JJ nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod auc conj 0.0-fold nmod *increased* nsubj drug0" } 4 : { 1 : "drug1 significantly increased the area under the curve at steady state ( AUC ( ss ) ) of drug2 by 2.93-fold and the AUC ( ss ) of drug3 by 13.3-fold . " } 5 : { 1 : 1 } } 682 : { 1 : "NN compound NN nmod NNS dobj VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound hypertension nmod types dobj *attenuates* nsubj administration compound drug0" } 4 : { 1 : "Studies in rats have shown that drug1 administration attenuates certain types of drug2 dependent hypertension , including drug3 hypertension . " } 5 : { 1 : 1 } } 683 : { 1 : "NN dobj VB xcomp VB conj NN dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj use xcomp need conj drug0 dobj using acl patients nmod *contraindicated* nsubjpass drug0" } 4 : { 1 : "drug1 is contraindicated in patients using drug2 or who may need to use drug3 , because the combination may cause a sharp fall of the blood pressure . " } 5 : { 1 : 1 } } 684 : { 1 : "NN nmod NN nmod NN nmod VBN acl DT nmod NNS dobj VB xcomp VBD nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod mg nmod treatment nmod produced acl those nmod effects dobj produce xcomp *appeared* nsubj treatment nmod injection nmod drug0" } 4 : { 1 : "The treatment of ewes with an intravenous ( IV ) injection of drug1 , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase ( AChE ) activity , appeared to produce additive effects with those produced by subsequent treatment with 4 mg of drug2 / kg/day . " } 5 : { 1 : 1 } } 685 : { 1 : "NN conj VBN dep NN dep NN dobj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 conj induced dep drug0 dep release dobj *block* nsubj drug0" } 4 : { 1 : "Both drug1 and drug2 block drug3 - induced and drug4 - induced dopamine release in the nucleus accumbens ; " } 5 : { 1 : 1 } } 686 : { 1 : "NN nmod NN nmod NN appos NN nsubjpass VBN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod mg nmod effect appos kg nsubjpass *reduced* nmod ewes nmod mg nmod drug0" } 4 : { 1 : "In ewes given 40 mg of drug1 / kg for 5 days intraperitoneally ( IP ) , the anticholinesterase effect of 4 mg of drug2 / kg was significantly reduced and signs of toxicity were not present . " } 5 : { 1 : 1 } } 687 : { 1 : "NN compound NN nmod JJ amod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod secondary amod *clearance* compound drug0" } 4 : { 1 : "Enhanced drug1 clearance secondary to drug2 therapy . " } 5 : { 1 : 1 } } 688 : { 1 : "NN dobj VBG acl NNS nmod NN nsubjpass VBN advcl VB nmod NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl patients nmod use nsubjpass *recommended* advcl potentiate nmod drug0" } 4 : { 1 : "drug1 - Although drug2 did not potentiate the cognitive and motor effects of drug3 in a clinical trial , as with other drug4 , the use of drug5 by patients taking drug6 is not recommended . " } 5 : { 1 : 1 } } 689 : { 1 : "NN dep NN dobj NN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep release dobj *block* nsubj drug0 conj drug0" } 4 : { 1 : "Both drug1 and drug2 block drug3 - induced and drug4 - induced dopamine release in the nucleus accumbens ; " } 5 : { 1 : 1 } } 690 : { 1 : "NN compound NN dobj VBG acl NN" 2 : 1 3 : { 1 : "drug0 compound treatment dobj receiving acl *drug0*" } 4 : { 1 : "Patients on oral drug1 receiving drug2 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drug3 . " } 5 : { 1 : 1 } } 691 : { 1 : "NN nmod NN nsubj VBD dep NNS acl:relcl VBN nmod:tmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj *resulted* dep subjects acl:relcl received nmod:tmod days nmod drug0" } 4 : { 1 : "drug1 - In subjects who had received 21 days of 40 mg/day racemic drug2 , combined administration of 400 mg/day drug3 for 8 days resulted in an increase in drug4 AUC and Cmax of 43 % and 39 % , respectively . " } 5 : { 1 : 1 } } 692 : { 1 : "NN conj NN nmod NN nsubj VBD ccomp VBN nsubj NNS nmod NN acl:relcl VBN dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod use nsubj potentiated ccomp *shown* nsubj studies nmod design acl:relcl demonstrated dobj association nmod use nmod drug0" } 4 : { 1 : "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drug1 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drug2 or drug3 potentiated the risk of bleeding . " } 5 : { 1 : 1 } } 693 : { 1 : "NN conj VBN dep NN dep NN dobj NN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 conj induced dep drug0 dep release dobj *block* nsubj drug0 conj drug0" } 4 : { 1 : "Both drug1 and drug2 block drug3 - induced and drug4 - induced dopamine release in the nucleus accumbens ; " } 5 : { 1 : 1 } } 694 : { 1 : "NN compound NN nmod VBN acl NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod co-administered acl *dose* nmod mg compound drug0" } 4 : { 1 : "drug1 and drug2 - In a controlled study , a single dose of drug3 2 mg co-administered with racemic drug4 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to drug5 given alone . " } 5 : { 1 : 1 } } 695 : { 1 : "NN nmod NN nmod NN conj NN nmod VBD nsubj NN dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod auc nmod increase conj increase nmod *resulted* nsubj drug0 dep administration nmod drug0" } 4 : { 1 : "drug1 - Administration of 20 mg/day drug2 for 21 days in healthy volunteers resulted in a 50 % increase in Cmax and 82 % increase in AUC of the drug3 drug4 ( given in a single dose of 100 mg ) . " } 5 : { 1 : 1 } } 696 : { 1 : "NN appos NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 conj *drug0*" } 4 : { 1 : "If concomitant treatment with drug1 and an drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) is clinically warranted , appropriate observation of the patient is advised . " } 5 : { 1 : 1 } } 697 : { 1 : "NN appos NN nmod NN nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod *isomer* nsubj drug0" } 4 : { 1 : "Concomitant Administration with Racemic drug1 drug2 - Since drug3 is the active isomer of racemic drug4 ( drug5 ) , the two agents should not be coadministered . " } 5 : { 1 : 1 } } 698 : { 1 : "NN compound NN nmod VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound administration nmod *accelerated* nsubj clearance compound drug0" } 4 : { 1 : "This report describes two cases in which drug1 clearance accelerated markedly with concomitant drug2 administration . " } 5 : { 1 : 1 } } 699 : { 1 : "NN nmod NN conj NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod dose conj *increase* nmod course nmod mg/day compound drug0" } 4 : { 1 : "A study in six healthy volunteers has shown a significant increase in peak drug1 plasma levels ( 58 % ) and AUC ( 53 % ) after a 1-week course of drug2 1200 mg/day and a single dose of drug3 60mg . " } 5 : { 1 : 1 } } 700 : { 1 : "NN compound NN conj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound drug0 conj *patients* acl taking dobj drug0" } 4 : { 1 : "Seizures have been reported in patients taking another drug1 and the drug2 drug3 concurrently . " } 5 : { 1 : 1 } } 701 : { 1 : "NN compound NN nsubj VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound auc nsubj *increased* nmod patients acl receiving dobj drug0" } 4 : { 1 : "In patients receiving drug1 alone , drug2 AUC increased by 27 % and Cmax by 21 % . " } 5 : { 1 : 1 } } 702 : { 1 : "NN nmod NNS nmod VBN ccomp VBN advcl VBZ dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod alternatives nmod used ccomp *suggested* advcl requires dobj therapy compound drug0" } 4 : { 1 : "If a patient requires drug1 and drug2 therapy , it is suggested that drug3 , drug4 , or drug5 ( drug6 and drug7 s ) be used as alternatives to drug8 , as these agents have no effect on the pharmacokinetic profile of drug9 . " } 5 : { 1 : 1 } } 703 : { 1 : "NN compound NNS nmod NN nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 compound levels nmod increase nmod *resulted* nsubj drug0" } 4 : { 1 : "drug1 at doses of 100 mg BID ( OTC dose ) resulted in a 13 % increase in drug2 plasma levels ( 500 mcg single dose ) . " } 5 : { 1 : 1 } } 704 : { 1 : "NN nmod NN dobj VB xcomp VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod conversion dobj prevent xcomp shown acl:relcl *drug0*" } 4 : { 1 : "Prior administration of drug1 ( 90 mg kg ( -1 ) body weight ) was shown to prevent the conversion of drug2 ( 100 mg kg ( -1 ) body weight ) to drug3 in vivo and to eliminate the fluoride and citrate elevations seen in drug4 - intoxicated animals . " } 5 : { 1 : 1 } } 705 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *coadministered* nsubjpass inhibitors nmod isoenzyme dep drug0" } 4 : { 1 : "Inhibitors of this isoenzyme ( e.g. , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , grapefruit juice , drug8 , drug9 , drug10 , drug11 ) should be cautiously coadministered with drug12 as they can potentially increase drug13 levels . " } 5 : { 1 : 1 } } 706 : { 1 : "NN compound NNS dobj VB advcl VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj increase advcl *co-administered* nsubjpass drugs dep drug0" } 4 : { 1 : "In addition , drugs that are actively secreted via this route ( e.g. , drug1 , drug2 and drug3 ) should be co-administered with care as they might increase drug4 levels . " } 5 : { 1 : 1 } } 707 : { 1 : "NN nmod NN nmod VBN advcl VBN dobj NN nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod administered advcl *demonstrated* dobj reduction nmod bioavailability nmod drug0 conj drug0" } 4 : { 1 : "Previous studies have demonstrated a significant reduction in the oral bioavailability of drug1 and drug2 when administered concomitantly with an intravenous drug3 such as drug4 . " } 5 : { 1 : 1 } } 708 : { 1 : "NN nmod VBN advcl VBN dobj NN nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *demonstrated* dobj reduction nmod bioavailability nmod drug0 conj drug0" } 4 : { 1 : "Previous studies have demonstrated a significant reduction in the oral bioavailability of drug1 and drug2 when administered concomitantly with an intravenous drug3 such as drug4 . " } 5 : { 1 : 1 } } 709 : { 1 : "NN nmod NN dobj VBG acl:relcl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dobj taking acl:relcl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should be administered with caution to patients who are taking other drug2 or drug3 , including drug4 , drug5 and drug6 , or to those with a history of psychiatric disorder ( including manic-depressive illness and schizophrenia ) . " } 5 : { 1 : 1 } } 710 : { 1 : "NN appos NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod cmax dobj *decreased* nsubj drug0" } 4 : { 1 : "drug1 decreased the Cmax and AUC of sustained-release drug2 ( drug3 ) by approximately 31 % and 11 % , respectively . " } 5 : { 1 : 1 } } 711 : { 1 : "NN appos NN dep NN conj NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 conj drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 712 : { 1 : "NN dep NN conj NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 713 : { 1 : "NN conj NN dobj VBG acl:relcl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj taking acl:relcl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should be administered with caution to patients who are taking other drug2 or drug3 , including drug4 , drug5 and drug6 , or to those with a history of psychiatric disorder ( including manic-depressive illness and schizophrenia ) . " } 5 : { 1 : 1 } } 714 : { 1 : "NN nmod NN dobj VB acl JJ dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj increase acl potential dobj *has* nsubj drug0" } 4 : { 1 : "However , drug1 has the potential to increase the hypotensive effect of drug2 and drug3 . " } 5 : { 1 : 1 } } 715 : { 1 : "NN nmod VBN acl NNS nmod NN nsubj VBZ advcl VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod maintained acl patients nmod potential nsubj *is* advcl inhibits nsubj drug0" } 4 : { 1 : "Since drug1 inhibits platelet function , there is a potential for increased risk of bleeding , particularly in patients maintained on drug2 . " } 5 : { 1 : 1 } } 716 : { 1 : "NN conj NN nmod NN dobj VB acl JJ dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effect dobj increase acl potential dobj *has* nsubj drug0" } 4 : { 1 : "However , drug1 has the potential to increase the hypotensive effect of drug2 and drug3 . " } 5 : { 1 : 1 } } 717 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod absorption dobj *reduced* nsubj co-administration nmod dose nmod drug0" } 4 : { 1 : "drug1 : Co-administration of a single dose of intravenously administered drug2 ( 20 mg ) reduced the oral absorption of a single 400 mg dose of drug3 administered following a meal , as evidenced by a 27 % decrease in mean Cmax and a 22 % decrease in mean AUC . " } 5 : { 1 : 1 } } 718 : { 1 : "NN dobj VBG acl NNS nmod VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *given* nmod administration nmod drug0" } 4 : { 1 : "Special consideration should be given to the administration of drug1 in patients receiving drug2 or other drugs that could cause or potentiate hypotension . " } 5 : { 1 : 1 } } 719 : { 1 : "NN nmod NN nmod VBN advcl VBN dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod administered advcl *demonstrated* dobj reduction nmod bioavailability nmod drug0" } 4 : { 1 : "Previous studies have demonstrated a significant reduction in the oral bioavailability of drug1 and drug2 when administered concomitantly with an intravenous drug3 such as drug4 . " } 5 : { 1 : 1 } } 720 : { 1 : "NN nmod NNS nmod JJR amod NN nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod lower amod *%* nsubj clearances nmod drug0" } 4 : { 1 : "The mean clearances of drug1 were 16 % and 15 % lower in patients on drug2 and inhibitors of tubular organic cation transport , respectively . " } 5 : { 1 : 1 } } 721 : { 1 : "NN nmod NN nmod VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "drug1 or drug2 substantially interfere with the absorption of some drug3 , resulting in low urine levels . " } 5 : { 1 : 1 } } 722 : { 1 : "NN nmod NNS nmod JJR dobj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod less dobj *had* nmod drug0" } 4 : { 1 : "drug1 , like other drug2 , has had less than additive effects with drug3 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system " } 5 : { 1 : 1 } } 723 : { 1 : "NN nmod NNS nmod JJR dobj VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod less dobj *had* nsubj drug0" } 4 : { 1 : "drug1 , like other drug2 , has had less than additive effects with drug3 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system " } 5 : { 1 : 1 } } 724 : { 1 : "NN nmod NN nmod VBP nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod *interfere* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 or drug2 substantially interfere with the absorption of some drug3 , resulting in low urine levels . " } 5 : { 1 : 1 } } 725 : { 1 : "NN conj NN dobj VBG acl NN appos NN dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 appos drug0 dobj containing acl products nmod *administration* nmod drug0" } 4 : { 1 : "Also , concomitant administration of drug1 with products containing drug2 , drug3 containing drug4 , or drug5 ( drug6 ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels . " } 5 : { 1 : 1 } } 726 : { 1 : "NN dobj VBG acl NN appos NN dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 appos drug0 dobj containing acl products nmod *administration* nmod drug0" } 4 : { 1 : "Also , concomitant administration of drug1 with products containing drug2 , drug3 containing drug4 , or drug5 ( drug6 ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels . " } 5 : { 1 : 1 } } 727 : { 1 : "NN appos NN conj NN dobj VBG acl NN appos NN dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj drug0 dobj containing acl drug0 appos drug0 dobj containing acl products nmod *administration* nmod drug0" } 4 : { 1 : "Also , concomitant administration of drug1 with products containing drug2 , drug3 containing drug4 , or drug5 ( drug6 ) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels . " } 5 : { 1 : 1 } } 728 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *coadministered* nsubjpass inhibitors nmod isoenzyme dep drug0 appos drug0" } 4 : { 1 : "Inhibitors of this isoenzyme ( e.g. , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , grapefruit juice , drug8 , drug9 , drug10 , drug11 ) should be cautiously coadministered with drug12 as they can potentially increase drug13 levels . " } 5 : { 1 : 1 } } 729 : { 1 : "NN compound NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound toxicity nmod risk nsubjpass *increased* advcl used nsubjpass drug0" } 4 : { 1 : "If a drug1 is also used , the risk of drug2 toxicity may be increased . " } 5 : { 1 : 1 } } 730 : { 1 : "NN nmod NN dobj VBG advcl VB xcomp VBZ dobj NN" 2 : 1 3 : { 1 : "drug0 nmod effectiveness dobj increasing advcl open xcomp *allows* dobj drug0" } 4 : { 1 : "This allows drug1 to open air passages , increasing the effectiveness of the drug2 . " } 5 : { 1 : 1 } } 731 : { 1 : "NN nmod VBN advcl VBN dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *demonstrated* dobj reduction nmod bioavailability nmod drug0" } 4 : { 1 : "Previous studies have demonstrated a significant reduction in the oral bioavailability of drug1 and drug2 when administered concomitantly with an intravenous drug3 such as drug4 . " } 5 : { 1 : 1 } } 732 : { 1 : "NN compound NNS nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound s nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 1 } } 733 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NNS conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod caused acl loss dobj *attenuate* nsubj supplements conj lotensin compound drug0" } 4 : { 1 : "drug1 Supplements and drug2 Lotensin can attenuate potassium loss caused by drug3 . " } 5 : { 1 : 1 } } 734 : { 1 : "NN nmod NN conj NNS nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj s nmod effects dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 , drug2 and drug3 may enhance the effects of : other drug4 s , drug5 , general drug6 , drug7 such as drug8 , drug9 , or other drug10 , causing increased CNS depression . " } 5 : { 1 : 1 } } 735 : { 1 : "NN compound JJ dobj VB advcl VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound first dobj *take* advcl using dobj inhaler compound drug0" } 4 : { 1 : "If you are also using a drug1 inhaler , take drug2 first and then wait about 15 minutes before using the drug3 inhaler . " } 5 : { 1 : 1 } } 736 : { 1 : "NN compound NN nmod NN dobj VBG advcl VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound bioavailability nmod rate dobj lowering advcl *has* nsubj drug0" } 4 : { 1 : "drug1 , an anionic-binding resin , has a considerable effect in lowering the rate and extent of drug2 bioavailability . " } 5 : { 1 : 1 } } 737 : { 1 : "NN compound NN dobj VBG advcl VB conj VB dobj JJ compound NN" 2 : 1 3 : { 1 : "drug0 compound inhaler dobj using advcl wait conj *take* dobj first compound drug0" } 4 : { 1 : "If you are also using a drug1 inhaler , take drug2 first and then wait about 15 minutes before using the drug3 inhaler . " } 5 : { 1 : 1 } } 738 : { 1 : "NN nmod NN dep NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 739 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod potential nmod *added* nsubjpass drug0" } 4 : { 1 : "With combined use , clinicians should be aware , when drug1 is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum drug2 concentrations . " } 5 : { 1 : 1 } } 740 : { 1 : "NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj *inhibit* nsubj drug0" } 4 : { 1 : "drug1 and drug2 similarly inhibit and stimulate drug3 - or drug4 - induced proliferation of prostatic epithelium . " } 5 : { 1 : 1 } } 741 : { 1 : "NN nmod VBN acl NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod induced acl inhibition nmod effect dobj *had* nsubj drug0" } 4 : { 1 : "On the other hand , intrathecal drug1 ( 12-120 micrograms ) had only a very weak effect on the tail-flick inhibition induced by intraventricular drug2 ( 40 micrograms ) . " } 5 : { 1 : 1 } } 742 : { 1 : "NN nmod NN dobj VBD conj VBD advcl VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod exposure dobj increased conj decreased advcl *had* nsubj drug0" } 4 : { 1 : "drug1 had no significant impact on the Cmax and AUC of drug2 , although it significantly decreased the drug3 tmax by 44 % and increased the intracellular exposure to phosphorylated drug4 by 110 % . " } 5 : { 1 : 1 } } 743 : { 1 : "NN nmod NN nmod VBN acl NN nmod NN nmod NN dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod injection nmod induced acl response nmod inhibition nmod blockade dobj *caused* nsubj injection nmod drug0" } 4 : { 1 : "Intrathecal injection of drug1 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug2 , and a high dose of drug3 ( 40 micrograms ) completely blocked the tail-flick inhibition induced by intraventricular drug4 ( 16 micrograms ) . " } 5 : { 1 : 1 } } 744 : { 1 : "NN conj NN nmod VBN acl NN dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod induced acl inhibition dobj *antagonized* nsubj injection nmod drug0" } 4 : { 1 : "Intraventricular injection of drug1 at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drug2 and drug3 . " } 5 : { 1 : 1 } } 745 : { 1 : "NN conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj *decreased* nsubj drug0" } 4 : { 1 : "Similarly , drug1 decreased the antinociceptive effect of drug2 ( only in the tail-flick test ) and drug3 . " } 5 : { 1 : 1 } } 746 : { 1 : "NN nmod VBN acl NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod injected acl doses nmod *drug0*" } 4 : { 1 : "drug1 at doses of 0.25 mg/kg and 2.5 mg/kg injected with drug2 was found to decrease the antinociceptive effect of drug3 . " } 5 : { 1 : 1 } } 747 : { 1 : "NN nmod NN dobj VBD dep VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj decreased dep *used* nsubj drug0" } 4 : { 1 : "drug1 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug2 , drug3 ( only in the tail-flick test ) and drug4 . " } 5 : { 1 : 1 } } 748 : { 1 : "NN compound NN dobj VBD advcl VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 compound tmax dobj decreased advcl *had* nsubj drug0" } 4 : { 1 : "drug1 had no significant impact on the Cmax and AUC of drug2 , although it significantly decreased the drug3 tmax by 44 % and increased the intracellular exposure to phosphorylated drug4 by 110 % . " } 5 : { 1 : 1 } } 749 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod pretreatment nmod abolished acl:relcl striatum nmod increase dobj *caused* nsubj drug0" } 4 : { 1 : "Using in situ hybridization , we observed that drug1 caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist drug2 but not by an drug3 drug4 . " } 5 : { 1 : 1 } } 750 : { 1 : "NN nmod:poss NN dobj VBG advcl VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod:poss influence dobj attenuating advcl *augmented* nsubj pretreatment compound drug0" } 4 : { 1 : "drug1 pretreatment augmented the depressant effect of drug2 on the early components P1 and N1 , while attenuating drug3 's influence on components P2 and P3 . " } 5 : { 1 : 1 } } 751 : { 1 : "NN nmod VBN acl:relcl NN nmod JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod antagonized acl:relcl activity nmod *responsible* nsubj drug0" } 4 : { 1 : "Dose-response curves ( derived from the results of using the tablets as well as pure powders ) showed that drug1 was responsible for the inhibitory activity , which was partially antagonized by drug2 . " } 5 : { 1 : 1 } } 752 : { 1 : "NN compound NN nmod NNS nmod NN nsubj NNS nmod JJ conj DT acl VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod effects nmod *risk* nsubj patients nmod moderate conj those acl taking dobj therapy compound drug0" } 4 : { 1 : "however , patients with moderate to severe cardiovascular disease or those taking drug1 therapy are at increased risk for potentially serious cardiovascular adverse effects with drug2 therapy . " } 5 : { 1 : 1 } } 753 : { 1 : "NN nmod VBN acl NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod produced acl *pharmacokinetics* compound drug0" } 4 : { 1 : "These alterations in drug1 pharmacokinetics produced by drug2 explain the increase in serum drug3 level that has been observed when this drug combination has been used clinically . " } 5 : { 1 : 1 } } 754 : { 1 : "NN nmod NN nmod VBG advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod inhibiting advcl *active* nsubj drug0" } 4 : { 1 : "drug1 may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either drug2 or drug3 . " } 5 : { 1 : 1 } } 755 : { 1 : "NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects dep *drug0*" } 4 : { 1 : "However , the antagonism of the drug1 - induced anxiogenic effects by drug2 was only observed in the time spent in the light zone , and drug3 - induced anxiogenic effects were neither reversed by drug4 nor by drug5 . " } 5 : { 1 : 1 } } 756 : { 1 : "NN conj NN nmod NN nmod VBG advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod combination nmod inhibiting advcl *active* nsubj drug0" } 4 : { 1 : "drug1 may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either drug2 or drug3 . " } 5 : { 1 : 1 } } 757 : { 1 : "NN nmod VBN acl NN nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod induced acl number nmod reduction dobj *potentiates* nsubj drug0" } 4 : { 1 : "Our data suggest that drug1 significantly potentiates the reduction in cell number induced by drug2 alone . " } 5 : { 1 : 1 } } 758 : { 1 : "NN nmod NN nmod NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod screen nmod *level* nmod clinicians nmod cross-reactivity nmod drug0" } 4 : { 1 : "We report the case of an adolescent with altered consciousness caused by drug1 overdose with a positive drug2 level to alert clinicians to the cross-reactivity of drug3 with a toxicology screen for drug4 . " } 5 : { 1 : 1 } } 759 : { 1 : "NN conj NN compound NN dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 compound excretion dobj *enhanced* nsubj injection nmod drug0" } 4 : { 1 : "[ The effect of drug1 on the renal excretion of drug2 and drug3 in dogs ] The intravenous injection of drug4 in a dose of 20 mg/kg enhanced drug5 and drug6 excretion in chronic canine experiments . " } 5 : { 1 : 1 } } 760 : { 1 : "NN dobj VB conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj block conj *found* nsubjpass drug0" } 4 : { 1 : "drug1 alone was found to have no effect on CAS , but can completely block drug2 - induced phosphorylation of this protein in MDA-MB-435 cells . " } 5 : { 1 : 1 } } 761 : { 1 : "NN nmod NN nmod NN nmod NN nsubj VBD nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod clearance nmod median nmod decrease nsubj *was* nmod treatment nmod drug0" } 4 : { 1 : "RESULTS : During treatment with drug1 , there was a statistically significant decrease in the median of the total clearance of drug2 , from 845 mL/h to 688 mL/h , among the volunteers who received 75 mg/d . " } 5 : { 1 : 1 } } 762 : { 1 : "NN dobj VB acl:relcl NN nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj prevent acl:relcl *drug0* nsubj drug0" } 4 : { 1 : "drug1 is a novel drug2 that may selectively prevent drug3 - induced gastrointestinal effects without reversing analgesia . " } 5 : { 1 : 1 } } 763 : { 1 : "NN nmod NNS dobj VBZ dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj prevents dep *drug0*" } 4 : { 1 : "drug1 , a trans-3 ,4 - dimethyl-4 - ( 3-hydroxyphenyl ) piperidine , prevents gastrointestinal effects of intravenous drug2 without affecting analgesia . " } 5 : { 1 : 1 } } 764 : { 1 : "NN nmod VBN parataxis VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod prevented parataxis *prolonged* nsubj drug0" } 4 : { 1 : "drug1 prolonged gastrointestinal transit time from 69 to 103 minutes ( P = .005 ) ; this was prevented by drug2 ( P = .004 ) . " } 5 : { 1 : 1 } } 765 : { 1 : "NN nmod NNS dobj VBD nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj *potentiated* nsubj inhibitors dep drug0" } 4 : { 1 : "The uptake inhibitors drug1 and drug2 ( 3 mumol/liter ) potentiated the positive inotropic effects of drug3 in nonfailing myocardium ( p < 0.05 ) but not in functional class IV myocardium . " } 5 : { 1 : 1 } } 766 : { 1 : "NN nsubj NNS ccomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nsubj increases ccomp *prevents* nsubj drug0" } 4 : { 1 : "We conclude that drug1 prevents drug2 - induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia . " } 5 : { 1 : 1 } } 767 : { 1 : "NN nmod NNS dobj VBD nsubj NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj *potentiated* nsubj inhibitors dep drug0 conj drug0" } 4 : { 1 : "The uptake inhibitors drug1 and drug2 ( 3 mumol/liter ) potentiated the positive inotropic effects of drug3 in nonfailing myocardium ( p < 0.05 ) but not in functional class IV myocardium . " } 5 : { 1 : 1 } } 768 : { 1 : "NN nmod NNS dobj VBZ conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj inhibits conj *had* nsubj drug0" } 4 : { 1 : "drug1 alone had no effect on tyrosine phosphorylation in T24 cells , but dose-dependently inhibits the effects of drug2 when both are added simultaneously . " } 5 : { 1 : 1 } } 769 : { 1 : "NN nmod JJ nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *supersensitive* nsubj rings nmod group compound drug0" } 4 : { 1 : "Aortic rings with intact endothelium from the high-dose ( 4 mg/kg/day ) drug1 group were supersensitive to drug2 compared to the vehicle or low-dose ( 10 microg/kg/day ) estradiol groups ( pD2 values = 7.86 + / -0.09 , 7.30 + / -0.11 and 7.35 + / -0.04 , respectively ) . " } 5 : { 1 : 1 } } 770 : { 1 : "NN compound NN nmod VBD nsubj NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound coadministration nmod *increased* nsubj mean dep area compound drug0" } 4 : { 1 : "RESULTS : The geometric mean ( 90 % confidence interval ) whole blood drug1 area under the plasma concentration time-curve increased 60 % ( 35 % -90 % ) , from 736 to 1178 ng x h/mL , and maximum concentration increased 43 % ( 14 % -81 % ) , from 67 to 96 ng/mL , with drug2 coadministration , whereas the mean elimination half-life of drug3 decreased slightly , from 79 to 67 hours . " } 5 : { 1 : 1 } } 771 : { 1 : "NN nmod NNS nmod NN dobj VBD dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod tolerance dobj produced dep *drug0*" } 4 : { 1 : "The drug1 - induced neuronal damage produced a tolerance to the disruptive effects of drug2 and a supersensitivity to the disruptive effects of drug3 in rats responding in a schedule controlled paradigm . " } 5 : { 1 : 1 } } 772 : { 1 : "NN dobj VBD conj JJ nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj depressed conj *strong* nsubj effects nmod drug0" } 4 : { 1 : "The effects of drug1 were very strong and completely depressed the drug2 - induced hyperlocomotion . " } 5 : { 1 : 1 } } 773 : { 1 : "NN compound NN nmod VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound exposure nmod *leads* nsubj coadministration compound drug0" } 4 : { 1 : "CONCLUSIONS : Single-dose drug1 coadministration leads to higher drug2 exposure , presumably by inhibition of the first-pass metabolism of drug3 . " } 5 : { 1 : 1 } } 774 : { 1 : "NN nmod NNS nmod NN conj NN nmod NNS nmod NN dobj VBD dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod supersensitivity conj drug0 nmod effects nmod tolerance dobj produced dep *drug0*" } 4 : { 1 : "The drug1 - induced neuronal damage produced a tolerance to the disruptive effects of drug2 and a supersensitivity to the disruptive effects of drug3 in rats responding in a schedule controlled paradigm . " } 5 : { 1 : 1 } } 775 : { 1 : "NN nmod NN nmod NN nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod mg nmod administration nmod h nmod *taken* nsubjpass drug0" } 4 : { 1 : "drug1 may be taken with a light meal 1 h following the administration of 400 mg of drug2 . " } 5 : { 1 : 1 } } 776 : { 1 : "VB xcomp JJ nsubj NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 xcomp *supersensitive* nsubj rings nmod rats compound drug0" } 4 : { 1 : "Endothelium-intact aortic rings from high - drug1 rats were supersensitive to drug2 when compared to vehicle - , drug3 - and drug4 + high - drug5 - treated rats ( pD2 values = 7.77 + / -0.12 , 7.21 + / -0.13 , 6.93 + / -0.04 and 7.22 + / -0.18 , respectively ) . " } 5 : { 1 : 1 } } 777 : { 1 : "NN compound NN dobj VBG advcl JJ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound absorption dobj elevating advcl *effective* nsubj administration compound drug0" } 4 : { 1 : "drug1 administration to rachitic chicks was effective in significantly elevating duodenal drug2 absorption , acting primarily to enhance serosal transport . " } 5 : { 1 : 1 } } 778 : { 1 : "NN nsubj VBD advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj *exhibited* advcl combined nmod drug0" } 4 : { 1 : "When combined with drug1 , drug2 exhibited strong synergistic activity while only additive effects were observed with the combination of drug3 ( or drug4 ) and drug5 . " } 5 : { 1 : 1 } } 779 : { 1 : "NN compound NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound level nmod *overdose* compound drug0" } 4 : { 1 : "We report the case of an adolescent with altered consciousness caused by drug1 overdose with a positive drug2 level to alert clinicians to the cross-reactivity of drug3 with a toxicology screen for drug4 . " } 5 : { 1 : 1 } } 780 : { 1 : "NN conj NN nmod NNS nmod VBN dobj VBG acl NN nmod NNS dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod doses nmod produced dobj responding acl fi nmod increases dobj *reduced* nsubj drug0" } 4 : { 1 : "drug1 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug2 or drug3 in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug4 . " } 5 : { 1 : 1 } } 781 : { 1 : "NN nmod NN nmod NN dobj VB conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod proliferation dobj inhibit conj *stimulated* nsubj drug0" } 4 : { 1 : "However , drug1 stimulated , but did not significantly inhibit , proliferation in the presence of drug2 . " } 5 : { 1 : 1 } } 782 : { 1 : "NN nmod NN dobj VBP dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod activity dobj enhance dep x dep *drug0*" } 4 : { 1 : "Higher concentrations of drug1 ( 10 ( -8 ) - 10 ( -6 ) M ) or drug2 ( 3 X 10 ( -8 ) - 10 ( -7 ) M ) enhance the mitogenic activity of drug3 . " } 5 : { 1 : 1 } } 783 : { 1 : "NN nmod NN dobj VBP dep NN dep NN conj CD dep NN" 2 : 1 3 : { 1 : "drug0 nmod activity dobj enhance dep x dep drug0 conj 0 dep *drug0*" } 4 : { 1 : "Higher concentrations of drug1 ( 10 ( -8 ) - 10 ( -6 ) M ) or drug2 ( 3 X 10 ( -8 ) - 10 ( -7 ) M ) enhance the mitogenic activity of drug3 . " } 5 : { 1 : 1 } } 784 : { 1 : "NN nmod NN nmod NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod activity nmod modification nmod *regulate* nsubj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 1 } } 785 : { 1 : "NN nmod NN nmod NN nmod VB nsubj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod activity nmod modification nmod *regulate* nsubj drug0 conj drug0 conj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 1 } } 786 : { 1 : "NN conj NN nmod NN nmod NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod activity nmod modification nmod *regulate* nsubj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 1 } } 787 : { 1 : "NN conj NN nmod NN nmod NN nmod VB nsubj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod activity nmod modification nmod *regulate* nsubj drug0 conj drug0 conj drug0" } 4 : { 1 : "These results suggest that both drug1 and drug2 , and possibly other drug3 and drug4 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug5 and drug6 . " } 5 : { 1 : 1 } } 788 : { 1 : "NN nmod NN nmod NN conj NN dobj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod injection nmod % conj % dobj *depressed* nsubjpass requirement compound drug0" } 4 : { 1 : "However , drug1 anesthetic requirement ( i.e. , MAC ) was depressed in a dose-dependent fashion as much as 56 % 1-2 hours and as much as 14 % 5-6 hours after injection of drug2 , 50 mg/kg , im . " } 5 : { 1 : 1 } } 789 : { 1 : "NN nmod VBN acl NN dobj VBZ nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod stimulated acl proliferation dobj *inhibits* nsubj drug0 nmod m conj drug0" } 4 : { 1 : "drug1 at 10 ( -10 ) M or drug2 at about 3 X 10 ( -9 ) M inhibits proliferation stimulated by drug3 . " } 5 : { 1 : 1 } } 790 : { 1 : "NN dep NN dobj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 dep release dobj *block* nsubj drug0" } 4 : { 1 : "Both drug1 and drug2 block drug3 - induced and drug4 - induced dopamine release in the nucleus accumbens ; " } 5 : { 1 : 1 } } 791 : { 1 : "NN dobj VBP nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj *inhibit* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 similarly inhibit and stimulate drug3 - or drug4 - induced proliferation of prostatic epithelium . " } 5 : { 1 : 1 } } 792 : { 1 : "NN conj NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj *inhibit* nsubj drug0" } 4 : { 1 : "drug1 and drug2 similarly inhibit and stimulate drug3 - or drug4 - induced proliferation of prostatic epithelium . " } 5 : { 1 : 1 } } 793 : { 1 : "NN conj NN nmod NN dobj VBP advcl VBD nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effect dobj *modify* advcl affected nsubj drug0 conj drug0" } 4 : { 1 : "Although neither drug1 nor drug2 affected the proliferation of prostatic epithelium in RPMI1640 containing drug3 alone , they modify the mitogenic effect of drug4 and drug5 . " } 5 : { 1 : 1 } } 794 : { 1 : "NN conj NN dobj VBP nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj *inhibit* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 similarly inhibit and stimulate drug3 - or drug4 - induced proliferation of prostatic epithelium . " } 5 : { 1 : 1 } } 795 : { 1 : "NN conj NN nmod NN dobj VBP advcl VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effect dobj *modify* advcl affected nsubj drug0" } 4 : { 1 : "Although neither drug1 nor drug2 affected the proliferation of prostatic epithelium in RPMI1640 containing drug3 alone , they modify the mitogenic effect of drug4 and drug5 . " } 5 : { 1 : 1 } } 796 : { 1 : "NN nmod NN dobj VBP advcl VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *modify* advcl affected nsubj drug0" } 4 : { 1 : "Although neither drug1 nor drug2 affected the proliferation of prostatic epithelium in RPMI1640 containing drug3 alone , they modify the mitogenic effect of drug4 and drug5 . " } 5 : { 1 : 1 } } 797 : { 1 : "NN nmod NN dobj VBP advcl VBD nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *modify* advcl affected nsubj drug0 conj drug0" } 4 : { 1 : "Although neither drug1 nor drug2 affected the proliferation of prostatic epithelium in RPMI1640 containing drug3 alone , they modify the mitogenic effect of drug4 and drug5 . " } 5 : { 1 : 1 } } 798 : { 1 : "NN nmod NN nmod VBD nsubj NN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod excretion nmod *resulted* nsubj rate nmod groups acl receiving dobj drug0" } 4 : { 1 : "The lower rate of absorption in the groups receiving 446 mg drug1 instead of 48 mg of drug2 per kg diet resulted in a decreased renal excretion of drug3 . " } 5 : { 1 : 1 } } 799 : { 1 : "NN nmod NN nmod RBR nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *longer* nsubj half-life nmod drug0" } 4 : { 1 : "The half-life of drug1 in plasma and brain was longer in the presence of drug2 than when drug3 was given alone . " } 5 : { 1 : 1 } } 800 : { 1 : "NN nmod NN nsubjpass VBN conj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod use nsubjpass expected conj *drug* nsubj drug0" } 4 : { 1 : "It is concluded that drug1 is not a short-acting drug and that concomitant use with drug2 would be expected to prolong further the duration of its action on the central nervous system . " } 5 : { 1 : 1 } } 801 : { 1 : "NN nmod NN nsubj JJ advcl VBD nsubj NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj due advcl *reached* nsubj concentrations nmod drug0 conj drug0" } 4 : { 1 : "( 1968 , 1970 ) , the higher serum concentrations of drug1 and drug2 reached after administration of drug3 are due not only to slower renal elimination but also to an altered distribution in the body . " } 5 : { 1 : 1 } } 802 : { 1 : "NN nmod NN nsubj JJ advcl VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj due advcl *reached* nsubj concentrations nmod drug0" } 4 : { 1 : "( 1968 , 1970 ) , the higher serum concentrations of drug1 and drug2 reached after administration of drug3 are due not only to slower renal elimination but also to an altered distribution in the body . " } 5 : { 1 : 1 } } 803 : { 1 : "NN nmod NN dobj VBZ conj VBZ dep VBN nmod NNS nmod JJ acl:relcl VBP" 2 : 1 3 : { 1 : "drug0 nmod action dobj reduces conj removes dep *shown* nmod rats nmod toxic acl:relcl drug0" } 4 : { 1 : "[ The GABA-ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that drug1 ( 1 mg/kg ) removes the antiedematous action of drug2 , drug3 , drug4 and drug5 and reduces the action of drug6 . " } 5 : { 1 : 1 } } 804 : { 1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *administered* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 should not be administered to patients receiving drug3 . " } 5 : { 1 : 1 } } 805 : { 1 : "NN nmod NNS dobj VB xcomp VBN acl DT nmod JJR nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj antagonize xcomp required acl those nmod *higher* nsubj doses nmod drug0" } 4 : { 1 : "the doses of drug1 required to antagonize the effects of drug2 were more than 100 times higher than those required to antagonize the effects of drug3 . " } 5 : { 1 : 1 } } 806 : { 1 : "NN nmod NNS dobj VB xcomp VBN acl NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj antagonize xcomp required acl *doses* nmod drug0" } 4 : { 1 : "the doses of drug1 required to antagonize the effects of drug2 were more than 100 times higher than those required to antagonize the effects of drug3 . " } 5 : { 1 : 1 } } 807 : { 1 : "NN nmod NNS nmod VBN dobj VBG acl NN nmod NNS dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod produced dobj responding acl fi nmod increases dobj *reduced* nsubj drug0" } 4 : { 1 : "drug1 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug2 or drug3 in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug4 . " } 5 : { 1 : 1 } } 808 : { 1 : "NN nmod VBP nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *interact* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 interact pharmacologically with orally administered drug3 , but the effect is not clinically significant . " } 5 : { 1 : 1 } } 809 : { 1 : "NN nmod NN dobj VBZ dep VBN nmod NNS nmod JJ acl:relcl VBP" 2 : 1 3 : { 1 : "drug0 nmod action dobj removes dep *shown* nmod rats nmod toxic acl:relcl drug0" } 4 : { 1 : "[ The GABA-ergic system and brain edema ] It has been shown in rats with experimental toxic and traumatic edemas that drug1 ( 1 mg/kg ) removes the antiedematous action of drug2 , drug3 , drug4 and drug5 and reduces the action of drug6 . " } 5 : { 1 : 1 } } 810 : { 1 : "NN dep NN nmod VBN acl:relcl NN nmod NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 dep cyp0a0 nmod metabolized acl:relcl drug0 nmod metabolism dobj *inhibit* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : drug1 inhibit the metabolism of drug2 that are metabolized by CYP3A4 ( i.e. , drug3 , drug4 , drug5 , drug6 ) . " } 5 : { 1 : 1 } } 811 : { 1 : "NN conj NN nsubj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 conj weight nsubj *increased* nmod drug0" } 4 : { 1 : "The successive application of drug1 ( 5 or 10 mg/kg egg weight ( e.w. ) and drug2 ( 15 mg/kg e.w. ) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drug3 alone . " } 5 : { 1 : 1 } } 812 : { 1 : "VB acl NN nmod VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 acl reaction nmod *is* nsubj effect nmod drug0" } 4 : { 1 : "There is thus an enhancement effect of drug1 upon the reaction of placental vessels to drug2 in vitro . " } 5 : { 1 : 1 } } 813 : { 1 : "NN appos NN dep NN nmod VBN acl:relcl NN nmod NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep cyp0a0 nmod metabolized acl:relcl drug0 nmod metabolism dobj *inhibit* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : drug1 inhibit the metabolism of drug2 that are metabolized by CYP3A4 ( i.e. , drug3 , drug4 , drug5 , drug6 ) . " } 5 : { 1 : 1 } } 814 : { 1 : "NN nmod VB conj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod interact conj *interfere* nsubj treatment nmod drug0" } 4 : { 1 : "Treatment with drug1 can directly interfere with blood glucose levels or may interact with drug2 . " } 5 : { 1 : 1 } } 815 : { 1 : "NN nmod NN nmod VBN nsubjpass NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod *converted* nsubjpass tachycardia acl induced nmod drug0" } 4 : { 1 : "Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug2 , drug3 , or drug4 but not after administration of drug5 alone or after drug6 . " } 5 : { 1 : 1 } } 816 : { 1 : "NN nmod NN nsubj VBN nmod NN nmod NN nmod NNS amod JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dosage nsubj *needed* nmod comparison nmod tolerance nmod dogs amod anesthetized nmod drug0" } 4 : { 1 : "In a comparison of drug1 tolerance in dogs anesthetized with drug2 , drug3 , or drug4 , the dosage of drug5 needed to cause ventricular tachycardia was significantly higher , as was the LD50 of drug6 , with drug7 or drug8 than with drug9 . " } 5 : { 1 : 1 } } 817 : { 1 : "NN compound NN nmod JJ amod NN appos NN nsubj NN" 2 : 1 3 : { 1 : "drug0 compound metabolism nmod responsible amod enzyme appos *inhibitor* nsubj drug0" } 4 : { 1 : "DISCUSSION : drug1 is a potent inhibitor of CYP3A4 , the major enzyme responsible for drug2 metabolism . " } 5 : { 1 : 1 } } 818 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 819 : { 1 : "NN appos NN dep NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 820 : { 1 : "NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 821 : { 1 : "NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 822 : { 1 : "NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 823 : { 1 : "NN nmod NNS nmod NNS dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod changes dobj *produced* nsubj drug0" } 4 : { 1 : "drug1 produced only minor changes in the levels of drug2 and its metabolites . " } 5 : { 1 : 1 } } 824 : { 1 : "NN compound NNS nmod NN nmod VB nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound levels nmod increase nmod *result* nsubj discontinuation nmod administration compound drug0" } 4 : { 1 : "Although concomitant use of drug1 and drug2 is not recommended , it should be noted that discontinuation of concomitant drug3 administration may result in an increase in drug4 plasma levels . " } 5 : { 1 : 1 } } 825 : { 1 : "NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 826 : { 1 : "NN appos NN dep NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 827 : { 1 : "NN dep NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 828 : { 1 : "NN dep NN conj NN nmod VBN acl NNS conj NN nmod NN appos NN dep NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod classified acl drugs conj drug0 nmod drug0 appos drug0 dep medications nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with the following medications : drug2 ( drug3 ) , drug4 such as drug5 and drug6 , drug7 ( drug8 , drug9 , drug10 , drug11 , drug12 , drug13 ) , drug14 ( drug15 , drug16 , drug17 ) , drug18 ( drug19 ) , drug20 ( drug21 ) , drug22 ( drug23 , drug24 ) , HIV drugs classified as drug25 ( drug26 , drug27 , drug28 , drug29 , drug30 , drug31 , drug32 ) , drug33 ( drug34 , drug35 , drug36 ) , drug37 , drug38 ( drug39 ) , drug40 ( drug41 ) , St. Johns wort , drug42 , drug43 ( drug44 ) , and drug45 . " } 5 : { 1 : 1 } } 829 : { 1 : "NN conj NN nmod NN dobj VB dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj increase dep *drug0*" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 } } 830 : { 1 : "NN compound NNS nmod NNS conj NN nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound drugs nmod effects conj drug0 nmod effects dobj *potentiate* nsubj drug0" } 4 : { 1 : "drug1 may potentiate the hypotensive effects of drug2 and the anticholinergic effects of drug3 - type drugs . " } 5 : { 1 : 1 } } 831 : { 1 : "NN nmod NN dobj VB conj VBP nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod excretion dobj increase conj *decrease* nsubj agents compound drug0" } 4 : { 1 : "drug1 agents decrease blood levels and increase excretion of drug2 . " } 5 : { 1 : 1 } } 832 : { 1 : "NN appos NN compound NNS appos NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 appos drug0 compound classes appos drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 833 : { 1 : "NN compound NNS appos NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound classes appos drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 834 : { 1 : "NN conj NNS nmod VBG advcl VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drugs nmod using advcl *advised* nmod effects nmod drug0" } 4 : { 1 : "Given the primary CNS effects of drug1 , caution is advised in using it concomitantly with other CNS-active drugs or drug2 . " } 5 : { 1 : 1 } } 835 : { 1 : "NN conj NN compound NNS appos NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 compound classes appos drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 836 : { 1 : "NN conj NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 837 : { 1 : "NN appos NN conj NN compound NNS appos NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj drug0 compound classes appos drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 838 : { 1 : "NN nmod NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod drug0 nsubjpass used advcl *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with care when drug2 or inhibitors of AV conduction , such as certain drug3 ( particularly of the drug4 [ drug5 ] and drug6 [ drug7 ] classes ) , or drug8 , such as drug9 , are used concurrently . " } 5 : { 1 : 1 } } 839 : { 1 : "NN nmod NN nsubj VB advcl VBN nsubjpass NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod action nsubj produce advcl *monitored* nsubjpass patients nmod drug0 conj drug0" } 4 : { 1 : "Patients receiving catecholamine-depleting drugs , such as drug1 or drug2 , should be closely monitored , because the added beta-adrenergic blocking action of drug3 may produce excessive reduction of sympathetic activity . " } 5 : { 1 : 1 } } 840 : { 1 : "NN nmod NN dobj VB dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj increase dep *drug0* dep drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 } } 841 : { 1 : "NN nmod NN dobj VB dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj increase dep *drug0* dep drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 } } 842 : { 1 : "NN compound NNS nmod VBN advcl VB nsubj NNS appos NN" 2 : 1 3 : { 1 : "drug0 compound agents nmod given advcl *have* nsubj drugs appos drug0" } 4 : { 1 : "Catecholamine-depleting drugs ( e.g. , drug1 ) may have an additive effect when given with drug2 agents . " } 5 : { 1 : 1 } } 843 : { 1 : "NN nmod NN nmod VBN csubjpass VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treatment nmod *recommended* csubjpass reduced dobj dosage nmod drug0" } 4 : { 1 : "Thus in order to avoid bleeding , reduced dosage of drug1 is recommended during treatment with drug2 ( human ) . " } 5 : { 1 : 1 } } 844 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN conj VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod used conj *induce* nsubj drugs nmod drug0" } 4 : { 1 : "drug1 : Drugs such as drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 and others that interfere with platelet-aggregation reactions ( the main hemostatic defense of heparinized patients ) may induce bleeding and should be used with caution in patients receiving drug9 . " } 5 : { 1 : 1 } } 845 : { 1 : "VB xcomp JJ nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 xcomp *refractory* nsubj patients nmod drug0" } 4 : { 1 : "Risk of Anaphylactic Reaction : Although it is known that patients on drug1 may be refractory to drug2 in the treatment of anaphylactic shock , drug3 can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks . " } 5 : { 1 : 1 } } 846 : { 1 : "NN dobj VBG nsubj NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj *taking* nsubj patient acl receiving dobj drug0" } 4 : { 1 : "Tablet If a patient receiving drug1 is also taking drug2 , the effect of drug3 may be reduced , thus necessitating an increase in dosage . " } 5 : { 1 : 1 } } 847 : { 1 : "NN nmod NN conj NN nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj drug0 nmod effects dobj *have* nsubj drug0" } 4 : { 1 : "drug1 may have additive effects with drug2 and other drug3 , e.g. , drug4 , drug5 , drug6 , drug7 . " } 5 : { 1 : 1 } } 848 : { 1 : "NN dep NN conj NN dobj VB xcomp VBN acl NNS nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep conduction conj function dobj affect xcomp known acl agents nmod *receiving* dobj drug0" } 4 : { 1 : "Also , due to the potential for additive effects such as bradycardia and AV block , caution is warranted in patients receiving drug1 with agents known to affect sinus node function or AV nodal conduction ( e.g. , drug2 , drug3 , and drug4 . ) " } 5 : { 1 : 1 } } 849 : { 1 : "NN conj NN nmod NN dobj VB dep NN dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj increase dep *drug0* dep drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 } } 850 : { 1 : "NN nmod VBN advcl VBP nsubj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod given advcl *are* nsubj reports nmod effects nmod drug0" } 4 : { 1 : "There are reports of enhanced as well as diminished effects of drug1 when given concurrently with drug2 . " } 5 : { 1 : 1 } } 851 : { 1 : "NN nmod NN dobj VB nsubj NNS acl:relcl VBP dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod clearance dobj *increase* nsubj drugs acl:relcl induce dobj enzymes nmod drug0" } 4 : { 1 : "Drugs that induce hepatic enzymes such as drug1 , drug2 and drug3 may increase the clearance of drug4 and may require increases in drug5 dose to achieve the desired response . " } 5 : { 1 : 1 } } 852 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod concentration dobj increase xcomp *reported* nsubjpass doses nmod drug0 appos drug0" } 4 : { 1 : "drug1 : Doses of drug2 ( drug3 ) 1 g/day have been reported to increase plasma concentration of drug4 by ~ 47 % , possibly by inhibiting conjugation ; " } 5 : { 1 : 1 } } 853 : { 1 : "NN conj NN nmod NN dobj VB dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj increase dep *drug0* dep drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 , drug5 , drug6 ) : Increase the metabolism of drug7 and/or some drug8 , leading to possible decrease in contraceptive effectiveness . " } 5 : { 1 : 1 } } 854 : { 1 : "NN compound NN nmod NNS dobj VB conj VB nsubj NNS acl:relcl VBP dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound dose nmod increases dobj require conj *increase* nsubj drugs acl:relcl induce dobj enzymes nmod drug0" } 4 : { 1 : "Drugs that induce hepatic enzymes such as drug1 , drug2 and drug3 may increase the clearance of drug4 and may require increases in drug5 dose to achieve the desired response . " } 5 : { 1 : 1 } } 855 : { 1 : "NN nmod NN dep NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod biotransformation dep cyp0c0 dobj *inhibits* nsubj drug0" } 4 : { 1 : "drug1 inhibits the CYP2C9 catalyzed biotransformation of drug2 . " } 5 : { 1 : 1 } } 856 : { 1 : "NN appos NN compound VBG conj NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 compound resulting conj metabolism dobj *increases* nsubj drug0" } 4 : { 1 : "drug1 : drug2 increases the metabolism of drug3 and some drug4 ( drug5 ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities . " } 5 : { 1 : 1 } } 857 : { 1 : "NN compound VBG conj NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound resulting conj metabolism dobj *increases* nsubj drug0" } 4 : { 1 : "drug1 : drug2 increases the metabolism of drug3 and some drug4 ( drug5 ) resulting in decreased contraceptive effectiveness and increased menstrual irregularities . " } 5 : { 1 : 1 } } 858 : { 1 : "NN nmod VBN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod inhibited dep *drug0* dep drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , drug4 ) : Metabolism may be inhibited by drug5 , increasing plasma levels of drug6 ; " } 5 : { 1 : 1 } } 859 : { 1 : "NN compound NN nmod VBN nmod NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *occurred* nmod patients acl treated nmod drug0" } 4 : { 1 : "However , in patients treated with oral drug1 , rare instances of drug interactions have occurred with high-dose drug2 therapy . " } 5 : { 1 : 1 } } 860 : { 1 : "NN nmod NN nsubj VB advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod action nsubj produce advcl *monitored* nsubjpass patients nmod drug0" } 4 : { 1 : "Patients receiving catecholamine-depleting drugs , such as drug1 or drug2 , should be closely monitored , because the added beta-adrenergic blocking action of drug3 may produce excessive reduction of sympathetic activity . " } 5 : { 1 : 1 } } 861 : { 1 : "NN conj NN nmod NNS nmod VB conj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod abnormalities nmod lead conj prolong acl:relcl medications nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval ( e.g. certain drug2 or drug3 ) or lead to electrolyte abnormalities ( such as drug4 or drug5 ) . " } 5 : { 1 : 1 } } 862 : { 1 : "NN nmod NN conj NN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod dose conj *coadministration* nmod mg dep drug0" } 4 : { 1 : "After the coadministration of 200 mg oral drug1 twice daily and one 20 mg dose of drug2 to 11 subjects , the AUC and Cmax of drug3 averaged 302 % ( 142 S.D. ) and 251 % ( 68 S.D. ) , respectively , of those obtained after co-treatment with placebo . " } 5 : { 1 : 1 } } 863 : { 1 : "NN compound NNS dobj VB xcomp VBN nsubjpass NN appos NN" 2 : 1 3 : { 1 : "drug0 compound concentrations dobj affect xcomp *reported* nsubjpass drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 ) is also reported to affect drug3 concentrations adversely . " } 5 : { 1 : 1 } } 864 : { 1 : "NN dobj VBG acl NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *concentrations* compound drug0" } 4 : { 1 : "It is , therefore , advisable to monitor drug1 concentrations in patients receiving drug2 . " } 5 : { 1 : 1 } } 865 : { 1 : "NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod window dobj have conj metabolized acl:relcl medications nmod *used* nsubjpass drug0" } 4 : { 1 : "Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window , such as drug2 , drug3 and drug4 ( see CLINICAL PHARMACOLOGY ) . " } 5 : { 1 : 1 } } 866 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0 appos drug0" } 4 : { 1 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " } 5 : { 1 : 1 } } 867 : { 1 : "NN nmod NN dobj VB acl NN nmod VBN advcl NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj inhibit acl ability nmod indicated advcl *inhibitor* nsubj drug0" } 4 : { 1 : "drug1 is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of drug2 . " } 5 : { 1 : 1 } } 868 : { 1 : "NN conj NN nmod NN dobj VB nsubj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod action dobj *potentiate* nsubj drugs nmod drug0 appos drug0" } 4 : { 1 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . " } 5 : { 1 : 1 } } 869 : { 1 : "NN nmod VBG nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *mixing* nmod drug0" } 4 : { 1 : "drug1 : The mixing of drug2 with an drug3 in vitro can result in substantial inactivation of the drug4 . " } 5 : { 1 : 1 } } 870 : { 1 : "NN nmod NN dobj VBP nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj *inhibit* nsubj tablets compound drug0" } 4 : { 1 : "The following drug interactions have been identified involving drug1 Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system : drug2 tablets inhibit the metabolism of drug3 , resulting in an increased plasma concentration of drug4 and a delay in the elimination of its acid metabolite . " } 5 : { 1 : 1 } } 871 : { 1 : "NN conj NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 872 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 873 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 874 : { 1 : "NN nmod NN nmod VBN xcomp VB advcl VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod discontinuation nmod reduced xcomp *need* advcl adjusted nsubjpass dose compound drug0" } 4 : { 1 : "If the drug1 dose is adjusted upward , the dose will need to be reduced upon discontinuation of drug2 or other inducers . " } 5 : { 1 : 1 } } 875 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 876 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 877 : { 1 : "NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 878 : { 1 : "NN appos NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct NN root , punct TO dep VBN acl NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct drug0 root , punct to dep limited acl inhibitors conj drug0 nmod *drug0*" } 4 : { 1 : "Caution should be used when administering or taking drug1 with drug2 and other strong CYP3A4 inhibitors such as , but not limited to , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( drug13 ) , and drug14 . " } 5 : { 1 : 1 } } 879 : { 1 : "NN nsubjpass VBN advcl VBN dep VBZ nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl seen dep *increases* nmod patients nmod doses nmod drug0" } 4 : { 1 : "In patients given very high doses ( 3900 mg ) of drug1 daily , increases in serum drug2 levels were seen when drug3 , 150 mg b.i.d. , was administered concurrently . " } 5 : { 1 : 1 } } 880 : { 1 : "NN nmod NN nmod VBN nsubjpass NN acl VBN nmod DT nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *prolonged* nsubjpass blockade acl produced nmod any nmod drug0" } 4 : { 1 : "Due to their similar mechanism of action , it is expected that the neuromuscular blockade produced by any of the drug1 could be prolonged in the presence of drug2 . " } 5 : { 1 : 1 } } 881 : { 1 : "NN nmod NNS dobj VBN dep VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drugs dobj bound dep *displace* nsubj drug0" } 4 : { 1 : "In vitro , drug1 may displace less firmly bound drugs like drug2 . " } 5 : { 1 : 1 } } 882 : { 1 : "NN compound NNS conj NN dep VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound salts conj drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; drug3 ; drug4 ; certain drug5 , especially the drug6 and drug7 ; drug8 ; drug9 salts ; drug10 ; and drug11 . " } 5 : { 1 : 1 } } 883 : { 1 : "NN conj NN appos NN conj NN dep VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 appos drug0 conj drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; drug3 ; drug4 ; certain drug5 , especially the drug6 and drug7 ; drug8 ; drug9 salts ; drug10 ; and drug11 . " } 5 : { 1 : 1 } } 884 : { 1 : "NN appos NN conj NN dep VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj drug0 dep *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Drugs which may enhance the neuromuscular blocking action of drug1 include : drug2 ; drug3 ; drug4 ; certain drug5 , especially the drug6 and drug7 ; drug8 ; drug9 salts ; drug10 ; and drug11 . " } 5 : { 1 : 1 } } 885 : { 1 : "NN nmod VBN acl NN nmod NN dobj VB conj VBZ conj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod induced acl block nmod depth dobj increase conj quickens conj *enhance* nsubj administration nmod drug0" } 4 : { 1 : "The prior administration of drug1 does not enhance the duration , but quickens the onset and may increase the depth , of neuromuscular block induced by drug2 . " } 5 : { 1 : 1 } } 886 : { 1 : "NN conj NN dep NN dobj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep interval dobj prolong acl:relcl medications nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval ( e.g. certain drug2 or drug3 ) or lead to electrolyte abnormalities ( such as drug4 or drug5 ) . " } 5 : { 1 : 1 } } 887 : { 1 : "NN dep NN dobj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep interval dobj prolong acl:relcl medications nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval ( e.g. certain drug2 or drug3 ) or lead to electrolyte abnormalities ( such as drug4 or drug5 ) . " } 5 : { 1 : 1 } } 888 : { 1 : "NN nmod NNS nmod VB conj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod abnormalities nmod lead conj prolong acl:relcl medications nmod *coadministered* nsubjpass drug0" } 4 : { 1 : "Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval ( e.g. certain drug2 or drug3 ) or lead to electrolyte abnormalities ( such as drug4 or drug5 ) . " } 5 : { 1 : 1 } } 889 : { 1 : "NN nmod VBN acl NN nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patient nmod regimen nmod *added* nsubjpass drug0" } 4 : { 1 : "However , there has been one report of prolonged prothrombin time when drug1 was added to the regimen of a patient treated with drug2 . " } 5 : { 1 : 1 } } 890 : { 1 : "NN nmod VBN acl NNS nmod VBD conj VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod reduced conj *monitored* nsubjpass concentrations nmod drug0" } 4 : { 1 : "Plasma concentrations of drug1 should therefore be closely monitored , and its dosage reduced accordingly , in patients treated with drug2 . " } 5 : { 1 : 1 } } 891 : { 1 : "NN compound NNS nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod reduction dobj *cause* nsubj drug0" } 4 : { 1 : "Furthermore , drug1 , drug2 , drug3 , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug4 concentrations . " } 5 : { 1 : 1 } } 892 : { 1 : "NN nmod NNS nmod NNS nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod minutes nmod *interactions* nmod administration nmod mg nmod drug0" } 4 : { 1 : "Drug Interactions with drug1 Administration of 120 mg of drug2 ( 2 x 60 mg capsule ) within 15 minutes of an drug3 and drug4 containing drug5 ( drug6 ) decreased drug7 AUC by 41 % and cmax by 43 % . " } 5 : { 1 : 1 } } 893 : { 1 : "NN compound NN dobj VBZ nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound absorption dobj *enhances* nsubj drug0 conj drug0" } 4 : { 1 : "These studies indicate that drug1 or drug2 co-administration enhances drug3 gastrointestinal absorption . " } 5 : { 1 : 1 } } 894 : { 1 : "NN compound NNS nmod NN dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod reduction dobj *cause* nsubj drug0 conj drug0" } 4 : { 1 : "Furthermore , drug1 , drug2 , drug3 , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug4 concentrations . " } 5 : { 1 : 1 } } 895 : { 1 : "NN conj NN nmod NNS nmod NNS nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod minutes nmod *interactions* nmod administration nmod mg nmod drug0" } 4 : { 1 : "Drug Interactions with drug1 Administration of 120 mg of drug2 ( 2 x 60 mg capsule ) within 15 minutes of an drug3 and drug4 containing drug5 ( drug6 ) decreased drug7 AUC by 41 % and cmax by 43 % . " } 5 : { 1 : 1 } } 896 : { 1 : "NN appos NN dobj VBG acl NN nmod NNS nmod NNS nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dobj containing acl drug0 nmod minutes nmod *interactions* nmod administration nmod mg nmod drug0" } 4 : { 1 : "Drug Interactions with drug1 Administration of 120 mg of drug2 ( 2 x 60 mg capsule ) within 15 minutes of an drug3 and drug4 containing drug5 ( drug6 ) decreased drug7 AUC by 41 % and cmax by 43 % . " } 5 : { 1 : 1 } } 897 : { 1 : "NN dobj VBG acl NN nmod NNS nmod NNS nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nmod minutes nmod *interactions* nmod administration nmod mg nmod drug0" } 4 : { 1 : "Drug Interactions with drug1 Administration of 120 mg of drug2 ( 2 x 60 mg capsule ) within 15 minutes of an drug3 and drug4 containing drug5 ( drug6 ) decreased drug7 AUC by 41 % and cmax by 43 % . " } 5 : { 1 : 1 } } 898 : { 1 : "NN compound NNS nmod NN dobj VB nmod:tmod NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod reduction dobj *cause* nmod:tmod drug0" } 4 : { 1 : "Furthermore , drug1 , drug2 , drug3 , and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug4 concentrations . " } 5 : { 1 : 1 } } 899 : { 1 : "NN dep NN nmod NN dobj VBP conj VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod index dobj have conj metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain drug2 ( drug3 [ drug4 ] , such as drug5 , drug6 , and drug7 ) , drug8 and drug9 ( e.g. , drug10 , drug11 ) , should be approached with caution . " } 5 : { 1 : 1 } } 900 : { 1 : "NN compound NN nmod VBN conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound dosage nmod made conj *used* nsubjpass drug0" } 4 : { 1 : "These drug1 should be used in the myasthenic patient only where definitely indicated , and then careful adjustment should be made of adjunctive drug2 dosage . " } 5 : { 1 : 1 } } 901 : { 1 : "NN dobj VBG acl NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nmod *impaired* nsubjpass absorption nmod drug0" } 4 : { 1 : "Absorption of drug1 is impaired by drug2 containing drug3 , drug4 , or drug5 , and drug6 - containing preparations . " } 5 : { 1 : 1 } } 902 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod effect dobj *attenuated* nsubj pretreatment compound drug0" } 4 : { 1 : "drug1 pretreatment attenuated the hypotensive effect of a single dose of drug2 but not drug3 . " } 5 : { 1 : 1 } } 903 : { 1 : "NN dobj VBG acl NNS nmod VBG dobj VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod bleeding dobj affect xcomp *shown* nsubjpass drug0 nmod drug0" } 4 : { 1 : "drug1 : drug2 like other drug3 , has been shown to affect bleeding parameters in patients receiving drug4 , and serious clinical bleeding has been reported . " } 5 : { 1 : 1 } } 904 : { 1 : "NN dobj VBG acl NNS nmod VBG dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod bleeding dobj affect xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 like other drug3 , has been shown to affect bleeding parameters in patients receiving drug4 , and serious clinical bleeding has been reported . " } 5 : { 1 : 1 } } 905 : { 1 : "NN compound NN nmod NN dobj VBG acl NN nsubj JJ conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound effect nmod interference dobj lying acl mechanism nsubj unknown conj *affect* nsubj drug0" } 4 : { 1 : "drug1 did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with drug2 s hypotensive effect is unknown . " } 5 : { 1 : 1 } } 906 : { 1 : "NN nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod interfere xcomp *shown* nsubjpass drug0" } 4 : { 1 : "Other drug1 that inhibit prostaglandin synthesis have been shown to interfere with drug2 in some studies and with drug3 . " } 5 : { 1 : 1 } } 907 : { 1 : "NN nmod VBD nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *resulted* nsubj increase nmod curve nmod drug0" } 4 : { 1 : "drug1 , drug2 : In normal volunteers ( n = 9 ) , pretreatment with drug3 or drug4 did not affect drug5 pharmacokinetics except that a small ( 13 % ) but statistically significant increase in the area under the serum concentration curve of drug6 resulted with drug7 . " } 5 : { 1 : 1 } } 908 : { 1 : "NN conj NNS nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj studies nmod interfere xcomp *shown* nsubjpass drug0" } 4 : { 1 : "Other drug1 that inhibit prostaglandin synthesis have been shown to interfere with drug2 in some studies and with drug3 . " } 5 : { 1 : 1 } } 909 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod clearance dobj increase xcomp *expected* nsubjpass drugs dep drug0" } 4 : { 1 : "Drugs which induce CYP3A4 activity ( eg , drug1 , drug2 , drug3 ) would be expected to increase the clearance of drug4 resulting in lowered plasma concentrations . " } 5 : { 1 : 1 } } 910 : { 1 : "NN dobj VBG acl DT conj NN nmod DT nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl those conj overdosage nmod those nmod *decrease* nsubj drug0" } 4 : { 1 : "drug1 and drug2 - drug3 may decrease hepatic toxicity in those with drug4 overdosage or in those taking drug5 . " } 5 : { 1 : 1 } } 911 : { 1 : "NN compound NN nmod VBP dobj NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *discontinue* dobj drug0" } 4 : { 1 : "Rarely drug1 toxicity may occur in patients who discontinue drug2 after concurrent high-dose drug3 therapy . " } 5 : { 1 : 1 } } 912 : { 1 : "NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 1 } } 913 : { 1 : "NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 1 } } 914 : { 1 : "NN compound NN nmod DT nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound overdosage nmod those nmod *decrease* nsubj drug0" } 4 : { 1 : "drug1 and drug2 - drug3 may decrease hepatic toxicity in those with drug4 overdosage or in those taking drug5 . " } 5 : { 1 : 1 } } 915 : { 1 : "NN nmod NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 1 } } 916 : { 1 : "NN dep NN conj NN nmod NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 1 } } 917 : { 1 : "NN appos NN nmod NN conj NN dobj VBG advcl VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod drug0 conj drug0 dobj taking advcl *tell* advcl taking dobj drug0" } 4 : { 1 : "Before taking drug1 , tell your doctor if you are taking any of the following medicines : - drug2 or another drug3 such as drug4 ( drug5 ) , drug6 ( drug7 , others ) , drug8 ( drug9 ) , drug10 ( drug11 ) , or drug12 ( drug13 ) ; " } 5 : { 1 : 1 } } 918 : { 1 : "NN compound NN dobj VBG acl NNS nmod VBN nsubjpass NNS" 2 : 1 3 : { 1 : "drug0 compound therapy dobj receiving acl patients nmod *contraindicated* nsubjpass drug0" } 4 : { 1 : "In addition , most drug1 are contraindicated in patients receiving drug2 therapy who have pre-existing cardiac abnormalities ( arrhythmia , bradycardia , QT c interval prolongation , ischemic heart disease , congestive heart failure , etc. ) or electrolyte disturbances . " } 5 : { 1 : 1 } } 919 : { 1 : "NN nmod NN nmod NN nmod JJ xcomp VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod interference nmod moderate xcomp *demonstrated* nsubj drug0" } 4 : { 1 : "Other drug1 have demonstrated moderate to marked interference with the metabolism of drug2 , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of drug3 . " } 5 : { 1 : 1 } } 920 : { 1 : "NN nmod NN nmod VBN advcl VBN nsubjpass NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod used advcl *recommended* nsubjpass increase dep drug0" } 4 : { 1 : "A dose increase of drug1 / drug2 to 533/133 mg ( 4 capsules or 6.5 mL ) twice daily taken with food is recommended when used in combination with drug3 . " } 5 : { 1 : 1 } } 921 : { 1 : "NN conj NN nmod NNS dobj VB acl JJ dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod concentrations dobj decrease acl potential dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has the potential to decrease plasma concentrations of drug2 and drug3 . " } 5 : { 1 : 1 } } 922 : { 1 : "NN nmod NN dobj VBP acl:relcl NNS nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod motility dobj alter acl:relcl drugs nmod effects dobj *antagonize* nsubj drug0" } 4 : { 1 : "drug1 may antagonize the effects of the drugs that alter gastrointestinal motility , such as drug2 . " } 5 : { 1 : 1 } } 923 : { 1 : "NN nmod VBN acl NNS nmod VBN acl NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl animals nmod seen acl *properties* nmod drug0" } 4 : { 1 : "We conclude that the prophylactic and antidotal properties of drug1 seen in animals treated with drug2 derive from its capacity to inhibit the NAD + - dependent oxidation responsible for converting drug3 to drug4 in the committed step of the toxic pathway . " } 5 : { 1 : 1 } } 924 : { 1 : "NN nmod NNS dobj VBG acl NNS nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod forms dobj dissolving acl drugs nmod absorption dobj *affect* nsubj drug0" } 4 : { 1 : "drug1 may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of drug2 ; " } 5 : { 1 : 1 } } 925 : { 1 : "NN conj NN nsubjpass VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nsubjpass added advcl *reduced* nsubjpass clearance nmod drug0" } 4 : { 1 : "Total body clearance of drug1 was reduced by an average 22 % and 51 % when drug2 and drug3 , respectively , were added to a regimen consisting of drug4 , USP ( MODIFIED ) and drug5 . " } 5 : { 1 : 1 } } 926 : { 1 : "NN nmod NN nmod VBN conj VBN nsubjpass NNS compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod prolonged conj *increased* nsubjpass levels compound drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 ) blood levels may be increased and prolonged by concurrent administration of drug3 . " } 5 : { 1 : 1 } } 927 : { 1 : "NN nmod NN nmod VBN conj VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod prolonged conj *increased* nsubjpass levels compound drug0" } 4 : { 1 : "drug1 ( drug2 ) blood levels may be increased and prolonged by concurrent administration of drug3 . " } 5 : { 1 : 1 } } 928 : { 1 : "NN conj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj *reported* nmod administration nmod drug0" } 4 : { 1 : "drug1 Reversible increases in serum drug2 concentrations and toxicity have been reported during concomitant administration of drug3 with drug4 , and with some drug5 . " } 5 : { 1 : 1 } } 929 : { 1 : "NN nmod NNS dobj VB acl JJ dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj decrease acl potential dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has the potential to decrease plasma concentrations of drug2 and drug3 . " } 5 : { 1 : 1 } } 930 : { 1 : "NN nmod VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *interact* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 may interact with drug3 In studies with male rats , drug4 was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day . " } 5 : { 1 : 1 } } 931 : { 1 : "NN appos NN conj NNS dobj VBG acl NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj preparations dobj containing acl drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 932 : { 1 : "NN nmod NN nmod NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod absorption nmod delay nmod *taking* dobj drug0" } 4 : { 1 : "However , the peak plasma level of drug1 was reduced by approximately 20 % when taking drug2 due to a slight delay in the absorption of drug3 . " } 5 : { 1 : 1 } } 933 : { 1 : "NN nmod NN dobj VB nsubj NN dep FW appos NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *reduce* nsubj drug0 dep g. appos drug0" } 4 : { 1 : "drug1 ( e. g. , drug2 ) and drug3 containing carbohydrate-splitting enzymes ( e. g. , drug4 , drug5 ) may reduce the effect of drug6 and should not be taken concomitantly . " } 5 : { 1 : 1 } } 934 : { 1 : "NN compound NN conj NNS dobj VBG acl NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound use conj preparations dobj containing acl drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 935 : { 1 : "NN appos NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 936 : { 1 : "NN appos NN conj NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 937 : { 1 : "NN conj NN dep NN conj NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 938 : { 1 : "NN conj NNS dep NNS dobj VBG acl NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj sunscreens dep preparations dobj containing acl drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 ( e.g. , drug3 ) , drug4 ( e.g. , drug5 ) , local drug6 ( e.g. , drug7 and drug8 ) , drug9 ( drug10 ) - containing preparations ( e.g. , sunscreens and some drug11 ) , drug12 ( e.g. , drug13 ) , drug14 ( sulfa medicines ) , drug15 ( use of these medicines during the test period will affect the test results ) , and pancreatic supplements ( use of pancreatic supplements may give false test results ) . " } 5 : { 1 : 1 } } 939 : { 1 : "NN compound NN conj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound clearance conj *decreased* nsubj administration nmod drug0" } 4 : { 1 : "however , in a study of 12 normal subjects , concurrent administration of drug1 decreased drug2 protein binding and increased drug3 plasma clearance from 0.07 L/kg/h without drug4 to 0.11 L/kg/h with drug5 . " } 5 : { 1 : 1 } } 940 : { 1 : "NN nmod VBN nsubj NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *administered* nsubj drug0 acl containing dobj drug0" } 4 : { 1 : "drug1 - and drug2 - containing drug3 , administered concomitantly with drug4 , significantly decreased the bioavailability ( 48 % ) of drug5 . " } 5 : { 1 : 1 } } 941 : { 1 : "NN dep NNS nmod VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 dep hours nmod *administered* nsubj drug0" } 4 : { 1 : "drug1 administered 2 hours before drug2 resulted in a slower absorption ( mean C max decreased by 30 % and mean T max increased by 1 hour ) and a lesser extent of absorption ( mean AUC decreased by approximately 25 % ) . " } 5 : { 1 : 1 } } 942 : { 1 : "NN nmod NN dobj VB acl JJ dobj VBZ nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj enhance acl potential dobj *has* nsubj antagonism appos drug0" } 4 : { 1 : "1 - adrenergic receptor antagonism , drug1 has the potential to enhance the effect of certain drug2 . " } 5 : { 1 : 1 } } 943 : { 1 : "NN compound NN nmod VBN advcl VB nmod NN nmod NN acl VBN nmod NN conj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod administered advcl *increase* nmod addition nmod bleeding acl associated nmod drug0 conj drugs nmod drug0" } 4 : { 1 : "In addition to bleeding associated with drug1 and drug2 , drugs that alter platelet function ( such as drug3 , drug4 and drug5 ) may increase the risk of bleeding if administered prior to , during , or after drug6 therapy . " } 5 : { 1 : 1 } } 944 : { 1 : "NN compound NN nmod VBN advcl VB nmod NN nmod NN acl VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod administered advcl *increase* nmod addition nmod bleeding acl associated nmod drug0 conj drug0" } 4 : { 1 : "In addition to bleeding associated with drug1 and drug2 , drugs that alter platelet function ( such as drug3 , drug4 and drug5 ) may increase the risk of bleeding if administered prior to , during , or after drug6 therapy . " } 5 : { 1 : 1 } } 945 : { 1 : "NN compound NN nmod NN dobj VB nsubj NNS dep FW appos NN" 2 : 1 3 : { 1 : "drug0 compound clearance nmod increase dobj *cause* nsubj agents dep eg appos drug0" } 4 : { 1 : "Agents that induce CYP3A4 ( eg , drug1 ) could cause an increase in drug2 clearance and lower blood levels . " } 5 : { 1 : 1 } } 946 : { 1 : "NN compound NN dobj VB nsubj NNS nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound elimination dobj *inhibit* nsubj inhibitors nmod cyp0a0 conj cyp0d0 dep drug0" } 4 : { 1 : "Inhibitors of CYP3A4 ( eg , drug1 ) or CYP2D6 ( eg , drug2 , drug3 , or drug4 ) can inhibit drug5 elimination and cause increased blood levels . " } 5 : { 1 : 1 } } 947 : { 1 : "NN compound NN dobj VB nsubj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound elimination dobj *inhibit* nsubj inhibitors nmod cyp0a0 appos drug0" } 4 : { 1 : "Inhibitors of CYP3A4 ( eg , drug1 ) or CYP2D6 ( eg , drug2 , drug3 , or drug4 ) can inhibit drug5 elimination and cause increased blood levels . " } 5 : { 1 : 1 } } 948 : { 1 : "NN compound NN nmod NN nmod VBN dep VBD nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound administration nmod dose nmod induced dep *provided* nsubj pretreatment nmod drug0 conj drug0" } 4 : { 1 : "Pretreatment of rats with drug1 ( 100 mg/kg , ip ) or drug2 ( 100 mg/kg per day , ig , for 3 days and a dose of 40 mg/kg on the 4th day ) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues , induced by single high dose of oral drug3 administration within 4 h. " } 5 : { 1 : 1 } } 949 : { 1 : "NN compound NN nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound dose nsubjpass *reduced* advcl withdrawn nsubjpass drug0" } 4 : { 1 : "When drug1 is withdrawn from the combination therapy , drug2 dose should then be reduced . " } 5 : { 1 : 1 } } 950 : { 1 : "NN compound NN nmod VBN advcl VB nmod NN nmod NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod administered advcl *increase* nmod addition nmod bleeding acl associated nmod drug0" } 4 : { 1 : "In addition to bleeding associated with drug1 and drug2 , drugs that alter platelet function ( such as drug3 , drug4 and drug5 ) may increase the risk of bleeding if administered prior to , during , or after drug6 therapy . " } 5 : { 1 : 1 } } 951 : { 1 : "NN nsubjpass VBN advcl VB ccomp VB nsubj NN dep NN" 2 : 1 3 : { 1 : "drug0 nsubjpass withdrawn advcl rebound ccomp *exacerbate* nsubj drug0 dep drug0" } 4 : { 1 : "drug1 ( drug2 , porpranolol , drug3 ) may exacerbate rebound hypertension when drug4 is withdrawn . " } 5 : { 1 : 1 } } 952 : { 1 : "NN compound NN conj NNS nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound dosage conj patients nmod *initiating* dobj drug0" } 4 : { 1 : "However , appropriate monitoring of blood glucose should be performed when initiating drug1 in diabetic patients and drug2 dosage should be adjusted if needed . " } 5 : { 1 : 1 } } 953 : { 1 : "NN nsubj JJ xcomp VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj effective xcomp *render* nsubj use nmod drug0" } 4 : { 1 : "Concurrent use of drug1 may render oral drug2 less effective . " } 5 : { 1 : 1 } } 954 : { 1 : "NN nsubjpass VBN advcl VB ccomp VB nsubj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nsubjpass withdrawn advcl rebound ccomp *exacerbate* nsubj drug0 dep drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , porpranolol , drug3 ) may exacerbate rebound hypertension when drug4 is withdrawn . " } 5 : { 1 : 1 } } 955 : { 1 : "NN dep NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod *combining* dobj drug0" } 4 : { 1 : "Exert particular caution in combining drug1 with other drug2 ( drug3 and drug4 ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . " } 5 : { 1 : 1 } } 956 : { 1 : "NN compound NN nmod IN advmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound administration nmod before advmod hours nmod *administered* nsubjpass drug0" } 4 : { 1 : "Until data on possible interactions between drug1 and drug2 are obtained , drug3 should not be administered within 48 hours before or 24 hours after drug4 administration . " } 5 : { 1 : 1 } } 957 : { 1 : "NN conj NN dep NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep drug0 nmod *combining* dobj drug0" } 4 : { 1 : "Exert particular caution in combining drug1 with other drug2 ( drug3 and drug4 ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . " } 5 : { 1 : 1 } } 958 : { 1 : "NN nsubjpass VBN advcl VB ccomp VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass withdrawn advcl rebound ccomp *exacerbate* nsubj drug0" } 4 : { 1 : "drug1 ( drug2 , porpranolol , drug3 ) may exacerbate rebound hypertension when drug4 is withdrawn . " } 5 : { 1 : 1 } } 959 : { 1 : "NN nmod VBN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *administered* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 - and drug2 - containing drug3 , administered concomitantly with drug4 , significantly decreased the bioavailability ( 48 % ) of drug5 . " } 5 : { 1 : 1 } } 960 : { 1 : "NN dobj VBG advcl VB dobj NN" 2 : 1 3 : { 1 : "drug0 dobj taking advcl *avoid* dobj drug0" } 4 : { 1 : "As with most psychoactive medications , patients should be advised to avoid drug1 while taking drug2 " } 5 : { 1 : 1 } } 961 : { 1 : "NN compound NN nmod NN nmod VBN dep VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound administration nmod dose nmod induced dep *provided* nsubj pretreatment nmod drug0" } 4 : { 1 : "Pretreatment of rats with drug1 ( 100 mg/kg , ip ) or drug2 ( 100 mg/kg per day , ig , for 3 days and a dose of 40 mg/kg on the 4th day ) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues , induced by single high dose of oral drug3 administration within 4 h. " } 5 : { 1 : 1 } } 962 : { 1 : "NN nmod NN nmod VBN advcl VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod used advcl *proves* nsubj drug0" } 4 : { 1 : "drug1 sometimes proves to be fatal when used in combination with drug2 . " } 5 : { 1 : 1 } } 963 : { 1 : "NN conj NN nmod NN appos NN nmod NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 appos drug0 nmod drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 964 : { 1 : "NN appos NN nmod NN appos NN nmod NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod drug0 appos drug0 nmod drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 965 : { 1 : "NN nmod VB nsubj NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *form* nsubj drug0 acl containing dobj drug0" } 4 : { 1 : "drug1 and drug2 : drug3 and drug4 containing drug5 or drug6 , as well as formulations containing divalent and trivalent cations such as drug7 ( drug8 ) , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug9 and interfere with its bioavailability . " } 5 : { 1 : 1 } } 966 : { 1 : "NN nmod VB nsubj NN conj NNS acl VBG dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *form* nsubj drug0 conj formulations acl containing dobj cations nmod drug0" } 4 : { 1 : "drug1 and drug2 : drug3 and drug4 containing drug5 or drug6 , as well as formulations containing divalent and trivalent cations such as drug7 ( drug8 ) , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug9 and interfere with its bioavailability . " } 5 : { 1 : 1 } } 967 : { 1 : "NN nmod VB nsubj NN acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *form* nsubj drug0 acl containing dobj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 : drug3 and drug4 containing drug5 or drug6 , as well as formulations containing divalent and trivalent cations such as drug7 ( drug8 ) , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug9 and interfere with its bioavailability . " } 5 : { 1 : 1 } } 968 : { 1 : "NN nmod VB nsubj NN conj NNS acl VBG dobj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *form* nsubj drug0 conj formulations acl containing dobj cations nmod drug0 appos drug0" } 4 : { 1 : "drug1 and drug2 : drug3 and drug4 containing drug5 or drug6 , as well as formulations containing divalent and trivalent cations such as drug7 ( drug8 ) , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug9 and interfere with its bioavailability . " } 5 : { 1 : 1 } } 969 : { 1 : "NN nmod NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod activity nmod *use* nmod injection compound drug0" } 4 : { 1 : "The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity , such as drug3 , drug4 , or drug5 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects . " } 5 : { 1 : 1 } } 970 : { 1 : "NN nmod NN appos NN nmod NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 appos drug0 nmod drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 971 : { 1 : "NN nmod NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 972 : { 1 : "NN dep NN nmod NN dobj VBZ advcl VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep inhibitor nmod therapy dobj initiates advcl monitored conj *required* nsubjpass adjustment nmod drug0" } 4 : { 1 : "Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor ( e.g. , drug2 , drug3 , drug4 ; " } 5 : { 1 : 1 } } 973 : { 1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drugs nmod combination nmod *avoided* nsubjpass use nmod drug0" } 4 : { 1 : "Because of drug1 s tendency to cause renal impairment , the use of drug2 should be avoided in combination with potentially nephrotoxic drugs such as drug3 , drug4 and intravenous drug5 unless the potential benefits outweigh the risks to the patient . " } 5 : { 1 : 1 } } 974 : { 1 : "NN appos NN nmod NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 975 : { 1 : "NN conj NN dep NN nmod NN dobj VBZ advcl VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep inhibitor nmod therapy dobj initiates advcl monitored conj *required* nsubjpass adjustment nmod drug0" } 4 : { 1 : "Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor ( e.g. , drug2 , drug3 , drug4 ; " } 5 : { 1 : 1 } } 976 : { 1 : "NN conj NN nmod VBN dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *prevented* dep drug0" } 4 : { 1 : "drug1 - induced oxidative stress in rat brain and liver is prevented by drug2 or drug3 . " } 5 : { 1 : 1 } } 977 : { 1 : "NN appos NN dep NN nmod NN dobj VBZ advcl VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep inhibitor nmod therapy dobj initiates advcl monitored conj *required* nsubjpass adjustment nmod drug0" } 4 : { 1 : "Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor ( e.g. , drug2 , drug3 , drug4 ; " } 5 : { 1 : 1 } } 978 : { 1 : "NN nmod NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod involvement dobj *reveal* nsubj studies nmod drug0" } 4 : { 1 : "Toxicology studies of drug1 - related deaths reveal frequent involvement of other drug2 , including drug3 , drug4 such as drug5 ( drug6 ) , and , to a rising degree , drug7 . " } 5 : { 1 : 1 } } 979 : { 1 : "NN nsubjpass VBN advcl VBN dep NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl reported dep *drug0*" } 4 : { 1 : "drug1 and drug2 : Increased prothrombin time , with or without clinical bleeding , has been reported when drug3 is administered concomitantly . " } 5 : { 1 : 1 } } 980 : { 1 : "NN compound NNS conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound salts conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod agents nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug2 ( e. g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 ) , drug11 salts , drug12 , local drug13 , drug14 , and drug15 . " } 5 : { 1 : 1 } } 981 : { 1 : "NN dep NN nmod NNS nmod NNS acl VBN xcomp VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep inhibition nmod *examples* nmod drugs acl known xcomp inhibit dobj metabolism nmod drug0" } 4 : { 1 : "The following are examples of drugs known to inhibit the metabolism of other related drug1 , presumably through inhibition of CYP3A : drug2 , drug3 , drug4 , drug5 , drug6 , and some drug7 . " } 5 : { 1 : 1 } } 982 : { 1 : "NN nsubjpass VBN advcl VBN nsubjpass NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass added advcl *reported* nsubjpass increases nmod levels nmod drug0" } 4 : { 1 : "Increases in plasma levels of drug1 , and in the frequency and severity of side effects , particularly drug2 , have been reported when drug3 was added to the drug4 regimen . " } 5 : { 1 : 1 } } 983 : { 1 : "NN dobj VBG advcl VBN acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj administering advcl recommended acl:relcl *reduction* nmod drug0" } 4 : { 1 : "Dose reduction of drug1 to 600 mg every 8 hours is recommended when administering drug2 concurrently . " } 5 : { 1 : 1 } } 984 : { 1 : "NN nmod NN nmod NN nmod NN dobj VB conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod drug0 nmod drug0 dobj consider conj *dose* nmod drug0" } 4 : { 1 : "Use lowest possible dose of drug1 with careful monitoring , or consider drug2 that are not primarily metabolized by CYP3A4 , such as drug3 , drug4 , or drug5 in combination with drug6 . " } 5 : { 1 : 1 } } 985 : { 1 : "NN nmod VBN acl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 and drug2 : drug3 should be administered with extreme caution in patients being treated with drug4 or drug5 because the action of drug6 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 986 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NNS conj NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *increase* nsubj drug0 nmod derivatives conj drug0" } 4 : { 1 : "drug1 including coumarin derivatives , indandione derivatives , and drug2 such as drug3 ( drug4 ) , and drug5 may increase the risk of bleeding when administered concomitantly with drug6 . " } 5 : { 1 : 1 } } 987 : { 1 : "NN conj NN nmod VBN acl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod treated acl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 and drug2 : drug3 should be administered with extreme caution in patients being treated with drug4 or drug5 because the action of drug6 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 988 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *increase* nsubj drug0 nmod derivatives conj drug0 nmod drug0" } 4 : { 1 : "drug1 including coumarin derivatives , indandione derivatives , and drug2 such as drug3 ( drug4 ) , and drug5 may increase the risk of bleeding when administered concomitantly with drug6 . " } 5 : { 1 : 1 } } 989 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NNS conj NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *increase* nsubj drug0 nmod derivatives conj drug0 nmod drug0 appos drug0" } 4 : { 1 : "drug1 including coumarin derivatives , indandione derivatives , and drug2 such as drug3 ( drug4 ) , and drug5 may increase the risk of bleeding when administered concomitantly with drug6 . " } 5 : { 1 : 1 } } 990 : { 1 : "NN compound NNS advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations advcl *effective* nsubj drug0" } 4 : { 1 : "drug1 may not be effective due to decreased drug2 concentrations in patients taking these agents concomitantly . " } 5 : { 1 : 1 } } 991 : { 1 : "NN nmod VBN nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod *taken* nsubj supplements compound drug0" } 4 : { 1 : "drug1 - Theoretically , drug2 supplements taken concomitantly with drug3 , may potentiate the effects of the drug . " } 5 : { 1 : 1 } } 992 : { 1 : "NN conj NN parataxis VBN xcomp VBN nmod NN nmod NNS acl:relcl VBN xcomp VB dobj NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 parataxis needed xcomp *needed* nmod coadministration nmod drugs acl:relcl reported xcomp decrease dobj elimination conj doses compound drug0" } 4 : { 1 : "Based on adult data , lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug2 elimination ( e.g. , drug3 and drug4 ) and higher drug5 doses may be needed following coadministration of drugs that increase drug6 elimination ( e.g. , drug7 and drug8 ) . " } 5 : { 1 : 1 } } 993 : { 1 : "NN parataxis VBN xcomp VBN nmod NN nmod NNS acl:relcl VBN xcomp VB dobj NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 parataxis needed xcomp *needed* nmod coadministration nmod drugs acl:relcl reported xcomp decrease dobj elimination conj doses compound drug0" } 4 : { 1 : "Based on adult data , lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug2 elimination ( e.g. , drug3 and drug4 ) and higher drug5 doses may be needed following coadministration of drugs that increase drug6 elimination ( e.g. , drug7 and drug8 ) . " } 5 : { 1 : 1 } } 994 : { 1 : "NN compound NN dobj VBG advcl VBN acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg dobj taking advcl considered acl:relcl *reduction* nmod drug0" } 4 : { 1 : "Dose reduction of drug1 to 600 mg every 8 hours should be considered when taking drug2 400 mg three times a day . " } 5 : { 1 : 1 } } 995 : { 1 : "NN dobj VBG acl NN dep JJ advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl product dep *important* advcl using dobj drug0" } 4 : { 1 : "When you are using drug1 , it is especially important that your health care professional know if you are using the following : Eye product containing drug2 . " } 5 : { 1 : 1 } } 996 : { 1 : "NN ccomp JJ parataxis NN nsubj NNS acl VB dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 ccomp reasonable parataxis *following* nsubj agents acl decrease dobj levels nmod drug0" } 4 : { 1 : "Agents that are CYP inducers that have been found , or are expected , to decrease plasma levels of drug1 are the following : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 ( 2 ) , drug8 , drug9 , and drug10 Thus , if a patient has been titrated to a stable dosage on drug11 , and then begins a course of treatment with one of these CYP3A4 inducers , it is reasonable to expect that a dose increase for drug12 may be necessary . " } 5 : { 1 : 1 } } 997 : { 1 : "NN dep NN nsubj NNS acl VB dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep *following* nsubj agents acl increase dobj levels nmod drug0" } 4 : { 1 : "Agents that are CYP3A4 inhibitors that have been found , or are expected , to increase plasma levels of drug1 are the following : drug2 , drug3 , drug4 , drug5 ( 1 ) , drug6 , drug7 , drug8 , drug9 , drug10 ( 1 ) , drug11 , drug12 , grapefruit juice , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 , drug23 , drug24 , drug25 ( 1 ) , drug26 , drug27 . " } 5 : { 1 : 1 } } 998 : { 1 : "NN dep NN nsubj NNS acl:relcl VBN conj VBN xcomp VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep *following* nsubj agents acl:relcl found conj expected xcomp decreased nmod presence nmod drug0" } 4 : { 1 : "Agents that have been found , or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 , drug23 , drug24 , drug25 , drug26 , drug27 , drug28 , drug29 , drug30 , oral drug31 ( 3 ) , drug32 , drug33 ( 4 ) , drug34 , drug35 , drug36 , drug37 , drug38 , drug39 , drug40 , drug41 , drug42 , drug43 , drug44 ( 5 ) , drug45 , and drug46 . " } 5 : { 1 : 1 } } 999 : { 1 : "NN conj NN dep NN dobj VB xcomp VBN acl:relcl NNS nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep elimination dobj decrease xcomp reported acl:relcl drugs nmod coadministration nmod *needed* nsubjpass doses nmod drug0" } 4 : { 1 : "Based on adult data , lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug2 elimination ( e.g. , drug3 and drug4 ) and higher drug5 doses may be needed following coadministration of drugs that increase drug6 elimination ( e.g. , drug7 and drug8 ) . " } 5 : { 1 : 1 } } 1000 : { 1 : "NN nmod VBN advcl VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *increase* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 including coumarin derivatives , indandione derivatives , and drug2 such as drug3 ( drug4 ) , and drug5 may increase the risk of bleeding when administered concomitantly with drug6 . " } 5 : { 1 : 1 } } 1001 : { 1 : "NN nmod NNS nmod JJR xcomp VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod greater xcomp *tended* nsubj effect nmod drug0" } 4 : { 1 : "The blood pressure effect of drug1 tended to be greater in patients on drug2 than in patients on no other drug3 therapy . " } 5 : { 1 : 1 } } 1002 : { 1 : "NN nsubj VBZ appos NN" 2 : 1 3 : { 1 : "drug0 nsubj enhances appos *drug0*" } 4 : { 1 : "drug1 : drug2 enhances the effect of drug3 . " } 5 : { 1 : 1 } } 1003 : { 1 : "NN nmod NNS nmod VB dep VBN nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod result dep *eliminated* nsubj use nmod drug0" } 4 : { 1 : "Concurrent use with drug1 or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of drug2 . " } 5 : { 1 : 1 } } 1004 : { 1 : "NN nsubjpass VBN acl:relcl NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nsubjpass employed acl:relcl condition nmod *used* nsubjpass drug0" } 4 : { 1 : "Therefore , drug1 should not be used in any condition in which a drug2 is being employed . " } 5 : { 1 : 1 } } 1005 : { 1 : "NN dobj VBG acl NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patient nmod *given* nsubjpass drug0" } 4 : { 1 : "Therefore , when drug1 is given to a patient receiving drug2 , the dosage of drug3 should be reduced to prevent excessive prolongation of the prothrombin time . " } 5 : { 1 : 1 } } 1006 : { 1 : "NN nmod VBG dobj NNS amod JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects amod nephrotoxic dep drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1007 : { 1 : "NN compound NNS dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj *lower* nsubj administration nmod drug0" } 4 : { 1 : "drug1 : Concurrent administration of drug2 may lower drug3 plasma levels , possibly by competing for protein-binding sites . " } 5 : { 1 : 1 } } 1008 : { 1 : "NN nmod VBG dobj NNS amod JJ dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects amod nephrotoxic dep drug0 appos drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1009 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod *observed* nsubjpass increase nmod auc nmod drug0" } 4 : { 1 : "A 30 to 45 % increase in AUC and Cmax of drug1 was observed with concomitant administration of drug2 twice daily . " } 5 : { 1 : 1 } } 1010 : { 1 : "NN dep NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass drug0" } 4 : { 1 : "drug1 should be administered with caution to patients receiving drug2 ( drug3 , Wyeth-Ayerst Laboratories ) . " } 5 : { 1 : 1 } } 1011 : { 1 : "NN nmod VBN acl NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod caused acl loss dobj *attenuate* nsubj drug0" } 4 : { 1 : "Agents Increasing Serum Potassium : drug1 and drug2 IV attenuate potassium loss caused by drug3 . " } 5 : { 1 : 1 } } 1012 : { 1 : "NN compound NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound *concentrations* compound drug0" } 4 : { 1 : "The immediate release , but not the coat-core formulation of drug1 increased plasma drug2 concentrations by about 20 % . " } 5 : { 1 : 1 } } 1013 : { 1 : "NN nmod NN amod DT dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod bioavailability amod the dobj *decreased* nsubj drug0" } 4 : { 1 : "drug1 at 648 mg bid decreased the bioavailability ( AUC ) of drug2 by 26 % , but not the peak concentration . " } 5 : { 1 : 1 } } 1014 : { 1 : "NN nmod VBN acl NN dobj VBP nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod caused acl loss dobj *attenuate* nsubj drug0 conj drug0" } 4 : { 1 : "Agents Increasing Serum Potassium : drug1 and drug2 IV attenuate potassium loss caused by drug3 . " } 5 : { 1 : 1 } } 1015 : { 1 : "NN conj NN nmod NN nmod VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod initiation nmod *experience* nsubj patients nmod drug0" } 4 : { 1 : "Hypotension : Patients on Diuretic Therapy : Patients on drug1 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2 or drug3 . " } 5 : { 1 : 1 } } 1016 : { 1 : "NN dep VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep *augmented* nsubjpass effect nmod drug0" } 4 : { 1 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . " } 5 : { 1 : 1 } } 1017 : { 1 : "NN dobj VBG advcl VBN nsubjpass NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj discontinuing advcl *minimized* nsubjpass possibility nmod effects nmod drug0 conj drug0" } 4 : { 1 : "The possibility of hypotensive effects with drug1 or drug2 can be minimized by either discontinuing the drug3 or increasing the salt intake prior to initiation of treatment with drug4 or drug5 . " } 5 : { 1 : 1 } } 1018 : { 1 : "NN dep VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dep *augmented* nsubjpass effect nmod drug0 conj drug0" } 4 : { 1 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . " } 5 : { 1 : 1 } } 1019 : { 1 : "NN nmod VBG dobj NNS amod JJ conj JJ dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects amod nephrotoxic conj myelotoxic dep chemotherapy compound drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1020 : { 1 : "NN dep NN dobj VB xcomp VBN acl:relcl NNS nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep elimination dobj decrease xcomp reported acl:relcl drugs nmod coadministration nmod *needed* nsubjpass doses nmod drug0" } 4 : { 1 : "Based on adult data , lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug2 elimination ( e.g. , drug3 and drug4 ) and higher drug5 doses may be needed following coadministration of drugs that increase drug6 elimination ( e.g. , drug7 and drug8 ) . " } 5 : { 1 : 1 } } 1021 : { 1 : "NN conj NN nmod NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod *taking* dobj drug0" } 4 : { 1 : "drug1 Altered coagulation parameters and/or bleeding have been reported in patients taking drug2 concomitantly with drug3 such as drug4 and drug5 . " } 5 : { 1 : 1 } } 1022 : { 1 : "NN nmod NNS dobj VBG acl NNS conj NN dobj VBG acl NN conj NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod cations dobj containing acl formulations conj drug0 dobj containing acl drug0 conj drug0 nmod cations nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 1 } } 1023 : { 1 : "NN conj NN dobj VBG acl NN conj NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj containing acl drug0 conj drug0 nmod cations nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 1 } } 1024 : { 1 : "NN dobj VBG acl NN conj NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 conj drug0 nmod cations nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 1 } } 1025 : { 1 : "NN appos NN nmod NNS dobj VBG acl NNS conj NN dobj VBG acl NN conj NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod cations dobj containing acl formulations conj drug0 dobj containing acl drug0 conj drug0 nmod cations nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 1 } } 1026 : { 1 : "NN nmod NN nmod NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod *inhibitor* nsubj drug0" } 4 : { 1 : "drug1 : drug2 is a competitive inhibitor of the metabolism of drug3 . " } 5 : { 1 : 1 } } 1027 : { 1 : "NN conj NN nmod NN dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod metabolism dobj *inhibit* nsubj drug0 nmod drug0" } 4 : { 1 : "drug1 drug2 drug3 , like other drug4 , may inhibit the metabolism of drug5 and drug6 . " } 5 : { 1 : 1 } } 1028 : { 1 : "NN nmod VBD acl NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod maintained acl patient nmod *initiated* nsubjpass drug0" } 4 : { 1 : "Serum drug1 concentrations increase when drug2 is initiated in a patient maintained on drug3 . " } 5 : { 1 : 1 } } 1029 : { 1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod use nmod period nmod *halved* nsubjpass dose compound drug0" } 4 : { 1 : "When initiating a multi-day course of drug1 in a patient maintained on drug2 , the drug3 maintenance dose should be halved for the period of concurrent use of drug4 and monitoring of serum drug5 concentrations should be initiated as a guide to further dosage adjustments . " } 5 : { 1 : 1 } } 1030 : { 1 : "NN dobj VBG acl NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with drug2 containing drug3 , drug4 , or drug5 , with drug6 , with metal cations such as drug7 , or with drug8 containing drug9 or drug10 , or with formulations containing divalent and trivalent cations such as drug11 ( drug12 ) chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of drug13 , resulting in systemic concentrations considerably lower than desired . " } 5 : { 1 : 1 } } 1031 : { 1 : "NN dep NN conj NNS nmod VBN advcl VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep decrease conj inhibitors nmod given advcl *increase* nsubj concentration nmod drug0" } 4 : { 1 : "The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e.g. , drug2 , drug3 ) and decrease by concomitant administration of hepatic enzyme inducers ( e.g. , drug4 , drug5 ) , and adjustment of the dosage of drug6 may therefore be necessary . " } 5 : { 1 : 1 } } 1032 : { 1 : "NN nsubj VB ccomp VBN advcl VB dobj NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nsubj potentiate ccomp reported advcl *avoid* dobj use nmod preparations nmod drug0 conj drug0" } 4 : { 1 : "Avoid the use of preparations such as drug1 and local drug2 which contain any drug3 ( e.g. , drug4 , drug5 ) , since it has been reported that drug6 can potentiate the effects of catecholamines . " } 5 : { 1 : 1 } } 1033 : { 1 : "NN nsubj VB ccomp VBN advcl VB dobj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj potentiate ccomp reported advcl *avoid* dobj use nmod preparations nmod drug0" } 4 : { 1 : "Avoid the use of preparations such as drug1 and local drug2 which contain any drug3 ( e.g. , drug4 , drug5 ) , since it has been reported that drug6 can potentiate the effects of catecholamines . " } 5 : { 1 : 1 } } 1034 : { 1 : "NN appos NN dep NN conj NNS nmod VBN advcl VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep decrease conj inhibitors nmod given advcl *increase* nsubj concentration nmod drug0" } 4 : { 1 : "The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e.g. , drug2 , drug3 ) and decrease by concomitant administration of hepatic enzyme inducers ( e.g. , drug4 , drug5 ) , and adjustment of the dosage of drug6 may therefore be necessary . " } 5 : { 1 : 1 } } 1035 : { 1 : "NN nsubj VB ccomp VBN advcl VB dobj NN nmod NNS acl:relcl VBP dobj NN" 2 : 1 3 : { 1 : "drug0 nsubj potentiate ccomp reported advcl *avoid* dobj use nmod preparations acl:relcl contain dobj drug0" } 4 : { 1 : "Avoid the use of preparations such as drug1 and local drug2 which contain any drug3 ( e.g. , drug4 , drug5 ) , since it has been reported that drug6 can potentiate the effects of catecholamines . " } 5 : { 1 : 1 } } 1036 : { 1 : "NN nsubj VB ccomp VBN advcl VB dobj NN nmod NNS acl:relcl VBP dobj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nsubj potentiate ccomp reported advcl *avoid* dobj use nmod preparations acl:relcl contain dobj drug0 dep drug0 appos drug0" } 4 : { 1 : "Avoid the use of preparations such as drug1 and local drug2 which contain any drug3 ( e.g. , drug4 , drug5 ) , since it has been reported that drug6 can potentiate the effects of catecholamines . " } 5 : { 1 : 1 } } 1037 : { 1 : "NN nsubj VB ccomp VBN advcl VB dobj NN nmod NNS acl:relcl VBP dobj NN dep NN" 2 : 1 3 : { 1 : "drug0 nsubj potentiate ccomp reported advcl *avoid* dobj use nmod preparations acl:relcl contain dobj drug0 dep drug0" } 4 : { 1 : "Avoid the use of preparations such as drug1 and local drug2 which contain any drug3 ( e.g. , drug4 , drug5 ) , since it has been reported that drug6 can potentiate the effects of catecholamines . " } 5 : { 1 : 1 } } 1038 : { 1 : "NN appos NN dep NNS nmod VBN advcl VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep inhibitors nmod given advcl *increase* nsubj concentration nmod drug0" } 4 : { 1 : "The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors ( e.g. , drug2 , drug3 ) and decrease by concomitant administration of hepatic enzyme inducers ( e.g. , drug4 , drug5 ) , and adjustment of the dosage of drug6 may therefore be necessary . " } 5 : { 1 : 1 } } 1039 : { 1 : "NN nmod VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod enhanced conj *increased* nsubjpass concentration nmod drug0" } 4 : { 1 : "drug1 : The concentration of drug2 is increased and its toxicity may be enhanced by drug3 . " } 5 : { 1 : 1 } } 1040 : { 1 : "NN compound NNS conj NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound supplements conj remedies nmod administration nmod *affected* nsubjpass absorption nmod drug0" } 4 : { 1 : "The absorption of drug1 may be affected by the simultaneous administration of indigestion remedies , drug2 or drug3 supplements . " } 5 : { 1 : 1 } } 1041 : { 1 : "NN compound NNS nsubj JJ advcl VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nsubj *likely* advcl required nsubjpass therapy compound drug0" } 4 : { 1 : "If drug1 therapy is required , drug2 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drug3 . " } 5 : { 1 : 1 } } 1042 : { 1 : "NN appos NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj *drug0* conj drug0 appos drug0" } 4 : { 1 : "The concurrent use of two or more drugs with anticholinergic activity -- such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . " } 5 : { 1 : 1 } } 1043 : { 1 : "NN compound NNS dobj VBZ dobj VBN acl NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj increases dobj given acl *drug0*" } 4 : { 1 : "drug1 given concurrently increases drug2 anion plasma levels and extends its plasma half-life significantly . " } 5 : { 1 : 1 } } 1044 : { 1 : "NN conj NN nmod NN dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effect dobj *reduce* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and other drug2 can reduce the antihypertensive effect of drug3 and other drug4 . " } 5 : { 1 : 1 } } 1045 : { 1 : "NN nmod NN nmod VBD nmod NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod *stabilized* nmod administration nmod doses nmod drug0" } 4 : { 1 : "During administration of multiple oral doses of drug1 to healthy subjects stabilized on a maintenance dose of drug2 , a 13 % -19 % increase in plasma drug3 levels occurred at six hours postdose . " } 5 : { 1 : 1 } } 1046 : { 1 : "NN compound NNS nsubj VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound levels nsubj *increased* nmod subjects acl receiving dobj drug0" } 4 : { 1 : "In healthy subjects receiving drug1 ( 1 gm daily ) for one week , plasma drug2 levels increased by about 30 % and half-life increased by about 10 % . " } 5 : { 1 : 1 } } 1047 : { 1 : "NN compound NN nmod NN nmod NN dobj VBP nsubj NNS nmod NNS acl VBG dobj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound elimination nmod rate nmod increase dobj *indicate* nsubj data nmod patients acl receiving dobj inducers dep drug0" } 4 : { 1 : "Limited data in patients receiving known enzyme inducers ( drug1 , drug2 , drug3 ) indicate only a 30 % increase in the rate of drug4 elimination . " } 5 : { 1 : 1 } } 1048 : { 1 : "NN nmod NNS dobj VB nsubj NNS acl:relcl VBP dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj *increase* nsubj drugs acl:relcl inhibit dobj p0iid0 nmod drug0" } 4 : { 1 : "Drugs that inhibit cytochrome P450IID6 , such as drug1 , might increase the plasma concentrations of drug2 in patients that are on chronic drug3 therapy ; " } 5 : { 1 : 1 } } 1049 : { 1 : "NN compound NN dobj VBG acl NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound monitoring dobj receiving acl patient nmod *initiated* nsubjpass therapy compound drug0" } 4 : { 1 : "If drug1 therapy is initiated in a patient currently receiving drug2 careful monitoring for adverse reactions is advised and downward dose adjustment may be required . " } 5 : { 1 : 1 } } 1050 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod efficacy dobj reduce xcomp *reported* nsubjpass administration nmod drug0" } 4 : { 1 : "The concomitant administration of drug1 has been reported to reduce the efficacy of oral drug2 and to increase the incidence of breakthrough bleeding . " } 5 : { 1 : 1 } } 1051 : { 1 : "NN nmod NN dobj VBG acl NNS nmod VBN nsubjpass JJS nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod inhibition dobj involving acl mechanisms nmod *attributed* nsubjpass most nmod effects acl concerning dobj drug0" } 4 : { 1 : "Most of the above effects concerning drug1 have been attributed , at least in part , to mechanisms involving inhibition of prostaglandin synthesis by drug2 . " } 5 : { 1 : 1 } } 1052 : { 1 : "NN nmod NNS dobj VBD conj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod levels dobj increased conj *decreased* nsubj administration nmod drug0" } 4 : { 1 : "In normal volunteers receiving drug1 , the administration of drug2 decreased the renal clearance and significantly increased the plasma levels of drug3 . " } 5 : { 1 : 1 } } 1053 : { 1 : "NN conj NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod use nmod *anesthesia* compound drug0" } 4 : { 1 : "drug1 Anesthesia : Severe hypotension has been reported during drug2 anesthesia with concomitant use of a drug3 and a drug4 . " } 5 : { 1 : 1 } } 1054 : { 1 : "NN compound NN nmod VB nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *require* nsubj patients nmod therapy compound drug0" } 4 : { 1 : "Patients on drug1 therapy may require dosage adjustment of the anticoagulant during and after drug2 therapy . " } 5 : { 1 : 1 } } 1055 : { 1 : "NN compound NNS dobj VBZ nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj *decreases* nsubj administration nmod g nmod drug0" } 4 : { 1 : "In a study in normal volunteers , it was found that chronic concurrent administration of 3.6 g of drug1 per day decreases drug2 blood levels approximately 20 % . " } 5 : { 1 : 1 } } 1056 : { 1 : "NN nmod RB nsubjpass VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concomitantly nsubjpass *associated* nsubjpass administration nmod drug0" } 4 : { 1 : "Administration of drug1 concomitantly with drug2 has been associated with an increase in drug3 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin . " } 5 : { 1 : 1 } } 1057 : { 1 : "NN compound NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod patients nmod treatment nmod *added* nsubjpass drug nmod drug0" } 4 : { 1 : "However , when any additional drug , including drug1 , is added to the treatment of patients on drug2 therapy , the patients should be observed for alterations of the prothrombin time . " } 5 : { 1 : 1 } } 1058 : { 1 : "NN nmod NN dobj VBD ccomp VBP" 2 : 1 3 : { 1 : "drug0 nmod elevation dobj produced ccomp *drug0*" } 4 : { 1 : "Capsules drug1 50 mg t.i.d. produced a clinically relevant elevation of plasma drug2 and reduction in renal drug3 clearance in psychiatric patients and normal subjects with steady state plasma drug4 concentrations . " } 5 : { 1 : 1 } } 1059 : { 1 : "NN nmod NN nsubj JJ advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effect nsubj *pronounced* advcl noted nmod drug0" } 4 : { 1 : "Moreover , as noted with drug1 , the effect of drug2 may even be more pronounced when it is administered at higher doses . " } 5 : { 1 : 1 } } 1060 : { 1 : "NN nmod VBG dobj NNS amod JJ conj JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects amod nephrotoxic conj cardiotoxic dep drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1061 : { 1 : "NN nmod VBG dobj NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects dep drug0 appos drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1062 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod exposure nmod increase dobj *caused* nsubj administration nmod drug0" } 4 : { 1 : "Concomitant oral administration of drug1 ( a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa ) caused an eight-fold increase of the systemic exposure to oral drug2 . " } 5 : { 1 : 1 } } 1063 : { 1 : "NN compound NN nmod VBG nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *monitoring* nmod toxicity nmod concentration compound drug0" } 4 : { 1 : "Monitoring for drug1 toxicity and serial measurement of drug2 serum concentration during concomitant drug3 therapy should be considered . " } 5 : { 1 : 1 } } 1064 : { 1 : "NN nmod NN nmod NNS nmod VBD acl NNS conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod co-administration nmod days nmod increased acl *patients* conj auc compound drug0" } 4 : { 1 : "drug1 : In hypercholesterolemic patients , steady-state drug2 AUC and Cmax increased approximately 50 % and 24 % respectively after 10 days with co-administration of drug3 , a known inhibitor of cytochrome P450 3A4 . " } 5 : { 1 : 1 } } 1065 : { 1 : "NN compound NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound dose nmod reduction nsubjpass *considered* advcl indicated nsubjpass treatment nmod inhibitors nmod drug0" } 4 : { 1 : "If treatment with inhibitors of CYP3A4 activity ( such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , etc. ) is indicated , reduction of the drug7 dose should be considered . " } 5 : { 1 : 1 } } 1066 : { 1 : "NN dobj VBG acl NNS nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl patients nmod risk dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 may enhance the seizure risk in patients taking drug2 " } 5 : { 1 : 1 } } 1067 : { 1 : "NN compound NN nmod VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *become* nsubj levels nmod drug0" } 4 : { 1 : "Plasma levels of drug1 may become subtherapeutic during drug2 therapy . " } 5 : { 1 : 1 } } 1068 : { 1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod half-life nmod decrease nmod *associated* nsubjpass administration nmod drug0" } 4 : { 1 : "Chronic administration of drug1 , a known enzyme inducer , may be associated with a decrease in the plasma half-life of drug2 . " } 5 : { 1 : 1 } } 1069 : { 1 : "NN nmod NN appos NN nmod TO nsubjpass VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod adjustment appos treatment nmod to nsubjpass *required* advcl added nsubjpass drug0" } 4 : { 1 : "When drug1 is added to or withdrawn from treatment , dosage adjustment of drug2 may be required . " } 5 : { 1 : 1 } } 1070 : { 1 : "NN nmod NNS nmod NNS dobj VB acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod hormones nmod levels dobj decrease acl:relcl drugs nmod *administered* nsubjpass drug0" } 4 : { 1 : "Caution should be exercised if an drug1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drug2 , drug3 , and drug4 . " } 5 : { 1 : 1 } } 1071 : { 1 : "NN conj NN nmod NNS dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod values dobj *increased* nsubj coadministration nmod drug0" } 4 : { 1 : "Oral drug1 : Coadministration of drug2 and an oral drug3 increased AUC values for drug4 and drug5 by approximately 30 % and 20 % . " } 5 : { 1 : 1 } } 1072 : { 1 : "NN compound NNS nmod NN appos NNS nmod VBN conj NNS nmod NNS conj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod % appos increases nmod associated conj *studies* nmod volunteers conj drug0" } 4 : { 1 : "drug1 : In controlled studies in healthy volunteers , drug2 either had no effect ( one study ) or was associated with modest increases , about 30 % ( two studies ) in steady-state serum drug3 concentrations . " } 5 : { 1 : 1 } } 1073 : { 1 : "NN nmod NN nsubjpass VBN nmod NNS acl VBG dobj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod exposure nsubjpass *decreased* nmod subjects acl receiving dobj inducer appos drug0" } 4 : { 1 : "drug1 : In healthy subjects receiving the CYP3A4 inducer , drug2 , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days , systemic exposure ( AUC ) to drug3 was decreased approximately 72 % . " } 5 : { 1 : 1 } } 1074 : { 1 : "NN dobj VBG acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl woman nmod *drug0*" } 4 : { 1 : "These increases should be considered when selecting an oral drug1 for a woman taking drug2 . " } 5 : { 1 : 1 } } 1075 : { 1 : "NN nmod VBN acl NN nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod observed acl interval nmod prolongation dobj *exaggerate* nsubj drug0" } 4 : { 1 : "drug1 and drug2 could exaggerate the prolongation of the QT interval observed with drug3 . " } 5 : { 1 : 1 } } 1076 : { 1 : "NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effect nmod possibility nsubjpass *considered* advcl conducted nmod drug0" } 4 : { 1 : "Although specific drug interaction studies have not been conducted with drug1 , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , or drug7 ) should be considered . " } 5 : { 1 : 1 } } 1077 : { 1 : "NN nmod VBN acl NN nmod NN dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod observed acl interval nmod prolongation dobj *exaggerate* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 could exaggerate the prolongation of the QT interval observed with drug3 . " } 5 : { 1 : 1 } } 1078 : { 1 : "NN dep NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod effect nmod possibility nsubjpass *considered* advcl conducted nmod drug0" } 4 : { 1 : "Although specific drug interaction studies have not been conducted with drug1 , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , or drug7 ) should be considered . " } 5 : { 1 : 1 } } 1079 : { 1 : "NN nmod NN conj NN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod exposure conj mg nmod *subjects* acl receiving dobj drug0" } 4 : { 1 : "drug1 : In healthy subjects receiving drug2 , a CYP3A4 inhibitor , at 200 mg twice daily for 7 days , systemic exposure ( AUC ) to drug3 was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control . " } 5 : { 1 : 1 } } 1080 : { 1 : "NN nmod NNS nmod JJ nsubj NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod *resistant* nsubj patients acl treated nmod drug0" } 4 : { 1 : "Patients treated with drug1 may be resistant to the effects of drug2 . " } 5 : { 1 : 1 } } 1081 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NNS dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj agents dep agents dep drug0" } 4 : { 1 : "Urinary acidifying agents These agents ( drug1 , drug2 , etc. ) increase the concentration of the ionized species of the drug3 molecule , thereby increasing urinary excretion . " } 5 : { 1 : 1 } } 1082 : { 1 : "NN nmod NN nmod JJ amod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod responsible amod system dobj *inhibits* nsubj drug0" } 4 : { 1 : "In vitro data suggest that drug1 also markedly inhibits the biotransformation system mainly responsible for the metabolism of drug2 ; " } 5 : { 1 : 1 } } 1083 : { 1 : "NN nmod NN nmod JJ amod NN nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod responsible amod system nmod *has* nsubj drug0" } 4 : { 1 : "In vitro data suggest that drug1 , when compared to drug2 , has a less pronounced effect on the biotransformation system responsible for the metabolism of drug3 . " } 5 : { 1 : 1 } } 1084 : { 1 : "NN nmod NN dobj VBZ nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj *inhibits* nsubj drug0 appos drug0" } 4 : { 1 : "Another oral drug1 , drug2 , inhibits the metabolism of drug3 , resulting in elevated plasma concentrations of drug4 and its active metabolite drug5 which may prolong QT intervals . " } 5 : { 1 : 1 } } 1085 : { 1 : "NN conj VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj *observed* nmod patients acl receiving dobj drug0" } 4 : { 1 : "Rhabdomyolysis has been observed in patients receiving drug1 administered alone ( at recommended dosages ) or concomitantly with drug2 including drug3 . " } 5 : { 1 : 1 } } 1086 : { 1 : "NN nmod NNS conj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod inhibitors conj drug0 nmod *use* nmod drug0" } 4 : { 1 : "The concomitant use of transdermal drug1 with drug2 or other potent 3A4 inhibitors such as drug3 , drug4 , drug5 , drug6 , drug7 , and nefazadone may result in an increase in drug8 plasma concentrations . " } 5 : { 1 : 1 } } 1087 : { 1 : "NN nmod NN conj VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj *observed* nmod patients acl receiving dobj drug0" } 4 : { 1 : "Rhabdomyolysis has been observed in patients receiving drug1 administered alone ( at recommended dosages ) or concomitantly with drug2 including drug3 . " } 5 : { 1 : 1 } } 1088 : { 1 : "NN nmod VBN dep VBG acl NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 1 } } 1089 : { 1 : "NN compound NN conj NNP nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg conj *coadministration* nmod drug0" } 4 : { 1 : "( See CLINICAL PHARMACOLOGY ) Coadministration of drug1 and drug2 20 mg daily resulted in a reduction of drug3 plasma levels by 38 % on average . " } 5 : { 1 : 1 } } 1090 : { 1 : "NN compound NN nmod NN nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *method* nsubj preparations compound drug0" } 4 : { 1 : "Micro-dosed drug1 Preparations : Micro-dosed drug2 preparations ( minipills that do not contain an drug3 ) may be an inadequate method of contraception during drug4 therapy . " } 5 : { 1 : 1 } } 1091 : { 1 : "NN nmod NNS nmod NN nmod VB nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod preparations nmod use nmod *refer* nmod insert nmod preparations compound drug0" } 4 : { 1 : "Refer to the package insert for drug1 preparations before use of such preparations with drug2 . " } 5 : { 1 : 1 } } 1092 : { 1 : "NN compound NN nmod VBN acl NNS nmod VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod used acl agents nmod reduced conj *increased* nsubjpass excretion nmod drug0" } 4 : { 1 : "drug1 therapy Urinary excretion of drug2 is increased , and efficacy is reduced by acidifying agents used in drug3 therapy . " } 5 : { 1 : 1 } } 1093 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NNS dep NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj agents dep agents dep drug0 appos drug0" } 4 : { 1 : "Urinary acidifying agents These agents ( drug1 , drug2 , etc. ) increase the concentration of the ionized species of the drug3 molecule , thereby increasing urinary excretion . " } 5 : { 1 : 1 } } 1094 : { 1 : "NN nmod NN dobj JJ acl:relcl NN nmod NNS nmod NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod use dobj involved acl:relcl cerebri nmod cases nmod number nmod *associated* nsubjpass use compound drug0" } 4 : { 1 : "drug1 : Concomitant treatment with drug2 and drug3 should be avoided because drug4 use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of drug5 " } 5 : { 1 : 1 } } 1095 : { 1 : "NN dobj IN dep VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj with dep *avoid* dobj administration nmod drug0" } 4 : { 1 : "It is recommended to avoid concurrent administration of drug1 with drug2 containing drug3 for at least 4 hours following drug4 administration . " } 5 : { 1 : 1 } } 1096 : { 1 : "NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *bind* nsubj doses nmod drug0" } 4 : { 1 : "Single doses of either drug1 or drug2 drug3 bind the drug4 and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent , respectively . " } 5 : { 1 : 1 } } 1097 : { 1 : "NN nmod NN nmod JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *impaired* nsubj absorption nmod drug0" } 4 : { 1 : "drug1 and drug2 drug3 : Absorption of drug4 is impaired in the presence of drug5 . " } 5 : { 1 : 1 } } 1098 : { 1 : "NN dobj VBP nsubj NNS nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj *bind* nsubj doses nmod drug0 conj drug0 compound drug0" } 4 : { 1 : "Single doses of either drug1 or drug2 drug3 bind the drug4 and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent , respectively . " } 5 : { 1 : 1 } } 1099 : { 1 : "NN nmod VBG dobj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod *possessing* dobj effects dep drug0" } 4 : { 1 : "Concurrent administration of drugs possessing nephrotoxic ( e.g. , drug1 , drug2 ) , myelotoxic ( e.g. , drug3 chemotherapy ) , cardiotoxic ( e.g. , drug4 ) or hepatotoxic ( e.g. , drug5 , drug6 ) effects with drug7 may increase toxicity in these organ systems . " } 5 : { 1 : 1 } } 1100 : { 1 : "NN nmod NNS nmod NN nmod RB advmod VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects nmod resolution nmod prior advmod *exacerbated* nmod administration nmod drug0" } 4 : { 1 : "Excessive neuromuscular weakness may be exacerbated by administration of another drug1 prior to the resolution of the effects of a previously administered drug2 . " } 5 : { 1 : 1 } } 1101 : { 1 : "NN dep NN dobj VBP nsubj NNS nmod NNS nmod NN amod JJ nmod NN" 2 : 1 3 : { 1 : "drug0 dep interaction dobj *suggest* nsubj data nmod studies nmod drug0 amod other nmod drug0" } 4 : { 1 : "Data from in vitro studies of drug1 other than drug2 suggest a possible drug interaction for the following : drug3 , drug4 , drug5 , drug6 , and drug7 . " } 5 : { 1 : 1 } } 1102 : { 1 : "NN nmod VBN advcl VBN xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod coadministered advcl increased xcomp *expected* nsubjpass exposure nmod drug0" } 4 : { 1 : "Systemic exposure to drug1 is expected to be increased when coadministered with drug2 . " } 5 : { 1 : 1 } } 1103 : { 1 : "NN dep NN dep NNS nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep triazolo dep drugs nmod plasmaconcentration dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo - drug2 , drug3 , certain drug4 , etc. ) . " } 5 : { 1 : 1 } } 1104 : { 1 : "NN conj NN dep VBN advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep *recommended* advcl administering dobj drug0" } 4 : { 1 : "Particular caution is recommended when administering drug1 with CYP3A4 substrates that have a narrow therapeutic window ( e.g. , drug2 or drug3 ) . " } 5 : { 1 : 1 } } 1105 : { 1 : "NN nmod JJ xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod antagonistic xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 has been shown to be antagonistic to drug2 , including drug3 , based on in vitro studies and time kill curves with enteric gram-negative bacilli . " } 5 : { 1 : 1 } } 1106 : { 1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod interfere xcomp *shown* nsubjpass drug0 nmod drug0" } 4 : { 1 : "Some drug1 , including drug2 , have also been shown to interfere with the metabolism of drug3 . " } 5 : { 1 : 1 } } 1107 : { 1 : "NN nmod NN nmod JJ xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod antagonistic xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 has been shown to be antagonistic to drug2 , including drug3 , based on in vitro studies and time kill curves with enteric gram-negative bacilli . " } 5 : { 1 : 1 } } 1108 : { 1 : "NN dobj VBG acl NNS nmod NN nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod creatinine nmod elevations nmod *associated* nsubjpass drug0" } 4 : { 1 : "Some drug1 , including drug2 , have been associated with transient elevations in serum creatinine in patients receiving drug3 concomitantly . " } 5 : { 1 : 1 } } 1109 : { 1 : "NN dobj VBG acl NNS nmod NN nmod NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod creatinine nmod elevations nmod *associated* nsubjpass drug0 nmod drug0" } 4 : { 1 : "Some drug1 , including drug2 , have been associated with transient elevations in serum creatinine in patients receiving drug3 concomitantly . " } 5 : { 1 : 1 } } 1110 : { 1 : "NN dep VBN advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep *recommended* advcl administering dobj drug0" } 4 : { 1 : "Particular caution is recommended when administering drug1 with CYP3A4 substrates that have a narrow therapeutic window ( e.g. , drug2 or drug3 ) . " } 5 : { 1 : 1 } } 1111 : { 1 : "NN nmod NN nmod VBN nsubj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod *followed* nsubj pretreatment nmod doses nmod drug0" } 4 : { 1 : "Pretreatment of healthy volunteers with multiple doses of drug1 followed by a single dose of drug2 , increased drug3 oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC ( 0-8 ) . " } 5 : { 1 : 1 } } 1112 : { 1 : "NN root , punct NN root , punct RB dep NNS acl VBG dobj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 root , punct drug0 root , punct specifically dep *patients* acl receiving dobj regimens acl containing dobj drug0" } 4 : { 1 : "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug2 , specifically , drug3 , drug4 , drug5 and drug6 . " } 5 : { 1 : 1 } } 1113 : { 1 : "NN root , punct RB dep NNS acl VBG dobj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 root , punct specifically dep *patients* acl receiving dobj regimens acl containing dobj drug0" } 4 : { 1 : "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug2 , specifically , drug3 , drug4 , drug5 and drug6 . " } 5 : { 1 : 1 } } 1114 : { 1 : "NN nmod NN dobj VBZ nsubj NNS acl:relcl VB dobj NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod cmax dobj *increases* nsubj drugs acl:relcl have dobj concentration acl altered nmod drug0" } 4 : { 1 : "Drugs that may have their plasma concentration altered by drug1 drug2 increases the mean cmax and AUC of drug3 ( CYP3A4 substrate ) 2 - and 3.5-fold , respectively , suggesting an inhibition of the CYP3A4 by drug4 . " } 5 : { 1 : 1 } } 1115 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod seen acl hypotension dobj *potentiate* nsubj drug0 conj drug0" } 4 : { 1 : "Although drug1 have been shown to reduce drug2 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with drug3 may reduce the antitumor effectiveness of drug4 and thus should be avoided . 12 drug5 and other drug6 may potentiate the hypotension seen with drug7 . " } 5 : { 1 : 1 } } 1116 : { 1 : "NN dep NNS nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep inhibitors nmod *administering* dobj drug0" } 4 : { 1 : "Drugs that may alter drug1 plasma concentrations Drugs that may increase drug2 plasma concentrations : Caution is recommended when administering drug3 with inhibitors of the CYP3A4 family ( e.g. , drug4 , drug5 , drug6 , drug7 ) . " } 5 : { 1 : 1 } } 1117 : { 1 : "NN dobj VBN acl:relcl NNS dobj VBG acl NN" 2 : 1 3 : { 1 : "drug0 dobj administered acl:relcl regimens dobj containing acl *drug0*" } 4 : { 1 : "Delayed Adverse Reactions to drug1 : A review of the literature revealed that 12.6 % ( range 11-28 % ) of 501 patients treated with various drug2 containing regimens who were subsequently administered drug3 experienced acute , atypical adverse reactions . " } 5 : { 1 : 1 } } 1118 : { 1 : "NN appos NN dep NNS nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep inhibitors nmod *administering* dobj drug0" } 4 : { 1 : "Drugs that may alter drug1 plasma concentrations Drugs that may increase drug2 plasma concentrations : Caution is recommended when administering drug3 with inhibitors of the CYP3A4 family ( e.g. , drug4 , drug5 , drug6 , drug7 ) . " } 5 : { 1 : 1 } } 1119 : { 1 : "NN nmod RB advmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concomitantly advmod *administration* nmod drug0" } 4 : { 1 : "drug1 : Administration of drug2 concomitantly with drug3 has been associated with an increase in drug4 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin . " } 5 : { 1 : 1 } } 1120 : { 1 : "NN compound NN nsubjpass VBN advcl VBN nsubjpass NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nsubjpass indicated advcl *monitored* nsubjpass patients nmod therapy compound drug0" } 4 : { 1 : "Therefore , patients under drug1 therapy should be carefully monitored when concomitant drug2 therapy is indicated . " } 5 : { 1 : 1 } } 1121 : { 1 : "NN dobj VBG acl NNS conj NNS dobj VBD acl NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl products conj tablets dobj chewable/buffered acl drug0 nmod products nmod *drug0*" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 1 } } 1122 : { 1 : "NN compound NNS nmod NN nmod VBN xcomp VBN nsubjpass NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound tablets nmod administration nmod increased xcomp *reported* nsubjpass concentrations nmod drug0 conj drug0" } 4 : { 1 : "The steady state plasma concentrations of drug1 and drug2 have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of drug3 tablets in doses up to 4 mg/day . " } 5 : { 1 : 1 } } 1123 : { 1 : "NN compound NNS nmod NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound tablets nmod administration nmod increased xcomp *reported* nsubjpass concentrations nmod drug0" } 4 : { 1 : "The steady state plasma concentrations of drug1 and drug2 have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of drug3 tablets in doses up to 4 mg/day . " } 5 : { 1 : 1 } } 1124 : { 1 : "NN nmod VBN advcl VBP nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod co-administered advcl *produce* nsubj drug0 nmod drug0" } 4 : { 1 : "The drug1 , including drug2 , produce additive CNS depressant effects when co-administered with other drug3 , drug4 , drug5 , drug6 , and other drugs which themselves produce CNS depression . " } 5 : { 1 : 1 } } 1125 : { 1 : "NN dep VBP dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep *suggest* dobj interaction nmod drug0" } 4 : { 1 : "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving drug1 metabolized similarly to drug2 or on the basis of in vitro studies with drug3 or other drug4 ( caution is recommended during coadministration with drug5 ) : Available data from clinical studies of drug6 other than drug7 suggest a possible drug interaction with drug8 for the following : drug9 , drug10 , drug11 such as drug12 and drug13 , and grapefruit juice . " } 5 : { 1 : 1 } } 1126 : { 1 : "NN conj NN nmod NN conj NN dep VBP dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 conj drug0 dep *suggest* dobj interaction nmod drug0" } 4 : { 1 : "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving drug1 metabolized similarly to drug2 or on the basis of in vitro studies with drug3 or other drug4 ( caution is recommended during coadministration with drug5 ) : Available data from clinical studies of drug6 other than drug7 suggest a possible drug interaction with drug8 for the following : drug9 , drug10 , drug11 such as drug12 and drug13 , and grapefruit juice . " } 5 : { 1 : 1 } } 1127 : { 1 : "NN nmod NN conj NN dep VBP dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj drug0 dep *suggest* dobj interaction nmod drug0" } 4 : { 1 : "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving drug1 metabolized similarly to drug2 or on the basis of in vitro studies with drug3 or other drug4 ( caution is recommended during coadministration with drug5 ) : Available data from clinical studies of drug6 other than drug7 suggest a possible drug interaction with drug8 for the following : drug9 , drug10 , drug11 such as drug12 and drug13 , and grapefruit juice . " } 5 : { 1 : 1 } } 1128 : { 1 : "NN dep NN dobj VBP nsubj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep interaction dobj *suggest* nsubj data nmod studies nmod drug0" } 4 : { 1 : "Data from in vitro studies of drug1 other than drug2 suggest a possible drug interaction for the following : drug3 , drug4 , drug5 , drug6 , and drug7 . " } 5 : { 1 : 1 } } 1129 : { 1 : "NN compound NN conj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound drug0 conj drug0 nmod products nmod *drug0*" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 1 } } 1130 : { 1 : "NN nmod VBN advcl VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod co-administered advcl *produce* nsubj drug0" } 4 : { 1 : "The drug1 , including drug2 , produce additive CNS depressant effects when co-administered with other drug3 , drug4 , drug5 , drug6 , and other drugs which themselves produce CNS depression . " } 5 : { 1 : 1 } } 1131 : { 1 : "NN nmod NNS nmod VB nsubj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod *result* nsubj coadministration dep drug0" } 4 : { 1 : "Coadministration with compounds that are potent inducers of CYP3A4 ( eg , drug1 , drug2 , drug3 , drug4 ) may result in decreased plasma levels of drug5 . " } 5 : { 1 : 1 } } 1132 : { 1 : "NN nmod NN dobj VB nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod absorption dobj *decrease* nsubj administration nmod drug0 nmod drug0" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 1 } } 1133 : { 1 : "NN dobj VBG acl NNS conj NNS dobj VBD acl NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl products conj tablets dobj chewable/buffered acl drug0 nmod products nmod *drug0* nmod drug0" } 4 : { 1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . " } 5 : { 1 : 1 } } 1134 : { 1 : "NN nmod NNS nmod VB nsubj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod *result* nsubj coadministration dep drug0 appos drug0" } 4 : { 1 : "Coadministration with compounds that are potent inducers of CYP3A4 ( eg , drug1 , drug2 , drug3 , drug4 ) may result in decreased plasma levels of drug5 . " } 5 : { 1 : 1 } } 1135 : { 1 : "NN nmod NNS dobj VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod hours dobj administered acl:relcl *drug0*" } 4 : { 1 : "This time window is different than for other oral formulations of drug1 , which are usually administered 2 hours before or 6 hours after drug2 . " } 5 : { 1 : 1 } } 1136 : { 1 : "NN nmod NN nsubj VB nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj *lead* nmod drug0" } 4 : { 1 : "drug1 : As with some other drug2 , concurrent administration of drug3 with drug4 may lead to elevated serum concentrations of drug5 and prolongation of its elimination half-life . " } 5 : { 1 : 1 } } 1137 : { 1 : "NN nmod NN nmod NN dobj VBZ conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod level nmod increase dobj produces conj *interferes* nsubj drug0" } 4 : { 1 : "drug1 : drug2 interferes with renal tubular secretion of drug3 and produces an increase in the level of drug4 in serum . " } 5 : { 1 : 1 } } 1138 : { 1 : "NN nmod VBN advcl VB nsubj NN nmod NNS acl:relcl VBN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod coadministered advcl *have* nsubj coadministration nmod drugs acl:relcl metabolized nmod cyp0a0 dep drug0" } 4 : { 1 : "Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , and drug16 ) may have elevated plasma concentrations when coadministered with drug17 ; " } 5 : { 1 : 1 } } 1139 : { 1 : "NN dep NN conj NN nmod VBN dep VBG acl NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 1 } } 1140 : { 1 : "NN appos NN conj NN nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 appos metabolite conj drug0 nmod clearance dobj *reduces* nsubj drug0" } 4 : { 1 : "Because drug1 reduces the clearance of both drug2 and its active metabolite , drug3 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration . " } 5 : { 1 : 1 } } 1141 : { 1 : "NN nmod VBN xcomp JJ advcl VBN nsubjpass NN acl VBN nmod NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod reduced xcomp likely advcl *used* nsubjpass drug0 acl metabolized nmod oxidation dep drug0 conj drug0" } 4 : { 1 : "Other Potentially Important Drug Interactions : drug1 : drug2 metabolized by hepatic oxidation ( e.g. , drug3 , drug4 , drug5 elc . ) should be used with caution because the clearance of these drugs is likely to be reduced by drug6 . " } 5 : { 1 : 1 } } 1142 : { 1 : "NN compound NN dep VBP nsubj NNS acl:relcl VB dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound intake dep *include* nsubj drugs acl:relcl increase dobj concentrations compound drug0" } 4 : { 1 : "The most commonly occurring drug interactions are listed below : - Drugs that may increase plasma drug1 concentrations include : acute drug2 intake , drug3 , chboramphenicol , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 " } 5 : { 1 : 1 } } 1143 : { 1 : "NN nmod NN dobj VB acl NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod malabsorption dobj produce acl *drug0* conj intake compound drug0" } 4 : { 1 : "drug1 drug2 and heavy drug3 intake for longer than 2 weeks may produce malabsorption of drug4 . " } 5 : { 1 : 1 } } 1144 : { 1 : "NN nmod NN dobj VB acl NN" 2 : 1 3 : { 1 : "drug0 nmod malabsorption dobj produce acl *drug0*" } 4 : { 1 : "drug1 drug2 and heavy drug3 intake for longer than 2 weeks may produce malabsorption of drug4 . " } 5 : { 1 : 1 } } 1145 : { 1 : "NN appos NN dep VBP nsubj NNS acl:relcl VB dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos intake dep *include* nsubj drugs acl:relcl increase dobj concentrations compound drug0" } 4 : { 1 : "The most commonly occurring drug interactions are listed below : - Drugs that may increase plasma drug1 concentrations include : acute drug2 intake , drug3 , chboramphenicol , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 , drug16 , drug17 , drug18 , drug19 , drug20 , drug21 , drug22 " } 5 : { 1 : 1 } } 1146 : { 1 : "NN compound NNS conj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound concentrations conj drug0 nmod *effects* nmod drug0" } 4 : { 1 : "Similarly , the effects of drug1 on drug2 , drug3 and sodium plasma drug4 concentrations are unpredictable " } 5 : { 1 : 1 } } 1147 : { 1 : "NN compound NN conj NN dep VBP nsubj NNS acl:relcl VB dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound abuse conj drug0 dep *include* nsubj drugs acl:relcl decrease dobj concentrations compound drug0" } 4 : { 1 : "- Drugs that may decrease plasma drug1 concentrations include : drug2 , chronic drug3 abuse , drug4 " } 5 : { 1 : 1 } } 1148 : { 1 : "NN compound NN conj NNS nmod NNS amod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound dosage conj patients nmod *seizures* amod precipitate nsubj drug0" } 4 : { 1 : "- Although not a true drug interaction , drug1 may precipitate seizures in susceptible patients and drug2 dosage may need to be adjusted " } 5 : { 1 : 1 } } 1149 : { 1 : "NN dep VBP nsubj NNS acl:relcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dep *include* nsubj drugs acl:relcl impaired nmod drug0" } 4 : { 1 : "- Drugs whose efficacy is impaired by drug1 include : drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , oral drug9 , drug10 , drug11 , drug12 , drug13 . " } 5 : { 1 : 1 } } 1150 : { 1 : "NN nmod NN dobj VB acl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod malabsorption dobj produce acl *drug0* compound drug0" } 4 : { 1 : "drug1 drug2 and heavy drug3 intake for longer than 2 weeks may produce malabsorption of drug4 . " } 5 : { 1 : 1 } } 1151 : { 1 : "NN conj NN nmod NNS conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj garlic nmod herbs conj *supplements* compound drug0" } 4 : { 1 : "Interactions may occur between drug1 supplements and drug2 and other drug3 and herbs such as garlic ( Allium sativum ) and drug4 ( drug5 ) . " } 5 : { 1 : 1 } } 1152 : { 1 : "NN compound NN conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 compound concentration conj *decreased* nsubj drug0" } 4 : { 1 : "drug1 , an inhibitor of P450 2C9 , decreased active metabolite concentration and increased drug2 concentration . " } 5 : { 1 : 1 } } 1153 : { 1 : "NN conj NN dep NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "Therefore , drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , drug2 , drug3 salts and drug4 ) . " } 5 : { 1 : 1 } } 1154 : { 1 : "NN appos NN conj NN nmod NNS conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj garlic nmod herbs conj *supplements* compound drug0" } 4 : { 1 : "Interactions may occur between drug1 supplements and drug2 and other drug3 and herbs such as garlic ( Allium sativum ) and drug4 ( drug5 ) . " } 5 : { 1 : 1 } } 1155 : { 1 : "NN compound NN dobj VBD nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound max dobj *increased* nsubj mg nmod q0h compound drug0" } 4 : { 1 : "however , 150 mg of drug1 q12h for 3 days increased the drug2 C max by 23 % and drug3 AUC by 16 % . " } 5 : { 1 : 1 } } 1156 : { 1 : "NN nmod VBN advcl VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *reported* advcl reported nmod trials nmod drug0" } 4 : { 1 : "Although acid-base and electrolyte disturbances were not reported in the clinical trials with drug1 , these disturbances have been reported with oral drug2 and have , in some instances , resulted in drug interactions ( e.g. , toxicity associated with high-dose drug3 therapy ) . " } 5 : { 1 : 1 } } 1157 : { 1 : "NN compound NN conj VBD nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound auc conj *increased* nsubj mg nmod q0h compound drug0" } 4 : { 1 : "however , 150 mg of drug1 q12h for 3 days increased the drug2 C max by 23 % and drug3 AUC by 16 % . " } 5 : { 1 : 1 } } 1158 : { 1 : "NN conj NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 conj *supplements* compound drug0" } 4 : { 1 : "Interactions may occur between drug1 supplements and drug2 and other drug3 and herbs such as garlic ( Allium sativum ) and drug4 ( drug5 ) . " } 5 : { 1 : 1 } } 1159 : { 1 : "NN compound NNS conj NN dep NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound salts conj drug0 dep absorption nmod *interfere* nsubj drug0" } 4 : { 1 : "Therefore , drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , drug2 , drug3 salts and drug4 ) . " } 5 : { 1 : 1 } } 1160 : { 1 : "NN nmod NN dep NN nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod metabolite dep decrease nmod *resulted* nsubj administration nmod drug0" } 4 : { 1 : "drug1 and drug2 Administration of drug3 or drug4 in patients ( n = 13 ) and volunteers ( n = 96 ) resulted in a rapid and significant decrease in plasma M1 ( the active metabolite of drug5 ) concentration . " } 5 : { 1 : 1 } } 1161 : { 1 : "NN nmod NNS dobj VBG acl NNS nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod doses dobj receiving acl subjects nmod *administration* nmod dose nmod drug0" } 4 : { 1 : "drug1 : Following concomitant administration of a single dose of drug2 to subjects receiving multiple doses of drug3 , M1 peak levels were increased ( ~ 40 % ) over those seen when drug4 was given alone . " } 5 : { 1 : 1 } } 1162 : { 1 : "NN nmod NNS dobj VB nsubj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj *reduce* nsubj drug0 dep drug0" } 4 : { 1 : "drug1 ( e.g. , drug2 , drug3 , drug4 ) and drug5 may reduce the therapeutic effects of drug6 . " } 5 : { 1 : 1 } } 1163 : { 1 : "NN nmod NN nmod VB nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod use nmod *refer* nmod insert nmod preparations compound drug0" } 4 : { 1 : "Refer to the package insert for drug1 preparations before use of such preparations with drug2 " } 5 : { 1 : 1 } } 1164 : { 1 : "NN nmod NN dobj VBP nsubj NN compound NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod potential dobj *have* nsubj drug0 compound drug0 conj drug0" } 4 : { 1 : "- drug1 and drug2 drug3 : drug4 and drug5 drug6 have the potential of binding drug7 and reducing drug8 absorption from the gastrointestinal tract " } 5 : { 1 : 1 } } 1165 : { 1 : "NN conj NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod reversed xcomp *reported* nsubjpass effects nmod drug0" } 4 : { 1 : "In addition , the beneficial effects of drug1 in Parkinsons disease have been reported to be reversed by drug2 and drug3 . " } 5 : { 1 : 1 } } 1166 : { 1 : "NN nmod NN nmod NNS nmod VBN advcl VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod hours nmod *administered* advcl needed nsubjpass therapy compound drug0" } 4 : { 1 : "If drug1 therapy is needed , the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of drug2 . " } 5 : { 1 : 1 } } 1167 : { 1 : "NN appos NN dep NN dobj VBP acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep cyp0a0 dobj inhibit acl:relcl *use* nmod drug0" } 4 : { 1 : "Concomitant use of drug1 and drugs that inhibit CYP3A4 ( eg , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ) may increase exposure to drug13 and should be avoided . " } 5 : { 1 : 1 } } 1168 : { 1 : "NN compound NN dobj VB xcomp JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound exposure dobj reduce xcomp *likely* nsubj suppression nmod drug0" } 4 : { 1 : "drug1 / drug2 : Long-term suppression of gastric acid secretion by drug3 or drug4 ( eg , drug5 and drug6 ) is likely to reduce drug7 exposure . " } 5 : { 1 : 1 } } 1169 : { 1 : "NN nmod NN dep NN nmod VBD nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolite dep decrease nmod *resulted* nsubj administration nmod drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 Administration of drug3 or drug4 in patients ( n = 13 ) and volunteers ( n = 96 ) resulted in a rapid and significant decrease in plasma M1 ( the active metabolite of drug5 ) concentration . " } 5 : { 1 : 1 } } 1170 : { 1 : "NN nmod NN dobj VBP nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod potential dobj *have* nsubj drug0 compound drug0" } 4 : { 1 : "- drug1 and drug2 drug3 : drug4 and drug5 drug6 have the potential of binding drug7 and reducing drug8 absorption from the gastrointestinal tract " } 5 : { 1 : 1 } } 1171 : { 1 : "NN nmod NN nmod VBD nsubj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod *occurred* nsubj decreases nmod auc nmod drug0" } 4 : { 1 : "Interactions with Other drug1 : Significant decreases in the AUC of drug2 ( 20 % ) and drug3 ( 84 % ) occurred following simultaneous administration of these agents with drug4 . " } 5 : { 1 : 1 } } 1172 : { 1 : "NN compound NNPS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound tablets nmod *administration* nmod drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 containing drug3 or drug4 with drug5 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug6 components . " } 5 : { 1 : 1 } } 1173 : { 1 : "NN nmod NN nmod VBD conj VBD advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod coadministration nmod decreased conj *increased* advcl coadministered nsubjpass drug0" } 4 : { 1 : "Blood levels of drug1 increased 24 % when drug2 was coadministered with drug3 ( nonselective inhibitor of cytochrome P-450 ) for 7 days , and decreased 28 % with coadministration of drug4 ( potent inducer of cytochrome P-450 ) for 7 days . " } 5 : { 1 : 1 } } 1174 : { 1 : "NN nmod NN nmod VBD nsubj NNS conj NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod *occurred* nsubj decreases conj drug0" } 4 : { 1 : "Interactions with Other drug1 : Significant decreases in the AUC of drug2 ( 20 % ) and drug3 ( 84 % ) occurred following simultaneous administration of these agents with drug4 . " } 5 : { 1 : 1 } } 1175 : { 1 : "NN compound NNPS nmod NN nmod NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound tablets nmod *administration* nmod drug0 acl containing dobj drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 containing drug3 or drug4 with drug5 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug6 components . " } 5 : { 1 : 1 } } 1176 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod dosing nmod *administered* nsubjpass drugs nmod drug0 conj drug0" } 4 : { 1 : "Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach : Drugs such as drug1 and drug2 should be administered at least 2 hours prior to dosing with drug3 . " } 5 : { 1 : 1 } } 1177 : { 1 : "NN compound NNPS nmod NN nmod NN acl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound tablets nmod *administration* nmod drug0 acl containing dobj drug0 conj drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 containing drug3 or drug4 with drug5 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug6 components . " } 5 : { 1 : 1 } } 1178 : { 1 : "NN nmod TO mark VBN acl NNS dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod to mark associated acl hours dep *administration* nmod drug0" } 4 : { 1 : "drug1 : Administration of drug2 2 hours prior to or concurrent with oral drug3 was associated with a 111 ( 114 ) % increase in the steady-state AUC of drug4 ( n = 12 ) . " } 5 : { 1 : 1 } } 1179 : { 1 : "NN compound NN dobj VB xcomp JJ nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound exposure dobj reduce xcomp *likely* nsubj suppression nmod drug0 conj drug0" } 4 : { 1 : "drug1 / drug2 : Long-term suppression of gastric acid secretion by drug3 or drug4 ( eg , drug5 and drug6 ) is likely to reduce drug7 exposure . " } 5 : { 1 : 1 } } 1180 : { 1 : "NN nmod RB advmod VB nsubj NNS acl VBG dobj NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concomitantly advmod *exhibit* nsubj patients acl receiving dobj s conj drug0 nmod drug0" } 4 : { 1 : "Patients receiving other drug1 s , general drug2 , drug3 , drug4 , drug5 , drug6 or other drug7 ( including drug8 ) concomitantly with drug9 may exhibit an additive CNS depression . " } 5 : { 1 : 1 } } 1181 : { 1 : "NN dobj VBG advcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj taking advcl *take* dobj supplement compound drug0" } 4 : { 1 : "Therefore you may need to take a drug1 supplement while taking drug2 . " } 5 : { 1 : 1 } } 1182 : { 1 : "NN dobj VBG acl NNS nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *administration* nmod tablets compound drug0" } 4 : { 1 : "Administration of drug1 Tablets to patients receiving either drug2 or drug3 concurrently should be undertaken with caution , using small initial doses and small gradual dose increases . " } 5 : { 1 : 1 } } 1183 : { 1 : "NN conj NN nmod NN nmod NNS nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *incidence* nmod experiences nmod patients acl receiving dobj drug0" } 4 : { 1 : "drug1 and drug2 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug3 concurrently with either drug4 or drug5 . " } 5 : { 1 : 1 } } 1184 : { 1 : "NN nmod NN nmod NNS nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *incidence* nmod experiences nmod patients acl receiving dobj drug0" } 4 : { 1 : "drug1 and drug2 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug3 concurrently with either drug4 or drug5 . " } 5 : { 1 : 1 } } 1185 : { 1 : "NN conj NN dobj VBG acl NNS nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod *administration* nmod tablets compound drug0" } 4 : { 1 : "Administration of drug1 Tablets to patients receiving either drug2 or drug3 concurrently should be undertaken with caution , using small initial doses and small gradual dose increases . " } 5 : { 1 : 1 } } 1186 : { 1 : "NN nmod NN dobj VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *potentiates* nsubj treatment compound drug0" } 4 : { 1 : "drug1 treatment , which causes a marked and persistent inhibition of cholinesterase activity , potentiates the effect of drug2 . " } 5 : { 1 : 1 } } 1187 : { 1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod administration nmod *increased* nsubjpass rate nmod metabolism conj activity nmod drug0" } 4 : { 1 : "The rate of metabolism and the leukopenic activity of drug1 reportedly are increased by chronic administration of high doses of drug2 . " } 5 : { 1 : 1 } } 1188 : { 1 : "NN dep JJ nmod VBN acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep systemically-administered nmod treated acl patients nmod *administered* nsubjpass drug0" } 4 : { 1 : "Drug-Drug Interactions drug1 - drug2 should be administered with caution to patients being treated with systemically-administered ( oral or intravenous ) drug3 ( or other drug4 ) because the action of drug5 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure . " } 5 : { 1 : 1 } } 1189 : { 1 : "NN dep FW dep VBN advcl JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep e.g. dep coadministered advcl *necessary* nsubj adjustment nmod drug0" } 4 : { 1 : "Dosage adjustment of drug1 may be necessary when coadministered with CYP2D6 inhibitors , e.g. , drug2 , drug3 , and drug4 . " } 5 : { 1 : 1 } } 1190 : { 1 : "NN appos NN conj NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 1 } } 1191 : { 1 : "NN dep NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 1 } } 1192 : { 1 : "NN compound NN nmod NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *cases* nmod levels compound drug0" } 4 : { 1 : "The effect of drug1 on plasma drug2 has not been studied , but cases of increased drug3 plasma levels during drug4 therapy have been reported . " } 5 : { 1 : 1 } } 1193 : { 1 : "NN conj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj *administration* nmod oral compound drug0" } 4 : { 1 : "drug1 : Concomitant administration of drug2 ORAL and drug3 resulted in decreased clearance of drug4 and significant increases in drug5 plasma levels ( total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL ) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours . " } 5 : { 1 : 1 } } 1194 : { 1 : "NN appos NN dep NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 1 } } 1195 : { 1 : "NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep *drug0*" } 4 : { 1 : "drug1 : Sporadic cases of seizures have been reported during concomitant use of drug2 and drug3 ( drug4 , drug5 ) . " } 5 : { 1 : 1 } } 1196 : { 1 : "NN nmod NN nmod VBN dep VBN acl NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod followed dep given acl *doses* nmod drug0" } 4 : { 1 : "In a study of 15 male subjects ( ages 19 to 35 years ) who were extensive metabolizers of the CYP2D6 isoenzyme , daily doses of drug1 given as 150 mg twice daily followed by a single dose of 50 mg drug2 increased the Cmax , AUC , and t1/2 of drug3 by an average of approximately 2 - , 5 - and 2-fold , respectively . " } 5 : { 1 : 1 } } 1197 : { 1 : "NN dep NN dobj VBG acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dobj taking acl patients nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 : Hallucinations have been reported when drug2 was used in patients taking drug3 ( drug4 , drug5 , drug6 ) . " } 5 : { 1 : 1 } } 1198 : { 1 : "NN nmod NN nmod VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod isoenzyme nmod metabolized acl:relcl drugs nmod *co-administration* nmod drug0" } 4 : { 1 : "Therefore , co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 ) , drug9 ( e.g. , drug10 , drug11 , drug12 ) , drug13 ( e.g. , drug14 ) , and drug15 ( e.g. , drug16 , drug17 ) , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication . " } 5 : { 1 : 1 } } 1199 : { 1 : "NN nmod RB advmod VB nsubj NNS acl VBG dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod concomitantly advmod *exhibit* nsubj patients acl receiving dobj s compound drug0" } 4 : { 1 : "Patients receiving other drug1 s , general drug2 , drug3 , drug4 , drug5 , drug6 or other drug7 ( including drug8 ) concomitantly with drug9 may exhibit an additive CNS depression . " } 5 : { 1 : 1 } } 1200 : { 1 : "NN nmod NN nsubj CD nmod NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod auc nsubj *0* nmod individuals acl treated nmod drug0" } 4 : { 1 : "In EM individuals treated with drug1 or drug2 , the AUC of drug3 is approximately 6 - to 8-fold and Css , max is about 3 - to 4-fold greater than drug4 alone . " } 5 : { 1 : 1 } } 1201 : { 1 : "NN nsubjpass VBN advcl VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass given advcl increase xcomp *reported* nsubjpass effect nmod drug0" } 4 : { 1 : "The hypoglycemic effect of drug1 has been reported to increase when drug2 is given concurrently . " } 5 : { 1 : 1 } } 1202 : { 1 : "NN compound NN nmod NN nmod NNP nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod patient nmod *prior* nmod drug0" } 4 : { 1 : "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO drug1 INTOXICATION , PRIOR TO ADMINISTERING drug2 TO A PATIENT ON drug3 THERAPY , A BASELINE drug4 SERUM LEVEL SHOULD BE OBTAINED . " } 5 : { 1 : 1 } } 1203 : { 1 : "NN compound NNS dobj VBG acl NNS dobj IN advmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound congeners dobj reveiving acl patients dobj in advmod *be* nsubj drug0" } 4 : { 1 : "drug1 SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING drug2 AND ITS CONGENERS . " } 5 : { 1 : 1 } } 1204 : { 1 : "NN nmod VBN advcl VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *produces* nsubj injection nmod drug0" } 4 : { 1 : "Injection : drug1 injection , like other injectable drug2 , produces depression of the central nervous system when administered with drug3 , drug4 , drug5 , drug6 , and other drug7 . When drug8 is used concomitantly with injectable drug9 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed . " } 5 : { 1 : 1 } } 1205 : { 1 : "NN dobj VBG advcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj beginning advcl *adjust* dobj dosage nmod drug0" } 4 : { 1 : "It may be necessary to adjust the dosage of oral drug1 upon beginning or stopping drug2 . since drug3 may prolong prothrombin time . " } 5 : { 1 : 1 } } 1206 : { 1 : "NN nsubj VBD dep NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj resulted dep inhibitors nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 with other CYP3A4 inhibitors ( e.g. , drug2 500 mg BID , drug3 240 mg QD , drug4 1200 mg TID , drug5 200 mg QD ) resulted in increases in Cmax of drug6 ranging from 1.4 - to 1.6 - fold and AUC from 2.0 - to 2.9 - fold . " } 5 : { 1 : 1 } } 1207 : { 1 : "NN compound NN nmod VBG dobj NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod *evaluating* dobj administration nmod dose nmod mg compound drug0" } 4 : { 1 : "A pharmacokinetic study evaluating the administration of a single dose of drug1 100 mg with drug2 200 mg BID , a potent inhibitor of the CYP3A4 pathway , showed a 1.7-fold increase in Cmax of drug3 and a 5.4-fold increase in AUC of drug4 . " } 5 : { 1 : 1 } } 1208 : { 1 : "NN compound NN nmod VBN acl NN compound NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod combined acl *mg* compound drug0" } 4 : { 1 : "In a study in diabetics with microalbuminuria drug1 200 mg combined with the drug2 drug3 10 mg increased the frequency of hyperkalemia ( serum potassium 5.5 mEq/L ) from 17 % on drug4 alone to 38 % . " } 5 : { 1 : 1 } } 1209 : { 1 : "NN nmod NN nsubj CD nmod NNS acl VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod auc nsubj *0* nmod individuals acl treated nmod drug0 conj drug0" } 4 : { 1 : "In EM individuals treated with drug1 or drug2 , the AUC of drug3 is approximately 6 - to 8-fold and Css , max is about 3 - to 4-fold greater than drug4 alone . " } 5 : { 1 : 1 } } 1210 : { 1 : "NN nmod VBN advcl VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod administered advcl *produces* nsubj injection compound drug0" } 4 : { 1 : "Injection : drug1 injection , like other injectable drug2 , produces depression of the central nervous system when administered with drug3 , drug4 , drug5 , drug6 , and other drug7 . When drug8 is used concomitantly with injectable drug9 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed . " } 5 : { 1 : 1 } } 1211 : { 1 : "NN nmod NNS nmod VBN advcl VBP nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod medications nmod administered advcl *produce* nsubj drug0 nmod drug0" } 4 : { 1 : "Tablets : The drug1 , including drug2 , produce CNS-depressant effects when administered with such medications as drug3 or drug4 . " } 5 : { 1 : 1 } } 1212 : { 1 : "NN nmod NN nsubj JJ advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod adjustment nsubj *necessary* advcl raise nsubj drug0" } 4 : { 1 : "Since drug1 may raise the serum uric acid level , dosage adjustment of drug2 may be necessary " } 5 : { 1 : 1 } } 1213 : { 1 : "NN appos NN nmod NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod drugs nmod *interact* nsubj drug0" } 4 : { 1 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 " } 5 : { 1 : 1 } } 1214 : { 1 : "NN conj NN nmod NNS nmod VBN advcl VBP nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod medications nmod administered advcl *produce* nsubj drug0 nmod drug0" } 4 : { 1 : "Tablets : The drug1 , including drug2 , produce CNS-depressant effects when administered with such medications as drug3 or drug4 . " } 5 : { 1 : 1 } } 1215 : { 1 : "NN compound NN nmod NN dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound toxicity nmod possibility dobj *enhance* nsubj use nmod drug0" } 4 : { 1 : "( Concurrent use with drug1 may enhance the possibility of drug2 toxicity associated with hypokalemia . ) " } 5 : { 1 : 1 } } 1216 : { 1 : "NN nmod NNS nmod VBN advcl VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod medications nmod administered advcl *produce* nsubj drug0" } 4 : { 1 : "Tablets : The drug1 , including drug2 , produce CNS-depressant effects when administered with such medications as drug3 or drug4 . " } 5 : { 1 : 1 } } 1217 : { 1 : "NN compound NN nmod JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *necessary* nsubj adjustment nmod drug0" } 4 : { 1 : "for adult-onset diabetics , dosage adjustment of drug1 may be necessary during and after drug2 therapy ; " } 5 : { 1 : 1 } } 1218 : { 1 : "NN conj NN nmod NNS nmod VBN advcl VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod medications nmod administered advcl *produce* nsubj drug0" } 4 : { 1 : "Tablets : The drug1 , including drug2 , produce CNS-depressant effects when administered with such medications as drug3 or drug4 . " } 5 : { 1 : 1 } } 1219 : { 1 : "NN nmod VBN xcomp JJ advcl VBN nsubjpass NN acl VBN nmod NN dep NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod reduced xcomp likely advcl *used* nsubjpass drug0 acl metabolized nmod oxidation dep drug0 conj elc compound drug0" } 4 : { 1 : "Other Potentially Important Drug Interactions : drug1 : drug2 metabolized by hepatic oxidation ( e.g. , drug3 , drug4 , drug5 elc . ) should be used with caution because the clearance of these drugs is likely to be reduced by drug6 . " } 5 : { 1 : 1 } } 1220 : { 1 : "NN compound NN dobj VB xcomp JJ nsubj NN nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound exposure dobj reduce xcomp *likely* nsubj suppression nmod drug0 conj drug0 dep drug0" } 4 : { 1 : "drug1 / drug2 : Long-term suppression of gastric acid secretion by drug3 or drug4 ( eg , drug5 and drug6 ) is likely to reduce drug7 exposure . " } 5 : { 1 : 1 } } 1221 : { 1 : "NN compound NN dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj receiving acl patients nmod *place* nmod drug0" } 4 : { 1 : "The use of drug1 should be considered in place of drug2 or drug3 in patients receiving drug4 therapy . " } 5 : { 1 : 1 } } 1222 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NNS acl:relcl VBP advcl VBG dobj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod produced acl tendency dobj *increase* nsubj drugs acl:relcl reduce advcl causing dobj depression dep drug0" } 4 : { 1 : "Drugs that reduce the number of blood platelets by causing bone marrow depression ( such as drug1 ) or drugs which inhibit platelet function ( eg , drug2 and other drug3 , drug4 , drug5 , drug6 , drug7 ) may increase the bleeding tendency produced by drug8 without altering prothrombin time determinations . " } 5 : { 1 : 1 } } 1223 : { 1 : "NN nsubj VBG dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubj acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 1 } } 1224 : { 1 : "NN dep VBG dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dep acting dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 1 } } 1225 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod produced acl tendency dobj *increase* nsubj drugs dep drug0" } 4 : { 1 : "Drugs that reduce the number of blood platelets by causing bone marrow depression ( such as drug1 ) or drugs which inhibit platelet function ( eg , drug2 and other drug3 , drug4 , drug5 , drug6 , drug7 ) may increase the bleeding tendency produced by drug8 without altering prothrombin time determinations . " } 5 : { 1 : 1 } } 1226 : { 1 : "NN compound NNS nmod JJ nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound preparations nmod *incompatible* nsubj preparations compound drug0" } 4 : { 1 : "drug1 preparations are incompatible with drug2 preparations . " } 5 : { 1 : 1 } } 1227 : { 1 : "NN nmod VBN acl NN dobj VB nsubj NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod produced acl tendency dobj *increase* nsubj drugs dep drug0 appos drug0" } 4 : { 1 : "Drugs that reduce the number of blood platelets by causing bone marrow depression ( such as drug1 ) or drugs which inhibit platelet function ( eg , drug2 and other drug3 , drug4 , drug5 , drug6 , drug7 ) may increase the bleeding tendency produced by drug8 without altering prothrombin time determinations . " } 5 : { 1 : 1 } } 1228 : { 1 : "NN dobj VBN acl:relcl NN dep NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj given acl:relcl toxicity dep *symptoms* nmod drug0" } 4 : { 1 : "In another report , nine patients with breast cancer were reported to have decreased symptoms of drug1 - related toxicity when given supplemental drug2 at a dose of 0.5 gram/kilogram/day . " } 5 : { 1 : 1 } } 1229 : { 1 : "NN dobj VBN acl:relcl NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj received acl:relcl patient nmod *use* nmod drug0" } 4 : { 1 : "Use of drug1 in a patient who has previously received drug2 increases the risk of cardiotoxicity . " } 5 : { 1 : 1 } } 1230 : { 1 : "NN compound NNS dep NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound deficiencies dep drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 1 } } 1231 : { 1 : "NN compound SYM dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound * dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; " } 5 : { 1 : 1 } } 1232 : { 1 : "NN dep JJ parataxis SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dep high parataxis * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1233 : { 1 : "CD nummod SYM dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nummod * dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1234 : { 1 : "NN dep VBP parataxis VBD nsubj NNS acl:relcl VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dep include parataxis *increased* nsubj drugs acl:relcl increase dobj response compound drug0" } 4 : { 1 : "Drugs that reportedly may increase oral drug1 response , ie , increased prothrombin response , in man include : drug2 * ; drug3 ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 ; drug9 * ; drug10 ; drug11 ; drug12 ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; dietary deficiencies ; drug18 ; drug19 ; drugs affecting blood elements ; drug20 ; drug21 ; drug22 ; hepatotoxic drugs ; drug23 ; drug24 ; drug25 ; inhalation drug26 ; drug27 ; drug28 ; drug29 ; drug30 ; drug31 ; drug32 ; drug33 ; drug34 ; drug35 ; drug36 ; drug37 ; drug38 ; drug39 ; drug40 ; prolonged hot weather ; drug41 ; drug42 ; drug43 ; drug44 ; drug45 * ; drug46 ; drug47 ; drug48 , long acting ; drug49 ; drug50 ; drug51 ; drug52 ; drug53 / drug54 ; unreliable prothrombin time determinations ; drug55 overdosage . " } 5 : { 1 : 1 } } 1235 : { 1 : "NN nmod JJ parataxis SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod high parataxis * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1236 : { 1 : "NN conj NN dep SYM dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep * dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1237 : { 1 : "NN compound SYM dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound * dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1238 : { 1 : "NN compound NN conj NN dep SYM dep SYM dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound under-dosage conj drug0 dep * dep * dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; drug3 * ; drug4 ; drug5 ; drug6 ; drug7 ; drug8 * ; drug9 ; drug10 ; diet high in drug11 ; drug12 * ; drug13 ; drug14 ; drug15 ; drug16 ; drug17 ; oral drug18 ; drug19 ; drug20 ; drug21 * ; drug22 ; unreliable prothrombin time determinations ; drug23 ; drug24 under-dosage . " } 5 : { 1 : 1 } } 1239 : { 1 : "NN dep NN nmod VBD nsubj NNS acl:relcl VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dep man nmod *decreased* nsubj drugs acl:relcl reported xcomp diminish dobj response compound drug0" } 4 : { 1 : "Drugs that have been reported to diminish oral drug1 response , ie , decreased prothrom-bin time response , in man significantly include : drug2 ; " } 5 : { 1 : 1 } } 1240 : { 1 : "NN nmod NNS dobj VBN acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod doses dobj received acl:relcl patients nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used in patients who have previously received the recommended maximum cumulative doses of drug2 or drug3 . " } 5 : { 1 : 1 } } 1241 : { 1 : "NN nmod JJ conj TO mark VB acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concurrent conj to mark result acl *use* nmod drug0" } 4 : { 1 : "Because drug1 is eliminated from the body via conjugation with glutathione , use of drug2 prior to ( 72 hours ) or concurrent with drug3 may result in reduced drug4 clearance based upon the known property of drug5 to decrease glutathione levels in the blood and tissues . " } 5 : { 1 : 1 } } 1242 : { 1 : "NN nmod NN dobj VBG acl NNS conj NN nmod NN nmod VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod treatment dobj discontinuing acl days conj drug0 nmod combination nmod *used* nsubjpass tablets compound drug0" } 4 : { 1 : "Therefore , it is recommended that drug1 Tablets not be used in combination with drug2 , or within 14 days of discontinuing treatment with a drug3 . " } 5 : { 1 : 1 } } 1243 : { 1 : "NN appos NN nmod NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod combination nmod *receiving* dobj drug0" } 4 : { 1 : "In patients receiving another drug1 in combination with drug2 ( drug3 ) , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma . " } 5 : { 1 : 1 } } 1244 : { 1 : "FW advmod VBG acl NNS nmod NN nmod NN dobj VB acl:relcl NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 advmod sharing acl products nmod interaction nmod potential dobj present acl:relcl activity dobj *demonstrates* nsubj drug0" } 4 : { 1 : "drug1 demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. drug2 . " } 5 : { 1 : 1 } } 1245 : { 1 : "NN dobj VBG advcl VBN advcl VBG dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj starting advcl *allowed* advcl stopping dobj tablets compound drug0" } 4 : { 1 : "After stopping drug1 Tablets , at least 2 weeks should be allowed before starting a drug2 . " } 5 : { 1 : 1 } } 1246 : { 1 : "NN nmod VBN xcomp JJ advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod reduced xcomp likely advcl *used* nsubjpass drug0" } 4 : { 1 : "Other Potentially Important Drug Interactions : drug1 : drug2 metabolized by hepatic oxidation ( e.g. , drug3 , drug4 , drug5 elc . ) should be used with caution because the clearance of these drugs is likely to be reduced by drug6 . " } 5 : { 1 : 1 } } 1247 : { 1 : "NN nsubj VBZ ccomp VBN conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nsubj blocks ccomp demonstrated conj *metabolized* nsubjpass drug0" } 4 : { 1 : "drug1 , drug2 and drug3 are all metabolized by the cytochrome P450IIIA4 isozyme , and it has been demonstrated that drug4 , a potent inhibitor of IIIA4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug . " } 5 : { 1 : 1 } } 1248 : { 1 : "NN nmod VBN xcomp JJ advcl VBN nsubjpass NN acl VBN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod reduced xcomp likely advcl *used* nsubjpass drug0 acl metabolized nmod oxidation dep drug0" } 4 : { 1 : "Other Potentially Important Drug Interactions : drug1 : drug2 metabolized by hepatic oxidation ( e.g. , drug3 , drug4 , drug5 elc . ) should be used with caution because the clearance of these drugs is likely to be reduced by drug6 . " } 5 : { 1 : 1 } } 1249 : { 1 : "NN nmod VBN acl NNS nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod *studied* nsubjpass pharmacokinetics nmod drug0" } 4 : { 1 : "Since the pharmacokinetics of drug1 were studied in patients treated with drug2 , the clearance of drug3 at the recommended dose may be lower and exposure ( AUC ) higher in patients not treated with drug4 . " } 5 : { 1 : 1 } } 1250 : { 1 : "NN nmod NN dobj VB csubj VBN ccomp VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod clearance dobj *influence* csubj known ccomp inhibited nmod products nmod drug0" } 4 : { 1 : "It is known that CYP1A2 is inhibited by several medicinal products , including drug1 , and such medicinal products could theoretically adversely influence the clearance of drug2 . " } 5 : { 1 : 1 } } 1251 : { 1 : "NN nmod VBN acl NNS nmod VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod anaesthetised acl patients nmod *exercised* nmod administration nmod drug0" } 4 : { 1 : "Caution should be exercised during the administration of drug1 to patients anaesthetised with drug2 as arrhythmias may be precipitated . " } 5 : { 1 : 1 } } 1252 : { 1 : "NN nmod NN dobj VB acl:relcl NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod withdrawal dobj follow acl:relcl hypertension dobj *exacerbate* nsubj drug0" } 4 : { 1 : "drug1 may exacerbate the rebound hypertension which can follow the withdrawal of drug2 . " } 5 : { 1 : 1 } } 1253 : { 1 : "NN compound NN nmod VBN advcl VB nsubj NNS dep FW appos NN" 2 : 1 3 : { 1 : "drug0 compound s. nmod given advcl *have* nsubj drugs dep eg appos drug0" } 4 : { 1 : "Catecholamine-depleting drugs ( eg , drug1 ) may have an additive effect when given with drug2 s. " } 5 : { 1 : 1 } } 1254 : { 1 : "NN nmod NN dobj VB conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod inhibition dobj enhance conj *had* nsubj drug0" } 4 : { 1 : "drug1 alone had no effect on platelet aggregation , but did slightly enhance the inhibition of platelet aggregation by drug2 . " } 5 : { 1 : 1 } } 1255 : { 1 : "NN compound NN nsubj VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound administration nsubj stopped advcl *delayed* nsubjpass introduction nmod drug0" } 4 : { 1 : "If replacing drug1 by drug2 therapy , the introduction of drug3 should be delayed for several days after drug4 administration has stopped . " } 5 : { 1 : 1 } } 1256 : { 1 : "NN nmod NNS conj NNS nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects conj s nmod action dobj *augments* nsubj drug0" } 4 : { 1 : "drug1 augments the action of drug2 s and the muscle relaxant effects of drug3 . " } 5 : { 1 : 1 } } 1257 : { 1 : "NN nmod NNS dobj VB nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj *decrease* nsubj use appos drug0" } 4 : { 1 : "Concomitant use of prostaglandin synthase inhibiting drugs , eg , drug1 , may decrease the hypotensive effects of drug2 . " } 5 : { 1 : 1 } } 1258 : { 1 : "NN nmod NN nmod VBN acl NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect nmod caused acl hypotension dobj *augment* nsubj drug0" } 4 : { 1 : "drug1 may augment the hypotension caused by the ganglionic-blocking effect of drug2 . " } 5 : { 1 : 1 } } 1259 : { 1 : "NN compound NN dobj VB xcomp JJ nsubj NN nmod NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound exposure dobj reduce xcomp *likely* nsubj suppression nmod drug0 conj drug0 dep drug0 conj drug0" } 4 : { 1 : "drug1 / drug2 : Long-term suppression of gastric acid secretion by drug3 or drug4 ( eg , drug5 and drug6 ) is likely to reduce drug7 exposure . " } 5 : { 1 : 1 } } 1260 : { 1 : "NN dobj VBG advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj displacing advcl *cause* nsubj drug0" } 4 : { 1 : "drug1 may cause an increased prothrombin response by displacing the drug2 from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction , thus leading to inter-patient variation in ultimate prothrombin effect . " } 5 : { 1 : 1 } } 1261 : { 1 : "NN dobj VBN acl NNS nmod VBN nsubjpass NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj administered acl patients nmod *demonstrated* nsubjpass resistance nmod action nmod drug0" } 4 : { 1 : "Resistance to the neuromuscular blocking action of drug1 has been demonstrated in patients chronically administered drug2 or drug3 . " } 5 : { 1 : 1 } } 1262 : { 1 : "NN nmod NNS nmod VBD nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod pharmacokinetics nmod *had* nsubj co-administration nmod drug0 conj drug0" } 4 : { 1 : "Co-administration with drug1 or drug2 had a modest effect on the pharmacokinetics of drug3 . " } 5 : { 1 : 1 } } 1263 : { 1 : "NN nmod NNS nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod pharmacokinetics nmod *had* nsubj co-administration nmod drug0" } 4 : { 1 : "Co-administration with drug1 or drug2 had a modest effect on the pharmacokinetics of drug3 . " } 5 : { 1 : 1 } } 1264 : { 1 : "NN conj NN dep NN nmod NNS nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep drug0 nmod pharmacokinetics nmod *had* nsubj drug0" } 4 : { 1 : "When used in therapeutic doses , drug1 had a modest effect on the pharmacokinetics of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( intravenous and oral ) , drug13 , drug14 / drug15 or drug16 . " } 5 : { 1 : 1 } } 1265 : { 1 : "NN compound NN dobj VB xcomp VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj require xcomp found acl:relcl *drug0*" } 4 : { 1 : "Patients stabilized on oral drug1 who are found to require drug2 replacement therapy should be watched very closely when thyroid is started . " } 5 : { 1 : 1 } } 1266 : { 1 : "NN nsubjpass VBN advcl VB xcomp VB nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass given advcl increase xcomp *need* nsubj patients nmod gland compound drug0" } 4 : { 1 : "Therefore , patients without a functioning drug1 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug2 or drug3 - containing oral drug4 are given . " } 5 : { 1 : 1 } } 1267 : { 1 : "NN conj NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj *binds* nsubj drug0" } 4 : { 1 : "drug1 : drug2 binds both drug3 and drug4 in the intestine , thus impairing absorption of these drug5 . " } 5 : { 1 : 1 } } 1268 : { 1 : "NN dobj VBG acl NN nsubjpass VBN advcl VB xcomp VB nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nsubjpass given advcl increase xcomp *need* nsubj patients nmod gland compound drug0" } 4 : { 1 : "Therefore , patients without a functioning drug1 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug2 or drug3 - containing oral drug4 are given . " } 5 : { 1 : 1 } } 1269 : { 1 : "NN nsubj VB advcl VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj *cause* advcl administered nmod patients nmod drug0" } 4 : { 1 : "drug1 : When administered to patients on a drug2 , this parenteral drug3 may cause hypertension and tachycardia . " } 5 : { 1 : 1 } } 1270 : { 1 : "NN dep NN nmod NNS nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod pharmacokinetics nmod *had* nsubj drug0" } 4 : { 1 : "When used in therapeutic doses , drug1 had a modest effect on the pharmacokinetics of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( intravenous and oral ) , drug13 , drug14 / drug15 or drug16 . " } 5 : { 1 : 1 } } 1271 : { 1 : "NN nmod NN nmod JJ nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod steady-state nmod *co-administration* nmod drug0" } 4 : { 1 : "Co-administration of drug1 at steady-state with a single dose of drug2 ( 2 x 600 mg tablets ) results in increased drug3 serum concentrations . " } 5 : { 1 : 1 } } 1272 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS acl VBN xcomp VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass substrates acl known xcomp have dobj index nmod drug0" } 4 : { 1 : "Therefore , CYP3A4 substrates known to have a narrow therapeutic index such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , or drug11 ( drug12 , drug13 ) should be administered with caution in patients receiving drug14 . " } 5 : { 1 : 1 } } 1273 : { 1 : "NN compound NN dobj VBG acl NNS nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj receiving acl patients nmod *place* nmod drug0 conj drug0" } 4 : { 1 : "The use of drug1 should be considered in place of drug2 or drug3 in patients receiving drug4 therapy . " } 5 : { 1 : 1 } } 1274 : { 1 : "NN nmod NNS nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod pharmacokinetics nmod *had* nsubj drug0" } 4 : { 1 : "When used in therapeutic doses , drug1 had a modest effect on the pharmacokinetics of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 ( intravenous and oral ) , drug13 , drug14 / drug15 or drug16 . " } 5 : { 1 : 1 } } 1275 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS acl VBN xcomp VB dobj NN nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass substrates acl known xcomp have dobj index nmod drug0 conj drug0 dep drug0" } 4 : { 1 : "Therefore , CYP3A4 substrates known to have a narrow therapeutic index such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , or drug11 ( drug12 , drug13 ) should be administered with caution in patients receiving drug14 . " } 5 : { 1 : 1 } } 1276 : { 1 : "NN nmod NN nmod JJ nsubj VBZ advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod interaction nmod potential nsubj *is* advcl absorbed nsubjpass drug0" } 4 : { 1 : "drug1 : Although drug2 is minimally absorbed into the systemic circulation , there is some potential for an additive interaction with concomitantly used drug3 . " } 5 : { 1 : 1 } } 1277 : { 1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NNS acl VBN xcomp VB dobj NN nmod NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod caution nmod *administered* nsubjpass substrates acl known xcomp have dobj index nmod drug0 conj drug0 dep drug0 appos drug0" } 4 : { 1 : "Therefore , CYP3A4 substrates known to have a narrow therapeutic index such as drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , or drug11 ( drug12 , drug13 ) should be administered with caution in patients receiving drug14 . " } 5 : { 1 : 1 } } 1278 : { 1 : "NN nmod VBN nmod NN nmod NNP compound NN" 2 : 1 3 : { 1 : "drug0 nmod *advised* nmod coadministration nmod aerosol compound drug0" } 4 : { 1 : "Caution is therefore advised in the coadministration of drug1 Inhalation Aerosol with other drug2 - containing drugs . " } 5 : { 1 : 1 } } 1279 : { 1 : "NN conj NN dobj VBN acl NNS nmod VBN nsubjpass NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj administered acl patients nmod *demonstrated* nsubjpass resistance nmod action nmod drug0" } 4 : { 1 : "Resistance to the neuromuscular blocking action of drug1 has been demonstrated in patients chronically administered drug2 or drug3 . " } 5 : { 1 : 1 } } 1280 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod catecholamines nmod effect dobj *increases* nsubj drug0" } 4 : { 1 : "drug1 s : drug2 increases the adrenergic effect of catecholamines such as drug3 and drug4 . " } 5 : { 1 : 1 } } 1281 : { 1 : "NN nmod NN nsubjpass VBN root , punct DT root IN dep VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nsubjpass employed root , punct all root if dep *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with caution , if at all , when potent inhalational drug2 such as drug3 are employed because of potential to sensitize the myocardium to effects of drug4 . " } 5 : { 1 : 1 } } 1282 : { 1 : "NN nmod NNS conj NN nsubj JJ nmod NNS nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod rates conj dosing nsubj *necessary* nmod procedures nmod drug0 conj anesthesia compound drug0" } 4 : { 1 : "In long surgical procedures during drug1 or drug2 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of drug3 may be necessary . " } 5 : { 1 : 1 } } 1283 : { 1 : "NN nmod NNS conj NN nsubj JJ nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod rates conj dosing nsubj *necessary* nmod procedures nmod drug0" } 4 : { 1 : "In long surgical procedures during drug1 or drug2 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of drug3 may be necessary . " } 5 : { 1 : 1 } } 1284 : { 1 : "NN nmod NN dobj VB conj VB parataxis NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod rate dobj decrease conj prolong parataxis *drug0* acl administered nmod drug0" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1285 : { 1 : "NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 1 } } 1286 : { 1 : "NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0 nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 1 } } 1287 : { 1 : "NN compound NNS conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound salts conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 1 } } 1288 : { 1 : "NN compound NNS conj NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound salts conj drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod drug0 nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . " } 5 : { 1 : 1 } } 1289 : { 1 : "NN nsubjpass VBN root , punct DT root IN dep VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nsubjpass employed root , punct all root if dep *used* nsubjpass drug0" } 4 : { 1 : "drug1 should be used with caution , if at all , when potent inhalational drug2 such as drug3 are employed because of potential to sensitize the myocardium to effects of drug4 . " } 5 : { 1 : 1 } } 1290 : { 1 : "NN nmod NNS nmod NN nmod NN dobj VB parataxis NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod action nmod duration dobj prolong parataxis *drug0* acl administered nmod drug0" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1291 : { 1 : "NN nmod NNS nmod NN nmod NN dobj VB parataxis NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod action nmod duration dobj prolong parataxis *drug0* conj drug0" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1292 : { 1 : "NN nmod NN dobj VBZ acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj inhibits acl:relcl *drug0*" } 4 : { 1 : "The effects of drug1 may be potentiated by drug2 which inhibits the metabolism of drug3 . " } 5 : { 1 : 1 } } 1293 : { 1 : "NN dep VBN root DT conj NN" 2 : 1 3 : { 1 : "drug0 dep administered root a conj *drug0*" } 4 : { 1 : "Even when an drug1 and a drug2 - type drug are administered separately by different routes , a reduction in drug3 serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function . " } 5 : { 1 : 1 } } 1294 : { 1 : "NN nmod NN dobj VB conj VB parataxis NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod rate dobj decrease conj prolong parataxis *drug0* conj drug0" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1295 : { 1 : "NN nmod NN nmod RBR nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod *faster* nsubj time nmod onset nmod drug0" } 4 : { 1 : "The time to onset of maximum block following drug1 is approximately 2 minutes faster with prior administration of drug2 . " } 5 : { 1 : 1 } } 1296 : { 1 : "NN nmod NN dobj VB conj VB parataxis NN" 2 : 1 3 : { 1 : "drug0 nmod rate dobj decrease conj prolong parataxis *drug0*" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1297 : { 1 : "NN nmod NNS nmod NN nmod NN dobj VB parataxis NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod action nmod duration dobj prolong parataxis *drug0*" } 4 : { 1 : "drug1 or drug2 administered with drug3 / drug4 to achieve 1.25 MAC [ Minimum Alveolar Concentration ] may prolong the clinically effective duration of action of initial and maintenance doses of drug5 and decrease the required infusion rate of drug6 . " } 5 : { 1 : 1 } } 1298 : { 1 : "NN nsubjpass VBN advcl VBG advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl postmarketing advcl *reported* nsubjpass levels compound drug0" } 4 : { 1 : "drug1 : Elevated drug2 levels have been reported in postmarketing experience when drug3 is administered concomitantly . " } 5 : { 1 : 1 } } 1299 : { 1 : "NN nmod NN nmod NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *use* nmod drug0 appos system compound drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 1 } } 1300 : { 1 : "NN dep NN conj NN nmod VBN dep VBG acl NN nmod NN nmod NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0 appos system compound drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 1 } } 1301 : { 1 : "NN nmod NN nsubj VBN ccomp JJ conj VBN nmod NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod administration nsubj enhanced ccomp possible conj *reported* nmod patients acl receiving dobj drug0" } 4 : { 1 : "Lymphocytopenia has been reported in patients receiving drug1 , and it is possible that the administration of drug2 as antiemetic prophylaxis may have enhanced the likelihood of this effect . " } 5 : { 1 : 1 } } 1302 : { 1 : "NN appos NN dobj VBG acl NNS nmod JJR nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dobj taking acl patients nmod *greater* nsubj clearance compound drug0" } 4 : { 1 : "drug1 ( drug2 ) : Population pharmacokinetic analyses indicate that drug3 clearance is 60 % greater in patients taking drug4 ( drug5 ) with or without other enzyme-inducing drug6 . " } 5 : { 1 : 1 } } 1303 : { 1 : "NN nmod VBN acl:relcl NN acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod administered acl:relcl *drug0* acl containing dobj drug0" } 4 : { 1 : "drug1 containing drug2 , when administered concomitantly with drug3 , reduce both the rate and extent of absorption . " } 5 : { 1 : 1 } } 1304 : { 1 : "NN nmod NN nmod VB dobj NN" 2 : 1 3 : { 1 : "drug0 nmod dosing nmod *withhold* dobj drug0" } 4 : { 1 : "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by drug1 , the physician may wish to withhold drug2 during dosing with drug3 and , certainly , during periods of active vomiting or diarrhea . " } 5 : { 1 : 1 } } 1305 : { 1 : "NN nmod NN conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod route conj *produce* nsubj drug0" } 4 : { 1 : "drug1 : Because drug2 can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of drug3 including drug4 , there is a risk that an interaction will lead to deterioration . " } 5 : { 1 : 1 } } 1306 : { 1 : "CD nsubj VB dep IN dep NN nmod:tmod VB dobj NN" 2 : 1 3 : { 1 : "drug0 nsubj avoid dep before dep hour nmod:tmod *take* dobj drug0" } 4 : { 1 : "drug1 : Since drug2 may bind other drugs given concurrently , patients should take drug3 at least 1 hour before or 4-6 hours after a drug4 to avoid impeding its absorption . " } 5 : { 1 : 1 } } 1307 : { 1 : "NN nmod NN nmod NN conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod route conj *produce* nsubj drug0" } 4 : { 1 : "drug1 : Because drug2 can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of drug3 including drug4 , there is a risk that an interaction will lead to deterioration . " } 5 : { 1 : 1 } } 1308 : { 1 : "CD nsubj VB dep IN dep NN dobj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nsubj avoid dep before dep hour dobj *taken* nsubjpass drug0" } 4 : { 1 : "Therefore , drug1 should be taken at least 1 hour before or 4-6 hours after a drug2 to avoid impeding its absorption . " } 5 : { 1 : 1 } } 1309 : { 1 : "NN dobj VBN advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj received advcl *ineffective* nsubj drug0" } 4 : { 1 : "Animal studies indicate that drug1 may be ineffective if the patient has recently received a drug2 . " } 5 : { 1 : 1 } } 1310 : { 1 : "NN compound NN dobj VBG acl NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj beginning acl *patients* compound drug0" } 4 : { 1 : "drug1 levels may be decreased ; increased dosages may be required to prevent symptoms of drug2 withdrawal . drug3 maintained patients beginning drug4 therapy should be monitored forevidence of withdrawal and drug5 dose should be adjusted accordingly . " } 5 : { 1 : 1 } } 1311 : { 1 : "NN dobj VBG conj VBG advcl VBN dep VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj discontinuing conj initiating advcl recommended dep *increased* dobj monitoring nmod drug0" } 4 : { 1 : "Therefore , increased monitoring of drug1 is recommended when initiating , adjusting , or discontinuing drug2 . " } 5 : { 1 : 1 } } 1312 : { 1 : "NN nmod NN nsubjpass VBN conj VBN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod dose nsubjpass adjusted conj *monitored* nmod initiation nmod therapy compound drug0" } 4 : { 1 : "Due to wide interindividual variability in the dose adjustment required , it is recommended that drug1 concentrations be monitored closely after initiation of drug2 therapy and that the dose of drug3 be adjusted as appropriate . " } 5 : { 1 : 1 } } 1313 : { 1 : "NN dep VBP nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep *result* nmod efficacy nmod drug0" } 4 : { 1 : "Compounds in these categories result in a decreased efficacy of drug1 : drug2 , drug3 , drug4 , drug5 . " } 5 : { 1 : 1 } } 1314 : { 1 : "NN compound NN nmod NN nmod VBN xcomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound type nmod drug0 nmod administered xcomp *is* nsubj drug0" } 4 : { 1 : "As with other drug1 , if drug2 is to be administered orally with drug3 of the drug4 or drug5 type , it is recommended that ECG and blood pressure be monitored . " } 5 : { 1 : 1 } } 1315 : { 1 : "NN dobj VBG acl NN nmod NN dobj JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl inwomen nmod method dobj *usedas* nsubj drug0" } 4 : { 1 : "Oral drug1 and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking drug2 , since nevirapinemay lower the plasma levels of thesemedications . " } 5 : { 1 : 1 } } 1316 : { 1 : "NN conj NN compound NN nmod NN nmod VBN xcomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 compound type nmod drug0 nmod administered xcomp *is* nsubj drug0" } 4 : { 1 : "As with other drug1 , if drug2 is to be administered orally with drug3 of the drug4 or drug5 type , it is recommended that ECG and blood pressure be monitored . " } 5 : { 1 : 1 } } 1317 : { 1 : "NN nmod NN nmod VBN acl NN nmod NN dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod isrecommended acl food nmod drug0 dep *increase* nmod drug0" } 4 : { 1 : "A dose increase of drug1 / drug2 to 533/133 mg twice daily with food isrecommended in combination with drug3 . " } 5 : { 1 : 1 } } 1318 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound treatment nmod initiation nmod *observed* nsubjpass increases nmod concentrations compound drug0" } 4 : { 1 : "drug1 : Modest increases in mean trough drug2 concentrations were observed following initiation of drug3 treatment in 21 renal transplant patients suffering from chronic vascular rejection . " } 5 : { 1 : 1 } } 1319 : { 1 : "NN nmod NN dep JJ xcomp VB dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *administration* dep equivalent xcomp 0mg dobj drug0" } 4 : { 1 : "Concomitant administration of drug1 ( equivalent to 145mg drug2 ) with drug3 ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for drug4 by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 - hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults . " } 5 : { 1 : 1 } } 1320 : { 1 : "NN nmod VBN nsubjpass NNS acl:relcl VB nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *worsened* nsubjpass changes acl:relcl result nmod administration nmod drug0" } 4 : { 1 : "The ECG changes and/or hypokalemia that may result from the administration of drug1 ( such as drug2 or drug3 ) can be acutely worsened by drug4 , especially when the recommended dose of the drug5 is exceeded . " } 5 : { 1 : 1 } } 1321 : { 1 : "NN conj NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 conj b.i.d. dep *mg* compound drug0" } 4 : { 1 : "drug1 : Co-administration of drug2 125 mg b.i.d. and drug3 , a potent CYP3A4 inhibitor , increased the plasma concentrations of drug4 by approximately 2-fold . " } 5 : { 1 : 1 } } 1322 : { 1 : "NN nmod NN nmod JJR nmod LS nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod absence nmod higher nmod *0* nsubj concentrations compound drug0" } 4 : { 1 : "Steady-state drug1 plasma concentrations were 3 - to 4-fold higher than in the absence of drug2 . " } 5 : { 1 : 1 } } 1323 : { 1 : "NN nsubj JJ advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nsubj co-administered advcl *reliable* nsubj drug0" } 4 : { 1 : "Therefore , drug1 , including oral , injectable , transdermal , and implantable forms , may not be reliable when drug2 is co-administered . " } 5 : { 1 : 1 } } 1324 : { 1 : "NN nmod NN nmod NNS dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod concentrations dobj reduce xcomp *expected* nsubjpass drug0" } 4 : { 1 : "drug1 is also expected to reduce plasma concentrations of other drug2 that have significant metabolism by CYP3A4 , such as drug3 and drug4 . " } 5 : { 1 : 1 } } 1325 : { 1 : "NN nsubjpass VBN advcl VBD ccomp VB nsubj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass initiated advcl monitored ccomp *have* nsubj patients acl using dobj drug0" } 4 : { 1 : "Patients using CYP3A4 metabolized drug1 should have cholesterol levels monitored after drug2 is initiated to see whether the drug3 dose needs adjustment . " } 5 : { 1 : 1 } } 1326 : { 1 : "NN conj NN nmod NN nmod NNS dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod concentrations dobj reduce xcomp *expected* nsubjpass drug0" } 4 : { 1 : "drug1 is also expected to reduce plasma concentrations of other drug2 that have significant metabolism by CYP3A4 , such as drug3 and drug4 . " } 5 : { 1 : 1 } } 1327 : { 1 : "NN nmod NNS dobj VBD nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj *decreased* nsubj co-administration nmod b.i.d. compound drug0" } 4 : { 1 : "drug1 : Co-administration of drug2 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug3 ( a CYP2C9 substrate ) and drug4 ( a CYP3A4 substrate ) by 29 and 38 % , respectively . " } 5 : { 1 : 1 } } 1328 : { 1 : "NN nmod NNS nsubjpass VBN advcl VBN advcl VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects nsubjpass potentiated advcl *used* advcl are nsubj drug0" } 4 : { 1 : "If additional drug1 are to be administered by any route , they should be used with caution because the pharmacologically predictable sympathetic effects of drug2 may be potentiated . " } 5 : { 1 : 1 } } 1329 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN nmod NNS nmod NNS acl VBG dobj NNP dep NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *treated* nsubjpass patients nmod history nmod reactions nmod products acl containing dobj el dep drug0 nmod concentrate conj drug0" } 4 : { 1 : "Hypersensitivity Reactions : Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL ( eg , drug1 for injection concentrate and drug2 for injection concentrate ) should not be treated with drug3 . " } 5 : { 1 : 1 } } 1330 : { 1 : "NN nmod NN nsubjpass VBN advcl VBN nmod NNS acl VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod action nsubjpass potentiated advcl *administered* nmod patients acl treated nmod drug0 conj drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 1331 : { 1 : "NN nmod VBN nsubjpass NNS acl:relcl VB nmod NN nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *worsened* nsubjpass changes acl:relcl result nmod administration nmod drug0 nmod drug0 conj drug0" } 4 : { 1 : "The ECG changes and/or hypokalemia that may result from the administration of drug1 ( such as drug2 or drug3 ) can be acutely worsened by drug4 , especially when the recommended dose of the drug5 is exceeded . " } 5 : { 1 : 1 } } 1332 : { 1 : "NN nmod VBN nsubjpass NNS acl:relcl VB nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *worsened* nsubjpass changes acl:relcl result nmod administration nmod drug0 nmod drug0" } 4 : { 1 : "The ECG changes and/or hypokalemia that may result from the administration of drug1 ( such as drug2 or drug3 ) can be acutely worsened by drug4 , especially when the recommended dose of the drug5 is exceeded . " } 5 : { 1 : 1 } } 1333 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN nmod NNS nmod NNS acl VBG dobj NNP dep NN" 2 : 1 3 : { 1 : "drug0 nmod *treated* nsubjpass patients nmod history nmod reactions nmod products acl containing dobj el dep drug0" } 4 : { 1 : "Hypersensitivity Reactions : Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL ( eg , drug1 for injection concentrate and drug2 for injection concentrate ) should not be treated with drug3 . " } 5 : { 1 : 1 } } 1334 : { 1 : "NN nmod VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *advised* nmod co-administration nmod drug0" } 4 : { 1 : "Although the clinical significance of these effects is not known , caution is advised in the co-administration of drug1 with drug2 . " } 5 : { 1 : 1 } } 1335 : { 1 : "NN conj NN nmod VBN acl NNS nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod treated acl patients nmod *administered* nmod drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 1336 : { 1 : "NN nmod VBN acl NNS nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod *administered* nmod drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 1337 : { 1 : "NN nmod NN nsubjpass VBN advcl VBN nmod NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod action nsubjpass potentiated advcl *administered* nmod patients acl treated nmod drug0" } 4 : { 1 : "drug1 , as with other drug2 , should be administered with extreme caution to patients being treated with drug3 , drug4 , or drugs known to prolong the QTc interval because the action of drug5 on the cardiovascular system may be potentiated by these agents . " } 5 : { 1 : 1 } } 1338 : { 1 : "NN conj NN nmod NNS dobj VBD nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod concentrations dobj *decreased* nsubj co-administration nmod b.i.d. compound drug0" } 4 : { 1 : "drug1 : Co-administration of drug2 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug3 ( a CYP2C9 substrate ) and drug4 ( a CYP3A4 substrate ) by 29 and 38 % , respectively . " } 5 : { 1 : 1 } } 1339 : { 1 : "NN conj NN dep VB acl:relcl NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep deplete acl:relcl drug conj *drug0*" } 4 : { 1 : "Catecholamine-depleting Agents : Patients taking both drug1 and a drug that can deplete catecholamines ( e.g. , drug2 and drug3 ) should be observed closely for signs of hypotension and/or severe bradycardia . " } 5 : { 1 : 1 } } 1340 : { 1 : "NN nmod NN dep NN nmod NNS dobj VB xcomp VBN conj VBN nsubjpass NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod enantiomer dep r nmod levels dobj increase xcomp expected conj *studied* nsubjpass interactions nmod inhibitors nmod drug0" } 4 : { 1 : "poor metabolizers of drug1 : Interactions of drug2 with strong inhibitors of CYP2D6 ( such as drug3 , drug4 , drug5 , and drug6 ) have not been studied , but these drugs would be expected to increase blood levels of the R ( + ) enantiomer of drug7 . " } 5 : { 1 : 1 } } 1341 : { 1 : "NN compound NN nmod VBN acl NNS nmod NN nmod VBN conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound parenteral nmod treated acl patients nmod caution nmod used conj *potentiate* nsubj drug0" } 4 : { 1 : "drug1 ( eg , drug2 ) and other drugs , including ether , drug3 , drug4 , drug5 and drug6 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug7 Parenteral . " } 5 : { 1 : 1 } } 1342 : { 1 : "NN nmod NN nmod DT conj CC advmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod binding nmod all conj or advmod *interferes* nsubj drug0" } 4 : { 1 : "Protein Binding In vitro , drug1 interferes minimally or not at all with the protein binding of drug2 ( 20 % decrease in binding ) , drug3 , drug4 ( 10 % decrease in binding ) , or drug5 . " } 5 : { 1 : 1 } } 1343 : { 1 : "NN compound NN nmod NN nmod VBN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod initiation nmod *occurred* nmod patient nmod treatment compound drug0" } 4 : { 1 : "drug1 toxicity has been reported to have occurred in a patient on chronic drug2 treatment following the initiation of drug3 therapy . " } 5 : { 1 : 1 } } 1344 : { 1 : "NN compound NN nmod VBN acl NNS nmod NN nmod VBN conj VB nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound parenteral nmod treated acl patients nmod caution nmod used conj *potentiate* nsubj drug0 appos drug0" } 4 : { 1 : "drug1 ( eg , drug2 ) and other drugs , including ether , drug3 , drug4 , drug5 and drug6 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug7 Parenteral . " } 5 : { 1 : 1 } } 1345 : { 1 : "NN dep JJ nmod IN advmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep oral nmod along advmod *receiving* dobj drug0" } 4 : { 1 : "Patients receiving drug1 along with either oral or intravenous drug2 should be monitored for possible atrioventricular conduction disturbances , left ventricular failure and hypotension . " } 5 : { 1 : 1 } } 1346 : { 1 : "NN compound NN nmod NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 compound parenteral nmod nephrotoxicity dobj *enhance* nsubj drug0" } 4 : { 1 : "drug1 may enhance the nephrotoxicity of drug2 Parenteral . " } 5 : { 1 : 1 } } 1347 : { 1 : "NN nmod VBP nsubj NN appos NN compound FW" 2 : 1 3 : { 1 : "drug0 nmod *have* nsubj drug0 appos drug0 compound drug0" } 4 : { 1 : "Other drug1 ( e.g. drug2 , drug3 , drug4 and general drug5 ) have additive or potentiating effects with drug6 . " } 5 : { 1 : 1 } } 1348 : { 1 : "NN nmod VBP nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *have* nsubj drug0 appos drug0" } 4 : { 1 : "Other drug1 ( e.g. drug2 , drug3 , drug4 and general drug5 ) have additive or potentiating effects with drug6 . " } 5 : { 1 : 1 } } 1349 : { 1 : "NN nmod NN nmod NNS nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *changes* nmod effects nmod drug0 conj drug0" } 4 : { 1 : "There are rare reports , however , from marketing experiences , of changes in effects of drug1 or oral drug2 in the presence of drug3 that necessitated changes in the doses of such agents . " } 5 : { 1 : 1 } } 1350 : { 1 : "NN compound NNS dobj VBZ conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj increases conj *decreases* nsubj drug0" } 4 : { 1 : "drug1 : drug2 decreases drug3 renal clearance and increases drug4 plasma levels . " } 5 : { 1 : 1 } } 1351 : { 1 : "NN conj NN dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 to patients receiving drug2 or drug3 such as drug4 which sensitize the myocardium , may induce cardiac arrhythmia . . " } 5 : { 1 : 1 } } 1352 : { 1 : "NN dep NNS nmod NN dobj VBP acl:relcl NNS nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep drugs nmod metabolism dobj affect acl:relcl medications nmod *altered* nsubjpass effects nmod drug0" } 4 : { 1 : "It is not known if the effects of drug1 are altered by concomitant medications that affect hepatic metabolism of drugs ( drug2 , etc. ) , but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed . " } 5 : { 1 : 1 } } 1353 : { 1 : "NN nmod NN nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *changes* nmod effects nmod drug0" } 4 : { 1 : "There are rare reports , however , from marketing experiences , of changes in effects of drug1 or oral drug2 in the presence of drug3 that necessitated changes in the doses of such agents . " } 5 : { 1 : 1 } } 1354 : { 1 : "NN nmod VBN advcl VBN advcl VBN dobj NN" 2 : 1 3 : { 1 : "drug0 nmod seen advcl *exercised* advcl shown dobj drug0" } 4 : { 1 : "drug1 : While studies have not shown drug2 to interact with drug3 , caution should be exercised , nonetheless , since interactions have been seen with other drug4 . " } 5 : { 1 : 1 } } 1355 : { 1 : "NN dobj VBG advcl VBP xcomp VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj taking advcl *begin* xcomp taking dobj drug0" } 4 : { 1 : "Patients who begin taking drug1 or who increase their drug2 dose or any other drug3 while taking drug4 , drug5 , or drug6 may develop toxicity characteristics for these drugs . " } 5 : { 1 : 1 } } 1356 : { 1 : "NN compound NN dobj NN conj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound nephrotoxicity dobj increase conj *increase* nsubj ingestion nmod drug0" } 4 : { 1 : "Ingestion of drug1 may increase serum concentrations of drug2 and drug3 and increase drug4 s nephrotoxicity . " } 5 : { 1 : 1 } } 1357 : { 1 : "NN dobj VBG advcl VBP xcomp VBG dobj NN conj VBP dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj taking advcl *begin* xcomp taking dobj drug0 conj increase dobj dose conj drug0" } 4 : { 1 : "Patients who begin taking drug1 or who increase their drug2 dose or any other drug3 while taking drug4 , drug5 , or drug6 may develop toxicity characteristics for these drugs . " } 5 : { 1 : 1 } } 1358 : { 1 : "NN dep VB acl:relcl NN conj NN" 2 : 1 3 : { 1 : "drug0 dep deplete acl:relcl drug conj *drug0*" } 4 : { 1 : "Catecholamine-depleting Agents : Patients taking both drug1 and a drug that can deplete catecholamines ( e.g. , drug2 and drug3 ) should be observed closely for signs of hypotension and/or severe bradycardia . " } 5 : { 1 : 1 } } 1359 : { 1 : "NN nmod NN nmod VBN advcl VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod use nmod *recommended* advcl observed nsubjpass interaction nmod drug0 conj drug0" } 4 : { 1 : "Although no interaction between drug1 and drug2 has been observed , it is not recommended for use with drug3 . " } 5 : { 1 : 1 } } 1360 : { 1 : "NN nmod NN nmod NN nmod NN dobj VBN acl:relcl NN nmod VBN nsubjpass NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod therapy nmod course dobj received acl:relcl patient nmod *administered* nsubjpass drug0 dep drug0" } 4 : { 1 : "Interactions with drug1 : drug2 ( eg , drug3 , drug4 , drug5 , drug6 and drug7 ) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug8 such as drug9 . " } 5 : { 1 : 1 } } 1361 : { 1 : "NN nmod NN conj NN dep NN nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod action conj function dep way nmod *modulates* nsubj drug0" } 4 : { 1 : "It is concluded that drug1 modulates in an opposite way the function of the enkephalinergic neurons and the central action of drug2 . " } 5 : { 1 : 1 } } 1362 : { 1 : "NN dobj VBP nsubj NNS acl:relcl VB dobj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *include* nsubj drugs acl:relcl enhance dobj action nmod agents nmod drug0" } 4 : { 1 : "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug2 ( e. g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 ) , drug11 salts , drug12 , local drug13 , drug14 , and drug15 . " } 5 : { 1 : 1 } } 1363 : { 1 : "NN compound NN nmod NN nsubj JJ conj VBN advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound dose nmod adjustment nsubj necessary conj *monitored* advcl started nsubjpass drug0" } 4 : { 1 : "It is recommended that if drug1 is started in patients already receiving drug2 , prothrombin times should be closely monitored and adjustment of the drug3 dose may be necessary . " } 5 : { 1 : 1 } } 1364 : { 1 : "NN dobj VBG acl NNS nmod VBN conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod shortened conj *lengthened* nmod drug0" } 4 : { 1 : "As with some other drug1 , the time of onset of neuromuscular block induced by drug2 is lengthened and the duration of block is shortened in patients receiving drug3 or drug4 . " } 5 : { 1 : 1 } } 1365 : { 1 : "NN dobj VBG acl NNS nmod VBN conj VBN nsubjpass NN nmod NN nmod NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod shortened conj *lengthened* nsubjpass time nmod onset nmod block acl induced nmod drug0" } 4 : { 1 : "As with some other drug1 , the time of onset of neuromuscular block induced by drug2 is lengthened and the duration of block is shortened in patients receiving drug3 or drug4 . " } 5 : { 1 : 1 } } 1366 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBN conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod shortened conj *lengthened* nmod drug0" } 4 : { 1 : "As with some other drug1 , the time of onset of neuromuscular block induced by drug2 is lengthened and the duration of block is shortened in patients receiving drug3 or drug4 . " } 5 : { 1 : 1 } } 1367 : { 1 : "NN conj NN dobj VBG acl NNS nmod VBN conj VBN nsubjpass NN nmod NN nmod NN acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj receiving acl patients nmod shortened conj *lengthened* nsubjpass time nmod onset nmod block acl induced nmod drug0" } 4 : { 1 : "As with some other drug1 , the time of onset of neuromuscular block induced by drug2 is lengthened and the duration of block is shortened in patients receiving drug3 or drug4 . " } 5 : { 1 : 1 } } 1368 : { 1 : "NN nmod NN nmod NN nmod NN dobj VBN acl:relcl NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod therapy nmod course dobj received acl:relcl patient nmod *administered* nsubjpass drug0" } 4 : { 1 : "Interactions with drug1 : drug2 ( eg , drug3 , drug4 , drug5 , drug6 and drug7 ) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug8 such as drug9 . " } 5 : { 1 : 1 } } 1369 : { 1 : "NN dobj VBG acl NN nmod VBN xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj containing acl drug0 nmod ingested xcomp *recommended* nsubjpass drug0" } 4 : { 1 : "The clinical significance of this reduction is not known , hence drug1 is not recommended to be ingested simultaneously with drug2 / drug3 - containing drug4 . " } 5 : { 1 : 1 } } 1370 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod ingested xcomp *recommended* nsubjpass drug0" } 4 : { 1 : "The clinical significance of this reduction is not known , hence drug1 is not recommended to be ingested simultaneously with drug2 / drug3 - containing drug4 . " } 5 : { 1 : 1 } } 1371 : { 1 : "NN dep NNS nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep drugs nmod metabolism nmod interact xcomp *known* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 is known to interact with the metabolism or renal tubular excretion of many drugs ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 agents , drug15 , and drug16 ) . " } 5 : { 1 : 1 } } 1372 : { 1 : "NN nmod NN nmod VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod coadministration nmod *decreased* nsubj concentrations nmod drug0" } 4 : { 1 : "Plasma concentrations ( AUC 0-24 hrs ) of drug1 decreased 15 % with coadministration of drug2 relative to that observed with drug3 alone . " } 5 : { 1 : 1 } } 1373 : { 1 : "NN dep NN nmod VBN xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod ingested xcomp *recommended* nsubjpass drug0" } 4 : { 1 : "The clinical significance of this reduction is not known , hence drug1 is not recommended to be ingested simultaneously with drug2 / drug3 - containing drug4 . " } 5 : { 1 : 1 } } 1374 : { 1 : "NN compound NNS conj NN dep NNS nmod NN nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound agents conj drug0 dep drugs nmod metabolism nmod interact xcomp *known* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 is known to interact with the metabolism or renal tubular excretion of many drugs ( e.g. , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 agents , drug15 , and drug16 ) . " } 5 : { 1 : 1 } } 1375 : { 1 : "NN nmod NN nmod VBG acl NNS dobj VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod clearance nmod interfering acl events dobj *increase* nsubj drugs nmod drug0" } 4 : { 1 : "drug1 , drug2 , and drug3 : Drugs such as drug4 , drug5 , and drug6 may increase the risk of developing peripheral neuropathy or other drug7 - associated adverse events by interfering with the renal clearance of drug8 ( thereby raising systemic exposure ) . " } 5 : { 1 : 1 } } 1376 : { 1 : "NN conj NN dobj VBG acl NN dobj VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj neuropathy dobj developing acl risk dobj *increase* nsubj drugs nmod drug0" } 4 : { 1 : "drug1 , drug2 , and drug3 : Drugs such as drug4 , drug5 , and drug6 may increase the risk of developing peripheral neuropathy or other drug7 - associated adverse events by interfering with the renal clearance of drug8 ( thereby raising systemic exposure ) . " } 5 : { 1 : 1 } } 1377 : { 1 : "NN nmod NN dobj VBZ nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod elimination dobj *decreases* nsubj administration nmod drug0 conj drug0" } 4 : { 1 : "drug1 or drug2 : Concomitant administration of drug3 or drug4 decreases the elimination of drug5 , most likely by inhibition of renal tubular secretion of drug6 . " } 5 : { 1 : 1 } } 1378 : { 1 : "NN compound NN nmod VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound spray nmod administered advcl *diminished* nsubjpass effect nmod drug0" } 4 : { 1 : "These results suggest that the analgesic effect of drug1 may be diminished when it is administered shortly after drug2 nasal spray , but by 30 minutes any such reduction in effect should be minimal . " } 5 : { 1 : 1 } } 1379 : { 1 : "NN nmod NN nmod NN nmod NN dep CD nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treatment nmod start nmod % dep 0 nmod *reduced* nsubjpass dose nmod drug0" } 4 : { 1 : "For this reason , the dose of the drug1 should be reduced by 30 - 50 % at the start of treatment with drug2 or drug3 retard and then titrated according to the blood clotting parameters " } 5 : { 1 : 1 } } 1380 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *enhanced* nsubjpass action nmod drug0 conj drug0" } 4 : { 1 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . " } 5 : { 1 : 1 } } 1381 : { 1 : "NN compound NNS nmod NN nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound levels nmod increase nmod *resulted* nsubj coadministration nmod drug0" } 4 : { 1 : "Coadministration with drug1 ( 40 mg BID for 7 days ) resulted in a significant increase in drug2 plasma levels suggesting that , at these doses , drug3 is a weak inhibitor of 2D6 . " } 5 : { 1 : 1 } } 1382 : { 1 : "NN compound NN nmod NN nmod VBN ccomp VBD nmod NN" 2 : 1 3 : { 1 : "drug0 compound coadministration nmod loss nmod monitored ccomp *stabilized* nmod drug0" } 4 : { 1 : "Patients already stabilized on drug1 should be closely monitored for loss of symptom control with drug2 coadministration . " } 5 : { 1 : 1 } } 1383 : { 1 : "NN nmod NNS nmod VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod doses nmod co-administered advcl *decreased* nsubjpass exposure nmod drug0" } 4 : { 1 : "drug1 ( drug2 ) : Steady state plasma exposure ( AUC ) of drug3 ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of drug4 ( a CYP 3A4 inducer ) . " } 5 : { 1 : 1 } } 1384 : { 1 : "NN nmod NNS nmod NN nmod NNS amod JJ" 2 : 1 3 : { 1 : "drug0 nmod doses nmod presence nmod *concentrations* amod drug0" } 4 : { 1 : "Even so drug1 plasma concentrations in the presence of high doses of drug2 were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary . " } 5 : { 1 : 1 } } 1385 : { 1 : "NN nmod NNS nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod exposures nmod increase dobj *caused* nsubj drug0" } 4 : { 1 : "drug1 caused a statistically significant increase in plasma exposures of drug2 and drug3 ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of drug4 . " } 5 : { 1 : 1 } } 1386 : { 1 : "NN compound NN nmod NNS dobj VBD nsubj NNP compound NN" 2 : 1 3 : { 1 : "drug0 compound clearance nmod decreases dobj *produced* nsubj bid compound drug0" } 4 : { 1 : "drug1 : drug2 40 mg BID for 7 days produced significant decreases in drug3 serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to drug4 alone . " } 5 : { 1 : 1 } } 1387 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod exposures nmod increase dobj *caused* nsubj drug0" } 4 : { 1 : "drug1 caused a statistically significant increase in plasma exposures of drug2 and drug3 ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of drug4 . " } 5 : { 1 : 1 } } 1388 : { 1 : "NN nmod NNS conj NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects conj increase dobj *caused* nsubj drug0" } 4 : { 1 : "drug1 caused a statistically significant increase in plasma exposures of drug2 and drug3 ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of drug4 . " } 5 : { 1 : 1 } } 1389 : { 1 : "NN conj NNS conj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj *s* conj agents nmod drug0" } 4 : { 1 : "The concomitant use of drug1 s , vasoconstricting agents ( such as drug2 ) and some drug3 may result in severe hypertension . " } 5 : { 1 : 1 } } 1390 : { 1 : "NN nmod NN nmod VB conj NN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod action nmod sensitize conj *increase* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 or drug2 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug3 , such as drug4 . " } 5 : { 1 : 1 } } 1391 : { 1 : "NN nmod NN nmod RB advmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod prior advmod *treated* nmod drug0" } 4 : { 1 : "Patients who have been treated with drug1 within two to three weeks prior to the administration of drug2 should receive initial doses of drug3 no greater than one-tenth ( 1/10 ) of the usual dose . " } 5 : { 1 : 1 } } 1392 : { 1 : "NN compound NN nmod JJ dep VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound metabolism nmod responsible dep *inhibits* nsubj drug0" } 4 : { 1 : "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 drug1 : drug2 inhibits both aldehyde oxidase ( in vitro ) and CYP3A4 ( in vitro and in vivo ) , the primary and secondary enzymes , respectively , responsible for drug3 metabolism . " } 5 : { 1 : 1 } } 1393 : { 1 : "NN nmod NN nmod NN nmod VB conj NN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod action nmod sensitize conj *increase* nsubj drug0 conj drug0" } 4 : { 1 : "drug1 or drug2 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug3 , such as drug4 . " } 5 : { 1 : 1 } } 1394 : { 1 : "NN nmod VBN nsubjpass NN acl VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *antagonized* nsubjpass vasoconstriction acl caused nmod doses nmod drug0" } 4 : { 1 : "The peripheral vasoconstriction caused by high doses of drug1 is antagonized by drug2 . " } 5 : { 1 : 1 } } 1395 : { 1 : "NN nmod NN nmod VB conj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod action nmod sensitize conj *increase* nsubj drug0" } 4 : { 1 : "drug1 or drug2 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug3 , such as drug4 . " } 5 : { 1 : 1 } } 1396 : { 1 : "NN compound NN dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound vasodilation dobj *suppress* nsubj drug0 nmod drug0" } 4 : { 1 : "drug1 ( such as drug2 ) and drug3 can suppress the drug4 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion . " } 5 : { 1 : 1 } } 1397 : { 1 : "NN nmod NN nmod NN nmod VB conj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod action nmod sensitize conj *increase* nsubj drug0" } 4 : { 1 : "drug1 or drug2 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug3 , such as drug4 . " } 5 : { 1 : 1 } } 1398 : { 1 : "NN compound NN nmod NNS dobj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound g/kg nmod effects dobj *potentiated* nsubj mg compound drug0" } 4 : { 1 : "CNS-Active Drugs drug1 : drug2 10 mg potentiated the CNS-impairing effects of drug3 0.75 g/kg on balance testing and reaction time for 1 hour after drug4 administration and on the digit symbol substitution test ( DSST ) , symbol copying test , and the variability component of the divided attention test for 2.5 hours after drug5 administration . " } 5 : { 1 : 1 } } 1399 : { 1 : "NN compound NNS dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound agents dobj receiving acl patients nmod *therapy* nmod drug0" } 4 : { 1 : "drug1 therapy should be monitored , particularly during the first few weeks , after initiating therapy with drug2 in patients receiving drug3 or similar agents . " } 5 : { 1 : 1 } } 1400 : { 1 : "NN nmod NN nmod VBN acl NNS dobj VB advcl JJ nsubj NN acl:relcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod exposure nmod caused acl effects dobj *experience* advcl sufficient nsubj magnitude acl:relcl coadministered nmod drug0" } 4 : { 1 : "Although the magnitude of changes in drug1 plasma exposure when coadministered with drug2 were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of drug3 under this circumstance . " } 5 : { 1 : 1 } } 1401 : { 1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NNS appos NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *used* nsubjpass inhibitors appos drug0" } 4 : { 1 : "Although clinical studies have not been performed , based on the involvement of the cytochrome P-450 3A family in drug1 metabolism , inhibitors of this enzyme system , notably oral drug2 , should be used cautiously in patients receiving drug3 . " } 5 : { 1 : 1 } } 1402 : { 1 : "NN compound NN dobj VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound metabolism dobj *induce* nsubj inducers nmod drug0" } 4 : { 1 : "Cytochrome P-450 inducers , such as drug1 , drug2 and drug3 , induce drug4 metabolism , causing an approximately 30 % decrease in plasma drug5 levels . " } 5 : { 1 : 1 } } 1403 : { 1 : "NN nmod JJR advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod lower advcl *administered* nsubjpass drug0" } 4 : { 1 : "In a study in which the 2 mg drug1 orally disintegrating tablet was administered with and without drug2 ( an drug3 with multiple effects on the GI tract ) to healthy volunteers , the AUC of drug4 was 10 % lower and the Cmax of drug5 was 20 % lower when the orally disintegrating tablet was given with drug6 compared to when it was given alone . " } 5 : { 1 : 1 } } 1404 : { 1 : "NN nmod NN advcl JJ xcomp VB dobj NN" 2 : 1 3 : { 1 : "drug0 nmod *therapy* advcl necessary xcomp continue dobj drug0" } 4 : { 1 : "If it is necessary to continue the drug1 , initiate therapy with drug2 at a dose of 5 mg daily , and provide close medical supervision after the initial dose until blood pressure has stabilized . " } 5 : { 1 : 1 } } 1405 : { 1 : "NN nmod NNS acl:relcl NNS appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod inducers acl:relcl compounds appos cyp0a nmod *drug0*" } 4 : { 1 : "While no in vivo drug-drug interaction studies were conducted between drug1 and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as drug2 , drug3 , drug4 , and drug5 ) would be expected to decrease drug6 concentrations . " } 5 : { 1 : 1 } } 1406 : { 1 : "NN dobj VBG acl NN nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patient nmod therapy nmod *added* nsubjpass drug0" } 4 : { 1 : "When a drug1 is added to the therapy of a patient receiving drug2 , an additional antihypertensive effect is usually observed . " } 5 : { 1 : 1 } } 1407 : { 1 : "NN compound NNS dobj VB xcomp VBN advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 compound concentrations dobj decrease xcomp *expected* advcl conducted nmod drug0" } 4 : { 1 : "While no in vivo drug-drug interaction studies were conducted between drug1 and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as drug2 , drug3 , drug4 , and drug5 ) would be expected to decrease drug6 concentrations . " } 5 : { 1 : 1 } } 1408 : { 1 : "NN nmod VBN advcl VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod coadministered advcl coadministered advcl *increased* nsubjpass exposure nmod drug0" } 4 : { 1 : "Plasma exposure ( AUC ) to drug1 was increased 62 % when coadministered with drug2 and 38 % when coadministered with drug3 . " } 5 : { 1 : 1 } } 1409 : { 1 : "NN nmod NNS dobj NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj *mask* nsubj drug0" } 4 : { 1 : "In patients who have received drug1 , drug2 may temporarily mask the residual effects of drug3 . " } 5 : { 1 : 1 } } 1410 : { 1 : "NN dobj VBZ conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj inhibits conj *blunts* nsubj drug0" } 4 : { 1 : "- drug1 : drug2 blunts the increases in urine volume and sodium excretion seen during drug3 treatment and inhibits the drug4 - induced increase in plasma renin activity . " } 5 : { 1 : 1 } } 1411 : { 1 : "NN nsubj VBD advcl NNS compound NN" 2 : 1 3 : { 1 : "drug0 nsubj *increased* advcl concentrations compound drug0" } 4 : { 1 : "Based on total drug1 concentrations , drug2 increased the AUC by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively . " } 5 : { 1 : 1 } } 1412 : { 1 : "NN nmod NN dobj VBZ conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod clearance dobj reduces conj *competes* nsubj drug0" } 4 : { 1 : "When drug1 is co-administered with drug2 ( 500 mg p.o. every 6 hours ) , drug3 competes for active tubular secretion and reduces the renal clearance of drug4 . " } 5 : { 1 : 1 } } 1413 : { 1 : "NN conj NN dobj VBG acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dobj receiving acl:relcl patients nmod *administration* nmod drug0" } 4 : { 1 : "Administration of drug1 to patients who are receiving drug2 or drug3 may result in an additive pressor effect . " } 5 : { 1 : 1 } } 1414 : { 1 : "NN nmod NN dobj VB acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod half-life dobj extend acl *coadministration* nmod drug0" } 4 : { 1 : "Because of the small effect on half-life , the coadministration with drug1 to extend the half-life of drug2 is not recommended . " } 5 : { 1 : 1 } } 1415 : { 1 : "NN nmod VBN acl NN dobj VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod produced acl natriuresis dobj *reduces* nsubj pretreatment nmod drug0" } 4 : { 1 : "- drug1 : Pretreatment with drug2 reduces both the natriuresis and hyperreninemia produced by drug3 . " } 5 : { 1 : 1 } } 1416 : { 1 : "NN nsubjpass VBN acl:relcl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass given acl:relcl patients nmod *use* nmod drug0" } 4 : { 1 : "- Drugs with ototoxic potential : Especially in the presence of impaired renal function , the use of parenterally administered drug1 in patients to whom drug2 are also being given should be avoided , except in life-threatening conditions . " } 5 : { 1 : 1 } } 1417 : { 1 : "NN compound NN nmod VBN acl NNS dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound treatment nmod seen acl increases dobj *blunts* nsubj drug0" } 4 : { 1 : "- drug1 : drug2 blunts the increases in urine volume and sodium excretion seen during drug3 treatment and inhibits the drug4 - induced increase in plasma renin activity . " } 5 : { 1 : 1 } } 1418 : { 1 : "NN conj NN nmod NN nmod NN nmod NN dep CD nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod treatment nmod start nmod % dep 0 nmod *reduced* nsubjpass dose nmod drug0" } 4 : { 1 : "For this reason , the dose of the drug1 should be reduced by 30 - 50 % at the start of treatment with drug2 or drug3 retard and then titrated according to the blood clotting parameters " } 5 : { 1 : 1 } } 1419 : { 1 : "NN nmod VBN acl NNS nmod VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod treated acl patients nmod *increased* nsubjpass concentrations compound drug0" } 4 : { 1 : "drug1 : drug2 concentrations in bile and cystic fluid were increased ( about 2-fold ) in hydatid cyst patients treated with drug3 ( 10 mg/kg/day ) ( n = 7 ) compared with drug4 ( 20 mg/kg/day ) alone ( n = 12 ) . " } 5 : { 1 : 1 } } 1420 : { 1 : "NN appos NN nmod NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod effect dobj *enhance* nsubj hypokalemia compound drug0" } 4 : { 1 : "drug1 : drug2 - induced hypokalemia may enhance the curariform effect of drug3 ( e.g. , drug4 ) . " } 5 : { 1 : 1 } } 1421 : { 1 : "NN nmod NN nmod NN nsubjpass VBN advcl VBG dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose nmod decrease nsubjpass *required* advcl using dobj doses nmod drug0" } 4 : { 1 : "Therefore , when using doses of drug1 greater than 1200 mg/day during adjunctive therapy , a decrease in the dose of drug2 may be required . " } 5 : { 1 : 1 } } 1422 : { 1 : "NN nsubjpass VBN acl:relcl NN appos NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass given acl:relcl *increase* appos levels nmod drug0" } 4 : { 1 : "1 - nc denotes a mean change of less than 10 % 2 - Pediatrics 3 - Mean increase in adults at high drug1 doses In vivo , the plasma levels of drug2 increased by up to 40 % , when drug3 was given at doses above 1200 mg/day . " } 5 : { 1 : 1 } } 1423 : { 1 : "NN conj VBN dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj reduced dep *effectiveness* nmod drug0" } 4 : { 1 : "The effectiveness of drug1 - only pills is reduced by hepatic enzyme-inducing drugs such as the drug2 drug3 , drug4 , and drug5 , and the drug6 drug7 . " } 5 : { 1 : 1 } } 1424 : { 1 : "NN nmod VBN advcl JJ nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod given advcl *small* nsubj increase nmod level compound drug0" } 4 : { 1 : "The increase of drug1 level , however , is small ( 15 % ) when given with drug2 . " } 5 : { 1 : 1 } } 1425 : { 1 : "NN nmod VBZ advcl VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod is advcl *considered* nsubjpass action nmod must compound drug0" } 4 : { 1 : "THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug2 SUCH AS drug3 , drug4 AND drug5 . " } 5 : { 1 : 1 } } 1426 : { 1 : "NN compound NN nmod VBZ advcl VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound drug0 nmod is advcl *considered* nsubjpass action nmod must compound drug0" } 4 : { 1 : "THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug2 SUCH AS drug3 , drug4 AND drug5 . " } 5 : { 1 : 1 } } 1427 : { 1 : "NN appos NN nmod VBZ advcl VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod is advcl *considered* nsubjpass action nmod must compound drug0" } 4 : { 1 : "THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug2 SUCH AS drug3 , drug4 AND drug5 . " } 5 : { 1 : 1 } } 1428 : { 1 : "NN conj NN appos NN nmod VBZ advcl VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 appos drug0 nmod is advcl *considered* nsubjpass action nmod must compound drug0" } 4 : { 1 : "THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug2 SUCH AS drug3 , drug4 AND drug5 . " } 5 : { 1 : 1 } } 1429 : { 1 : "NN nmod NNS nmod VBN dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drugs nmod reduced dep *effectiveness* nmod drug0" } 4 : { 1 : "The effectiveness of drug1 - only pills is reduced by hepatic enzyme-inducing drugs such as the drug2 drug3 , drug4 , and drug5 , and the drug6 drug7 . " } 5 : { 1 : 1 } } 1430 : { 1 : "NN nsubjpass VBN advcl VBN dep VBD advcl VBN nsubjpass NN nmod NN conj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nsubjpass used advcl expected dep *increased* advcl studied nsubjpass interaction nmod drug0 conj inhibitors dep drug0" } 4 : { 1 : "Although the interaction between drug1 and other potent CYP3A4 inhibitors ( e.g. , drug2 , drug3 , and drug4 ) has not been studied , increased exposures to drug5 may be expected when drug6 is used concomitantly with these medications . " } 5 : { 1 : 1 } } 1431 : { 1 : "NN conj NN nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *administered* nsubjpass drug0 conj drug0" } 4 : { 1 : "- drug1 or drug2 ( with hepatotoxic potential ) must not be administered together with drug3 or drug4 . " } 5 : { 1 : 1 } } 1432 : { 1 : "NN appos NN nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod *used* nsubjpass drug0 conj drug0" } 4 : { 1 : "- When drug1 or drug2 is used concurrently with drug3 ( e.g. drug4 ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of drug5 or drug6 is impaired " } 5 : { 1 : 1 } } 1433 : { 1 : "NN dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *potentiate* nsubj administration nmod drug0" } 4 : { 1 : "Administration of drug1 may potentiate drug2 - induced neuromuscular block . " } 5 : { 1 : 1 } } 1434 : { 1 : "NN conj NN nmod NNS dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effects dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has additive effects with drug2 and other drug3 ( drug4 , drug5 , drug6 , etc ) . " } 5 : { 1 : 1 } } 1435 : { 1 : "NN conj NN nmod NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod action nmod *interfere* nsubj drug0" } 4 : { 1 : "drug1 may interfere with the anti-glaucoma action of drug2 or drug3 ; " } 5 : { 1 : 1 } } 1436 : { 1 : "NN dep NN conj NN nmod NNS dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj drug0 nmod effects dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has additive effects with drug2 and other drug3 ( drug4 , drug5 , drug6 , etc ) . " } 5 : { 1 : 1 } } 1437 : { 1 : "NN nmod NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod treatment nmod hours nmod *use* nmod drug0" } 4 : { 1 : "Other drug1 Concomitant use of other drug2 within 24 hours of treatment with drug3 is contraindicated . " } 5 : { 1 : 1 } } 1438 : { 1 : "NN dep NNS dep NNS appos NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep antimycotics dep inhibitors appos inducers nmod *affected* nsubjpass metabolism nmod drug0" } 4 : { 1 : "Although no clinical studies have been conducted , it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers ( such as drug2 , drug3 , drug4 ) , CYP3A4 inhibitors ( azole antimycotics e.g. , drug5 ; " } 5 : { 1 : 1 } } 1439 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod use nmod *advised* nsubjpass patients acl receiving dobj drug0" } 4 : { 1 : "Patients receiving drug1 should be advised against the concurrent use of other drug2 . " } 5 : { 1 : 1 } } 1440 : { 1 : "NN compound NN nmod NN dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound clearance nmod decrease dobj cause xcomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 have been reported to cause a significant decrease in drug3 clearance . " } 5 : { 1 : 1 } } 1441 : { 1 : "NN compound NN nmod NNS nmod JJR nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod patients nmod *lower* nsubj concentrations nmod drug0" } 4 : { 1 : "drug1 : In a pharmacokinetic study , maximum plasma concentrations of drug2 were considerably lower in epileptic patients on long-term drug3 therapy ( eg , drug4 , drug5 , or drug6 ) than in healthy volunteers . " } 5 : { 1 : 1 } } 1442 : { 1 : "NN compound NN nsubjpass VBN advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nsubjpass discontinued advcl *deferred* nsubjpass administration nmod drug0" } 4 : { 1 : "Routine administration of drug1 or toxoids should be deferred until drug2 therapy is discontinued if possible . " } 5 : { 1 : 1 } } 1443 : { 1 : "NN nmod VBD ccomp VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod contained ccomp *potentiate* nsubj drug0" } 4 : { 1 : "drug1 may also potentiate the replication of some organisms contained in drug2 . " } 5 : { 1 : 1 } } 1444 : { 1 : "NN dep JJR nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep *lower* nsubj concentrations nmod drug0" } 4 : { 1 : "drug1 : In a pharmacokinetic study , maximum plasma concentrations of drug2 were considerably lower in epileptic patients on long-term drug3 therapy ( eg , drug4 , drug5 , or drug6 ) than in healthy volunteers . " } 5 : { 1 : 1 } } 1445 : { 1 : "NN compound NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound toxicity dobj *potentiate* nsubj hypokalemia compound drug0" } 4 : { 1 : "drug1 : drug2 - induced hypokalemia may potentiate drug3 toxicity . " } 5 : { 1 : 1 } } 1446 : { 1 : "NN compound NN dobj VB dep NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound hypokalemia dobj potentiate dep *drug0* conj drug0 appos drug0" } 4 : { 1 : "drug1 and drug2 ( drug3 ) : may potentiate drug4 - induced hypokalemia which may predispose the patient to cardiac dysfunction . " } 5 : { 1 : 1 } } 1447 : { 1 : "NN nmod NN dobj VB advcl VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod toxicity dobj *increase* advcl reported nsubjpass relationship nmod drug0" } 4 : { 1 : "drug1 : while a synergistic relationship with drug2 has been reported , concomitant use may increase the toxicity of drug3 by possibly increasing its cellular uptake and/or impairing its renal excretion . " } 5 : { 1 : 1 } } 1448 : { 1 : "NN dobj VBG acl NNS conj VBG advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl weeks conj taking advcl *taking* dobj drug0" } 4 : { 1 : "Taking a drug1 while you are taking or within 2 weeks of taking drug2 may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction . " } 5 : { 1 : 1 } } 1449 : { 1 : "NN conj NN conj NNS nmod NN dobj VB nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 conj toxoids nmod response dobj *exhibit* nsubj patients nmod therapy compound drug0" } 4 : { 1 : "drug1 : Patients on drug2 therapy may exhibit a diminished response to toxoids and drug3 or drug4 due to inhibition of antibody response . " } 5 : { 1 : 1 } } 1450 : { 1 : "NN compound NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound co-administration nmod *levels* compound drug0" } 4 : { 1 : "drug1 : In post-marketing experience , there have been reports of both increases and decreases in drug2 levels with drug3 co-administration , leading to alterations in seizure control . " } 5 : { 1 : 1 } } 1451 : { 1 : "NN nmod NN dobj VB nsubj NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj *enhance* nsubj drugs dep drug0 appos drug0" } 4 : { 1 : "Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , drug1 , drug2 , drug3 , drug4 ) may enhance the metabolism of drug5 and require that the dosage of the drug6 be increased . " } 5 : { 1 : 1 } } 1452 : { 1 : "NN nmod NNS nsubjpass VBN advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod adjustments nsubjpass *required* advcl increase nsubj drug0" } 4 : { 1 : "drug1 : Because drug2 may increase blood glucose concentrations , dosage adjustments of drug3 may be required . " } 5 : { 1 : 1 } } 1453 : { 1 : "NN conj NNS nmod NN dobj VB nsubj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj toxoids nmod response dobj *exhibit* nsubj patients nmod therapy compound drug0" } 4 : { 1 : "drug1 : Patients on drug2 therapy may exhibit a diminished response to toxoids and drug3 or drug4 due to inhibition of antibody response . " } 5 : { 1 : 1 } } 1454 : { 1 : "NN nmod NNS nmod VB acl JJ dobj VBP nsubj NNS acl:relcl VBP dobj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod result acl potential dobj *have* nsubj drugs acl:relcl inhibit dobj 0a0 dep drug0" } 4 : { 1 : "Drugs which inhibit CYP 3A4 ( e.g. , drug1 , drug2 such as drug3 ) have the potential to result in increased plasma concentrations of drug4 . " } 5 : { 1 : 1 } } 1455 : { 1 : "NN nmod NNS nmod VB acl JJ dobj VBP nsubj NNS acl:relcl VBP dobj NN dep NN appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod result acl potential dobj *have* nsubj drugs acl:relcl inhibit dobj 0a0 dep drug0 appos drug0 nmod drug0" } 4 : { 1 : "Drugs which inhibit CYP 3A4 ( e.g. , drug1 , drug2 such as drug3 ) have the potential to result in increased plasma concentrations of drug4 . " } 5 : { 1 : 1 } } 1456 : { 1 : "NN nmod NNS nmod VB acl JJ dobj VBP nsubj NNS acl:relcl VBP dobj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod result acl potential dobj *have* nsubj drugs acl:relcl inhibit dobj 0a0 dep drug0 appos drug0" } 4 : { 1 : "Drugs which inhibit CYP 3A4 ( e.g. , drug1 , drug2 such as drug3 ) have the potential to result in increased plasma concentrations of drug4 . " } 5 : { 1 : 1 } } 1457 : { 1 : "NN nmod VBN dep VBG acl NN nmod NN nmod NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod limited dep including acl drug0 nmod *use* nmod drug0 appos system compound drug0" } 4 : { 1 : "drug1 : The concomitant use of drug2 ( drug3 transdermal system ) with other drug4 , including but not limited to other drug5 , drug6 , drug7 , drug8 ( e.g. , drug9 ) , general drug10 , drug11 , drug12 , and drug13 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death . " } 5 : { 1 : 1 } } 1458 : { 1 : "NN compound NN dep NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound spray dep minutes nmod *administered* nsubjpass drug0" } 4 : { 1 : "When the drug1 was administered 30 minutes after the drug2 nasal spray , the AUC of drug3 increased 11 % and Cmax decreased 18 % . " } 5 : { 1 : 1 } } 1459 : { 1 : "NN dobj VBG acl NNS nmod NN nmod NNS nmod VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod creatinine nmod elevations nmod associated conj *shown* nsubjpass administration nmod drug0" } 4 : { 1 : "However , the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug2 , interfere with the metabolism of drug3 , and enhance the effects of the oral drug4 drug5 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drug6 concomitantly . " } 5 : { 1 : 1 } } 1460 : { 1 : "NN compound NNS dobj VB conj NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj decrease conj increase nmod *reported* nsubjpass drug0" } 4 : { 1 : "Since drug1 ( drug2 ) may interact with concurrently administered drug3 , periodic serum level determinations of these drugs may be necessary ( eg , drug4 may elevate drug5 serum levels and drug6 has been reported to both increase and decrease drug7 levels ) . " } 5 : { 1 : 1 } } 1461 : { 1 : "NN nmod VB nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *interact* nsubj drug0 appos drug0" } 4 : { 1 : "Since drug1 ( drug2 ) may interact with concurrently administered drug3 , periodic serum level determinations of these drugs may be necessary ( eg , drug4 may elevate drug5 serum levels and drug6 has been reported to both increase and decrease drug7 levels ) . " } 5 : { 1 : 1 } } 1462 : { 1 : "NN nsubjpass VBN acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered acl:relcl *drug0* nmod drug0" } 4 : { 1 : "There have been greater than 2-fold increases in previously stable plasma levels of other drug1 , including drug2 , when drug3 has been administered in combination with these agents . " } 5 : { 1 : 1 } } 1463 : { 1 : "NN compound NN nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod *taking* dobj drug0" } 4 : { 1 : "International Normalized Ratio ( INR ) elevations and/or bleeding events have been reported in some patients taking drug1 while on drug2 therapy . " } 5 : { 1 : 1 } } 1464 : { 1 : "NN compound NNS conj NN dobj NN nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound concentrations conj metabolism dobj *decrease* nsubj substances dep drug0" } 4 : { 1 : "Substances that are potent inhibitors of CYP3A4 activity ( eg , drug1 and drug2 ) decrease drug3 metabolism and increase drug4 plasma concentrations . " } 5 : { 1 : 1 } } 1465 : { 1 : "NN compound NN dobj NN nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound metabolism dobj *decrease* nsubj substances dep drug0" } 4 : { 1 : "Substances that are potent inhibitors of CYP3A4 activity ( eg , drug1 and drug2 ) decrease drug3 metabolism and increase drug4 plasma concentrations . " } 5 : { 1 : 1 } } 1466 : { 1 : "NN compound NN dobj NN nsubj NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound metabolism dobj *decrease* nsubj substances dep drug0 conj drug0" } 4 : { 1 : "Substances that are potent inhibitors of CYP3A4 activity ( eg , drug1 and drug2 ) decrease drug3 metabolism and increase drug4 plasma concentrations . " } 5 : { 1 : 1 } } 1467 : { 1 : "NN compound NNS conj NN dobj NN nsubj NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations conj metabolism dobj *decrease* nsubj substances dep drug0 conj drug0" } 4 : { 1 : "Substances that are potent inhibitors of CYP3A4 activity ( eg , drug1 and drug2 ) decrease drug3 metabolism and increase drug4 plasma concentrations . " } 5 : { 1 : 1 } } 1468 : { 1 : "NN nmod NNS nmod NN nsubj VB nmod NNS acl VBG nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod decrease nsubj *occur* nmod patients acl undergoing nmod drug0" } 4 : { 1 : "In well-controlled patients undergoing concurrent therapy with drug1 , a decrease in the steady-state serum concentrations of drug2 may occur when cime-tidine therapy is discontinued . " } 5 : { 1 : 1 } } 1469 : { 1 : "NN nsubjpass VBN advcl VBN nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass added advcl *associated* nmod elevations nmod levels nmod drug0" } 4 : { 1 : "Serious anticholinergic symptoms ( severe dry mouth , urinary retention , blurred vision ) have been associated with elevations in the serum levels of drug1 when drug2 is added to the drug regimen . " } 5 : { 1 : 1 } } 1470 : { 1 : "NN nmod VBG dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *blocking* dobj metabolism nmod drug0" } 4 : { 1 : "The interaction is a consequence of blocking hepatic metabolism of drug1 by drug2 , a highly potent CYP3A4 inhibitor , which also inhibits CYP2C9 . " } 5 : { 1 : 1 } } 1471 : { 1 : "NN compound NN nmod JJ amod NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod co-administered amod *drug0*" } 4 : { 1 : "drug1 ( 600 mg b.i.d. ) co-administered with drug2 5 mg resulted in a 49-fold increase in drug3 AUC and a 13-fold increase in drug4 Cmax . " } 5 : { 1 : 1 } } 1472 : { 1 : "NN dobj VBG acl NNS nmod VBN advcl VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl patients nmod initiated advcl *observed* nsubjpass concentrations nmod drug0" } 4 : { 1 : "In addition , higher-than expected steady-state serum concentrations of drug1 have been observed when therapy is initiated in patients already taking drug2 . " } 5 : { 1 : 1 } } 1473 : { 1 : "NN dep NNS nmod VBN acl NN" 2 : 1 3 : { 1 : "drug0 dep hours nmod taken acl *drug0*" } 4 : { 1 : "In vivo studies : drug1 : The blood pressure lowering effects of sublingual drug2 ( 0.4 mg ) taken 1 and 4 hours after drug3 and increases in heart rate when taken at 1 , 4 and 8 hours were potentiated by a 20 mg dose of drug4 in healthy middle-aged subjects . " } 5 : { 1 : 1 } } 1474 : { 1 : "NN compound NN nmod NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound therapy nmod patients nmod *used* nsubjpass drug0" } 4 : { 1 : "Based on these data , drug1 should not be used in patients on drug2 therapy . " } 5 : { 1 : 1 } } 1475 : { 1 : "NN compound NN nsubj VBD nmod NNS acl:relcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg nsubj *produced* nmod patients acl:relcl controlled nmod drug0" } 4 : { 1 : "In these patients whose hypertension was controlled with drug1 , drug2 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo . " } 5 : { 1 : 1 } } 1476 : { 1 : "NN nsubjpass VBN advcl VB xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass added advcl fluctuate xcomp *reported* nsubjpass concentrations nmod drug0" } 4 : { 1 : "Steady-state serum concentrations of drug1 are reported to fluctuate significantly when drug2 is either added or deleted from the drug regimen . " } 5 : { 1 : 1 } } 1477 : { 1 : "NN compound NN nmod JJ compound NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod *co-administered* compound drug0" } 4 : { 1 : "drug1 : drug2 ( 800 mg t.i.d. ) co-administered with drug3 10 mg resulted in a 16-fold increase in drug4 AUC , a 7-fold increase in drug5 Cmax and a 2-fold increase in drug6 half-life . " } 5 : { 1 : 1 } } 1478 : { 1 : "NN nmod NNS dobj VB nsubj NNS acl:relcl VBP dobj NN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj *reduce* nsubj drugs acl:relcl cause dobj elevation nmod ph dep drug0" } 4 : { 1 : "Drugs that cause significant sustained elevation in gastric pH ( drug1 such as drug2 or drug3 ) may reduce plasma concentrations of drug4 and therefore potentially may reduce efficacy . " } 5 : { 1 : 1 } } 1479 : { 1 : "NN nmod NNS dobj VB nsubj NNS acl:relcl VBP dobj NN nmod NN dep NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj *reduce* nsubj drugs acl:relcl cause dobj elevation nmod ph dep drug0 nmod drug0 conj drug0" } 4 : { 1 : "Drugs that cause significant sustained elevation in gastric pH ( drug1 such as drug2 or drug3 ) may reduce plasma concentrations of drug4 and therefore potentially may reduce efficacy . " } 5 : { 1 : 1 } } 1480 : { 1 : "NN nmod NN root , punct NNS nmod CC root , punct IN dep VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod administration root , punct hours nmod or root , punct with dep *administered* nsubjpass drug0" } 4 : { 1 : "drug1 , or other products containing drug2 or drug3 , drug4 or drug5 should not be administered concomitantly with , or within 2 hours of , the administration of drug6 , because they may interfere with absorption resulting in lower serum and urine levels of drug7 . " } 5 : { 1 : 1 } } 1481 : { 1 : "NN nmod VBN nsubjpass NNS acl:relcl VBP dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *decreased* nsubjpass drugs acl:relcl induce dobj exposure compound drug0" } 4 : { 1 : "Drugs That Induce CYP3A4 ( drug1 ) Racemic drug2 exposure was decreased 80 % by concomitant useof drug3 , a potent inducer of CYP3A4 . " } 5 : { 1 : 1 } } 1482 : { 1 : "NN dobj VBP advcl VB nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj take advcl *increase* nsubj concentration nmod drug0 conj drug0" } 4 : { 1 : "Serum concentration of drug1 and drug2 may increase when patients take drug3 . " } 5 : { 1 : 1 } } 1483 : { 1 : "NN nmod NN root , punct NNS nmod CC root , punct IN dep VBN nsubjpass NN conj NNS acl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod administration root , punct hours nmod or root , punct with dep *administered* nsubjpass drug0 conj products acl containing dobj drug0" } 4 : { 1 : "drug1 , or other products containing drug2 or drug3 , drug4 or drug5 should not be administered concomitantly with , or within 2 hours of , the administration of drug6 , because they may interfere with absorption resulting in lower serum and urine levels of drug7 . " } 5 : { 1 : 1 } } 1484 : { 1 : "NN nmod NN root , punct NNS nmod CC root , punct IN dep VBN cc VBD nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod administration root , punct hours nmod or root , punct with dep administered cc *chewable/buffered* nsubj drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within 2 hours of , the administration of drug3 , because these products may interfere with absorption resulting in lower serum and urine levels of drug4 . " } 5 : { 1 : 1 } } 1485 : { 1 : "NN nmod NN root , punct NNS nmod CC root , punct IN dep VBN cc VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod administration root , punct hours nmod or root , punct with dep administered cc *chewable/buffered* nsubj drug0" } 4 : { 1 : "drug1 ( drug2 ) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within 2 hours of , the administration of drug3 , because these products may interfere with absorption resulting in lower serum and urine levels of drug4 . " } 5 : { 1 : 1 } } 1486 : { 1 : "NN nmod NNS nmod VBG acl NNS dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod leading acl changes dobj *cause* nsubj cyclosporine conj drug0" } 4 : { 1 : "Cyclosporine , Digoxin , Methotrexate drug1 , like other drug2 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drug3 , drug4 , drug5 , and increased toxicity . " } 5 : { 1 : 1 } } 1487 : { 1 : "NN nmod NNS dobj VB nsubj NNS acl:relcl VBP dobj NN nmod NN dep NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations dobj *reduce* nsubj drugs acl:relcl cause dobj elevation nmod ph dep drug0 nmod drug0" } 4 : { 1 : "Drugs that cause significant sustained elevation in gastric pH ( drug1 such as drug2 or drug3 ) may reduce plasma concentrations of drug4 and therefore potentially may reduce efficacy . " } 5 : { 1 : 1 } } 1488 : { 1 : "NN dobj VBP advcl VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj take advcl *increase* nsubj concentration nmod drug0" } 4 : { 1 : "Serum concentration of drug1 and drug2 may increase when patients take drug3 . " } 5 : { 1 : 1 } } 1489 : { 1 : "NN dobj VBG acl NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *therapy* compound drug0" } 4 : { 1 : "drug1 : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing drug2 therapy in patients receiving drug3 or similar agents , since these patients are at an increased risk of bleeding complications . " } 5 : { 1 : 1 } } 1490 : { 1 : "NN conj NN nmod NN conj NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 , drug3 s , drug4 ( allergy , cold , and sinus medicines ) , diabetic drugs , drug5 , drug6 , drug7 like drug8 or drug9 , and high blood pressure medications . " } 5 : { 1 : 1 } } 1491 : { 1 : "NN nmod NN conj NN nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj drug0 nmod *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with drug2 , drug3 s , drug4 ( allergy , cold , and sinus medicines ) , diabetic drugs , drug5 , drug6 , drug7 like drug8 or drug9 , and high blood pressure medications . " } 5 : { 1 : 1 } } 1492 : { 1 : "NN nmod VBN advcl VBD nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod co-administered advcl *was* nsubj increase nmod clearance nmod drug0" } 4 : { 1 : "Effect of drug1 in Pediatric Patients There was about a 22 % increase of apparent total body clearance of drug2 when it was co-administered with enzyme-inducing drug3 . " } 5 : { 1 : 1 } } 1493 : { 1 : "NN nmod NN dobj VBD nsubj NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod cmax dobj *increased* nsubj co-administration nmod doses nmod drug0" } 4 : { 1 : "drug1 : Co-administration with high doses of drug2 [ 800 mg twice daily ] increased the Cmax of drug3 by 21 % , the AUC0-120hr by 23 % and the t1/2 by 15 % . " } 5 : { 1 : 1 } } 1494 : { 1 : "NN compound NNS dep NNS nmod VBN acl NN conj NN" 2 : 1 3 : { 1 : "drug0 compound concentrations dep days nmod administered acl mg conj *drug0*" } 4 : { 1 : "drug1 drug2 12.5 , 25 , and 50 mg administered once daily for 7 days increased plasma drug3 concentrations ( AUC ( 0 - ) ) by 38 to 60 % in healthy subjects administered a single 300-mg dose of drug4 . " } 5 : { 1 : 1 } } 1495 : { 1 : "NN compound NN dobj VBG acl NNS nmod NN nmod VBN dep NNS dep NNS nmod VBN acl NN compound NN" 2 : 1 3 : { 1 : "drug0 compound mg/week dobj receiving acl patients nmod auc0-0hr nmod measured dep concentrations dep days nmod administered acl *mg* compound drug0" } 4 : { 1 : "At higher than recommended doses , drug1 75 mg administered once daily for 10 days increased plasma concentrations by 23 % as measured by AUC0-24hr in patients receiving drug2 7.5 to 15 mg/week for rheumatoid arthritis . " } 5 : { 1 : 1 } } 1496 : { 1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patients nmod *initiated* nsubjpass therapy nmod drug0" } 4 : { 1 : "Adequate monitoring of drug1 plasma concentrations should be considered when therapy with drug2 is initiated or changed in patients receiving drug3 . " } 5 : { 1 : 1 } } 1497 : { 1 : "NN nmod NNS nmod VBG acl NNS dobj VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod levels nmod leading acl changes dobj *cause* nsubj cyclosporine nmod drug0" } 4 : { 1 : "Cyclosporine , Digoxin , Methotrexate drug1 , like other drug2 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of drug3 , drug4 , drug5 , and increased toxicity . " } 5 : { 1 : 1 } } 1498 : { 1 : "NN compound NN nmod NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod combination nmod used acl:relcl period nmod *exceeded* nsubjpass dose nmod drug0" } 4 : { 1 : "Since higher doses of drug1 ( 400 mg daily ) may result in higher increases in Cmax and AUC , a single 2.5 mg dose of drug2 should not be exceeded in a 24-hour period when used in combination with drug3 400 mg daily . " } 5 : { 1 : 1 } } 1499 : { 1 : "NN compound NN nmod NN conj NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound auc nmod increase conj inhibition nmod *associated* nsubjpass treatment nmod drug0" } 4 : { 1 : "Treatment with drug1 once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25 % increase in drug2 AUC . " } 5 : { 1 : 1 } } 1500 : { 1 : "NN nsubjpass VBN advcl VBN nsubjpass NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass introduced advcl *monitored* nsubjpass patients nmod treatment compound drug0" } 4 : { 1 : "Patients on drug1 treatment should be closely monitored when drug2 is introduced or withdrawn . " } 5 : { 1 : 1 } } 1501 : { 1 : "NN compound NN nmod NNP compound NNP dep NN dobj NN" 2 : 1 3 : { 1 : "drug0 compound mg nmod bid compound bid dep mg dobj *drug0*" } 4 : { 1 : "drug1 : In a study conducted in healthy subjects , mean steady-state drug2 plasma levels increased approximately 17 % in subjects receiving drug3 450 mg BID with drug4 200 mg BID as compared to subjects receiving drug5 alone . " } 5 : { 1 : 1 } } 1502 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBZ nsubj NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod interactions nmod potential dobj *suggests* nsubj experience nmod drug0 appos drug0" } 4 : { 1 : "Experience with drug1 ( drug2 ) suggests the potential for interactions with drug3 and drug4 . " } 5 : { 1 : 1 } } 1503 : { 1 : "NN nmod VBN advcl VBG nmod NN" 2 : 1 3 : { 1 : "drug0 nmod seen advcl *administering* nmod drug0" } 4 : { 1 : "Caution should be exercised when administering drug1 with drug2 since interactions have been seen with other drug3 . " } 5 : { 1 : 1 } } 1504 : { 1 : "NN dobj VBG advcl VBN ccomp VBN dep NN" 2 : 1 3 : { 1 : "drug0 dobj starting advcl discontinued ccomp used dep *drug0*" } 4 : { 1 : "therefore , drug1 or other drug2 ( as used for management of angina ) or other drugs having vasodilator activity should , if possible , be discontinued before starting drug3 . " } 5 : { 1 : 1 } } 1505 : { 1 : "NN nmod NN dobj VBG acl NN nmod VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod dose dobj receiving acl hour nmod *experience* nsubj patients nmod drug0" } 4 : { 1 : "Hypotension Patients on drug1 Therapy : Patients on drug2 and especially those in whom drug3 therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of drug4 . " } 5 : { 1 : 1 } } 1506 : { 1 : "NN dobj VBG advcl VBN ccomp VBN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj starting advcl discontinued ccomp used dep *drug0* conj drug0" } 4 : { 1 : "therefore , drug1 or other drug2 ( as used for management of angina ) or other drugs having vasodilator activity should , if possible , be discontinued before starting drug3 . " } 5 : { 1 : 1 } } 1507 : { 1 : "NN nmod VBN nsubjpass NNS acl VBG dobj NN nmod:poss NN" 2 : 1 3 : { 1 : "drug0 nmod *augmented* nsubjpass agents acl causing dobj effect nmod:poss drug0" } 4 : { 1 : "Agents Causing Renin Release drug1 's effect will be augmented by drug2 that cause renin release . " } 5 : { 1 : 1 } } 1508 : { 1 : "NN nmod NNS nmod NN dobj VBZ nsubj NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod interactions nmod potential dobj *suggests* nsubj experience nmod drug0 appos drug0" } 4 : { 1 : "Experience with drug1 ( drug2 ) suggests the potential for interactions with drug3 and drug4 . " } 5 : { 1 : 1 } } 1509 : { 1 : "NN conj NN nmod NNS dobj VBN nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod interactions dobj *identified* nsubj studies nmod drug0" } 4 : { 1 : "Clinical studies with drug1 have identified potentially significant interactions with drug2 and drug3 . " } 5 : { 1 : 1 } } 1510 : { 1 : "NN nmod NN dobj VB xcomp VBN parataxis NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism dobj reduce xcomp reported parataxis *effect* nsubj drug0" } 4 : { 1 : "drug1 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , certain drug8 , drug9 , drug10 and drug11 , thereby delaying elimination and increasing blood levels of these drugs . " } 5 : { 1 : 1 } } 1511 : { 1 : "NN dobj VBN acl:relcl NNS nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dobj received acl:relcl patients nmod use nmod *recommended* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 is not recommended for use in patients who have received drug3 within 14 days because severe and unpredictable potentiation by drug4 has been reported with drug5 " } 5 : { 1 : 1 } } 1512 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod interactions nmod potential dobj *suggests* nsubj experience nmod drug0" } 4 : { 1 : "Experience with drug1 ( drug2 ) suggests the potential for interactions with drug3 and drug4 . " } 5 : { 1 : 1 } } 1513 : { 1 : "NN nsubjpass VBN advcl JJ nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass administered advcl *necessary* nsubj adjustment nmod dose compound drug0" } 4 : { 1 : "therefore , close monitoring of prothrombin time is recommended , and adjustment of the drug1 dose may be necessary when drug2 is administered concomitantly . " } 5 : { 1 : 1 } } 1514 : { 1 : "NN dep NN nmod NN nmod VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod dosage nmod *receiving* dobj q.i.d. compound drug0" } 4 : { 1 : "However , a crossover study in healthy subjects receiving either drug1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug2 ( drug3 , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state drug4 peak serum levels with the 800 mg h.s. regimen , particularly in subjects aged 54 years and older . " } 5 : { 1 : 1 } } 1515 : { 1 : "NN nmod NN nmod VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod dosage nmod *receiving* dobj q.i.d. compound drug0" } 4 : { 1 : "However , a crossover study in healthy subjects receiving either drug1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug2 ( drug3 , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state drug4 peak serum levels with the 800 mg h.s. regimen , particularly in subjects aged 54 years and older . " } 5 : { 1 : 1 } } 1516 : { 1 : "NN nmod NNS dobj VBN nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod interactions dobj *identified* nsubj studies nmod drug0" } 4 : { 1 : "Clinical studies with drug1 have identified potentially significant interactions with drug2 and drug3 . " } 5 : { 1 : 1 } } 1517 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod combination nmod used acl:relcl period nmod *exceed* dobj dose nmod drug0" } 4 : { 1 : "It is recommended not to exceed a single 5 mg dose of drug1 in a 24-hour period when used in combination with drug2 . " } 5 : { 1 : 1 } } 1518 : { 1 : "NN dep VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dep *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with any of the following : - drug2 ( e.g. , drug3 ) ( with long-term , high-dose use ) or " } 5 : { 1 : 1 } } 1519 : { 1 : "NN compound NN nmod VBN acl NN nmod NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound injection nmod caused acl norepinephrine nmod release nmod *aggravated* nsubjpass toxicity compound drug0" } 4 : { 1 : "drug1 toxicity may be aggravated by the initial release of norepinephrine caused by drug2 Injection . " } 5 : { 1 : 1 } } 1520 : { 1 : "NN nmod NN nmod VBD acl:relcl NN dep NNS nmod NN nmod VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod proportion nmod resulted acl:relcl liver dep patients nmod induction nmod *resulted* nsubj drug0" } 4 : { 1 : "Furthermore it has been proposed that drug1 resulted In induction of P-450IIE1 in the patients liver which , in turn , resulted in a greater proportion of the ingested drug2 being converted to the toxic metabolites . " } 5 : { 1 : 1 } } 1521 : { 1 : "NN dobj VBG acl NN nmod VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj receiving acl patient nmod *reported* nsubjpass report nmod toxicity compound drug0" } 4 : { 1 : "drug1 : A report of severe drug2 toxicity was reported in a patient receiving drug3 . " } 5 : { 1 : 1 } } 1522 : { 1 : "NN compound NNS nmod VB dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound concentrations nmod increase dobj *produced* nsubj discontinuation nmod drug0" } 4 : { 1 : "In 5 other schizophrenic patients treated with oral drug1 and drug2 , discontinuation of drug3 produced a mean 3.3-fold increase in drug4 concentrations . " } 5 : { 1 : 1 } } 1523 : { 1 : "NN nmod NN nmod RB advmod VBN xcomp VBN xcomp VB dobj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod prior advmod determined xcomp *known* xcomp slow dobj levels compound drug0" } 4 : { 1 : "drug1 : drug2 is known to slow the metabolism of drug3 and increase its serum levels drug4 levels should be determined prior to concurrent administration with drug5 , signs and symptoms of drug6 toxicity should be monitored closely , and appropriate dosage adjustment of the drug7 should be made . " } 5 : { 1 : 1 } } 1524 : { 1 : "NN dep NNS dobj VB xcomp VBN acl:relcl NNS nmod VBG dobj NN" 2 : 1 3 : { 1 : "drug0 dep activities dobj inhibit xcomp known acl:relcl drugs nmod *administering* dobj drug0" } 4 : { 1 : "Caution should be exercised when administering drug1 with drugs that are known to inhibit phosphatase activities ( e.g. , drug2 ) . " } 5 : { 1 : 1 } } 1525 : { 1 : "NN nmod VBN acl:relcl NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administered acl:relcl *increase* nmod level nmod drug0" } 4 : { 1 : "drug1 : A recent case study has shown a possible increase in the plasma level of drug2 when co administered with drug3 . " } 5 : { 1 : 1 } } 1526 : { 1 : "NN nmod VBN acl NNS nmod VBG acl NN" 2 : 1 3 : { 1 : "drug0 nmod administered acl concentrations nmod resulting acl *drug0*" } 4 : { 1 : "High-dose drug1 resulting in concentrations above 2000 ng/mL administered with oral drug2 has led to an 80 % increase in drug3 exposure with a 38 % decrease in total body clearance of drug4 compared to drug5 alone . " } 5 : { 1 : 1 } } 1527 : { 1 : "NN appos NN dep VB nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep *interact* nsubj drug0" } 4 : { 1 : "drug1 may interact with any of the following : - drug2 ( e.g. , drug3 ) ( with long-term , high-dose use ) or " } 5 : { 1 : 1 } } 1528 : { 1 : "NN nmod NN dobj VBG advcl JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dobj potentiating advcl *capable* nsubj drug0" } 4 : { 1 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 1 } } 1529 : { 1 : "NN dobj VBG advcl JJ ccomp VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj potentiating advcl capable ccomp *noted* nmod drug0" } 4 : { 1 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 1 } } 1530 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *enhanced* nsubjpass effects nmod drug0 nmod drug0 conj drug0" } 4 : { 1 : "The pressor effects of drug1 such as drug2 or drug3 are enhanced by drug4 . " } 5 : { 1 : 1 } } 1531 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *enhanced* nsubjpass effects nmod drug0 nmod drug0" } 4 : { 1 : "The pressor effects of drug1 such as drug2 or drug3 are enhanced by drug4 . " } 5 : { 1 : 1 } } 1532 : { 1 : "NN nmod NN dobj VBG advcl JJ ccomp VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dobj potentiating advcl capable ccomp *noted* nmod drug0" } 4 : { 1 : "As with other drug1 , it should be noted that drug2 may be capable of potentiating drug3 such as drug4 , drug5 , and drug6 . " } 5 : { 1 : 1 } } 1533 : { 1 : "NN nmod NN nsubj VB conj NN" 2 : 1 3 : { 1 : "drug0 nmod use nsubj result conj *drug0*" } 4 : { 1 : "drug1 or other drug2 ( concurrent use with drug3 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ; " } 5 : { 1 : 1 } } 1534 : { 1 : "NN nmod NN dobj VB advcl VBP nsubj NNS acl VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *have* advcl are nsubj data acl evaluate dobj possibility nmod drug0" } 4 : { 1 : "Although there are no study data to evaluate the possibility , drug1 , including drug2 and drug3 , may have an additive effect with drug4 on the risk of developing methemoglobinemia . " } 5 : { 1 : 1 } } 1535 : { 1 : "NN nmod NN dobj VB advcl VBP nsubj NNS acl VB dobj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *have* advcl are nsubj data acl evaluate dobj possibility appos drug0" } 4 : { 1 : "Although there are no study data to evaluate the possibility , drug1 , including drug2 and drug3 , may have an additive effect with drug4 on the risk of developing methemoglobinemia . " } 5 : { 1 : 1 } } 1536 : { 1 : "NN nmod NN dobj VB advcl VBP nsubj NNS acl VB dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj *have* advcl are nsubj data acl evaluate dobj possibility nmod drug0 conj drug0" } 4 : { 1 : "Although there are no study data to evaluate the possibility , drug1 , including drug2 and drug3 , may have an additive effect with drug4 on the risk of developing methemoglobinemia . " } 5 : { 1 : 1 } } 1537 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound spray nmod dose nmod *administered* nsubjpass dose nmod drug0" } 4 : { 1 : "However , in another study in healthy volunteers , the pharmacokinetics of drug1 were significantly altered ( 29 % decrease in AUC and 38 % decrease in Cmax ) when a 1-mg dose of drug2 was administered 1 minute after a 20-mg dose of drug3 nasal spray . " } 5 : { 1 : 1 } } 1538 : { 1 : "NN compound NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound capsules dep *drug0*" } 4 : { 1 : "Short-term pharmacokinetic studies have demonstrated that concomitant administration of drug1 and drug2 ( drug3 capsules and tablets ) results in reduced protein binding of drug4 , but there was no change in the clearance of free drug5 . " } 5 : { 1 : 1 } } 1539 : { 1 : "NN nmod JJ conj IN dep VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod subsequent conj with dep *given* nsubjpass drug0" } 4 : { 1 : "Because of the danger of a potentially fatal prolongation of the QTc interval , drug1 must not be given simultaneously with or subsequent to drug2 . " } 5 : { 1 : 1 } } 1540 : { 1 : "NN conj NN dep NNP nmod DT nmod NN dep NN dobj VB xcomp VBN acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep ia nmod those nmod drug0 dep interval dobj prolong xcomp known acl drugs nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used concomitantly with other drugs known to prolong the QT interval : certain drug2 , including those of Class IA ( such as drug3 and drug4 ) and Class III ( such as drug5 ) ; " } 5 : { 1 : 1 } } 1541 : { 1 : "NN dep NNP nmod DT nmod NN dep NN dobj VB xcomp VBN acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep ia nmod those nmod drug0 dep interval dobj prolong xcomp known acl drugs nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used concomitantly with other drugs known to prolong the QT interval : certain drug2 , including those of Class IA ( such as drug3 and drug4 ) and Class III ( such as drug5 ) ; " } 5 : { 1 : 1 } } 1542 : { 1 : "NN dep NN dobj VB xcomp VBN acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 dep interval dobj prolong xcomp known acl drugs nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used concomitantly with other drugs known to prolong the QT interval : certain drug2 , including those of Class IA ( such as drug3 and drug4 ) and Class III ( such as drug5 ) ; " } 5 : { 1 : 1 } } 1543 : { 1 : "NN nmod NN conj NNP nmod DT nmod NN dep NN dobj VB xcomp VBN acl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod class conj ia nmod those nmod drug0 dep interval dobj prolong xcomp known acl drugs nmod *used* nsubjpass drug0" } 4 : { 1 : "drug1 should not be used concomitantly with other drugs known to prolong the QT interval : certain drug2 , including those of Class IA ( such as drug3 and drug4 ) and Class III ( such as drug5 ) ; " } 5 : { 1 : 1 } } 1544 : { 1 : "NN nmod VBN conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *reported* nsubjpass drug0" } 4 : { 1 : "Several drug1 have been reported to block the pharmacologic effects of drug2 , drug3 , or similar agents , and such an effect may be anticipated with drug4 because of its structural similarity to other drug5 . " } 5 : { 1 : 1 } } 1545 : { 1 : "NN conj NN nmod NNS dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod effects dobj block xcomp *reported* nsubjpass drug0" } 4 : { 1 : "Several drug1 have been reported to block the pharmacologic effects of drug2 , drug3 , or similar agents , and such an effect may be anticipated with drug4 because of its structural similarity to other drug5 . " } 5 : { 1 : 1 } } 1546 : { 1 : "NN nmod NN nmod VBN conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod similarity nmod anticipated conj *reported* nsubjpass drug0" } 4 : { 1 : "Several drug1 have been reported to block the pharmacologic effects of drug2 , drug3 , or similar agents , and such an effect may be anticipated with drug4 because of its structural similarity to other drug5 . " } 5 : { 1 : 1 } } 1547 : { 1 : "NN nmod NN nmod VBN xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod increased xcomp *reported* nsubjpass concentration nmod drug0" } 4 : { 1 : "The plasma concentration of drug1 has been reported to be increased by the concomitant administration of drug2 ; " } 5 : { 1 : 1 } } 1548 : { 1 : "NN nmod NN nmod VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod concentration nmod *leads* nsubj coadministration compound drug0" } 4 : { 1 : "drug1 : drug2 coadministration leads to an increased peak plasma concentration and AUC of drug3 , there is no effect on drug4 absorption when it is coadministered with drug5 . " } 5 : { 1 : 1 } } 1549 : { 1 : "NN nmod NNS dobj VB xcomp VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj compromise xcomp *expected* nsubjpass administration nmod drug0 conj drug0" } 4 : { 1 : "drug1 : Concurrent administration of certain drug2 , such as drug3 and drug4 , would be expected to compromise the beneficial effects of drug5 . " } 5 : { 1 : 1 } } 1550 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj drug0 appos drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , etc. ) increase the concentration of the ionized species of the drug4 molecule , thereby increasing urinary excretion . " } 5 : { 1 : 1 } } 1551 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj drug0 appos drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , etc. ) increase the concentration of the ionized species of the drug4 molecule , thereby increasing urinary excretion . " } 5 : { 1 : 1 } } 1552 : { 1 : "NN compound NN nmod NN nmod VB nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound dose nmod adjustment nmod *check* nmod start nmod therapy compound drug0" } 4 : { 1 : "It is advisable to check coagulation time within the first few days after the start and discontinuation of drug1 therapy , with an appropriate adjustment of the drug2 dose , if necessary . " } 5 : { 1 : 1 } } 1553 : { 1 : "NN nmod NN dobj NN nsubj NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod absorption dobj *increase* nsubj agents appos drug0" } 4 : { 1 : "Alkalinizing agents : Gastrointestinal alkalinizing agents ( drug1 , etc. ) increase absorption of drug2 . " } 5 : { 1 : 1 } } 1554 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj agents dep drug0 appos drug0" } 4 : { 1 : "Urinary alkalinizing agents ( drug1 , some drug2 ) increase the concentration of the non-ionized species of the drug3 molecule , thereby decreasing urinary excretion . " } 5 : { 1 : 1 } } 1555 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj agents dep drug0" } 4 : { 1 : "Urinary alkalinizing agents ( drug1 , some drug2 ) increase the concentration of the non-ionized species of the drug3 molecule , thereby decreasing urinary excretion . " } 5 : { 1 : 1 } } 1556 : { 1 : "NN nmod NNS dobj VBG conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj inhibiting conj *blocks* nsubj drug0" } 4 : { 1 : "drug1 : drug2 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of drug3 , and can be used to treat drug4 poisoning . " } 5 : { 1 : 1 } } 1557 : { 1 : "NN compound NN nmod NNS nmod NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 compound molecule nmod species nmod concentration dobj *increase* nsubj drug0" } 4 : { 1 : "drug1 ( drug2 , drug3 , etc. ) increase the concentration of the ionized species of the drug4 molecule , thereby increasing urinary excretion . " } 5 : { 1 : 1 } } 1558 : { 1 : "NN nmod NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod administration nmod increased xcomp *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1559 : { 1 : "NN appos NN dep NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep administration nmod increased xcomp *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1560 : { 1 : "NN nmod NN nsubj VBZ advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod potential nsubj *is* advcl used nsubjpass drug0" } 4 : { 1 : "When other drug1 or drug2 are used concomitantly , there is the potential for drug3 to increase the risk of bleeding . " } 5 : { 1 : 1 } } 1561 : { 1 : "NN appos NN dep NN nmod VBN acl:relcl NNS dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep protein nmod bound acl:relcl drugs dobj taking acl patients nmod *administration* nmod drug0" } 4 : { 1 : "Because drug1 is highly bound to serum protein , the administration of drug2 to patients taking other drugs that are highly bound to protein ( e.g. , drug3 , drug4 ) may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects . " } 5 : { 1 : 1 } } 1562 : { 1 : "NN dep NN nmod VBN acl:relcl NNS dobj VBG acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep protein nmod bound acl:relcl drugs dobj taking acl patients nmod *administration* nmod drug0" } 4 : { 1 : "Because drug1 is highly bound to serum protein , the administration of drug2 to patients taking other drugs that are highly bound to protein ( e.g. , drug3 , drug4 ) may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects . " } 5 : { 1 : 1 } } 1563 : { 1 : "NN nmod NN nsubj VBZ advcl VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod potential nsubj *is* advcl used nsubjpass drug0 conj drug0" } 4 : { 1 : "When other drug1 or drug2 are used concomitantly , there is the potential for drug3 to increase the risk of bleeding . " } 5 : { 1 : 1 } } 1564 : { 1 : "NN nmod NN nmod VBP conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod metabolism nmod interfere conj *shown* nsubjpass administration nmod drug0" } 4 : { 1 : "However , the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug2 , interfere with the metabolism of drug3 , and enhance the effects of the oral drug4 drug5 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drug6 concomitantly . " } 5 : { 1 : 1 } } 1565 : { 1 : "NN nmod NN nsubjpass VBN advcl VBG dobj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod therapy nsubjpass initiated advcl *receiving* dobj drug0 conj drug0" } 4 : { 1 : "In clinical trials , drug1 was used with drug2 , drug3 , drug4 , oral drug5 , and supplemental drug6 . In a pharmacokinetic substudy in patients with congestive heart failure receiving drug7 or drug8 in whom therapy with drug9 was initiated , apparent oral clearance values for drug10 ( n = 23 ) and drug11 ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 . " } 5 : { 1 : 1 } } 1566 : { 1 : "NN nmod NNS dobj VBP conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effects dobj enhance conj *shown* nsubjpass administration nmod drug0" } 4 : { 1 : "However , the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug2 , interfere with the metabolism of drug3 , and enhance the effects of the oral drug4 drug5 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic drug6 concomitantly . " } 5 : { 1 : 1 } } 1567 : { 1 : "NN dep NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep administration nmod increased xcomp *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1568 : { 1 : "NN nmod VBN acl NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod withdrawn acl patient nmod *treatment* compound drug0" } 4 : { 1 : "Of particular importance , sufficient time must elapse before initiating drug1 treatment in a patient being withdrawn from drug2 , given the long half-life of the parent and active metabolite ( at least 5 weeks may be necessary ) . " } 5 : { 1 : 1 } } 1569 : { 1 : "NN nmod VBN conj VBN conj VBN nmod NN nmod NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *increased* conj decreased nmod administration nmod inducers dep drug0 appos drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1570 : { 1 : "NN appos NN dep NNS nmod NN nmod VBN conj VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep inducers nmod administration nmod decreased conj increased xcomp *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1571 : { 1 : "NN dep NNS nmod NN nmod VBN conj VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dep inducers nmod administration nmod decreased conj increased xcomp *reported* nsubjpass levels nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1572 : { 1 : "NN compound NN nmod VBN acl NN appos NN dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound metabolism nmod involved acl isoform appos 0a0 dobj inhibit xcomp *shown* nsubjpass drug0" } 4 : { 1 : "drug1 has also been shown to inhibit P450 1A2 , an isoform also involved in drug2 metabolism . " } 5 : { 1 : 1 } } 1573 : { 1 : "NN nmod VBN conj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *increased* nmod administration nmod drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1574 : { 1 : "NN nmod VBN conj VBN nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *increased* nmod administration dep drug0 appos drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1575 : { 1 : "NN nmod VBN conj VBN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *increased* nmod administration dep drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1576 : { 1 : "NN nmod VBN conj VBN conj VBN nmod NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod anticipated conj *increased* conj decreased nmod administration nmod inducers dep drug0" } 4 : { 1 : "plasma levels of several closely related drug1 have been reported to be increased by the concomitant administration of drug2 or hepatic enzyme inhibitors ( e.g. , drug3 , drug4 ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , drug5 , drug6 ) , and such an effect may be anticipated with drug7 as well . " } 5 : { 1 : 1 } } 1577 : { 1 : "NN compound NN dobj VBG acl NNS dep NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy dobj receiving acl patients dep *reports* nmod drug0" } 4 : { 1 : "However , caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times , with or without bleeding , in drug1 - treated patients receiving concomitant drug2 therapy . " } 5 : { 1 : 1 } } 1578 : { 1 : "NN nmod NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *absorption* compound drug0 appos drug0" } 4 : { 1 : "drug1 : drug2 ( drug3 , drug4 , drug5 , drug6 , fruit juices , etc. ) lower absorption of drug7 . " } 5 : { 1 : 1 } } 1579 : { 1 : "NN appos NN nmod VBN acl NNS nmod NNS nmod NNS nsubj VB advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 appos overdose nmod taken acl drugs nmod convulsions nmod effects nsubj emerge advcl *using* dobj drug0" } 4 : { 1 : "Particular caution is necessary when using drug1 in cases of mixed drug overdosage since the toxic effects ( such as convulsions and cardiac dysrhythmias ) of other drugs taken in overdose ( especially drug2 ) may emerge with the reversal of the drug3 effect by drug4 . " } 5 : { 1 : 1 } } 1580 : { 1 : "NN compound NNS dobj VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj decrease xcomp *reported* nsubjpass discontinuation nmod drug0" } 4 : { 1 : "In patients who have been reported to be well controlled on drug1 receiving concurrent drug2 therapy , discontinuation of drug3 has been reported to decrease established steady-state serum drug4 levels and compromise their therapeutic effects . " } 5 : { 1 : 1 } } 1581 : { 1 : "NN dobj VBG acl NNS nmod VBN advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj taking acl patients nmod begun advcl *observed* nsubjpass levels compound drug0" } 4 : { 1 : "Additionally , higher than expected drug1 levels have been observed when they are begun in patients already taking drug2 . " } 5 : { 1 : 1 } } 1582 : { 1 : "NN compound NN nsubjpass VBN advcl VBN nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound therapy nsubjpass initiated advcl *associated* nmod elevations nmod levels nmod drug0" } 4 : { 1 : "Serious anticholinergic symptoms ( i.e. , severe dry mouth , urinary retention and blurred vision ) have been associated with elevations in the serum levels of drug1 when drug2 therapy is initiated . " } 5 : { 1 : 1 } } 1583 : { 1 : "NN compound NN nmod JJ amod NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound overdosage nmod inherent amod danger dobj *increase* nsubj ingestion compound drug0" } 4 : { 1 : "drug1 : It should be borne in mind that drug2 ingestion may increase the danger inherent in any intentional or unintentional drug3 overdosage . " } 5 : { 1 : 1 } } 1584 : { 1 : "NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod effect nmod possibility nsubjpass *considered* advcl identified nmod studies nmod solution compound drug0" } 4 : { 1 : "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , drug7 ) should be considered . " } 5 : { 1 : 1 } } 1585 : { 1 : "NN nmod NN dep NNS nmod VBD nmod NN" 2 : 1 3 : { 1 : "drug0 nmod addition dep days nmod *maintained* nmod drug0" } 4 : { 1 : "drug1 : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on drug2 ( 1 gm/day ) 11 days after the addition of drug3 ( 75 mg/day ) . " } 5 : { 1 : 1 } } 1586 : { 1 : "NN dep NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dep drug0 nmod effect nmod possibility nsubjpass *considered* advcl identified nmod studies nmod solution compound drug0" } 4 : { 1 : "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , drug7 ) should be considered . " } 5 : { 1 : 1 } } 1587 : { 1 : "NN appos NN dep NN nmod NN nmod NN nsubjpass VBN advcl VBN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep drug0 nmod effect nmod possibility nsubjpass *considered* advcl identified nmod studies nmod solution compound drug0" } 4 : { 1 : "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with drug2 ( drug3 , drug4 , drug5 , drug6 , drug7 ) should be considered . " } 5 : { 1 : 1 } } 1588 : { 1 : "NN nmod NNS nmod VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod concentrations nmod produce xcomp *reported* nsubjpass drug0" } 4 : { 1 : "drug1 : drug2 has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various drug3 . " } 5 : { 1 : 1 } } 1589 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN dep NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod concentration dobj *increase* nsubj inhibitors nmod cyp0d0 dep drug0 appos drug0 appos drug0" } 4 : { 1 : "Inhibitors or substrates of CYP2D6 ( i.e. , drug1 , drug2 [ drug3 ] ) may increase the plasma concentration of drug4 when administered concomitantly . " } 5 : { 1 : 1 } } 1590 : { 1 : "NN dep NN dobj VB xcomp VBN acl NNS nmod NN nsubj VB acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 dep conduction dobj alter xcomp known acl drugs nmod coadministration nsubj contribute acl:relcl *interaction* nmod drug0" } 4 : { 1 : "This appears to be the only clinically relevant interaction of this kind with drug1 , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , drug2 or drug3 , drug4 , drug5 or drug6 , drug7 and drug8 ) might also contribute to a prolongation of the QTc interval . " } 5 : { 1 : 1 } } 1591 : { 1 : "NN dep NNS conj NN" 2 : 1 3 : { 1 : "drug0 dep compounds conj *drug0*" } 4 : { 1 : "Concomitant administration of drug1 and other related compounds ( eg , drug2 , drug3 and drug4 ) may produce electrocardiographic abnormalities and increase the risk of convulsions . " } 5 : { 1 : 1 } } 1592 : { 1 : "NN nmod NN nmod RB advmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod initiation nmod prior advmod *discontinued* nsubjpass drug0" } 4 : { 1 : "Therefore , drug1 should be discontinued at least two weeks prior to the cautious initiation of therapy with drug2 . " } 5 : { 1 : 1 } } 1593 : { 1 : "NN nmod NN nsubj VB nmod NNS acl VBG dobj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod use nsubj *reduce* nmod patients acl taking dobj drug0 dep drug0" } 4 : { 1 : "In patients taking an drug1 ( eg , drug2 , drug3 , drug4 or drug5 ) , the concomitant use of drug6 may reduce seizure control by lowering the plasma levels of the drug7 . " } 5 : { 1 : 1 } } 1594 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod concentration dobj *increase* nsubj inhibitors nmod cyp0d0 dep drug0" } 4 : { 1 : "Inhibitors or substrates of CYP2D6 ( i.e. , drug1 , drug2 [ drug3 ] ) may increase the plasma concentration of drug4 when administered concomitantly . " } 5 : { 1 : 1 } } 1595 : { 1 : "NN dobj VBG acl NNS appos NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj using acl diabetics appos travelers nmod *effects* nmod drug0" } 4 : { 1 : "Nevertheless , the effects of drug1 on travelers receiving comedication , particularly diabetics or patients using drug2 , should be checked before departure . " } 5 : { 1 : 1 } } 1596 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod concentration dobj *increase* nsubj inhibitors nmod cyp0d0 dep drug0 appos drug0" } 4 : { 1 : "Inhibitors or substrates of CYP2D6 ( i.e. , drug1 , drug2 [ drug3 ] ) may increase the plasma concentration of drug4 when administered concomitantly . " } 5 : { 1 : 1 } } 1597 : { 1 : "NN compound NN nmod NN nmod NN nsubj VB advcl VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound agonist nmod effect nmod suppression nsubj *give* advcl exerts nsubj drug0" } 4 : { 1 : "Although drug1 exerts a slight intrinsic anticonvulsant effect , its abrupt suppression of the protective effect of a drug2 agonist can give rise to convulsions in epileptic patients . " } 5 : { 1 : 1 } } 1598 : { 1 : "NN nmod NNS dobj VBG acl NN nsubjpass VBN advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod drugs dobj using acl caution nsubjpass *advised* advcl reduce nsubj drug0" } 4 : { 1 : "Since drug1 may reduce pulse and blood pressure , caution in using drugs such as drug2 ( ophthalmic and systemic ) , drug3 , and drug4 is advised . " } 5 : { 1 : 1 } } 1599 : { 1 : "NN dobj VBD acl:relcl NNS conj NN nmod NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj bound acl:relcl drugs conj drug0 nmod drugs nmod *potentiated* nsubjpass action nmod drug0" } 4 : { 1 : "Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 , some drug3 and other drugs that are highly protein bound , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 . " } 5 : { 1 : 1 } } 1600 : { 1 : "NN nmod NN dobj VB acl NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect dobj antagonize acl tendency dobj *has* nsubj drug0" } 4 : { 1 : "drug1 has a tendency to antagonize the skeletal muscle relaxing effect of drug2 and may potentiate the action of drug3 . " } 5 : { 1 : 1 } } 1601 : { 1 : "NN nmod NNS acl VBG dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *patients* acl receiving dobj doses nmod drug0" } 4 : { 1 : "Patients receiving high doses of drug1 concomitantly with drug2 , as in rheumatic disease , may experience drug3 toxicity at lower doses because of competitive renal excretory sites . " } 5 : { 1 : 1 } } 1602 : { 1 : "NN appos NN dep VB nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep *occur* nmod use nmod drug0" } 4 : { 1 : "Reciprocal interactions may occur with concomitant use of drug1 and drugs that increase or inhibit the cytochrome P450 system ( e.g. , drug2 , drug3 , drug4 , drug5 ) , though this has not been studied " } 5 : { 1 : 1 } } 1603 : { 1 : "NN nmod NN dobj VB conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod action dobj potentiate conj *has* nsubj drug0" } 4 : { 1 : "drug1 has a tendency to antagonize the skeletal muscle relaxing effect of drug2 and may potentiate the action of drug3 . " } 5 : { 1 : 1 } } 1604 : { 1 : "NN nmod VBN nsubjpass NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *inhibited* nsubjpass pathway nmod detoxification nmod drug0" } 4 : { 1 : "Use with drug1 : The principal pathway for detoxification of drug2 is inhibited by drug3 . " } 5 : { 1 : 1 } } 1605 : { 1 : "NN compound NN compound NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound *clearance* compound drug0 dep im compound drug0" } 4 : { 1 : "After multiple dosing , drug1 ( drug2 30 mcg IM once weekly ) reduced drug3 clearance by approximately 30 % . " } 5 : { 1 : 1 } } 1606 : { 1 : "NN nmod NNS nmod NN dobj VB acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod hypertension dobj control acl *use* nmod drug0" } 4 : { 1 : "Use with drug1 : The use of drug2 to control hypertension in patients on drug3 has been reported to induce severe leukopenia . " } 5 : { 1 : 1 } } 1607 : { 1 : "NN conj NN nmod NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drugs nmod *potentiated* nsubjpass action nmod drug0" } 4 : { 1 : "Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 , some drug3 and other drugs that are highly protein bound , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , and drug10 . " } 5 : { 1 : 1 } } 1608 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod elimination nmod rate dobj *reduced* nsubj doses nmod drug0" } 4 : { 1 : "Oral doses of drug1 ( 10-20 mg/kg ) , via alcohol dehydrogenase inhibition , significantly reduced the rate of elimination of drug2 ( by approximately 40 % ) given to healthy volunteers in moderate doses . " } 5 : { 1 : 1 } } 1609 : { 1 : "NN nmod NN nsubjpass VBN ccomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod effect nsubjpass reduced ccomp *potentiates* nsubj drug0" } 4 : { 1 : "drug1 potentiates the muscle relaxant effect of all drug2 , most notably drug3 , and MAC ( minimum alveolar concentration ) is reduced by concomitant administration of N 2O . " } 5 : { 1 : 1 } } 1610 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN compound NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod combined advcl *associated* nsubjpass use compound drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 use may be rarely associated with ventricular fibrillation when combined with drug3 . " } 5 : { 1 : 1 } } 1611 : { 1 : "NN compound NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound administration nmod *increase* nmod auc compound drug0" } 4 : { 1 : "The mean percentage increase in the drug1 AUC after drug2 administration was 56.9 % ( range : 35 to 81 ) . " } 5 : { 1 : 1 } } 1612 : { 1 : "NN appos NN nmod NN nsubjpass VBN ccomp VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod effect nsubjpass reduced ccomp *potentiates* nsubj drug0" } 4 : { 1 : "drug1 potentiates the muscle relaxant effect of all drug2 , most notably drug3 , and MAC ( minimum alveolar concentration ) is reduced by concomitant administration of N 2O . " } 5 : { 1 : 1 } } 1613 : { 1 : "NN nsubj JJ conj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj effective conj *required* nmod presence nmod drug0" } 4 : { 1 : "In the presence of these drug1 , larger doses of drug2 may be required or drug3 may not be effective . " } 5 : { 1 : 1 } } 1614 : { 1 : "NN nmod NN nmod VBN advcl VBZ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *produced* advcl is nsubj effect nmod drug0" } 4 : { 1 : "As the primary effect of drug1 is to decrease conduction through the A-V node , higher degrees of heart block may be produced in the presence of drug2 . " } 5 : { 1 : 1 } } 1615 : { 1 : "NN nmod NN nmod JJ nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod presence nmod *effective* nsubj doses nmod drug0" } 4 : { 1 : "Thus , smaller doses of drug1 may be effective in the presence of drug2 . " } 5 : { 1 : 1 } } 1616 : { 1 : "NN nmod VBN acl:relcl NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod enhanced acl:relcl invasion nmod incidence dobj *decreased* nsubj drug0" } 4 : { 1 : "drug1 also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by drug2 . " } 5 : { 1 : 1 } } } }